0001531048-24-000060.txt : 20241028 0001531048-24-000060.hdr.sgml : 20241028 20241028161224 ACCESSION NUMBER: 0001531048-24-000060 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 96 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241028 DATE AS OF CHANGE: 20241028 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inari Medical, Inc. CENTRAL INDEX KEY: 0001531048 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 452902923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39293 FILM NUMBER: 241401008 BUSINESS ADDRESS: STREET 1: 6001 OAK CANYON, SUITE 100 CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-923-4747 MAIL ADDRESS: STREET 1: 6001 OAK CANYON, SUITE 100 CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: Inceptus Newco1 Inc. DATE OF NAME CHANGE: 20110923 10-Q 1 nari-20240930.htm 10-Q nari-20240930
0001531048--12-312024Q3falseonehttp://fasb.org/us-gaap/2024#QualifiedPlanMemberxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purenari:patentnari:letterOfCredit00015310482024-01-012024-09-3000015310482024-10-2400015310482024-09-3000015310482023-12-3100015310482024-07-012024-09-3000015310482023-07-012023-09-3000015310482023-01-012023-09-300001531048us-gaap:CommonStockMember2023-12-310001531048us-gaap:AdditionalPaidInCapitalMember2023-12-310001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001531048us-gaap:RetainedEarningsMember2023-12-310001531048us-gaap:CommonStockMember2024-01-012024-03-310001531048us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100015310482024-01-012024-03-310001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001531048us-gaap:RetainedEarningsMember2024-01-012024-03-310001531048us-gaap:CommonStockMember2024-03-310001531048us-gaap:AdditionalPaidInCapitalMember2024-03-310001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001531048us-gaap:RetainedEarningsMember2024-03-3100015310482024-03-310001531048us-gaap:CommonStockMember2024-04-012024-06-300001531048us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000015310482024-04-012024-06-300001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001531048us-gaap:RetainedEarningsMember2024-04-012024-06-300001531048us-gaap:CommonStockMember2024-06-300001531048us-gaap:AdditionalPaidInCapitalMember2024-06-300001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001531048us-gaap:RetainedEarningsMember2024-06-3000015310482024-06-300001531048us-gaap:CommonStockMember2024-07-012024-09-300001531048us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001531048us-gaap:RetainedEarningsMember2024-07-012024-09-300001531048us-gaap:CommonStockMember2024-09-300001531048us-gaap:AdditionalPaidInCapitalMember2024-09-300001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001531048us-gaap:RetainedEarningsMember2024-09-300001531048us-gaap:CommonStockMember2022-12-310001531048us-gaap:AdditionalPaidInCapitalMember2022-12-310001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001531048us-gaap:RetainedEarningsMember2022-12-3100015310482022-12-310001531048us-gaap:CommonStockMember2023-01-012023-03-310001531048us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100015310482023-01-012023-03-310001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001531048us-gaap:RetainedEarningsMember2023-01-012023-03-310001531048us-gaap:CommonStockMember2023-03-310001531048us-gaap:AdditionalPaidInCapitalMember2023-03-310001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001531048us-gaap:RetainedEarningsMember2023-03-3100015310482023-03-310001531048us-gaap:CommonStockMember2023-04-012023-06-300001531048us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000015310482023-04-012023-06-300001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001531048us-gaap:RetainedEarningsMember2023-04-012023-06-300001531048us-gaap:CommonStockMember2023-06-300001531048us-gaap:AdditionalPaidInCapitalMember2023-06-300001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001531048us-gaap:RetainedEarningsMember2023-06-3000015310482023-06-300001531048us-gaap:CommonStockMember2023-07-012023-09-300001531048us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001531048us-gaap:RetainedEarningsMember2023-07-012023-09-300001531048us-gaap:CommonStockMember2023-09-300001531048us-gaap:AdditionalPaidInCapitalMember2023-09-300001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001531048us-gaap:RetainedEarningsMember2023-09-3000015310482023-09-300001531048nari:VenousThromboembolismVTEMember2024-07-012024-09-300001531048nari:VenousThromboembolismVTEMember2023-07-012023-09-300001531048nari:VenousThromboembolismVTEMember2024-01-012024-09-300001531048nari:VenousThromboembolismVTEMember2023-01-012023-09-300001531048nari:EmergingTherapiesMember2024-07-012024-09-300001531048nari:EmergingTherapiesMember2023-07-012023-09-300001531048nari:EmergingTherapiesMember2024-01-012024-09-300001531048nari:EmergingTherapiesMember2023-01-012023-09-300001531048country:US2024-07-012024-09-300001531048country:US2023-07-012023-09-300001531048country:US2024-01-012024-09-300001531048country:US2023-01-012023-09-300001531048us-gaap:NonUsMember2024-07-012024-09-300001531048us-gaap:NonUsMember2023-07-012023-09-300001531048us-gaap:NonUsMember2024-01-012024-09-300001531048us-gaap:NonUsMember2023-01-012023-09-300001531048nari:LimFlowMember2024-01-012024-09-300001531048nari:LimFlowMember2023-11-152023-11-150001531048nari:LimFlowMember2023-11-150001531048nari:LimFlowMembernari:NetRevenueMember2023-11-150001531048nari:LimFlowMembernari:ReimbursementMilestonesMember2023-11-150001531048nari:LimFlowMember2023-11-140001531048nari:LimFlowMember2023-01-012023-12-310001531048nari:LimFlowMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-11-150001531048nari:LimFlowMemberus-gaap:TechnologyBasedIntangibleAssetsMember2023-11-152023-11-150001531048nari:LimFlowMember2023-07-012023-09-300001531048nari:LimFlowMember2023-01-012023-09-300001531048us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001531048us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001531048us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001531048us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001531048us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001531048us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001531048us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001531048us-gaap:FairValueMeasurementsRecurringMember2024-09-300001531048us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001531048us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001531048us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001531048us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001531048us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001531048us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001531048us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001531048us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001531048us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001531048us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001531048us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001531048us-gaap:FairValueMeasurementsRecurringMember2023-12-310001531048us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001531048us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001531048us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001531048us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001531048us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001531048us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001531048us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001531048us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001531048us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembernari:CorporateDebtSecuritiesAndCommercialPaperMember2023-12-310001531048us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembernari:CorporateDebtSecuritiesAndCommercialPaperMember2023-12-310001531048us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembernari:CorporateDebtSecuritiesAndCommercialPaperMember2023-12-310001531048us-gaap:FairValueMeasurementsRecurringMembernari:CorporateDebtSecuritiesAndCommercialPaperMember2023-12-310001531048us-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2024-09-300001531048us-gaap:CashAndCashEquivalentsMember2024-09-300001531048us-gaap:ShortTermInvestmentsMemberus-gaap:USTreasurySecuritiesMember2024-09-300001531048us-gaap:ShortTermInvestmentsMember2024-09-300001531048us-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2023-12-310001531048us-gaap:CashAndCashEquivalentsMember2023-12-310001531048us-gaap:ShortTermInvestmentsMemberus-gaap:USTreasurySecuritiesMember2023-12-310001531048us-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001531048us-gaap:ShortTermInvestmentsMembernari:CorporateDebtSecuritiesAndCommercialPaperMember2023-12-310001531048us-gaap:ShortTermInvestmentsMember2023-12-310001531048us-gaap:ManufacturingFacilityMember2024-09-300001531048us-gaap:ManufacturingFacilityMember2023-12-310001531048us-gaap:ComputerEquipmentMember2024-09-300001531048us-gaap:ComputerEquipmentMember2023-12-310001531048us-gaap:AssetUnderConstructionMember2024-09-300001531048us-gaap:AssetUnderConstructionMember2023-12-310001531048us-gaap:FurnitureAndFixturesMember2024-09-300001531048us-gaap:FurnitureAndFixturesMember2023-12-310001531048us-gaap:LeaseholdImprovementsMember2024-09-300001531048us-gaap:LeaseholdImprovementsMember2023-12-310001531048us-gaap:OperatingExpenseMember2024-07-012024-09-300001531048us-gaap:OperatingExpenseMember2023-07-012023-09-300001531048us-gaap:CostOfSalesMember2024-07-012024-09-300001531048us-gaap:CostOfSalesMember2023-07-012023-09-300001531048us-gaap:OperatingExpenseMember2023-01-012023-09-300001531048us-gaap:OperatingExpenseMember2024-01-012024-09-300001531048us-gaap:CostOfSalesMember2024-01-012024-09-300001531048us-gaap:CostOfSalesMember2023-01-012023-09-300001531048us-gaap:TechnologyBasedIntangibleAssetsMember2024-09-300001531048us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310001531048srt:MaximumMember2024-09-3000015310482023-10-310001531048nari:PatentInfringementLawsuitAgainstImperativeCareAndTruvicMember2024-05-222024-05-220001531048nari:PatentInfringementLawsuitAgainstImperativeCareAndTruvicMember2024-07-092024-07-090001531048us-gaap:RelatedPartyMember2024-09-300001531048us-gaap:RelatedPartyMember2023-12-310001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-160001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:FederalFundsEffectiveSwapRateMember2022-12-162022-12-160001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembernari:BloombergShortTermBankYieldIndexBSBYMember2022-12-162022-12-160001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:FederalFundsEffectiveSwapRateMembersrt:MinimumMember2022-12-162022-12-160001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:FederalFundsEffectiveSwapRateMembersrt:MaximumMember2022-12-162022-12-160001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembernari:BloombergShortTermBankYieldIndexBSBYMembersrt:MinimumMember2022-12-162022-12-160001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembernari:BloombergShortTermBankYieldIndexBSBYMembersrt:MaximumMember2022-12-162022-12-160001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-162022-12-160001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2022-12-160001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2023-02-280001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2024-01-012024-09-300001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-11-010001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMembersrt:MinimumMember2023-11-012023-11-010001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:BaseRateMembersrt:MaximumMember2023-11-012023-11-010001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembernari:BloombergShortTermBankYieldIndexBSBYMembersrt:MinimumMember2023-11-012023-11-010001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembernari:BloombergShortTermBankYieldIndexBSBYMembersrt:MaximumMember2023-11-012023-11-010001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembernari:BloombergShortTermBankYieldIndexBSBYMember2023-11-012023-11-010001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2023-11-010001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-09-300001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2024-09-300001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-01-012024-09-300001531048nari:BankOfAmericaCreditFacilityMembernari:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-01-012023-12-310001531048us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310001531048us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001531048us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-03-310001531048us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310001531048us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-03-310001531048us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310001531048us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-04-012024-06-300001531048us-gaap:AccumulatedTranslationAdjustmentMember2024-04-012024-06-300001531048us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-06-300001531048us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300001531048us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-07-012024-09-300001531048us-gaap:AccumulatedTranslationAdjustmentMember2024-07-012024-09-300001531048us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-09-300001531048us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300001531048us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310001531048us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001531048us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-03-310001531048us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310001531048us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-310001531048us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310001531048us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-04-012023-06-300001531048us-gaap:AccumulatedTranslationAdjustmentMember2023-04-012023-06-300001531048us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-06-300001531048us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300001531048us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-07-012023-09-300001531048us-gaap:AccumulatedTranslationAdjustmentMember2023-07-012023-09-300001531048us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300001531048us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300001531048nari:TwoThousandTwentyIncentiveAwardPlanMembersrt:MaximumMember2020-03-012020-03-310001531048nari:TwoThousandTwentyIncentiveAwardPlanMember2020-03-012020-03-310001531048nari:TwoThousandTwentyIncentiveAwardPlanMember2024-09-300001531048nari:TwoThousandTwentyIncentiveAwardPlanMember2024-01-010001531048nari:TwoThousandAndElevenEquityIncentivePlanMember2023-12-310001531048nari:TwoThousandAndElevenEquityIncentivePlanMember2023-01-012023-12-310001531048nari:TwoThousandAndElevenEquityIncentivePlanMember2024-01-012024-09-300001531048nari:TwoThousandAndElevenEquityIncentivePlanMember2024-09-300001531048us-gaap:RestrictedStockUnitsRSUMembernari:TwoThousandTwentyIncentiveAwardPlanMember2024-01-012024-09-300001531048nari:TwoThousandTwentyIncentiveAwardPlanMembernari:VestingOptionOneMemberus-gaap:RestrictedStockUnitsRSUMembernari:ShareBasedPaymentArrangementTrancheFourMember2024-01-012024-09-300001531048nari:TwoThousandTwentyIncentiveAwardPlanMembernari:VestingOptionOneMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-01-012024-09-300001531048nari:TwoThousandTwentyIncentiveAwardPlanMembernari:VestingOptionOneMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-09-300001531048nari:TwoThousandTwentyIncentiveAwardPlanMembernari:VestingOptionOneMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-09-300001531048us-gaap:RestrictedStockUnitsRSUMembernari:VestingOptionTwoMember2024-01-012024-09-300001531048us-gaap:RestrictedStockUnitsRSUMembernari:TwoThousandTwentyIncentiveAwardPlanMember2023-12-310001531048us-gaap:RestrictedStockUnitsRSUMembernari:TwoThousandTwentyIncentiveAwardPlanMember2024-09-300001531048us-gaap:RestrictedStockUnitsRSUMembernari:TwoThousandTwentyIncentiveAwardPlanMember2024-07-012024-09-300001531048us-gaap:RestrictedStockUnitsRSUMembernari:TwoThousandTwentyIncentiveAwardPlanMember2023-07-012023-09-300001531048us-gaap:RestrictedStockUnitsRSUMembernari:TwoThousandTwentyIncentiveAwardPlanMember2023-01-012023-09-300001531048us-gaap:PerformanceSharesMembernari:TwoThousandTwentyIncentiveAwardPlanMember2024-01-012024-09-300001531048nari:TwoThousandTwentyIncentiveAwardPlanMemberus-gaap:PerformanceSharesMembersrt:MinimumMember2024-09-300001531048nari:TwoThousandTwentyIncentiveAwardPlanMemberus-gaap:PerformanceSharesMembersrt:MaximumMember2024-09-300001531048us-gaap:PerformanceSharesMembernari:TwoThousandTwentyIncentiveAwardPlanMember2023-12-310001531048us-gaap:PerformanceSharesMembernari:TwoThousandTwentyIncentiveAwardPlanMember2024-09-300001531048us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001531048us-gaap:EmployeeStockOptionMembernari:TwoThousandTwentyIncentiveAwardPlanMember2024-01-012024-09-300001531048us-gaap:EmployeeStockOptionMembernari:TwoThousandTwentyIncentiveAwardPlanMember2023-01-012023-09-300001531048nari:TwoThousandTwentyIncentiveAwardPlanMember2023-12-310001531048nari:TwoThousandTwentyIncentiveAwardPlanMember2023-01-012023-12-310001531048nari:TwoThousandTwentyIncentiveAwardPlanMember2024-01-012024-09-300001531048nari:TwoThousandTwentyEmployeeStockPurchasePlanMember2020-05-012020-05-310001531048nari:TwoThousandTwentyEmployeeStockPurchasePlanMember2021-01-012021-01-010001531048nari:TwoThousandTwentyEmployeeStockPurchasePlanMember2024-01-012024-09-300001531048nari:TwoThousandTwentyEmployeeStockPurchasePlanMember2023-01-012023-09-300001531048us-gaap:CommonStockMembernari:TwoThousandTwentyEmployeeStockPurchasePlanMember2020-05-012024-09-3000015310482024-07-012024-07-3100015310482024-01-012024-01-310001531048nari:TwoThousandTwentyEmployeeStockPurchasePlanMember2024-09-3000015310482024-01-010001531048nari:EmployeeStockPurchasePlanMember2024-07-012024-09-300001531048nari:EmployeeStockPurchasePlanMember2023-07-012023-09-300001531048nari:EmployeeStockPurchasePlanMember2024-01-012024-09-300001531048nari:EmployeeStockPurchasePlanMember2023-01-012023-09-300001531048us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001531048us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001531048us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001531048us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001531048us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001531048us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001531048us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001531048us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-3000015310482021-01-012021-01-3100015310482024-01-012024-01-010001531048us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001531048us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001531048us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001531048us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001531048nari:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember2024-07-012024-09-300001531048nari:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember2023-07-012023-09-300001531048nari:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember2024-01-012024-09-300001531048nari:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember2023-01-012023-09-300001531048us-gaap:EmployeeStockMember2024-07-012024-09-300001531048us-gaap:EmployeeStockMember2023-07-012023-09-300001531048us-gaap:EmployeeStockMember2024-01-012024-09-300001531048us-gaap:EmployeeStockMember2023-01-012023-09-300001531048us-gaap:StockCompensationPlanMember2024-07-012024-09-300001531048us-gaap:StockCompensationPlanMember2023-07-012023-09-300001531048us-gaap:StockCompensationPlanMember2024-01-012024-09-300001531048us-gaap:StockCompensationPlanMember2023-01-012023-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________to ___________
Commission File Number: 001-39293
InariMedical_Logo_R small.jpg
Inari Medical, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware45-2902923
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
6001 Oak Canyon, Suite 100
Irvine, California
92618
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (877) 923-4747
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value per shareNARIThe Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of October 24, 2024, the registrant had 58,544,158 shares of common stock, $0.001 par value per share, outstanding.

Table of Contents
Page
i
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risks and uncertainties. We intend such forward-looking statements contained in this Quarterly Report to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may”, “will”, “would”, “should”, “expects”, “plans”, “anticipates”, “could”, “intends”, “targets”, “projects”, “contemplates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements contained in this Quarterly Report include, but are not limited to statements regarding our future results of operations and financial position, plans for our current and future products, anticipated product launches, expectations regarding our acquisition of LimFlow S.A. and expectations regarding market penetration, the impact of macroeconomic conditions, industry and business trends, and our expectations regarding stock compensation, business strategy, plans, market growth, regulatory climate, competitive landscape and our objectives for future operations.
The forward-looking statements in this Quarterly Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, and results of operations. Forward-looking statements involve known and unknown risks and uncertainties, and are subject to other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, as such risks and uncertainties may be amended, supplemented or superseded from time to time by our subsequent reports on Forms 10-Q and 10-K we file with the United States Securities and Exchange Commission. We qualify all of our forward-looking statements by these cautionary statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.
The forward-looking statements in this Quarterly Report on Form 10-Q are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed as exhibits to this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.


ii
PART I — FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements (Unaudited)
INARI MEDICAL, INC.
Condensed Consolidated Balance Sheets
(in thousands, except share data and par value)
(unaudited)
September 30,
2024		December 31,
2023
Assets
Current assets
Cash and cash equivalents$41,141 $38,597 
Restricted cash
67 611 
Short-term investments in debt securities70,397 76,855 
Accounts receivable, net84,403 70,119 
Inventories, net55,210 42,900 
Prepaid expenses and other current assets12,168 6,481 
Total current assets263,386 235,563 
Property and equipment, net24,098 20,929 
Operating lease right-of-use assets48,301 48,407 
Goodwill213,345 214,335 
Intangible assets143,808 150,884 
Deposits and other assets4,301 4,117 
Total assets$697,239 $674,235 
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable$15,523 $10,577 
Payroll-related accruals54,797 48,706 
Accrued expenses and other current liabilities76,881 15,364 
Operating lease liabilities, current portion1,579 1,692 
Total current liabilities148,780 76,339 
Operating lease liabilities, noncurrent portion31,145 30,355 
Deferred tax liability36,748 36,231 
Other long-term liability45,805 66,400 
Total liabilities262,478 209,325 
Commitments and contingencies (Note 9)
Stockholders' equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2024 and December 31, 2023
— — 
Common stock, $0.001 par value, 300,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 58,435,576 and 57,762,414 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively
58 58 
Additional paid in capital543,961 504,453 
Accumulated other comprehensive income
13,145 8,885 
Accumulated deficit(122,403)(48,486)
Total stockholders' equity434,761 464,910 
Total liabilities and stockholders' equity$697,239 $674,235 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3
INARI MEDICAL, INC.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share data)
(unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Revenue$153,390 $126,366 $442,404 $361,538 
Cost of goods sold19,846 14,477 58,732 42,062 
Gross profit133,544 111,889 383,672 319,476 
Operating expenses
Research and development29,431 21,492 81,216 64,641 
Selling, general and administrative108,271 85,603 325,479 256,889 
Change in fair value of contingent consideration
6,578 — 18,609 — 
Amortization of intangible asset
2,504 — 7,414 — 
Acquisition-related expenses
328 2,681 4,143 2,681 
Total operating expenses147,112 109,776 436,861 324,211 
(Loss) income from operations
(13,568)2,113 (53,189)(4,735)
Other income (expense)
Interest income1,104 4,202 3,371 12,899 
Interest expense(78)(43)(233)(127)
Other expense
(130)(682)(130)(617)
Total other income896 3,477 3,008 12,155 
(Loss) income before income taxes
(12,672)5,590 (50,181)7,420 
Provision for income taxes5,695 2,428 23,736 4,391 
Net (loss) income
$(18,367)$3,162 $(73,917)$3,029 
Other comprehensive income (loss)
Foreign currency translation adjustments13,918 (68)4,200 (138)
Unrealized gain (loss) on available-for-sale debt securities
64 91 60 (1,869)
Total other comprehensive income (loss)
13,982 23 4,260 (2,007)
Comprehensive income (loss)
$(4,385)$3,185 $(69,657)$1,022 
Net (loss) income per share
Basic$(0.31)$0.06 $(1.27)$0.05 
Diluted$(0.31)$0.05 $(1.27)$0.05 
Weighted average common shares used to compute net (loss) income per share
Basic58,366,36457,384,88458,149,29656,478,317
Diluted58,366,36458,588,45258,149,29658,495,921
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
INARI MEDICAL, INC.
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
(unaudited)
Common StockAdditional Paid In
Capital		Accumulated Other Comprehensive
Income (Loss)
Accumulated
Deficit
Total
Stockholders'
Equity
SharesAmount
Balance, December 31, 202357,762,414$58 $504,453 $8,885 $(48,486)$464,910 
Options exercised for common stock81,952 — 145 — — 145 
Shares issued under Employee Stock Purchase Plan82,816 — 3,983 — — 3,983 
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes
73,963 — (3,113)— — (3,113)
Share-based compensation expense—— 12,870 — — 12,870 
Other comprehensive loss—— — (7,363)— (7,363)
Net loss—— — — (24,202)(24,202)
Balance, March 31, 202458,001,14558 518,338 1,522 (72,688)447,230 
Options exercised for common stock47,750 — 98 — — 98 
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes
117,414 — (2,851)— — (2,851)
Share-based compensation expense—— 13,039 — — 13,039 
Other comprehensive loss—— — (2,359)— (2,359)
Net loss
—— — — (31,348)(31,348)
Balance, June 30, 202458,166,30958 528,624 (837)(104,036)423,809 
Options exercised for common stock41,104 — 117 — — 117 
Shares issued under Employee Stock Purchase Plan133,430 — 5,281 — — 5,281 
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes
94,733 — (3,012)— — (3,012)
Share-based compensation expense—— 12,951 — — 12,951 
Other comprehensive income
—— — 13,982 — 13,982 
Net loss—— — — (18,367)(18,367)
Balance, September 30, 202458,435,576$58 $543,961 $13,145 $(122,403)$434,761 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5
INARI MEDICAL, INC.
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
(unaudited)
Common StockAdditional Paid In
Capital		Accumulated Other Comprehensive
Income (Loss)		Accumulated
Deficit
Total
Stockholders'
Equity
SharesAmount
Balance, December 31, 202254,021,656$54 $462,949 $849 $(46,850)$417,002 
Options exercised for common stock209,966— 226 — — 226 
Shares issued under Employee Stock Purchase Plan86,051— 4,172 — — 4,172 
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes
2,766,0433 (1,932)— — (1,929)
Share-based compensation expense—— 10,339 — — 10,339 
Other comprehensive loss—— — (856)— (856)
Net loss—— — — (2,218)(2,218)
Balance, March 31, 202357,083,71657 475,754 (7)(49,068)426,736 
Options exercised for common stock81,712— 214 — — 214 
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes
101,027— (2,569)— — (2,569)
Share-based compensation expense—— 10,353 — — 10,353 
Other comprehensive loss—— — (1,174)— (1,174)
Net income
—— — — 2,085 2,085 
Balance, June 30, 202357,266,45557 483,752 (1,181)(46,983)435,645 
Options exercised for common stock43,547— 107 — — 107 
Shares issued under Employee Stock Purchase Plan118,4941 5,748 — — 5,749 
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes
77,966— (2,388)— — (2,388)
Share-based compensation expense—— 9,844 — — 9,844 
Other comprehensive income—— — 23 — 23 
Net income—— — — 3,162 3,162 
Balance, September 30, 202357,506,462$58 $497,063 $(1,158)$(43,821)$452,142 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6
INARI MEDICAL, INC.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
Nine Months Ended September 30,
20242023
Cash flows from operating activities
Net (loss) income
$(73,917)$3,029 
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization11,879 4,186 
Amortization of deferred financing costs
65 30 
Amortization of right-of-use assets2,858 3,099 
Share-based compensation expense38,860 30,536 
Impairment loss on strategic investment
— 565 
Allowance for credit losses, net622 526 
Loss on disposal of fixed assets436 26 
Impairment of capitalized software development costs
3,789 — 
Amortization of premium and discount on marketable securities(1,707)(11,407)
Change in fair value of contingent consideration liability
18,609 — 
Changes in:
Accounts receivable(15,107)(11,566)
Inventories(12,378)(7,797)
Prepaid expenses, deposits and other assets(3,278)4,294 
Accounts payable4,927 2,436 
Payroll-related accruals, accrued expenses and other liabilities28,356 7,218 
Operating lease liabilities(1,797)(1,031)
Lease prepayments for lessor's owned leasehold improvements(280)(458)
Net cash provided by operating activities
1,937 23,686 
Cash flows from investing activities
Purchases of property and equipment(7,899)(3,801)
Purchases of marketable securities(91,085)(394,496)
Maturities of marketable securities
96,708 400,560 
Purchases of other investments— (565)
Working capital adjustment related to acquisition
3,722 — 
Capitalized software development costs(2,298)— 
Net cash (used in) provided by investing activities
(852)1,698 
Cash flows from financing activities
Proceeds from issuance of common stock under employee stock purchase plan9,264 9,920 
Proceeds from exercise of stock options360 547 
Payment of taxes related to vested equity awards
(8,976)(6,886)
Net cash provided by financing activities
648 3,581 
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash
267 (5)
Net increase in cash, cash equivalents and restricted cash
2,000 28,960 
Cash, cash equivalents and restricted cash beginning of period39,208 60,222 
Cash, cash equivalents and restricted cash end of period$41,208 $89,182 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements

1. ORGANIZATION
Description of Business
Inari Medical, Inc. (the “Company”) was incorporated in Delaware in July 2011 and is headquartered in Irvine, California. The Company purpose builds and markets a variety of medical products, including minimally invasive, novel, catheter-based mechanical thrombectomy systems for the unique characteristics of specific disease states.
On November 15, 2023, the Company acquired LimFlow S.A. (“LimFlow”), a medical device company focused on limb salvage for patients with chronic limb-threatening ischemia (“CLTI”). LimFlow focuses on transforming the treatment of CLTI, an advanced stage of peripheral artery disease that is associated with increased mortality, risk of amputation and impaired quality of life.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and include the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to prior period financial statements to conform to classifications used in the current period.
The interim condensed consolidated balance sheet as of September 30, 2024 and the condensed consolidated statements of operations and comprehensive income (loss), stockholders’ equity, and cash flows for the three and nine months ended September 30, 2024 and 2023 are unaudited. The consolidated balance sheet as of December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed consolidated financial position as of September 30, 2024 and its consolidated results of operations and cash flows for the three and nine months ended September 30, 2024 and 2023. The financial data and the other financial information disclosed in the notes to the condensed consolidated financial statements related to the three and nine months ended September 30, 2024 and 2023 are also unaudited. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. These interim condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
Management Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements may include, but are not limited to, contingent consideration liability, collectability of receivables, recoverability of long-lived assets, valuation of inventory, operating lease right-of-use (“ROU”) assets and liabilities, other investments, fair value of stock options, recoverability of net deferred tax assets and related valuation allowance, and certain accruals. Estimates are based on historical experience and on various assumptions that the Company believes are reasonable under current circumstances. Actual results could differ materially from those estimates. Management periodically evaluates such estimates and assumptions, and they are adjusted prospectively based upon such periodic evaluation.
8
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
Revenue Recognition
The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company sells its products primarily to hospitals in the United States through its direct sales force and also sells its products directly and through distributors in select international markets. The Company recognizes revenue for arrangements where the Company has satisfied its performance obligation of shipping or delivering the product. For sales where the Company’s sales representatives hand-deliver products directly to the hospitals, control of the products transfers to the customers upon such hand-delivery. For sales where products are shipped, control of the products transfers either upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. Revenue from product sales is comprised of product revenue, net of product returns, discounts, administrative fees and sales rebates. The Company has elected to account for shipping and handling activities that occur after the customer has obtained control as a fulfillment activity, and not a separate performance obligation.
Performance Obligation—The Company has revenue arrangements that consist of a single performance obligation, the shipping or delivery of the Company’s products. The satisfaction of this performance obligation occurs with the transfer of control of the Company’s product to its customers, either upon shipment or delivery of the product.
Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of revenue recognized is based on the transaction price, which represents the invoiced amount, net of discounts, administrative fees and sales rebates, where applicable. The Company provides a standard 30-day unconditional right of return period. The Company establishes estimated provisions for returns at the time of sale based on historical experience. Historically, the actual product returns have been insignificant to the Company’s condensed consolidated financial statements.
As of September 30, 2024 and December 31, 2023, the Company recorded $1.2 million of unbilled receivables, and $1.9 million and $1.3 million, respectively, of allowance for credit losses, which are included in accounts receivable, net, in the accompanying condensed consolidated balance sheets.
The Company disaggregates revenue between Venous Thromboembolism (“VTE”) and Emerging Therapies. VTE comprises revenue from the sale of the Company’s solutions addressing deep vein thrombosis and pulmonary embolism. Emerging Therapies comprises revenue from the sale of the Company’s solutions addressing chronic venous disease, CLTI, acute limb ischemia and dialysis access management. Revenue from VTE and Emerging Therapies is as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
VTE
$145,346 $121,460 $420,213 $349,604 
Emerging Therapies
8,044 4,906 22,191 11,934 
Total revenue
$153,390 $126,366 $442,404 $361,538 
9
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
Revenue from the Company's products by geographic area, based on the location where title transfers, is as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
United States$141,854$119,825$411,321$345,473
International11,5366,54131,08316,065
Total revenue
$153,390 $126,366$442,404$361,538
The Company offers payment terms to its customers of less than three months and these terms do not include a significant financing component. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.
The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to cost of goods sold.
Costs associated with product sales include commissions which are recorded in selling, general and administrative (“SG&A”) expenses. The Company applies the practical expedient and recognizes commissions as an expense when incurred because the amortization period is less than one year.
Equity Investments
The Company has strategic investments in certain privately held companies, with no readily determinable fair value. The Company elected the measurement alternative under which it measures these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments. The Company will monitor the information that becomes available from time to time and adjust the carrying values of these investments if there are identified events or changes in circumstances that have a significant adverse effect on the fair values or if there are observable changes in fair value. Impairment loss, which is generally the difference between the carrying value and the fair value of the investment, is recorded in other income (expense) in the consolidated statements of operations and comprehensive income (loss). As of September 30, 2024 and December 31, 2023, the Company’s equity investments were $1.5 million and were included in deposits and other assets on the condensed consolidated balance sheets. Additionally, during the three and nine months ended September 30, 2023, the Company recorded an impairment loss of $0.6 million in other income (expense) within the condensed consolidated statements of operations and comprehensive income (loss). There was no impairment recorded during the three and nine months ended September 30, 2024.
Significant Accounting Policies
As of September 30, 2024, there were no changes to the Company’s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
Recently Issued Not Yet Adopted Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting, Topic 280, which requires enhanced disclosures primarily around segment expenses for all public entities, including public entities with a single reportable segment. On an annual and interim basis, entities are required to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of the new standard and does not expect there to be a material impact on its consolidated financial statements and related disclosures upon adoption.
10
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
In December 2023, FASB issued ASU 2023-09, Income Tax, Topic 740, which requires public companies to disclose specific categories in the rate reconciliation, disaggregate information related to income taxes paid, income or loss from operations before income tax expense or benefit, and income tax expense or benefit from operations. The ASU is effective for annual fiscal years beginning after December 15, 2024, with early adoption permitted. Amendments are applicable on a prospective basis with retrospective application permitted. The Company is currently evaluating the impact of the new standard on its consolidated financial statements and related disclosures.
Supplemental Cash Flow Information
Supplemental cash flow information includes the following (in thousands):
Nine Months Ended September 30,
20242023
Supplemental disclosures of cash flow information:
Cash paid for income taxes$7,371 $3,562 
Cash paid for interest$168 $98 
Noncash investing and financing:
Lease liabilities arising from obtaining new right-of-use assets$2,447 $1,030 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
$41,141 $89,182 
Restricted cash
67 — 
Total cash, cash equivalents and restricted cash as shown in the statement of cash flows
$41,208 $89,182 
3. BUSINESS COMBINATION
Acquisition of LimFlow S.A.
On November 15, 2023, the Company completed its acquisition of LimFlow, a medical device company focused on limb salvage for patients with CLTI. As a result of the acquisition, LimFlow’s stockholders received as consideration (i) cash, and (ii) contingent consideration related to certain commercial and reimbursement milestones. The results of operations of LimFlow have been included in the condensed consolidated financial statements from the date of the acquisition.
During the nine months ended September 30, 2024, the Company recorded an adjustment related to the finalization of the working capital, which reduced the consideration transferred and the acquisition date fair value of goodwill by $3.7 million.
Purchase Price
The total purchase price as of the date of the acquisition consisted of the following (in thousands):
As of November 15, 2023
Cash$238,279 
Fair value of contingent consideration65,931 
Fair value of previously held investment10,235 
Total purchase price$314,445 
11
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
Contingent Consideration
The LimFlow stockholders can achieve up to $165.0 million of additional contingent consideration if certain commercial and reimbursement milestones are achieved, as outlined under the Contingent Payments section of the share purchase agreement with LimFlow. Such payments include (i) up to $140.0 million based on net revenue generated from the sale of the LimFlow System for the years 2024 through 2026 and (ii) up to $25.0 million based on the achievement of certain reimbursement milestones related to the LimFlow System.
The acquisition-date fair value of the contingent consideration was measured using a Monte Carlo simulation which represents Level 3 measurements because they are supported by little or no market activity and reflect the Company’s assumptions in measuring fair value. Estimates and assumptions used in the fair value assessment included forecasted revenues for LimFlow, revenue risk premium, revenue volatility, operational leverage ratio, counterparty credit spread, and weighted average cost of capital. The Company has determined that the range of the potential payments on such contingencies is $65.9 million to $165.0 million. The fair value of the contingent consideration was $65.9 million as of the acquisition date. See Note 4. Fair Value Measurements for additional information.
Previously Held Investment
Prior to the acquisition, the Company held an investment in LimFlow, which represented approximately 3.7% of LimFlow's outstanding equity, and was recorded at cost minus impairment. Authoritative guidance on accounting for business combinations requires that an acquirer remeasure its previously held equity investment in the acquiree at its acquisition-date fair value and recognize the resulting gain or loss in earnings. In connection with acquiring the remaining 96.3% equity interest of LimFlow, the Company remeasured its previously held equity investment to its fair value, as of the date of acquisition, based on the fair value of total consideration transferred. Estimates and assumptions used in the remeasurement represent a Level 3 measurement because they are supported by little or no market activity and reflect the Company’s assumptions in measuring the fair value. As a result of the remeasurement, the Company valued its previously held equity investment in LimFlow at $10.2 million and recognized a gain of $3.5 million, included in other income (expense) in the consolidated statements of operations and comprehensive income (loss) during the year ended December 31, 2023.
Transaction Costs
The transaction costs associated with the acquisition of LimFlow consisted primarily of legal and financial advisory fees of approximately $8.7 million in addition to $1.7 million of severance and integration related costs, which were expensed as incurred as SG&A expense during the year ended December 31, 2023.
12
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
Net Assets Acquired and Liabilities Assumed
The purchase price allocation for the LimFlow acquisition was finalized as of September 30, 2024, and there were no measurement period adjustments recorded. The final allocation of fair value of assets acquired and liabilities assumed were (in thousands):
As of November 15, 2023
Cash and cash equivalents$1,582 
Accounts receivable919 
Inventories2,635 
Property and equipment266 
Goodwill204,078 
Intangible asset146,000 
Other current and noncurrent assets2,155 
Accounts payable(2,509)
Deferred tax liability(36,500)
Other current and noncurrent liabilities(4,181)
Total net assets acquired$314,445 
The fair value assigned to the intangible asset acquired was as follows (in thousands, except for estimated useful life which is in years):
Fair value
Useful life
Developed technology$146,000 15 years
The fair value assigned to identifiable intangible asset, the developed technology, acquired as part of the LimFlow acquisition, was estimated using the multi-period excess earnings method. Under this method, an intangible asset’s fair value is equal to the present value of future economic benefits to be derived from ownership of the asset. The estimated fair value was developed by discounting future net cash flows to their present value at market-based rates of return. Such assumptions included forecasted revenues, cost of sales and operating expenses, technology obsolescence, and weighted average cost of capital. The useful life of the developed technology for amortization purposes was determined by considering the period of expected cash flows used to measure the fair values of the intangible asset adjusted as appropriate for entity-specific factors including competitive, economic and other factors that may limit the useful life. The developed technology asset will be amortized on a straight-line basis over its estimated useful life.
Unaudited Pro Forma Financial Information
The following unaudited pro forma financial information summarizes the combined results of operations of the Company and LimFlow as if the companies had been combined as of the beginning of fiscal year 2023 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
20232023
Revenue$126,757 $362,848 
Net loss
$(6,245)$(28,452)
13
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
The unaudited pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved had the acquisition been completed at the beginning of the fiscal year ended December 31, 2023. In addition, the unaudited pro forma financial information is not a projection of future results of operations of the combined company nor does it reflect the expected realization of any synergies or cost savings associated with the acquisition. The unaudited pro forma financial information includes adjustments to reflect the elimination of intercompany transactions, incremental amortization of the identifiable intangible asset and elimination of the remeasurement the Company’s previously held investment in LimFlow.
4. FAIR VALUE MEASUREMENTS
Investments in debt securities have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. As of September 30, 2024, all of the Company's investments in debt securities had maturities of less than 12 months and were classified as short-term investments on the condensed consolidated balance sheets.
The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024
Level 1Level 2Level 3Aggregate Fair Value
Financial Assets
Cash and cash equivalents:
Money market mutual funds$7,288 $— $— $7,288 
Total included in cash and cash equivalents7,288 — — 7,288 
Investments:
U.S. treasury securities
70,397 — — 70,397 
Total included in short-term investments70,397 — — 70,397 
Total financial assets
$77,685 $— $— $77,685 
Financial Liability
Contingent consideration$— $— $84,540 $84,540 
Total financial liabilities$— $— $84,540 $84,540 
14
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
December 31, 2023
Level 1Level 2Level 3Aggregate Fair Value
Financial Assets
Cash and cash equivalents:
Money market mutual funds$2,753 $— $— $2,753 
Total included in cash and cash equivalents2,753 — — 2,753 
Investments:
U.S. treasury securities
41,685 — — 41,685 
U.S. government agencies
— 26,238 — 26,238 
Corporate debt securities and commercial paper— 8,932 — 8,932 
Total included in short-term investments41,685 35,170 — 76,855 
Total financial assets
$44,438 $35,170 $— $79,608 
Financial Liability
Contingent consideration$— $— $65,931 $65,931 
Total financial liabilities$— $— $65,931 $65,931 
There were no transfers between Levels 1, 2 or 3 for the periods presented.
Contingent payments are related to the acquisition of LimFlow and consist of commercial and reimbursement milestones, which were valued using a Monte Carlo simulation and probability weighted discounted cash flow analysis, respectively, and represent Level 3 measurements because they are based upon significant unobservable inputs such as forecasted revenues of LimFlow, revenue risk premium, revenue volatility, operational leverage ratio, credit risk, weighted average cost of capital, and probability assumptions in achieving certain milestones.
The following table summarizes the changes in the estimated fair value of the Company’s contingent consideration liabilities (in thousands):
Contingent Consideration Fair Value
Balance as of December 31, 2023
$65,931 
Change in estimated fair value
18,609 
Balance as of September 30, 2024
$84,540 
The fair value of the contingent consideration was $84.5 million as of September 30, 2024, of which $39.2 million was recorded within accrued expenses and other current liabilities and $45.3 million was recorded within other long-term liabilities, and $65.9 million as of December 31, 2023, which was recorded within other long-term liabilities. The change in estimated fair value of contingent consideration was recorded in operating expenses within the condensed consolidated statements of operations and comprehensive income (loss).
15
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
5. CASH EQUIVALENTS AND INVESTMENTS
The following is a summary of the Company’s cash equivalents and investments in debt securities as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024
Amortized Cost BasisUnrealized GainUnrealized LossFair Value
Financial Assets
Cash and cash equivalents:
Money market mutual funds$7,288 $— $— $7,288 
Total included in cash and cash equivalents7,288 — — 7,288 
Investments:
U.S. treasury securities
70,346 51 — 70,397 
Total included in short-term investments70,346 51 — 70,397 
Total financial assets
$77,634 $51 $— $77,685 
December 31, 2023
Amortized Cost BasisUnrealized GainUnrealized LossFair Value
Financial Assets
Cash and cash equivalents:
Money market mutual funds$2,753 $— $— $2,753 
Total included in cash and cash equivalents2,753 — — 2,753 
Investments:
U.S. treasury securities
41,672 13 — 41,685 
U.S. government agencies
26,248 — (10)26,238 
Corporate debt securities and commercial paper8,935 — (3)8,932 
Total included in short-term investments76,855 13 (13)76,855 
Total financial assets
$79,608 $13 $(13)$79,608 
The Company regularly reviews any changes to the rating of its debt securities and reasonably monitors the surrounding economic conditions to assess the risk of expected credit losses. As of September 30, 2024, the risk of expected credit losses was not significant.
6. INVENTORIES, NET
Inventories, net of reserves, consist of the following (in thousands):
September 30,
2024		December 31,
2023
Raw materials$21,983 $14,310 
Work-in-process6,179 5,330 
Finished goods27,048 23,260 
Total inventories, net
$55,210 $42,900 
16
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
7. PROPERTY AND EQUIPMENT, NET
Property and equipment consist of the following (in thousands):
September 30,
2024		December 31,
2023
Manufacturing equipment$18,527 $16,653 
Computer hardware6,671 5,641 
Assets in progress5,902 3,135 
Furniture and fixtures4,584 4,491 
Leasehold improvements4,531 4,682 
Total property and equipment, gross40,215 34,602 
Accumulated depreciation(16,117)(13,673)
Total property and equipment, net$24,098 $20,929 
Depreciation expense of $1.1 million was included in operating expenses and $0.3 million was included in cost of goods sold for the three months ended September 30, 2024 and 2023, respectively. Depreciation expense of $3.4 million was included in operating expenses for the nine months ended September 30, 2024 and 2023, and $1.0 million and $0.8 million was included in cost of goods sold for the nine months ended September 30, 2024 and 2023, respectively.
8. GOODWILL AND INTANGIBLE ASSETS
Goodwill
The changes in carrying amount of goodwill for the nine months ended September 30, 2024 were as follows (in thousands):
Balance as of December 31, 2023
$214,335 
Working capital adjustment
(3,722)
Foreign currency translation adjustments2,732 
Balance as of September 30, 2024
$213,345 
The working capital adjustment relates to the acquisition of LimFlow. See Note 3. Business Combination for additional information.
17
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
Intangible Assets
The intangible assets consist of the following (in thousands):
September 30, 2024
Gross Carrying AmountAccumulated AmortizationIntangible Assets, Net
Developed technology
$152,716 $(8,908)$143,808 
Total intangible assets, net
$152,716 $(8,908)$143,808 
December 31, 2023
Gross Carrying AmountAccumulated AmortizationIntangible Assets, Net
Developed technology
$150,649 $(1,256)$149,393 
Capitalized software(a)
1,491 — 1,491 
Total intangible assets, net
$152,140 $(1,256)$150,884 
_____________
(a) The useful life of the capitalized software was not determined as of December 31, 2023 as the asset was not put into service. No amortization expense has been recorded related to the capitalized software during the three and nine months ended September 30, 2023.
The gross carrying amount and the accumulated amortization of the developed technology asset is subject to foreign currency translation effects. During the three and nine months ended September 30, 2024, $2.5 million and $7.4 million, respectively, of amortization expense was recorded in operating expenses within the condensed consolidated statements of operations and comprehensive income (loss) related to the developed technology asset. There were no intangible assets and no amortization recorded for the three and nine months ended September 30, 2023.
During the three months ended September 30, 2024, the Company recorded a non-cash impairment of $3.8 million related to previously capitalized software development costs that reduced the carrying value of such asset to zero. The impairment charge was recorded in research and development expenses within the condensed consolidated statements of operations and comprehensive income (loss).
The estimated future annual amortization of the intangible assets in service is as follows (in thousands):
Year ending December 31:Amount
Remainder of 2024$2,545 
202510,181 
202610,181 
202710,181 
202810,181 
Thereafter100,539 
Total$143,808 
9. COMMITMENTS AND CONTINGENCIES
Operating Leases
The Company has operating leases for facilities and certain equipment. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. Lease expense for operating leases is recognized on a straight-line basis over the lease term. For lease agreements, other than long-term real estate leases, the Company combines lease and non-lease components. The variable lease payments primarily relate to common area maintenance, property taxes, and insurance. The operating leases for facilities expire at various dates through July 2041 and some contain renewal options, the longest of which is for five years. The ROU asset and lease liability includes renewal options if the Company is reasonably certain to exercise such renewal options.
18
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest rate the Company would incur to borrow on a collateralized basis, considering factors such as length of lease term.
The following table presents the weighted average remaining lease term and discount rate:
September 30,
20242023
Weighted average remaining term (in years)
16.118.2
Weighted average discount rate6.1 %6.1 %
Cash paid for amounts included in the measurement of operating leases were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Cash paid for amounts included in the measurement of operating lease liabilities$1,048 $866 $2,877 $2,564 
Total lease costs are as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Operating lease cost$1,385 $1,137 $3,929 $3,456 
Short-term lease cost48 22 141 85 
Variable lease cost184 402 746 809 
Total lease costs$1,617 $1,561 $4,816 $4,350 
Future minimum lease payments under operating leases liabilities as of September 30, 2024 are as follows (in thousands):
Year ending December 31:
Amount
Remainder of 2024$858 
20253,373 
20263,512 
20273,594 
20283,396 
Thereafter35,771 
Total lease payments50,504 
Less imputed interest(17,780)
Total lease liabilities32,724 
Less: lease liabilities - current portion(1,579)
Lease liabilities - noncurrent portion$31,145 
19
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
The Company signed a ten-year lease in Costa Rica for its second manufacturing facility in October 2023, with total undiscounted contractual payments of the lease of approximately $7.2 million, which is expected to commence in the fourth quarter of 2024.
Indemnification
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not been subject to any claims or required to defend any action related to its indemnification obligations.
The Company’s amended and restated certificate of incorporation contains provisions limiting the liability of directors, and its amended and restated bylaws provide that the Company will indemnify each of its directors to the fullest extent permitted under Delaware law. The Company’s amended and restated certificate of incorporation and amended and restated bylaws also provide its board of directors with discretion to indemnify its officers and employees when determined appropriate by the board. In addition, the Company has entered and expects to continue to enter into agreements to indemnify its directors and executive officers.
Legal Proceedings
From time to time, the Company is involved in various claims and proceedings arising in the ordinary course of its business. Management does not believe that any existing claims and proceedings, including potential losses relating to such contingencies, will have a material adverse effect on its consolidated financial position, results of operations or cash flows.
Civil Investigative Demand
As previously disclosed, in December 2023, the Company received a civil investigative demand (“CID”) from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act (the “Investigation”). The CID requests information and documents primarily relating to meals and consulting service payments provided to health care professionals. The Company is cooperating with the Investigation. The Company is unable to express a view at this time regarding the likely duration, or ultimate outcome, of the Investigation or estimate the possibility of, or amount or range of, any possible financial impact. Depending on the outcome of the Investigation, there may be a material impact on the Company’s business, results of operations, or financial condition.
20
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
Patent and Trade Secret Litigation
As previously disclosed, on May 22, 2024, the Company filed a patent infringement lawsuit against Imperative Care, Inc. (“Imperative Care”) and Truvic Medical, Inc. (“Truvic”) in the United States District Court for the Northern District of California, alleging that Imperative Care's Symphony Thrombectomy System infringes eight patents related to mechanical thrombectomy devices used for treating pulmonary emboli and deep vein thrombosis. On July 9, 2024, the Company filed an amended complaint to allege infringement of an additional, ninth patent, and to drop Truvic as a named defendant because Imperative Care confirmed that Truvic has been merged into Imperative Care. In the complaint, the Company seeks injunctive relief and damages for the alleged infringement. On July 24, 2024, the Company filed a motion for a preliminary injunction seeking to enjoin Imperative Care's sale or use, among other activities, of the Symphony Thrombectomy System outside of clinical trials. The court has indicated that it is likely to hear the preliminary injunction motion in December 2024. It has not otherwise set a case schedule.
On September 11, 2024, the Company filed a lawsuit against Inquis Medical, Inc. (“Inquis”) in the United States District Court for the District of Delaware. The Company’s complaint alleges that Inquis misappropriated the Company’s trade secrets in relation to Inquis’ engagement of the services of an Inari employee, and that Inquis’ Aventus Thrombectomy System and Aventus Clot Management System infringe four Inari patents related to mechanical thrombectomy devices used for treating pulmonary emboli and deep vein thrombosis. Inquis’ response to the Company’s complaint is due November 4, 2024. The court has not otherwise set a case schedule.
Securities Class Action
As previously disclosed, on May 13, 2024, purported stockholder Michiana Area Electrical Workers’ Pension Fund filed a verified class action complaint on behalf of itself and similarly situated Inari stockholders in the United States District Court for the Southern District of New York, captioned Michiana Area Elec. Workers’ Pension Fund v. Inari Medical, Inc., No. 1:24-cv-03686-JHR (the “MAEW Action”). On June 18, 2024, purported stockholder Paul Hartmann filed a verified class action complaint on behalf of himself and similarly situated Inari stockholders in the United States District Court for the Southern District of New York, captioned Hartmann v. Inari Medical, Inc., No. 1:24-cv-04662-JHR (the “Hartmann Action” and together with the MAEW Action, the “Related Actions”). Each of the Related Actions alleges the Company and certain of its officer and directors violated Sections 10(b) and 20(a) of the Securities Exchange Act by making false or misleading statements regarding the Company’s revenue and expenses.
As previously disclosed, on July 12, 2024, a group of pension funds consisting of Oklahoma Law Enforcement Retirement Systems, Local 353, I.B.E.W. Pension Fund, and City of Pontiac Reestablished General Employees’ Retirement System, Mr. Hartmann, and purported stockholder Arvin Nazerzadeh-Yazdi, each filed motions seeking to consolidate the Related Actions, be appointed lead plaintiff, and have their counsel appointed lead counsel. The matter is at a preliminary stage and the Company is not able to quantify the extent of any potential liability.
The Company believes that these complaints are without merit and intends to defend against them vigorously.
10. CONCENTRATIONS
The Company’s revenue is derived primarily from the sale of catheter-based therapeutic devices in the United States. For the three and nine months ended September 30, 2024 and 2023, there were no customers which accounted for more than 10% of the Company’s revenue. As of September 30, 2024 and December 31, 2023, there were no customers that accounted for more than 10% of the Company’s accounts receivable.
No vendor accounted for more than 10% of the Company’s purchases for the three and nine months ended September 30, 2024 and 2023. There were no vendors that accounted for more than 10% of the Company’s accounts payable as of September 30, 2024 and December 31, 2023.
21
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
11. RELATED PARTY
The Company utilizes MRI The Hoffman Group (“MRI”), a recruiting services company owned by the brother of the former Chief Executive Officer and President and current member of the board of directors of the Company. The Company paid for recruiting services provided by MRI amounting to nil and $67,000 for the three months ended September 30, 2024 and 2023, respectively, and $31,000 and $147,000 for the nine months ended September 30, 2024 and 2023, respectively, which was recorded in SG&A expenses within the condensed consolidated statements of operations and comprehensive income (loss). As of September 30, 2024 and December 31, 2023, there was no balance payable to MRI.
12. CREDIT FACILITY
Bank of America Credit Facility
On December 16, 2022, the Company amended its senior secured revolving credit facility with Bank of America (the “Previously Amended Credit Agreement”) under which the Company may borrow loans up to a maximum principal amount of $40.0 million and increase the optional accordion to $120.0 million.
Advances under the Previously Amended Credit Agreement will bear interest at a base rate per annum (“the Base Rate”) plus an applicable margin (the “Margin”). The Base Rate equals the greater of (i) the Prime Rate, (ii) the Federal funds rate plus 0.50%, or (iii) the Bloomberg Short-Term Bank Yield Index (“the BSBY”) rate based upon an interest period of one month plus 1.00%, in any case has a floor of 0%. The Margin ranges, depending on average daily availability, from 0.50% to 1.00% in the case of Prime Rate and the Federal funds rate loans, and 1.50% to 2.00% in the case of BSBY Rate loans. As a condition to entering into the Previously Amended Credit Agreement, the Company was obligated to pay a nonrefundable fee of $10,000. The Company is also required to pay an unused line fee at an annual rate of 0.25% per annum of the average daily unused portion of the aggregate revolving credit commitments under the Previously Amended Credit Agreement.
The Previously Amended Credit Agreement also includes a Letter of Credit subline facility (the “LC Facility”) of up to $5.0 million. In February 2023, the Company amended the LC Facility to increase the limit to up to $10.0 million. The Company is required to pay the following fees under the LC Facility: (a) a fee equal to the applicable margin in effect for BSBY loans (currently 2.25%) times the average daily stated amount of outstanding letters of credit; and (b) a fronting fee equal to 0.125% per annum on the stated amount of each letter of credit outstanding.
On November 1, 2023, the Company further amended its credit facility (the “Amended Credit Agreement”) to, among other things, increase the amount available for borrowing up to a maximum principal amount of $75.0 million. Additionally, advances under the Amended Credit Agreement will bear interest at the Base Rate or the BSBY rate, plus the Margin. The Margin ranges from 0.60% to 1.10% in the case of the Base Rate loans and 1.60% to 2.10% in the case of the BSBY rate loans depending on average daily availability, in each case with a floor of 0%. As a condition of entering into the Amended Credit Agreement, the Company was obligated to pay a nonrefundable fee of $88,000. Lastly, the Company amended the LC Facility to increase the limit up to $18.8 million. This amendment was accounted for as a debt modification in accordance ASC 470, Debt.
The Amended Credit Agreement contains certain customary covenants subject to certain exceptions, including, among others, the following: a fixed charge coverage ratio covenant, and limitations of indebtedness, liens, investments, asset sales, mergers, consolidations, liquidations, dispositions, restricted payments, transactions with affiliates and prepayments of certain debt. The Amended Credit Agreement also contains certain events of default subject to certain customary grace periods, including, among others, payment defaults, breaches of any representation, warranty or covenants, judgment defaults, cross defaults to certain other contracts, bankruptcy and insolvency defaults, material judgment defaults and a change of control default.
As of September 30, 2024, the amount available to borrow under the Amended Credit Agreement is approximately $67.9 million, and the Company had four letters of credit in the aggregated amount of $2.4 million outstanding under the LC Facility. The aggregate stated amount outstanding of the letter of credits reduces the total borrowing base available under the Amended Credit Agreement and is subject to certain fees.
22
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
As of September 30, 2024, there was no principal amount outstanding, and no cash was pledged under the Amended Credit Agreement, and the Company was in compliance with its covenant requirements. Obligations under the Amended Credit Agreement are secured by substantially all of the Company’s assets, excluding intellectual property. The Amended Credit Agreement matures on December 16, 2027.
Deferred Financing Costs
Costs incurred directly related to debt are presented in other assets and are being amortized over the five-year life of the Credit Agreement on the straight-line basis. The unamortized deferred financings costs as of September 30, 2024 and December 31, 2023 are as follows (in thousands):
September 30, 2024December 31, 2023
Deferred financing costs
$729 $1,454 
Accumulated amortization
(447)(382)
Unamortized deferred financing costs
$282 $1,072 
13. STOCKHOLDERS’ EQUITY
Accumulated Other Comprehensive Income (Loss)
The following is a summary of the changes in accumulated balances of other comprehensive income (loss) for the nine months ended September 30, 2024 and 2023 (in thousands):
Unrealized Gain (Loss) on InvestmentsForeign Currency Translation
Accumulated Other Comprehensive Income (Loss)
Balance, December 31, 2023$(9)$8,894 $8,885 
Other comprehensive loss
(4)(7,359)(7,363)
Balance, March 31, 2024
(13)1,535 1,522 
Other comprehensive loss
— (2,359)(2,359)
Balance, June 30, 2024
(13)(824)(837)
Other comprehensive income64 13,918 13,982 
Balance, September 30, 2024
$51 $13,094 $13,145 
Unrealized Gain (Loss) on InvestmentsForeign Currency Translation
Accumulated Other Comprehensive Income (Loss)
Balance, December 31, 2022$1,820 $(971)$849 
Other comprehensive loss
(865)9 (856)
Balance, March 31, 2023
955 (962)(7)
Other comprehensive loss
(1,095)(79)(1,174)
Balance, June 30, 2023
(140)(1,041)(1,181)
Other comprehensive income (loss)91 (68)23 
Balance, September 30, 2023
$(49)$(1,109)$(1,158)
23
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
14. EQUITY INCENTIVE PLANS
In 2011, the Company adopted the 2011 Equity Incentive Plan (the “2011 Plan”) to permit the grant of share-based awards, such as stock grants and incentives and non-qualified stock options to employees and directors. The Board has the authority to determine to whom awards will be granted, the number of shares, the term and the exercise price.
In March 2020, the Company adopted the 2020 Incentive Award Plan (the “2020 Plan”), which became effective in connection with the Company’s initial public offering in May 2020. As a result, the Company may not grant any additional awards under the 2011 Plan. The 2011 Plan will continue to govern outstanding equity awards granted thereunder. In addition, the number of shares of common stock reserved for issuance under the 2020 Plan will automatically increase on the first day of January for a period of up to ten years, commencing on January 1, 2021, in an amount equal to 3% of the total number of shares of the Company’s capital stock outstanding on the last day of the preceding year, or a lesser number of shares determined by the Company’s board of directors. As of September 30, 2024, there were 7,183,239 shares available for issuance under the 2020 Plan, including 1,732,872 additional shares reserved effective January 1, 2024.
2011 Equity Incentive Plan
Stock Options
A summary of stock option activity under the 2011 Plan for the nine months ended September 30, 2024 is as follows (intrinsic values in thousands):
Number of
Options
Weighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (in years)		Intrinsic
Value
Outstanding, December 31, 2023937,696$2.24 5.2$58,778 
Exercised(170,540)2.02 $8,211 
Cancelled(29)9.05 
Outstanding, September 30, 2024767,1272.28 4.5$29,884 
Vested and exercisable at September 30, 2024767,1272.28 4.5$29,884 
Vested and expected to vest at September 30, 2024767,127$2.28 4.5$29,884 
The aggregate intrinsic values of options outstanding, vested and exercisable, and vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair market value of the Company’s common stock.
2020 Incentive Award Plan
Restricted Stock Units
Restricted stock units (“RSUs”) are share awards that entitle the holder to receive freely tradable shares of the Company’s common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest over a four-year period with straight-line vesting and a 25% one-year cliff or over a three-year period in equal amounts on a quarterly basis, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of the Company’s common stock on the grant date.
24
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
RSU activity under the 2020 Plan is set forth below:
Number of
Awards 		Weighted
Average
Fair Value
Outstanding, December 31, 20231,307,998$67.91 
Granted1,006,24446.95 
Vested(456,160)67.69 
Cancelled(104,090)61.87 
Outstanding, September 30, 20241,753,992$56.30 
The total fair value of RSUs vested under the 2020 Plan was $7.7 million and $6.9 million for the three months ended September 30, 2024 and 2023, respectively, and $23.9 million and $21.0 million for the nine months ended September 30, 2024 and 2023, respectively.
Performance Stock Units
During the nine months ended September 30, 2024, the Company granted performance stock units (“PSUs”) to certain employees that are eligible to vest three years from the award date, based on achieving certain revenue based performance targets. The number of shares that may be earned can range from 0% to 200% of the target amount. The fair value of PSUs is determined by the closing stock price of the Company’s common stock on the awards’ grant date. The share-based compensation expense associated with PSUs is recognized on a straight-line basis based on the estimated number of awards that are expected to vest. At each reporting period, the Company monitors the probability of achieving the performance targets and adjusts the share-based compensation expense associated with PSUs accordingly.
PSU activity under the 2020 Plan is set forth below:
Number of
Awards		Weighted
Average
Fair Value
Outstanding, December 31, 2023— $— 
Granted90,48855.48 
Outstanding, September 30, 202490,488$55.48 
Stock Options
The Company grants non-qualified stock options to certain employees with vesting over a four-year period on a quarterly basis. The fair value of the stock options was calculated using the Black-Scholes option pricing model. The fair value for options granted was calculated using the following weighted average assumptions:
Nine Months Ended September 30,
20242023
Expected term (in years)4.54.6
Expected volatility
48.7% to 48.9%
50.4%
Dividend yield0.0%0.0%
Risk free interest rate
4.2% to 4.3%
4.1%
Weighted-average fair value of options granted$24.89 per share$25.98 per share
25
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
A summary of stock option activities under the 2020 Plan for the nine months ended September 30, 2024 is as follows (intrinsic values in thousands):
Number of
Options
Weighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (in years)		Intrinsic
Value
Outstanding, December 31, 2023166,203 $56.00 6.1$1,483 
Granted210,18854.83 
Exercised(270)56.00 $— 
Cancelled(7,157)56.00 
Outstanding, September 30, 2024368,96455.33 5.9$— 
Vested and exercisable at September 30, 202486,548 55.65 5.6$— 
Vested and expected to vest at September 30, 2024343,736$55.35 5.9$— 
Employee Stock Purchase Plan
In May 2020, the Company adopted the 2020 Employee Stock Purchase Plan (“ESPP”), which became effective on the date the ESPP was adopted by the Company’s board of directors. Each offering to the employees to purchase stock under the ESPP will begin on each August 1 and February 1 and will end on the following January 31 and July 31, respectively. The first offering period began on August 1, 2020. On each purchase date, which falls on the last date of each offering period, ESPP participants will purchase shares of common stock at a price per share equal to 85% of the lesser of (1) the fair market value per share of the common stock on the offering date or (2) the fair market value of the common stock on the purchase date. The occurrence and duration of offering periods under the ESPP are subject to the determinations of the Compensation Committee, in its sole discretion. The number of shares available for issuance under the ESPP increases automatically on January 1 of each calendar year of the Company beginning in 2021 and ending in 2030, in an amount equal to the lesser of (i) 1% of the aggregate number of outstanding shares of the Company’s common stock on the final day of the immediately preceding calendar year and (ii) such smaller number of shares determined by the Company’s board of directors.
The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model with the following assumptions:
Nine Months Ended September 30,
20242023
Expected term (in years)0.50.5
Expected volatility
57.0% - 60.8%
42.1% - 49.9%
Dividend yield0.0%0.0%
Risk free interest rate
5.1% - 5.2%
4.8% - 5.5%
As of September 30, 2024, a total of (i) 639,355 shares of common stock, including 133,430 shares purchased in July 2024 and 82,816 shares purchased in January 2024, have been purchased under the ESPP, and (ii) 2,465,007 shares of common stock are reserved under the ESPP for future purchases, including 577,624 additional shares, which were automatically added to the reserve on January 1, 2024 pursuant to the terms of the ESPP.
26
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
Share-based Compensation Expense
Total compensation cost for all share-based payment arrangements recognized, including $1.2 million and $0.7 million for the three months ended September 30, 2024 and 2023, respectively, and $3.5 million and $2.9 million for the nine months ended September 30, 2024 and 2023, respectively, of share-based compensation expense related to the ESPP, was as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Cost of goods sold$537 $393 $1,570 $1,232 
Research and development1,779 1,587 5,347 4,981 
Selling, general and administrative10,635 7,864 31,943 24,323 
Total share-based compensation expense
$12,951 $9,844 $38,860 $30,536 
Total compensation costs as of September 30, 2024 related to all non-vested awards to be recognized in future periods was $87.4 million and is expected to be recognized over the remaining weighted average period of 2.6 years.
15. INCOME TAXES
The following table reflects the Company’s provision for income taxes for the periods indicated (in thousands, except for percentages):
Three Months Ended September 30, Nine Months Ended September 30,
2024202320242023
(Loss) income before income taxes
$(12,672)$5,590$(50,181)$7,420
Provision for income taxes5,6952,42823,7364,391
Net (loss) income
$(18,367)$3,162$(73,917)$3,029
Provision for income taxes as a percentage of (loss) income before income taxes
(44.9%)43.4%(47.3%)59.2 %
The effective tax rate for all periods is driven by pre-tax income/(loss), business credits, equity compensation, state taxes, and the change in valuation allowance. The Company's income tax provision for interim reporting periods historically has been calculated by applying an estimate of the annual effective income tax rate for the full year to “ordinary” income (loss) for the interim reporting period. In addition, the tax effects of certain significant or unusual items are recognized discretely in the quarter in which they occur. For the nine months ended September 30, 2024 and September 30, 2023, the Company calculated the income tax provision using this methodology.
Beginning in 2024, many countries are implementing some or all of the Organization for Economic Co-operation and Development’s Base Erosion and Profit Shifting Two-Pillar in response to tax challenges arising from the digitalization of the global economy. While we continue to evaluate those countries’ implementations, we do not expect those implementations to have a material impact on our consolidated financial statements in 2024.
27
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
Valuation Allowance
ASC 740, Income Taxes requires that the tax benefit of net operating losses, or (“NOLs”), temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not”. Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryback or carryforward periods. As of December 31, 2023, the Company was in a net deferred tax liability position due to the LimFlow acquisition. However, a valuation allowance was maintained against certain deferred tax assets. As of September 30, 2024, the Company believes that the net deferred tax assets are currently not considered more likely than not to be realized and, accordingly, maintains a valuation allowance against certain deferred tax assets. The Company will continue to assess its position on the realizability of its deferred tax assets, until such time as sufficient positive evidence may become available to allow the Company to reach a conclusion that a significant portion of the valuation allowance will no longer be needed. Given the Company’s current earnings and anticipated future earnings, the Company believes that there is a reasonable possibility that sufficient positive evidence may become available in the near term to allow the Company to reach a conclusion that a significant portion of the valuation allowance is no longer needed. Any release of the valuation allowance will result in a material benefit recognized in the quarter of release.
Uncertain Tax Positions
The Company has recorded uncertain tax positions related to its federal and California research and development credit carryforwards. No interest or penalties have been recorded related to the uncertain tax positions due to credit carryforwards that are available to offset the uncertain tax positions. It is not expected that there will be a significant change in the uncertain tax position in the next 12 months. The Company is subject to U.S. federal and state income tax as well as to income tax in various foreign jurisdictions. In the normal course of business, the Company is subject to examination by tax authorities. As of the date of the financial statements, there are no income tax examinations in progress. The statute of limitations for tax years ended after December 31, 2020, December 31, 2019, and December 31, 2020 are open for federal, state, and foreign tax purposes, respectively.
16. RETIREMENT PLAN
In December 2017, the Company adopted the Inari Medical, Inc. 401(k) Plan which allows eligible employees after one month of service to contribute pre-tax and Roth contributions to the plan, as allowed by law. The plan assets are held by Vanguard and the plan administrator is Ascensus Trust Company. Beginning in January 2021, the Company contributed a $1.00 match for every $1.00 contributed by a participating employee up to the greater of $3,000 or 4% of eligible compensation under the plan, with such Company's contributions becoming fully vested immediately. On January 1, 2024, the plan was amended to provide that the Company contributes a $1.00 match for every $1.00 contributed by a participating employee for up to 5% of eligible compensation. The plan also includes a limit of $15,000 per individual of employer match, with such Company’s contributions becoming fully vested immediately. Matching contribution expense was $3.1 million and $2.0 million for the three months ended September 30, 2024 and 2023, respectively, and $10.6 million and $6.9 million for the nine months ended September 30, 2024 and 2023, respectively.
17. NET INCOME (LOSS) PER SHARE
Basic net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net income (loss) per share is computed using the treasury stock method by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net income (loss) per share calculation, shares from common stock options and equity awards are potentially dilutive securities. For the periods the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.
28
INARI MEDICAL, INC.
Notes to Unaudited Condensed Consolidated Financial Statements
The components of net (loss) income per share are as follows (in thousands, except share and per share amounts):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Numerator:
Net (loss) income$(18,367)$3,162 $(73,917)$3,029 
Denominator:
Weighted average number of common shares outstanding - basic58,366,36457,384,88458,149,29656,478,317
Common stock equivalents from outstanding equity grants
—1,102,642—1,173,190
Common stock equivalents from unvested RSUs and PSUs—94,531—832,873
Common stock equivalents from ESPP—6,395—11,541
Weighted average number of common shares outstanding - diluted58,366,36458,588,45258,149,29658,495,921
Net (loss) income per share:
Basic$(0.31)$0.06 $(1.27)$0.05 
Diluted$(0.31)$0.05 $(1.27)$0.05 
The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Stock options
1,136,091171,5261,136,0911,290,179
Equity awards
1,844,480555,4681,844,4801,332,500
Total potentially dilutive common stock equivalents excluded from calculation due to anti-dilutive effect
2,980,571726,9942,980,5712,622,679
29
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and related notes thereto for the year ended December 31, 2023, included in our Annual Report on Form 10-K for the year ended December 31, 2023. In addition to historical financial information, the following discussion contains forward-looking statements that are based upon current plans, expectations and beliefs that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023. Please also see the section titled “Cautionary Note Regarding Forward-Looking Statements” herein.
OVERVIEW
Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism (“VTE”), and four other disease states. We are just getting started.
We purpose build a variety of medical products, including minimally invasive, novel, catheter-based mechanical thrombectomy devices and their accessories to address the unique characteristics of specific disease states. In addition, in November 2023, we acquired LimFlow, a medical device company focused on limb salvage for patients with chronic limb-threatening ischemia (“CLTI”). CLTI is an advanced stage of peripheral artery disease that is associated with increased mortality, risk of amputation and impaired quality of life. The LimFlow system utilizes transcatheter arterialization of deep veins to bypass blocked arteries in the leg and deliver oxygenated blood back into the foot via the veins in CLTI patients. The results of operations of LimFlow have been included in our condensed consolidated financial statements from the date of the acquisition.
We launched VenaCore in June 2024, which is a multi-purpose device for the treatment of acute and chronic deep vein thrombosis (“DVT”). Together, our devices and systems provide solutions to address the following disease states: DVT, pulmonary embolism, chronic venous disease, CLTI, acute limb ischemia and dialysis access management.
We believe our mission-focused and highly-trained commercial organization provides a significant competitive advantage. Our most important relationships are between our sales representatives and our treating physicians, which include interventional cardiologists, interventional radiologists and vascular surgeons. We recruit sales representatives who have substantial and applicable medical device and/or sales experience. Our front-line sales representatives typically attend procedures, which puts us at the intersection of the patients and physicians. We have developed systems and processes to harness the information gained from these relationships and we leverage this information to rapidly iterate our solutions, introduce and execute physician education and training programs and scale our sales organization. We market and sell our solutions to hospitals, which are reimbursed by various third-party payors.
As of September 30, 2024, we had cash, cash equivalents, restricted cash and short-term investments of $111.6 million, no long-term debt outstanding and an accumulated deficit of $122.4 million.
For the three months ended September 30, 2024, we generated $153.4 million in revenues with a gross margin of 87.1% and net loss of $18.4 million, as compared to revenues of $126.4 million with a gross margin of 88.5% and net income of $3.2 million for the three months ended September 30, 2023.
For the nine months ended September 30, 2024, we generated 442.4 million in revenues with a gross margin of 86.7% and net loss of $73.9 million, as compared to revenues of $361.5 million with a gross margin of 88.4% and net income of $3.0 million for the nine months ended September 30, 2023.
30
Revenue
We derived substantially all our revenue from the sale of our VTE and Emerging Therapy products directly to hospitals. Our customers typically purchase our products through an initial stocking order, and then reorder replenishment inventory as procedures are performed. No single customer accounted for 10% or more of our revenue during the three and nine months ended September 30, 2024 and 2023. We expect our revenue to increase in absolute dollars as we expand our offerings, grow the sales organization and sales territories, continue to grow internationally, add customers, expand the base of physicians who gain experience with using our products, expand awareness of our products with new and existing customers and as physicians perform more procedures using our products.
We disaggregate revenue between VTE and Emerging Therapies markets. VTE comprises revenue from the sale of our solutions addressing DVT and pulmonary embolism. Emerging Therapies comprises revenue from the sale of our solutions addressing chronic venous disease, CLTI, acute limb ischemia and dialysis access management. Revenue from VTE and Emerging Therapies were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
VTE
$145,346 $121,460 $420,213 $349,604 
Emerging Therapies
8,044 4,906 22,191 11,934 
Total revenue
$153,390 $126,366 $442,404 $361,538 
31
RESULTS OF OPERATIONS
Comparison of the three months ended September 30, 2024 and 2023
The following table sets forth our results of operations in dollars and as percentage of revenue for the periods presented (dollars in thousands):
Three Months Ended September 30,Change $
2024%2023%
Revenue$153,390 100.0 %$126,366 100.0 %$27,024 
Cost of goods sold19,846 12.9 %14,477 11.5 %5,369 
Gross profit133,544 87.1 %111,889 88.5 %21,655 
Operating expenses
Research and development29,431 19.2 %21,492 17.0 %7,939 
Selling, general and administrative108,271 70.6 %85,603 67.7 %22,668 
Change in fair value of contingent consideration
6,578 4.3 %— — %6,578 
Amortization of intangible asset
2,504 1.6 %— — %2,504 
Acquisition-related expenses
328 0.2 %2,681 2.1 %(2,353)
Total operating expenses147,112 95.9 %109,776 86.9 %37,336 
(Loss) income from operations
(13,568)(8.8)%2,113 1.6 %(15,681)
Other income (expense)
Interest income1,104 0.7 %4,202 3.3 %(3,098)
Interest expense(78)(0.1)%(43)— %(35)
Other expense
(130)(0.1)%(682)(0.5)%552 
Total other income896 0.5 %3,477 2.8 %(2,581)
(Loss) income before income taxes
(12,672)(8.3)%5,590 4.4 %(18,262)
Provision for income taxes5,695 3.7 %2,428 1.9 %3,267 
Net (loss) income
$(18,367)(12.0)%$3,162 2.5 %$(21,529)
Revenue. Revenue increased $27.0 million, or 21.4%, to $153.4 million during the three months ended September 30, 2024, compared to $126.4 million during the three months ended September 30, 2023. The increase in revenue was primarily due to an expansion of our sales territories, opening of new accounts, increase in adoption of our procedures, global commercial expansion, and introduction of new products.
Cost of Goods Sold. Cost of goods sold increased $5.4 million, or 37.1%, to $19.8 million during the three months ended September 30, 2024, compared to $14.5 million during the three months ended September 30, 2023. This increase was primarily due to the increase in the number of products sold and additional manufacturing overhead costs to support anticipated future growth.
Gross Margin. Gross margin for the three months ended September 30, 2024 decreased to 87.1%, compared to 88.5% for the three months ended September 30, 2023, primarily due to product mix, the ramp up costs associated with new products, and increasing internationalization of the business.
Research and Development Expenses (“R&D”). R&D expenses increased $7.9 million, or 36.9%, to $29.4 million during the three months ended September 30, 2024, compared to $21.5 million during the three months ended September 30, 2023. The increase in R&D expenses was primarily due to a $3.8 million of impairment of previously capitalized software development costs, as well as increases of $2.8 million in personnel-related expenses, $0.3 million of clinical and regulatory expenses, and $0.3 million of professional fees.
32
Selling, General and Administrative Expenses (“SG&A”). SG&A expenses increased $22.7 million, or 26.5%, to $108.3 million during the three months ended September 30, 2024, compared to $85.6 million during the three months ended September 30, 2023. The increase in SG&A expenses was primarily due to increases of $14.3 million in personnel-related expenses, including increased commissions due to higher revenue and increased share-based compensation, $5.6 million of expenses related to professional fees, including legal expenses, $2.1 million of travel related costs, and $0.6 million in sales and marketing related expenses.
Other Operating Expenses. Other operating expenses increased by $6.6 million due to the change in fair value adjustment of our contingent consideration liability, and $2.5 million due to amortization expense related to the acquired intangible asset, offset by decrease of 2.4 million of acquisition-related expenses, which include integration, severance and retention costs, during the three months ended September 30, 2024.
Other income (expense). Other income consists primarily of interest income, interest expense, foreign currency transaction and strategic investment gains and losses. Interest income decreased by $3.1 million to $1.1 million during the three months ended September 30, 2024, compared to $4.2 million during the three months ended September 30, 2023. The decrease in interest income was primarily due to lower cash balances invested in short-term investments in debt securities during the three months ended September 30, 2024 compared to the three months ended September 30, 2023. Other expense decreased by $0.6 million primarily due to an impairment loss related to our strategic investment recognized during the three months ended September 30, 2023.
Income Taxes. Income taxes increased $3.3 million to $5.7 million during the three months ended September 30, 2024, compared to $2.4 million during the three months ended September 30, 2023. The increase in income taxes primarily relates to an increase in expected U.S. federal and state cash taxes due to prior utilization of tax credit carryforwards and a higher annual effective tax rate applied to pretax earnings during the three months ended September 30, 2024 compared to the three months ended September 30, 2023.
33
Comparison of the nine months ended September 30, 2024 and 2023
The following table sets forth the components of our unaudited condensed consolidated statements of operations in dollars and as percentage of revenue for the periods presented (dollars in thousands):
Nine Months Ended September 30,Change $
2024%2023%
Revenue$442,404 100.0 %$361,538 100.0 %$80,866 
Cost of goods sold58,732 13.3 %42,062 11.6 %16,670 
Gross profit383,672 86.7 %319,476 88.4 %64,196 
Operating expenses
Research and development81,216 18.4 %64,641 17.9 %16,575 
Selling, general and administrative325,479 73.6 %256,889 71.1 %68,590 
Change in fair value of contingent consideration
18,609 4.2 %— — %18,609 
Amortization of intangible asset
7,414 1.7 %— — %7,414 
Acquisition-related expenses
4,143 0.9 %2,681 0.7 %1,462 
Total operating expenses436,861 98.8 %324,211 89.7 %112,650 
(Loss) income from operations
(53,189)(12.1 %)(4,735)(1.3 %)(48,454)
Other income (expense)
Interest income3,371 0.8 %12,899 3.6 %(9,528)
Interest expense(233)(0.1 %)(127)— %(106)
Other expense
(130)— %(617)(0.2 %)487 
Total other income3,008 0.7 %12,155 3.4 %(9,147)
(Loss) income before income taxes
(50,181)(11.4 %)7,420 2.1 %(57,601)
Provision for income taxes23,736 5.4 %4,391 1.2 %19,345 
Net (loss) income
$(73,917)(16.8 %)$3,029 0.9 %$(76,946)
Revenue. Revenue increased $80.9 million, or 22.4%, to $442.4 million during the nine months ended September 30, 2024, compared to $361.5 million during the nine months ended September 30, 2023. The increase in revenue was primarily due to an expansion of our sales territories, opening of new accounts, increase in adoption of our procedures, global commercial expansion, and introduction of new products.
Cost of Goods Sold. Cost of goods sold increased $16.7 million, or 39.6%, to $58.7 million during the nine months ended September 30, 2024, compared to $42.1 million during the nine months ended September 30, 2023. This increase was primarily due to the increase in the number of products sold and additional manufacturing overhead costs to support anticipated future growth.
Gross Margin. Gross margin for the nine months ended September 30, 2024 decreased to 86.7%, compared to 88.4% for the nine months ended September 30, 2023, primarily due to product mix, the ramp up costs associated with new products, and increasing internationalization of the business.
Research and Development Expenses. R&D expenses increased $16.6 million, or 25.6%, to $81.2 million during the nine months ended September 30, 2024, compared to $64.6 million during the nine months ended September 30, 2023. The increase in R&D expenses was primarily due to increases of $5.9 million of personnel related expenses, $3.8 million of impairment of previously capitalized software development costs, $2.9 million of material and supplies related expenses, $1.7 million of clinical and regulatory expenses, $0.8 million of expenses related to professional fees, including legal expense, $0.7 million of software costs and depreciation expenses, and $0.6 million of travel related costs.
34
Selling, General and Administrative Expenses. SG&A expenses increased $68.6 million, or 26.7%, to $325.5 million during the nine months ended September 30, 2024, compared to $256.9 million during the nine months ended September 30, 2023. The increase in SG&A expenses was primarily due to increases of $47.7 million in personnel-related expenses, including increased commissions due to higher revenue and increased share-based compensation, $14.6 million of expenses related to professional fees, including legal expenses, $4.3 million in travel related expenses, $1.5 million in sales and marketing related expenses, $1.2 million of software costs and depreciation expenses, partially offset by a decrease of $0.9 million of materials and supplies related expense and $0.8 million of insurance related expenses.
Other Operating Expenses. Other operating expenses increased by $18.6 million due to the change in fair value adjustment of our contingent consideration liability, $7.4 million due to amortization expense related to the acquired intangible asset, and $1.5 million due to the acquisition-related expenses, which include integration, severance and retention costs, during the nine months ended September 30, 2024.
Other income (expense). Other income consists primarily of interest income, interest expense, and foreign currency transaction and strategic investment gains and losses. Interest income decreased by $9.5 million to $3.4 million during the nine months ended September 30, 2024, compared to $12.9 million during the nine months ended September 30, 2023. The decrease in interest income was primarily due to lower cash balances invested in short-term investments in debt securities during the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023. Other expense decreased by $0.5 million primarily due to an impairment loss related to our strategic investment recognized during the nine months ended September 30, 2023.
Income Taxes. Income taxes increased $19.3 million to $23.7 million for the nine months ended September 30, 2024, compared to $4.4 million during the nine months ended September 30, 2023. The increase in income taxes primarily relates to an increase in expected U.S. federal and state cash taxes due to prior utilization of tax credit carryforwards and a higher annual effective tax rate applied to pretax earnings during the nine months ended September 30, 2024 compared to September 30, 2023.
LIQUIDITY AND CAPITAL RESOURCES
To date, our primary sources of capital have been the revenue from the sale of our products and existing cash and cash equivalent balances. As of September 30, 2024, we had cash and cash equivalents of $41.1 million and short-term investments in debt securities of $70.4 million. We maintain cash and cash equivalents with financial institutions in excess of insured limits.
As of September 30, 2024, the fair value of contingent consideration related to our acquisition of LimFlow was $84.5 million, of which $39.2 million was recorded within accrued expenses and other current liabilities and $45.3 million was recorded within other long-term liabilities in the condensed consolidated balance sheets. The contingent payments related to certain commercial and reimbursement milestones can be up to $165.0 million which includes (i) up to $140.0 million based on net revenue generated from the sale of the LimFlow system for the years 2024 through 2026 and (ii) up to $25.0 million based on the achievement of certain reimbursement milestones related to the LimFlow System. Revenue-based milestone payments are expected to be due in the first quarter in each of the years 2025, 2026 and 2027. The timing of reimbursement-based milestone payments is dependent on the achievement of such milestones and other conditions set forth in the share purchase agreement with LimFlow and such payments are expected to be paid in the second quarter of 2025. As of September 30, 2024, we have not made any payments related to the contingent consideration. For additional information about the acquisition, see Note 3. Business Combination, which is included in “Part I, Item 1. Condensed Consolidated Financial Statements (Unaudited)”.
35
In December 2022, we amended our revolving Credit Agreement with Bank of America (as amended, the “Previously Amended Credit Agreement”) which provides for loans up to a maximum of $40.0 million and increases the optional accordion to $120.0 million. The Previously Amended Credit Agreement also included a Letter of Credit subline facility (the “LC Facility”) of up to $5.0 million. In February 2023, we amended the LC Facility to increase the limit to up to $10.0 million. In November 2023, we further amended the Amended Credit Agreement, as defined in Note 12. Credit Facility, to, among other things, increase the amount available for borrowing to up to a maximum principal amount of $75.0 million. We also amended the LC Facility to increase the limit to up to $18.8 million. As of September 30, 2024, we had no principal outstanding under the Amended Credit Agreement and the amount available to borrow was approximately $67.9 million. As of September 30, 2024, we had four letters of credit in the aggregated amount of $2.4 million outstanding under the LC Facility. The aggregate stated amount outstanding of the letter of credits reduces the total borrowing base available under the Amended Credit Agreement and is subject to certain fees. For additional information about the Amended Credit Agreement, see Note 12. Credit Facility, which is included in “Part I, Item 1. Condensed Consolidated Financial Statements (Unaudited)”.
In October 2023, we signed a ten-year lease in Costa Rica for our second manufacturing facility with total undiscounted contractual payments of the lease of approximately $7.2 million, which are expected to commence in the fourth quarter of 2024.
Our other short-term and long-term material cash requirements, from known contractual obligations as of September 30, 2024, include contingent consideration liability, operating lease liabilities and uncertain tax positions, as discussed in Note 3. Business Combination, Note 4. Fair Value Measurements, Note 9. Commitments and Contingencies and Note 15. Income Taxes to our condensed consolidated financial statements section of this report, which are included in “Part I, Item 1. Condensed Consolidated Financial Statements (Unaudited)” of this report.
Based on our current planned operations, we anticipate that our cash and cash equivalents, short-term investments and available borrowings under our Amended Credit Agreement will be sufficient to fund these cash requirements and our operating expenses for at least the next 12 months. Our primary short-term needs for capital for our current planned operations, which are subject to change, include:
•support of commercialization efforts to expand our sales force along with expanding into new markets, including internationally, and developing products to enhance performance and address unmet market needs;
•the continued advancement of research and development including ongoing clinical studies and related activities, including clearance or approval of our products or product modifications; and
•potential expansion needs of our facilities, including the lease in Costa Rica for our second manufacturing facility.
If our available cash balances and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements in the future, we may seek to sell additional common or preferred equity or convertible debt securities, enter into an additional credit facility or another form of third-party funding or seek other debt financing. The sale of equity and convertible debt securities may result in dilution to our stockholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products or grant licenses on terms that are not favorable to us. Additional capital may not be available on reasonable terms, or at all.
36
CASH FLOWS
The following table summarizes our cash flows for each of the periods indicated (in thousands):
Nine Months Ended September 30,
20242023
Net cash provided by (used in):
Operating activities$1,937 $23,686 
Investing activities(852)1,698 
Financing activities648 3,581 
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash
267 (5)
Net increase in cash, cash equivalents, and restricted cash
$2,000 $28,960 
Net cash provided by operating activities
Net cash provided by operating activities for the nine months ended September 30, 2024 was $1.9 million, consisting primarily of a net loss of $73.9 million, offset by non-cash charges of $75.4 million and a net change in our net operating assets and liabilities of $0.4 million. The non-cash charges primarily consisted of share-based compensation expense of $38.9 million, change in fair value of contingent consideration liability of $18.6 million, depreciation and amortization of $11.9 million, impairment of capitalized software development costs of $3.8 million, and amortization of the right-of-use assets of $2.9 million, partially offset by amortization of premium and discount on marketable securities of $1.7 million. The change in our net operating assets and liabilities was primarily due to increases in payroll-related accruals, accrued expenses and other liabilities of $28.4 million, accounts receivable of $15.1 million, inventories of $12.4 million, and accounts payable of $4.9 million, partially offset by a decrease in prepaid expenses, deposits and other assets of $3.3 million and operating lease liabilities of $1.8 million.
Net cash provided by operating activities for the nine months ended September 30, 2023 was $23.7 million, consisting primarily of net income of $3.0 million and non-cash charges of $27.6 million, offset by a net change in our net operating assets and liabilities of $6.9 million. The non-cash charges primarily consisted of share-based compensation expense of $30.5 million, depreciation of $4.2 million, and amortization of the right-of-use assets of $3.1 million, partially offset by amortization of premium and discount on marketable securities of $11.4 million. The change in our net operating assets and liabilities was primarily due to increases in accounts receivable of $11.6 million, inventories of $7.8 million, payroll-related accruals, accrued expenses and other liabilities of $7.2 million, and accounts payable of $2.4 million, in addition to a decrease in prepaid expenses, deposits and other assets of $4.3 million and operating lease liabilities of $1.0 million.
Net cash (used in) provided by investing activities
Net cash used in investing activities for the nine months ended September 30, 2024 was $0.9 million, consisting of $91.1 million purchases of short-term investments, $7.9 million of purchases of property and equipment, and $2.3 million of capitalized software development costs, offset by maturities of short-term investments of $96.7 million and finalization of working capital adjustment related to the LimFlow acquisition of $3.7 million.
Net cash provided by investing activities for the nine months ended September 30, 2023 was $1.7 million, consisting of $400.6 million maturities of short-term investments, offset by $394.5 million purchases of short-term investments, $3.8 million of purchases of property and equipment, and $0.6 million of other investments.
Net cash provided by financing activities
Net cash provided by financing activities in the nine months ended September 30, 2024 was $0.6 million, consisting of $9.3 million of proceeds from the issuance of common stock under our employee stock purchase plan, offset by $9.0 million of tax payments related to vested equity awards.
37
Net cash provided by financing activities in the nine months ended September 30, 2023 was $3.6 million, consisting of $9.9 million of proceeds from the issuance of common stock under our employee stock purchase plan and $0.5 million of proceeds from exercise of stock options, offset by $6.9 million of tax payments related to vested equity awards.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
There have been no significant changes in our critical accounting policies during the nine months ended September 30, 2024, as compared to the critical accounting policies disclosed under “Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024.
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
There have been no material changes to our quantitative and qualitative disclosures about market risk as compared to the quantitative and qualitative disclosures about market risk described in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024 under “Part II, Item 7A. Quantitative and Qualitative Disclosures about Market Risk”.
Item 4. Controls and Procedures.
Evaluation of disclosure controls and procedures
Our management, with the participation of our Principal Executive Officer and our Principal Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of September 30, 2024. Based on such evaluation, our Principal Executive Officer and Principal Financial Officer concluded that, as of September 30, 2024, these disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management as appropriate to allow timely decisions regarding required disclosures. In designing and evaluating our disclosure controls and procedures, management recognizes that any control and procedure, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Changes in internal control over financial reporting
During the quarter ended September 30, 2024, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
38
PART II — OTHER INFORMATION
Item 1. LEGAL PROCEEDINGS
See Note 9. Commitments and Contingencies, which is included in “Part I, Item 1. Condensed Consolidated Financial Statements (Unaudited)” for information regarding material legal proceedings.
Item 1A. RISK FACTORS
For a discussion of risk factors that may affect our business and financial results, see the information in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024. As of the date of this Report, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023.
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
Item 3. DEFAULTS UPON SENIOR SECURITIES
None.
Item 4. MINE SAFETY DISCLOSURES
Not applicable.
Item 5. OTHER INFORMATION
On October 25, 2024, the Company’s Board of Directors appointed Karen Silva to serve as the Company’s principal accounting officer, with the title of Vice President, Finance and Accounting, effective November 11, 2024 (the “Effective Date”). Ms. Silva will report to Kevin Strange, the Company’s Chief Financial Officer, who will continue to serve as principal accounting officer until the Effective Date.
Prior to joining the Company, Ms. Silva, age 53, held several positions of increasing responsibility with Align Technology, Inc., a public medical device company, including Vice President, Finance and Corporate Controller from February 2012 to September 2024 and Senior Director, Corporate Controller from January 2008 to January 2012. Prior to that, Ms. Silva held various financial reporting roles at Align Technology, Inc., Harmonic Inc., Divicom, KLA Corporation and a public accounting firm. Ms. Silva holds a BS in Accounting from Santa Clara University and is a Certified Public Accountant in the state of California.
In connection with her appointment, Ms. Silva will be entitled to (i) an annual base salary of $360,000, (ii) participation in the Company’s annual cash target incentive plan with a target of 40% of her base salary, (iii) a one-time signing bonus of $100,000, and (iv) a one-time relocation bonus of $70,000, with each of (iii) and (iv) subject to pro-rated repayment if her employment with the Company ends for any reason within the first two years. In addition, Ms. Silva will be entitled to receive a one-time restricted stock unit award valued at $450,000, scheduled to vest 25% on the first anniversary of the grant date and on a quarterly basis over the following three years, subject to continued employment with the Company. The Company will also enter into its standard form of indemnification agreement for executive officers with Ms. Silva, the form of which was previously filed as Exhibit 10.1 to Amendment No. 1 of the Company’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on May 5, 2020.
Ms. Silva has no family relationships with any director, executive officer or person nominated or chosen by the Company to become a director or executive officer of the Company, and there are no transactions between Ms. Silva and the Company that would be required to be reported under Item 404(a) of Regulation S-K.
Insider Trading Arrangements
None.
39
Amended and Restated Bylaws
On October 25, 2024, following a review of corporate law developments and market practice, the Board approved and adopted an amendment and restatement of the Company’s bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective as of October 25, 2024. Among other changes, the amendments effected by the Amended and Restated Bylaws include:
•requiring any stockholder providing advance notice of director nominations to comply with Rule 14a-19 of the Exchange Act, including applicable notice and solicitation requirements;
•updating the disclosure requirements and procedural mechanics in connection with director nominations and business proposals by stockholders (other than proposals to be included in the Company’s proxy statement pursuant to Rule 14a-8 of the Exchange Act) to require additional background information and disclosures, including information that is required to be disclosed in a Schedule 13D or amendment thereto; and
•requiring any stockholder directly or indirectly soliciting proxies from other stockholders to use a proxy card color other than white, with the white proxy card being reserved for exclusive use by the Board.
The amendments also eliminate the requirement that the Company make a stockholder list available during a meeting of stockholders, consistent with amendments to the General Corporation Law of the State of Delaware, and make various other conforming, technical, modernizing and clarifying changes.
The foregoing description of the amendments effected by the Amended and Restated Bylaws does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amended and Restated Bylaws, which is attached hereto as Exhibit 3.2 and incorporated herein by reference.
40
Item 6. EXHIBITS
Exhibit NumberDescriptionIncorporated by reference
FormFile NumberExhibitFiling Date
3.18-K001-392933.15/28/2020
3.2
10.1#
31.1
31.2
32.1†
32.2†
101.INS
Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page with Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).
_____________________________
# Indicates management contract or compensatory plan.
† The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the U.S. Securities and Exchange Commission and are not to be incorporated by reference into any filing of Inari Medical, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

41
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Inari Medical, Inc.
Date: October 28, 2024
By:/s/ Andrew Hykes
Andrew Hykes
Chief Executive Officer and President
(Principal Executive Officer)
Date: October 28, 2024
By:
/s/ Kevin Strange
Kevin Strange
Chief Financial Officer
(Principal Financial Officer and
Principal Accounting Officer)
42
 EX-3.2 2 exhibit32-amendedandrestat.htm EX-3.2 Document
Exhibit 3.2









AMENDED AND RESTATED BYLAWS
OF
INARI MEDICAL, INC.
(a Delaware corporation)
(amended and restated as of October 25, 2024)

TABLE OF CONTENTS

Page

ARTICLE I - CORPORATE OFFICES1
1.1 REGISTERED OFFICE1
1.2 OTHER OFFICES1
ARTICLE II - MEETINGS OF STOCKHOLDERS1
2.1 PLACE OF MEETINGS1
2.2 ANNUAL MEETING1
2.3 SPECIAL MEETINGS1
2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING2
2.5 ADVANCE NOTICE PROCEDURES FOR NOMINATIONS OF DIRECTORS6
2.6 ADDITIONAL REQUIREMENTS FOR VALID NOMINATION OF CANDIDATES TO SERVE AS DIRECTOR AND, IF ELECTED, TO BE SEATED AS DIRECTORS9
2.7 NOTICE OF STOCKHOLDERS’ MEETINGS11
2.8 MANNER OF GIVING NOTICE; AFFIDAVIT OF NOTICE11
2.9 QUORUM12
2.1 ADJOURNED MEETING; NOTICE12
2.11 CONDUCT OF BUSINESS13
2.12 VOTING13
2.13 STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A MEETING14
2.14 RECORD DATE FOR STOCKHOLDER NOTICE; VOTING14
2.15 PROXIES14
2.16 LIST OF STOCKHOLDERS ENTITLED TO VOTE15
2.17 POSTPONEMENT AND CANCELLATION OF MEETING15
2.18 INSPECTORS OF ELECTION16
2.19 DELIVERY TO THE CORPORATION16
ARTICLE III - DIRECTORS16
3.1 POWERS16
3.2 NUMBER OF DIRECTORS16
3.3 ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS17
3.4 RESIGNATION AND VACANCIES17
3.5 PLACE OF MEETINGS; MEETINGS BY TELEPHONE17
3.6 REGULAR MEETINGS18
3.7 SPECIAL MEETINGS; NOTICE18
3.8 QUORUM19
3.9 BOARD ACTION BY CONSENT WITHOUT A MEETING19
3.1 FEES AND COMPENSATION OF DIRECTORS19
3.11 REMOVAL OF DIRECTORS19

-i-


TABLE OF CONTENTS
(continued)
Page

ARTICLE IV - COMMITTEES19
4.1 COMMITTEES OF DIRECTORS19
4.2 COMMITTEE MINUTES20
4.3 MEETINGS AND ACTION OF COMMITTEES20
ARTICLE V - OFFICERS20
5.1 OFFICERS20
5.2 APPOINTMENT OF OFFICERS21
5.3 SUBORDINATE OFFICERS21
5.4 REMOVAL AND RESIGNATION OF OFFICERS21
5.5 VACANCIES IN OFFICES21
5.6 REPRESENTATION OF SHARES OF OTHER CORPORATIONS21
5.7 AUTHORITY AND DUTIES OF OFFICERS22
ARTICLE VI - RECORDS AND REPORTS22
6.1 MAINTENANCE OF RECORDS22
ARTICLE VII - GENERAL MATTERS22
7.1 EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS22
7.2 CERTIFICATED AND UNCERTIFICATED STOCK; PARTLY PAID SHARES22
7.3 SPECIAL DESIGNATION ON CERTIFICATES23
7.4 LOST CERTIFICATES23
7.5 CONSTRUCTION; DEFINITIONS23
7.6 DIVIDENDS24
7.7 FISCAL YEAR24
7.8 SEAL24
7.9 TRANSFER OF STOCK24
7.1 STOCK TRANSFER AGREEMENTS24
7.11 REGISTERED STOCKHOLDERS24
7.12 WAIVER OF NOTICE25
7.13 ELECTRONIC SIGNATURES, ETC25
ARTICLE VIII - NOTICE BY ELECTRONIC TRANSMISSION25
8.1 NOTICE BY ELECTRONIC TRANSMISSION25
8.2 DEFINITION OF ELECTRONIC TRANSMISSION26
ARTICLE IX - INDEMNIFICATION26
9.1 INDEMNIFICATION OF DIRECTORS AND OFFICERS26
9.2 INDEMNIFICATION OF OTHERS27
9.3 PREPAYMENT OF EXPENSES27
9.4 DETERMINATION; CLAIM27
9.5 NON-EXCLUSIVITY OF RIGHTS28
9.6 INSURANCE28

-ii-


TABLE OF CONTENTS
(continued)
Page

9.7 OTHER INDEMNIFICATION28
9.8 AMENDMENT OR REPEAL; INTERPRETATION28
9.9 DEFINITIONS29
ARTICLE X - AMENDMENTS.29


-iii-



AMENDED AND RESTATED BYLAWS
OF
INARI MEDICAL, INC.
ARTICLE I - CORPORATE OFFICES
1.1    REGISTERED OFFICE.
The registered office of Inari Medical, Inc. (the “Corporation”) in the State of Delaware, and the name of its registered agent at such address, shall be as set forth in the Corporation’s certificate of incorporation, as the same may be amended and/or restated from time to time (the “Certificate of Incorporation”).
1.2    OTHER OFFICES.
The Corporation’s board of directors (the “Board”) may at any time establish other offices at any place or places where the Corporation is qualified to do business.
ARTICLE II - MEETINGS OF STOCKHOLDERS
2.1    PLACE OF MEETINGS.
Meetings of stockholders shall be held at any place, within or outside the State of Delaware, designated by the Board (or, to the fullest extent permitted by law, any committee of the Board or other person(s) authorized by the Board). The Board may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section 211(a)(2) of the General Corporation Law of the State of Delaware (the “DGCL”). In the absence of any such designation or determination, stockholders’ meetings shall be held at the Corporation’s principal executive office.
2.2    ANNUAL MEETING.
The Board (or, to the fullest extent permitted by law, any committee of the Board or other person(s) authorized by the Board) shall designate the date and time of the annual meeting. At the annual meeting, directors shall be elected and other proper business properly brought before the meeting in accordance with Section 2.4 of these bylaws may be transacted.
2.3    SPECIAL MEETINGS.
A special meeting of the stockholders may be called at any time by the Board, chairperson of the Board, chief executive officer or president (in the absence of a chief executive officer), but such special meetings may not be called by any other person or persons.


No business may be transacted at such special meeting other than the business specified in such notice to stockholders. Nothing contained in this paragraph of this Section 2.3 shall be construed as limiting, fixing or affecting the time when a meeting of stockholders called by action of the Board may be held.
2.4    ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING.
(a)    At an annual meeting of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual meeting, business must be (i) specified in a notice of meeting (or any supplement thereto) given by or at the direction of the Board, (ii) if not specified in a notice of meeting, otherwise brought before the meeting by the Board or the chairperson of the Board or (iii) otherwise properly brought before the meeting by a stockholder present in person who (A) (1) was a record owner of shares of the Corporation both at the time of giving the notice provided for in this Section 2.4 and at the time of the meeting, (2) is entitled to vote at the meeting, and (3) has complied with the notice procedures and other requirements set forth in this Section 2.4 in all applicable respects or (B) properly made such proposal in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (as so amended and inclusive of such rules and regulations, the “Exchange Act”). The foregoing clause (iii) shall be the exclusive means for a stockholder to propose business to be brought before an annual meeting of the stockholders. The only matters that may be brought before a special meeting are the matters specified in the notice of meeting given by or at the direction of the person calling the meeting pursuant to Section 2.3, and stockholders shall not be permitted to propose business to be brought before a special meeting of the stockholders. For purposes of this Section 2.4, “present in person” shall mean that the stockholder proposing that the business be brought before the annual meeting of the Corporation, or a qualified representative of such proposing stockholder, appear at such annual meeting. A “qualified representative” of such proposing stockholder shall be a duly authorized officer, manager or partner of such stockholder or any other person authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders. Stockholders seeking to nominate persons for election to the Board must comply with Section 2.5 and this Section 2.4 shall not be applicable to nominations except as expressly provided in Section 2.5 of these bylaws.
(b)     Without qualification, for business to be properly brought before an annual meeting by a stockholder, the stockholder must (i) provide Timely Notice (as defined below) thereof in writing and in proper form to the secretary of the Corporation and (ii) provide any updates or supplements to such notice at the times and in the forms required by this Section 2.4. To be timely, a stockholder’s notice must be delivered to, or mailed and received at, the principal executive offices of the Corporation, in accordance with Section 2.19 of these bylaws, not later than the close of business on the ninetieth (90th) day nor earlier than the close of business on the one hundred twentieth (120th) day prior to the one-year anniversary of the preceding year’s annual meeting; provided, however, that if the date of the annual meeting is more than thirty (30) days before or more than sixty (60) days after such anniversary date, notice by the stockholder to be timely must be so delivered, or mailed and received,
- 2 -


(A) not earlier than the close of business on the one hundred twentieth (120th) day prior to such annual meeting and (B) not later than the close of business on the ninetieth (90th) day prior to such annual meeting or the tenth (10th) day following the day on which public disclosure (as defined below) of the date of such annual meeting was first made by the Corporation (such notice within such time periods, “Timely Notice”). In no event shall any adjournment or postponement of an annual meeting or the announcement thereof commence a new time period (or extend any time period) for the giving of Timely Notice as described above.
(c)    To be in proper form for purposes of this Section 2.4, a stockholder’s notice to the secretary of the Corporation shall set forth:
(i)    As to each Proposing Person (as defined below), (A) the name and address of such Proposing Person (including, if applicable, the name and address that appear on the Corporation’s books and records); (B) the class or series and number of shares of the Corporation that are, directly or indirectly, owned of record or beneficially owned (within the meaning of Rule 13d-3 under the Exchange Act) by such Proposing Person, except that such Proposing Person shall in all events be deemed to beneficially own any shares of any class or series of the Corporation as to which such Proposing Person has a right to acquire beneficial ownership at any time in the future; (C) all information that would be required to be set forth in a Schedule 13D filed pursuant to Rule 13d-1(a) under the Exchange Act or an amendment pursuant to Rule 13d-2(a) under the Exchange Act if such statement were required to be filed under the Exchange Act and the rules and regulations promulgated thereunder by such Proposing Person, and (D) any proxy, contract, arrangement or relationship pursuant to which the Proposing Person has a right to vote, directly or indirectly, any shares of any security of the Corporation (the disclosures to be made pursuant to the foregoing clauses (A) through (D) are referred to as “Stockholder Information”);
(ii)    As to each Proposing Person, (A) the full notional amount of any securities that, directly or indirectly, underlie any “derivative security” (as such term is defined in Rule 16a-1(c) under the Exchange Act) that constitutes a “call equivalent position” (as such term is defined in Rule 16a-1(b) under the Exchange Act) or a “put equivalent position” (as such term is defined in Rule 16a-1(h) under the Exchange Act) or other derivative or synthetic arrangement in respect of any class or series of shares of the Corporation (“Synthetic Equity Position”) and that is, directly or indirectly, held or maintained by, held for the benefit of, or involving such Proposing Person, including, without limitation, (1) any option, warrant, convertible security, stock appreciation right, future or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of shares of the Corporation or with a value derived in whole or in part from the value of any class or series of shares of the Corporation, (2) any derivative or synthetic arrangement having the characteristics of a long position or a short position in any class or series of shares of the Corporation, including, without limitation, a stock loan transaction, a stock borrow transaction, or a share repurchase transaction, or (3) any contract, derivative, swap or other transaction or series of transactions designed to (x) produce economic benefits and risks that correspond substantially to the ownership of any class or series of shares of the Corporation, (y) mitigate any loss relating to, reduce the economic risk (of ownership or otherwise) of, or manage the risk of share price decrease in, any class or series of shares of the Corporation, or (z) increase or decrease the voting power in respect of any class or series of shares of the Corporation of such Proposing Person, including, without limitation, due to the fact that the value of
- 3 -


such contract, derivative, swap or other transaction or series of transactions is determined by reference to the price, value or volatility of any class or series of shares of the Corporation, whether or not such instrument, contract or right shall be subject to settlement in the underlying class or series of shares of the Corporation, through the delivery of cash or other property, or otherwise, and without regard to whether the holder thereof may have entered into transactions that hedge or mitigate the economic effect of such instrument, contract or right, or any other direct or indirect opportunity to profit or share in any profit derived from any increase or decrease in the price or value of any class or series of shares of stock of the Corporation; provided that, for the purposes of the definition of “Synthetic Equity Position,” the term “derivative security” shall also include any security or instrument that would not otherwise constitute a “derivative security” as a result of any feature that would make any conversion, exercise or similar right or privilege of such security or instrument becoming determinable only at some future date or upon the happening of a future occurrence, in which case the determination of the amount of securities into which such security or instrument would be convertible or exercisable shall be made assuming that such security or instrument is immediately convertible or exercisable at the time of such determination; and, provided, further, that any Proposing Person satisfying the requirements of Rule 13d-1(b)(1) under the Exchange Act (other than a Proposing Person that so satisfies Rule 13d-1(b)(1) under the Exchange Act solely by reason of Rule 13d-1(b)(1)(ii)(E)) shall not be required to disclose any Synthetic Equity Position that is, directly or indirectly, held or maintained by, held for the benefit of, or involving such Proposing Person as a hedge with respect to a bona fide derivatives trade or position of such Proposing Person arising in the ordinary course of such Proposing Person’s business as a derivatives dealer, (B) any material pending or threatened legal proceeding in which such Proposing Person is a party or material participant involving the Corporation or any of its officers or directors, or any affiliate of the Corporation, (C) any other material relationship between such Proposing Person, on the one hand, and the Corporation or any affiliate of the Corporation, on the other hand, (D) any direct or indirect material interest in any material contract or agreement of such Proposing Person with the Corporation or any affiliate of the Corporation (including, in any such case, any employment agreement, collective bargaining agreement or consulting agreement), (E) any proportionate interest in shares of the Corporation or a Synthetic Equity Position held, directly or indirectly, by a general or limited partnership, limited liability company or similar entity in which any such Proposing Person (1) is a general partner or, directly or indirectly, beneficially owns an interest in a general partner of such general or limited partnership or (2) is the manager or managing member or, directly or indirectly, beneficially owns an interest in the manager or managing member, of such limited liability company or similar entity, (F) a representation that such Proposing Person intends or is part of a group which intends to deliver a proxy statement or form of proxy to holders of at least the percentage of the Corporation’s outstanding capital stock required to approve or adopt the proposal or otherwise solicit proxies from stockholders in support of such proposal and (G) any other information relating to such Proposing Person that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies or consents by such Proposing Person in support of the business proposed to be brought before the meeting pursuant to Section 14(a) of the Exchange Act (the disclosures to be made pursuant to the foregoing clauses (A) through (G) are referred to as “Disclosable Interests”); provided, however, that Disclosable Interests shall not include any such disclosures with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder directed to prepare and submit the notice required by these bylaws on behalf of a beneficial owner; and
- 4 -


(iii)    As to each item of business that the stockholder proposes to bring before the annual meeting, (A) a brief description of the business desired to be brought before the annual meeting, the reasons for conducting such business at the annual meeting and any material interest in such business of each Proposing Person, (B) the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend the bylaws, the language of the proposed amendment), and (C) a reasonably detailed description of all agreements, arrangements and understandings (x) between or among any of the Proposing Persons or (y) between or among any Proposing Person and any other person or entity (including their names) in connection with the proposal of such business by such stockholder; and (D) any other information relating to such item of business that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies in support of the business proposed to be brought before the meeting pursuant to Section 14(a) of the Exchange Act; provided, however, that the disclosures required by this paragraph (iii) shall not include any disclosures with respect to any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder directed to prepare and submit the notice required by these bylaws on behalf of a beneficial owner.
For purposes of this Section 2.4, (A) the term “Proposing Person” shall mean (i) the stockholder providing the notice of business proposed to be brought before an annual meeting and their affiliates or associates, or others acting in concert therewith, (ii) the beneficial owner or beneficial owners, if different, on whose behalf the notice of the business proposed to be brought before the annual meeting is made and their affiliates or associates, or others acting in concert therewith, and (iii) any participant (as defined in paragraphs (a)(ii)-(vi) of Instruction 3 to Item 4 of Schedule 14A) with such stockholder in such solicitation; (B) the term “associates” and affiliates” shall each have the respective meanings set forth in Rule 12b-2 under the Exchange Act, provided, however, that the term “partner” as used in the definition of “associate” shall not include any limited partner that is not involved in the management of the relevant partnership and the term “registrant” as used in such definition shall be deemed to also include any stockholder giving a notice (or beneficial owner on whose behalf such notice is given) under this Section 2.4, Section 2.5 or Section 2.6; and (C) the term “acting in concert” shall mean persons who, pursuant to an agreement or understanding (whether formal or informal), knowingly cooperate or take actions substantially in parallel, with the purpose of attaining a common goal relating to the management, governance or control of the Corporation (it being understood that persons who have solely disclosed their intent to vote for a nominee or to deliver a revocable proxy to the stockholder giving notice under this Section 2.4, Section 2.5 or Section 2.6 or any beneficial owner shall not be deemed to be acting in concert with such stockholder or any beneficial owner.
(d)    A Proposing Person shall update and supplement its notice to the Corporation of its intent to propose business at an annual meeting, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section 2.4 shall be true and correct as of the record date for stockholders entitled to vote at the meeting and as of the date that is ten (10) business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the secretary of the Corporation at the principal executive offices of the Corporation, in accordance with Section 2.19 of these bylaws, not later than five (5) business days after the record date for stockholders entitled to vote at the meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight (8) business
- 5 -


days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of ten (10) business days prior to the meeting or any adjournment or postponement thereof). For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other Section of these bylaws shall not limit the Corporation’s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or to submit any new proposal, including by changing or adding matters, business or resolutions proposed to be brought before a meeting of the stockholders.
(e)    Notwithstanding anything in these bylaws to the contrary, no business shall be conducted at an annual meeting that is not properly brought before the meeting in accordance with this Section 2.4. The presiding officer of the meeting shall, if the facts warrant, determine that the business was not properly brought before the meeting in accordance with this Section 2.4, and if he or she should so determine, he or she shall so declare to the meeting and any such business not properly brought before the meeting shall not be transacted.
(f)    This Section 2.4 is expressly intended to apply to any business proposed to be brought before an annual meeting of stockholders other than any proposal made in accordance with Rule 14a-8 under the Exchange Act and included in the Corporation’s proxy statement. In addition to the requirements of this Section 2.4 with respect to any business proposed to be brought before an annual meeting, each Proposing Person shall comply with all applicable requirements of the Exchange Act with respect to any such business. Nothing in this Section 2.4 shall be deemed to affect the rights of stockholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under the Exchange Act.
(g)    For purposes of these bylaws, “public disclosure” shall mean disclosure in a press release reported by a national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d) of the Exchange Act.
2.5    ADVANCE NOTICE PROCEDURES FOR NOMINATIONS OF DIRECTORS.
(a)    Nominations of any person for election to the Board at an annual meeting or at a special meeting (but only if the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling such special meeting) may be made at such meeting only (i) by or at the direction of the Board, including by any committee or persons authorized to do so by the Board or these bylaws, or (ii) by a stockholder present in person (A) who was a record owner of shares of the Corporation both at the time of giving the notice provided for in this Section 2.5 and at the time of the meeting, (B) is entitled to vote at the meeting and (C) has complied with this Section 2.5 and Section 2.6 as to such notice and nomination. For purposes of this Section 2.5, “present in person” shall mean that the stockholder proposing that the business be brought before the meeting of the Corporation, or a qualified representative of such stockholder, appear at such meeting. A “qualified representative” of such proposing stockholder shall be a duly authorized officer, manager or partner of such stockholder or any other person authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and
- 6 -


such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders. The foregoing clause (ii) shall be the exclusive means for a stockholder to make any nomination of a person or persons for election to the Board at an annual meeting or special meeting.
(b)    (i) Without qualification, for a stockholder to make any nomination of a person or persons for election to the Board at an annual meeting, the stockholder must (1) provide Timely Notice (as defined in Section 2.4(b) of these bylaws) thereof in writing and in proper form to the secretary of the Corporation, (2) provide the information, agreements and questionnaires with respect to such stockholder and its candidate for nomination as required to be set forth by this Section 2.5 and Section 2.6 and (3) provide any updates or supplements to such notice at the times and in the forms required by this Section 2.5 and Section 2.6.
(ii)     Without qualification, if the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling a special meeting, then for a stockholder to make any nomination of a person or persons for election to the Board at a special meeting, the stockholder must (i) provide timely notice thereof in writing and in proper form to the secretary of the Corporation at the principal executive offices of the Corporation, (ii) provide the information with respect to such stockholder and its candidate for nomination as required by this Section 2.5 and Section 2.6 and (iii) provide any updates or supplements to such notice at the times and in the forms required by this Section 2.5. To be timely, a stockholder’s notice for nominations to be made at a special meeting must be delivered to, or mailed and received at, the principal executive offices of the Corporation, in accordance with Section 2.19 of these bylaws, not earlier than the close of business on the one hundred twentieth (120th) day prior to such special meeting and not later than the close of business on the ninetieth (90th) day prior to such special meeting or, if later, the tenth (10th) day following the day on which public disclosure (as defined in Section 2.4(g) of these bylaws) of the date of such special meeting was first made.
(iii)    In no event shall any adjournment or postponement of an annual meeting or special meeting or the announcement thereof commence a new time period (or extend any time period) for the giving of a stockholder’s notice as described above.
(iv)    In no event may a Nominating Person provide Timely Notice with respect to a greater number of director candidates than are subject to election by stockholders at the applicable meeting. If the Corporation shall, subsequent to such notice, increase the number of directors subject to election at the meeting, such notice as to any additional nominees shall be due on the later of (i) the conclusion of the time period for Timely Notice, (ii) the date set forth in Section 2.5(b)(ii) of these bylaws or (iii) the tenth (10th) day following the date of public disclosure (as defined in Section 2.4(g) of these bylaws) of such increase.
(c)    To be in proper form for purposes of this Section 2.5, a stockholder’s notice to the secretary of the Corporation shall set forth:
(i)    As to each Nominating Person (as defined below), the Stockholder Information (as defined in Section 2.4(c)(i) of these bylaws) except that for purposes of this Section 2.5,
- 7 -


the term “Nominating Person” shall be substituted for the term “Proposing Person” in all places it appears in Section 2.4(c)(i);
(ii)    As to each Nominating Person, any Disclosable Interests (as defined in Section 2.4(c)(ii), except that for purposes of this Section 2.5 the term “Nominating Person” shall be substituted for the term “Proposing Person” in all places it appears in Section 2.4(c)(ii) of these bylaws and the disclosure with respect to the business to be brought before the meeting in Section 2.4(c)(ii) shall be made with respect to the election of directors at the meeting); and provided further, that, in lieu of including the information set forth in Section 2.4(c)(ii)(F), the Nominating Person’s notice for purposes of this Section 2.5 shall include the information required to be included in a notice to the Corporation required by paragraph (b) of Rule 14a-19 promulgated under the Exchange Act, including a statement that such person intends to solicit the holders of shares representing at least 67% of the voting power of shares entitled to vote on the election of directors in support of director nominees other than the Corporation’s nominees; and
(iii)    As to each candidate whom a Nominating Person proposes to nominate for election as a director, (A) all information with respect to such candidate for nomination that would be required to be set forth in a stockholder’s notice pursuant to this Section 2.5 if such candidate for nomination were a Nominating Person, (B) all information relating to such candidate for nomination that is required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors in a contested election pursuant to Section 14(a) under the Exchange Act (including such candidate’s written consent to being named in the proxy statement and accompanying proxy card as a nominee and to serving as a director for a full term if elected), (C) a description of any direct or indirect material interest in any material contract or agreement between or among any Nominating Person, on the one hand, and each candidate for nomination or his or her respective associates or any other participants in such solicitation, on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Item 404 under Regulation S-K if such Nominating Person were the “registrant” for purposes of such rule and the candidate for nomination were a director or executive officer of such registrant (the disclosures to be made pursuant to the foregoing clauses (A) through (C) are referred to as “Nominee Information”) and (D) a completed and signed questionnaire, representation and agreement as provided in Section 2.6 of these bylaws.
For purposes of this Section 2.5, the term “Nominating Person” shall mean (i) the stockholder providing the notice of the nomination proposed to be made at the meeting, (ii) the beneficial owner or beneficial owners, if different, on whose behalf the notice of the nomination proposed to be made at the meeting is made and (iii) any other participant in such solicitation.
(d)    A stockholder providing notice of any nomination proposed to be made at a meeting shall further update and supplement such notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section 2.5 shall be true and correct as of the record date for stockholders entitled to vote at the meeting and as of the date that is ten (10) business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the secretary of the Corporation, in accordance with Section 2.19 of these bylaws, at the principal executive offices of the Corporation not later than five (5)
- 8 -


business days after the record date for stockholders entitled to vote at the meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight (8) business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of ten (10) business days prior to the meeting or any adjournment or postponement thereof). For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other section of these bylaws shall not limit the Corporation’s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any nomination or to submit any new nomination.
(e)    In addition to the requirements of this Section 2.5 with respect to any nomination proposed to be made at a meeting, each Nominating Person shall comply with all applicable requirements of the Exchange Act with respect to any such nominations. Further, notwithstanding the provisions of this Section 2.5 or Section 2.6, unless otherwise required by law, (i) a stockholder shall not solicit proxies in support of director nominees other than the Corporation’s nominees unless such stockholder has complied with Rule 14a-19 promulgated under the Exchange Act in connection with the solicitation of such proxies, and (ii) if any stockholder (A) provides notice of the information required by Rule 14a-19(b) promulgated under the Exchange Act and (B) subsequently fails to comply with the requirements of Rule 14a-19(a)(2) or Rule 14a-19(a)(3) promulgated under the Exchange Act, including the provision to the Corporation of notice required with respect to such nomination(s) in a timely manner, or fails to timely provide reasonable evidence sufficient to satisfy the Corporation that such Nominating Person has met the requirements of Rule 14a-19(a)(3) promulgated under the Exchange Act in accordance with the following sentence, then the nomination of each person nominated by such stockholder for election or re-election as a director shall be disregarded, notwithstanding that the nominee is included as a nominee in the Corporation’s proxy statement, notice of meeting or other proxy materials for any annual meeting (or any supplement thereto) and notwithstanding that proxies or votes in respect to the election of the candidate for nomination may have been received by the Corporation (which proxies and votes shall be disregarded). If any stockholder provides notice of the information required by Rule 14a-19(b) promulgated under the Exchange Act, such stockholder shall deliver to the Corporation, no later than five (5) business days prior to the applicable meeting, reasonable evidence that it has met the requirements of Rule 14a-19(a)(3) promulgated under the Exchange Act.

2.6    ADDITIONAL REQUIREMENTS FOR VALID NOMINATION OF CANDIDATES TO SERVE AS DIRECTOR AND, IF ELECTED, TO BE SEATED AS DIRECTORS.
(a)    To be eligible to be a candidate for election as a director of the Corporation at an annual or special meeting, a candidate must be nominated in the manner prescribed in Section 2.5 of these bylaws and the candidate for nomination, whether nominated by the Board or by a stockholder of record, must have previously delivered (in accordance with the time period prescribed for delivery in a notice to such candidate given by or on behalf of the Board), to the secretary of the Corporation at the principal executive offices of the Corporation, (i) a completed written questionnaire (in a form provided by the Corporation upon written request of any stockholder of record therefor) with respect to the
- 9 -


background, qualifications, stock ownership and independence of such proposed nominee and (ii) a written representation and agreement (in the form provided by the Corporation upon written request of any stockholder of record therefor) that such candidate for nomination (A) is not and, if elected as a director during his or her term of office, will not become a party to (1) any agreement, arrangement or understanding with, and has not given and will not give any commitment or assurance to, any person or entity as to how such proposed nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) or (2) any Voting Commitment that could limit or interfere with such proposed nominee’s ability to comply, if elected as a director of the Corporation, with such proposed nominee’s fiduciary duties under applicable law, (B) is not, and will not become a party to, any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation or reimbursement for service as a director that has not been disclosed to the Corporation, and (C) if elected as a director of the Corporation, will comply with all applicable corporate governance, conflict of interest, confidentiality, stock ownership and trading and other policies and guidelines of the Corporation applicable to directors and in effect during such person’s term in office as a director (and, if requested by any candidate for nomination, the secretary of the Corporation shall provide to such candidate for nomination all such policies and guidelines then in effect), and (D) if elected as director of the Corporation, intends to serve the entire term until the next meeting at which such candidate would face re-election.
(b)    The Board may also require any proposed candidate for nomination as a director to furnish such other information as may reasonably be requested by the Board in writing prior to the meeting of stockholders at which such candidate’s nomination is to be acted upon in order for the Board to determine the eligibility of such candidate for nomination to be an independent director of the Corporation in accordance with the Corporation’s Corporate Governance Guidelines.
(c)    A candidate for nomination as a director shall further update and supplement the materials delivered pursuant to this Section 2.6, if necessary, so that the information provided or required to be provided pursuant to this Section 2.6 shall be true and correct as of the record date for stockholders entitled to vote at the meeting and as of the date that is ten (10) business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the secretary of the Corporation at the principal executive offices of the Corporation, in accordance with Section 2.19 of these bylaws, not later than five (5) business days after the record date for stockholders entitled to vote at the meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight (8) business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of ten (10) business days prior to the meeting or any adjournment or postponement thereof). For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other Section of these bylaws shall not limit the Corporation’s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or to submit any new proposal, including by changing or adding nominees, matters, business or resolutions proposed to be brought before a meeting of the stockholders.
- 10 -


(d)    No candidate shall be eligible for nomination as a director of the Corporation unless such candidate for nomination and the Nominating Person seeking to place such candidate’s name in nomination has complied with Section 2.5 and this Section 2.6 of these bylaws, as applicable. The chair of the meeting or a presiding officer at the meeting shall, if the facts warrant, determine that a nomination was not properly made in accordance with this Article II, and if he or she should so determine, he or she shall so declare such determination to the meeting, the defective nomination shall be disregarded and any ballots cast for the candidate in question (but in the case of any form of ballot listing other qualified nominees, only the ballots cast for the nominee in question) shall be void and of no force or effect.
(e)    Notwithstanding anything in these bylaws to the contrary, no candidate for nomination shall be eligible to be seated as a director of the Corporation unless nominated and elected in accordance with this Section 2.
2.7    NOTICE OF STOCKHOLDERS’ MEETINGS.
Unless otherwise provided by law, the Certificate of Incorporation or these bylaws, the notice of any meeting of stockholders shall be sent or otherwise given in accordance with either Section 2.8 or Section 8.1 of these bylaws not less than ten (10) nor more than sixty (60) days before the date of the meeting to each stockholder entitled to vote at such meeting (in accordance with Section 232 of the DGCL). The notice shall specify the place, if any, date and hour of the meeting, the record date for determining the stockholders entitled to vote at the meeting (if such date is different from the record date for stockholders entitled to notice of the meeting), the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called.
2.8    MANNER OF GIVING NOTICE; AFFIDAVIT OF NOTICE.
Notice of any meeting of stockholders shall be deemed given:
(a)    if mailed, when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder’s address as it appears on the Corporation’s records; or
(b)    if electronically transmitted, as provided in Section 8.1 of these bylaws.
An affidavit of the secretary or an assistant secretary of the Corporation or of the transfer agent or any other agent of the Corporation that the notice has been given by mail or by a form of electronic transmission, as applicable, shall, in the absence of fraud, be prima facie evidence of the facts stated therein.
2.9    QUORUM.
Unless otherwise provided by law, the Certificate of Incorporation or these bylaws, the holders of a majority in voting power of the capital stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. A
- 11 -


quorum, once established at a meeting, shall not be broken by the withdrawal of enough votes to leave less than a quorum. If, however, a quorum is not present or represented at any meeting of the stockholders, then either (a) the chairperson of the meeting or (b) a majority in voting power of the stockholders entitled to vote thereon, present in person, or by remote communication, if applicable, or represented by proxy, shall have the power to adjourn the meeting from time to time in the manner provided in Section 2.10 of these bylaws until a quorum is present or represented. At such adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted at the meeting as originally noticed.
2.10    ADJOURNED MEETING; NOTICE.
Any meeting of stockholders, whether annual or special, may be adjourned from time to time to any other time or place, if any, either by the chairperson of the meeting or, if directed to be voted on by the chairperson of the meeting, by a majority in voting power of the capital stock issued and outstanding, present in person, or by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote thereon, regardless of whether a quorum is present, at any time and for any reason. When a meeting is adjourned to another time or place (including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), unless these bylaws otherwise require, notice need not be given of the adjourned meeting if the time, place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are (a) announced at the meeting at which the adjournment is taken, (b) displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote communication, (c) set forth in the notice of meeting given in accordance with the provisions of this Article II, or (d) are provided in any other manner permitted by the DGCL. At the adjourned meeting, the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days, or if after the adjournment a new record date for determining the stockholders entitled to vote is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the adjourned meeting as of the record date for determining the stockholders entitled to notice of the adjourned meeting.
2.11    CONDUCT OF BUSINESS.
The date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting by the person presiding over the meeting. The Board may adopt by resolution such rules and regulations for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board, the person presiding over any meeting of stockholders shall have the right and authority to postpone, convene and (for any or no reason) to recess and/or adjourn the meeting, to prescribe such rules, regulations and procedures (which need not be in writing) and to do all such acts as, in the judgment of such presiding person, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board or prescribed by the presiding person of the meeting, may include,
- 12 -


without limitation, the following: (a) the establishment of an agenda or order of business for the meeting; (b) rules and procedures for maintaining order at the meeting and the safety of those present (including, without limitation, rules and procedures for removal of disruptive persons from the meeting); (c) limitations on attendance at or participation in the meeting to stockholders entitled to vote at the meeting, their duly authorized and constituted proxies or such other persons as the presiding person of the meeting shall determine; (d) restrictions on entry to the meeting after the time fixed for the commencement thereof; and (e) limitations on the time allotted to questions or comments by participants. The presiding person at any meeting of stockholders, in addition to making any other determinations that may be appropriate to the conduct of the meeting (including, without limitation, determinations with respect to the administration and/or interpretation of any of the rules, regulations or procedures of the meeting, whether adopted by the Board or prescribed by the person presiding over the meeting), shall, if the facts warrant, determine and declare to the meeting that a matter or business was not properly brought before the meeting and if such presiding person should so determine, such presiding person shall so declare to the meeting and any such matter or business not properly brought before the meeting shall not be transacted or considered. Unless and to the extent determined by the Board or the person presiding over the meeting, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure.
2.12    VOTING.
The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions of Section 2.13 of these bylaws, subject to Section 217 (relating to voting rights of fiduciaries, pledgors and joint owners of stock) and Section 218 (relating to voting trusts and other voting agreements) of the DGCL.
Except as may be otherwise provided in the Certificate of Incorporation or these bylaws, each stockholder shall be entitled to one (1) vote for each share of capital stock held by such stockholder in respect of each matter upon which a vote is to be taken.
Except as otherwise provided by the Certificate of Incorporation, at all duly called or convened meetings of stockholders at which a quorum is present, for the election of directors, a plurality of the votes cast shall be sufficient to elect a director. Except as otherwise provided by the Certificate of Incorporation, these bylaws, the rules or regulations of any stock exchange applicable to the Corporation, or applicable law or pursuant to any regulation applicable to the Corporation or its securities, all other matters presented to the stockholders at a duly called or convened meeting at which a quorum is present shall be decided by the affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively (excluding abstentions and broker non votes) by the holders entitled to vote on such matter.
2.13    STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A MEETING.
Any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders of the Corporation and may not be effected by any consent in writing by such stockholders.
- 13 -


2.14    RECORD DATE FOR STOCKHOLDER NOTICE; VOTING.
In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board, and which record date shall, unless otherwise required by law, not be more than sixty (60) days nor less than ten (10) days before the date of such meeting. If the Board so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board may fix a new record date for determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance herewith at the adjourned meeting.
In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights, or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board may fix a record date, which shall not be more than sixty (60) days prior to such action. If no such record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto.
2.15    PROXIES.
Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy authorized by an instrument in writing or by a transmission permitted by law filed in accordance with the procedure established for the meeting, but no such proxy shall be voted or acted upon after three (3) years from its date, unless the proxy provides for a longer period. The revocability of a proxy that states on its face that it is irrevocable shall be governed by the provisions of Section 212 of the DGCL. The authorization of a person to act as a proxy may be documented, signed and delivered in accordance with Section 116 of the DGCL, provided that such authorization shall set forth, or be delivered with information, enable the Corporation to determine, the identity of the stockholder granting such authorization.
Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which color shall be reserved for the exclusive use of the Board.
- 14 -


2.16    LIST OF STOCKHOLDERS ENTITLED TO VOTE.
The officer who has charge of the stock ledger of the Corporation shall prepare and make, at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting (provided, however, if the record date for determining the stockholders entitled to vote is less than ten (10) days before the date of the meeting, the list shall reflect the stockholders entitled to vote as of the tenth day before the date of the meeting), arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. The Corporation shall not be required to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of at least ten (10) days ending on the day before the stockholder meeting date: (a) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (b) during ordinary business hours, at the Corporation’s principal executive office. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. Except as otherwise provided by law, the stock ledger shall be the only evidence as to the identity of the stockholders entitled to vote in person or by proxy and the number of shares held by each of them, and as to the stockholders entitled to examine the list of stockholders.
2.17    POSTPONEMENT AND CANCELLATION OF MEETING.
Any previously scheduled annual or special meeting of the stockholders may be postponed or rescheduled, and any previously scheduled annual or special meeting of the stockholders may be canceled, by resolution of the Board at any time, before or after notice of such meeting has been sent to the stockholders of the Corporation, upon public notice given prior to the time previously scheduled for such meeting.
2.18    INSPECTORS OF ELECTION.
Before any meeting of stockholders, the Board shall appoint an inspector or inspectors of election to act at the meeting or its adjournment or postponement and make a written report thereof. The number of inspectors shall be either one (1) or three (3). If any person appointed as inspector fails to appear or fails or refuses to act, then the chairperson of the meeting may, and upon the request of any stockholder or a stockholder’s proxy shall, appoint a person to fill that vacancy. Unless otherwise required by law, inspectors may be officers, employees or agents of the Corporation. Such inspectors shall have the duties prescribed by law and shall take charge of the polls and, when the vote is completed, shall make a certificate of the result of the vote taken and of such other facts as may be required by law. The inspectors of election shall perform their duties impartially, in good faith, to the best of their ability and as expeditiously as is practical. If there are three (3) inspectors of election, the decision, act or certificate of a majority is effective in all respects as the decision, act or certificate of all. Any report or certificate made by the inspectors of election is prima facie evidence of the facts stated therein.
2.19    DELIVERY TO THE CORPORATION
- 15 -


Whenever this Article II requires one or more persons (including a record or beneficial owner of shares of the Corporation) to deliver a document or information to the Corporation or any officer, employee or agent thereof (including any notice, request, questionnaire, revocation, representation or other document or agreement), such document or information shall be in writing exclusively (and not in an electronic transmission) and shall be delivered to the principal executive offices of the Corporation exclusively by hand (including, without limitation, overnight courier service) or by certified or registered mail, return receipt requested, and the Corporation shall not be required to accept delivery of any document not in such written form or so delivered. For the avoidance of doubt, except as permitted in Section 2.15 of these bylaws, the Corporation expressly opts out of Section 116 of the DGCL with respect to the delivery of information and documents to the Corporation required by this Article II.
ARTICLE III - DIRECTORS
3.1    POWERS.
Subject to the provisions of the DGCL and any limitations in the Certificate of Incorporation relating to action required to be approved by the stockholders or by the outstanding shares, the business and affairs of the Corporation shall be managed and all corporate powers shall be exercised by or under the direction of the Board.
3.2    NUMBER OF DIRECTORS.
The authorized number of directors shall be determined from time to time by resolution of the Board, provided the Board shall consist of at least one (1) member. No reduction of the authorized number of directors shall have the effect of removing any director before that director’s term of office expires.
3.3    ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS.
Except as provided in Section 3.4 of these bylaws, each director, including, without limitation, a director elected to fill a vacancy or newly created directorships, shall hold office until the expiration of the term of the class, if any, for which elected and until such director’s successor is elected and qualified or until such director’s earlier death, resignation or removal. Directors need not be stockholders unless so required by the Certificate of Incorporation or these bylaws. The Certificate of Incorporation or these bylaws may prescribe other qualifications for directors.
If so provided in the Certificate of Incorporation, the directors of the Corporation shall be divided into three (3) classes.
3.4    RESIGNATION AND VACANCIES.
Any director may resign at any time upon notice given in writing or by electronic transmission to the Corporation at its principal executive offices or to the chairperson of the Board, the chief executive officer, the president or the secretary of the Corporation. The resignation shall take effect at the time specified therein or upon the happening of an event
- 16 -


specified therein, and if no time or event is specified, at the time of its receipt. Unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective. When one or more directors so resigns and the resignation is effective at a future date or upon the happening of an event to occur on a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office as provided in this section in the filling of other vacancies.
Unless otherwise provided in the Certificate of Incorporation or these bylaws, vacancies and newly created directorships resulting from any increase in the authorized number of directors shall, unless the Board determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled only by a majority of the directors then in office, although less than a quorum, or by a sole remaining director. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the class, if any, of the director for which the vacancy was created or occurred and until such director’s successor shall have been elected and qualified. A vacancy in the Board shall be deemed to exist under these bylaws in the case of the death, removal or resignation of any director.
3.5    PLACE OF MEETINGS; MEETINGS BY TELEPHONE.
The Board may hold meetings, both regular and special, either within or outside the State of Delaware.
Unless otherwise restricted by the Certificate of Incorporation or these bylaws, members of the Board, or any committee designated by the Board, may participate in a meeting of the Board, or any committee, by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting pursuant to this bylaw shall constitute presence in person at the meeting.
3.6    REGULAR MEETINGS.
Regular meetings of the Board may be held without notice at such time and at such place as shall from time to time be determined by the Board; provided that any director who is absent when such determination is made shall be given notice of the determination. A regular meeting of the Board may be held without notice immediately after and at the same place as the annual meeting of stockholders.
3.7    SPECIAL MEETINGS; NOTICE.
Special meetings of the Board for any purpose or purposes may be called at any time by the chairperson of the Board, the chief executive officer, the president, the secretary or a majority of the total number of directors then in office (regardless of vacancies).
- 17 -


Notice of the time and place of special meetings shall be:
(a)    delivered personally by hand, by courier or by telephone;
(b)    sent by United States first-class mail, postage prepaid;
(c)    sent by facsimile or electronic mail; or
(d)    sent by other means of electronic transmission (including, without limitation, calendar invitation by electronic invitation),
directed to each director at that director’s address, telephone number, facsimile number or electronic mail address, or other address for electronic transmission, as the case may be, as shown on the Corporation’s records.
If the notice is (a) delivered personally by hand, by courier or by telephone, (b) sent by facsimile or (c) sent by electronic mail or other means of electronic transmission, it shall be delivered or sent at least twenty-four (24) hours before the time of the holding of the meeting. If the notice is sent by United States mail, it shall be deposited in the United States mail at least four (4) days before the time of the holding of the meeting. Any oral notice may be communicated to the director. The notice need not specify the place of the meeting (if the meeting is to be held at the Corporation’s principal executive office) nor the purpose of the meeting.
3.8    QUORUM.
The greater of (a) a majority of the directors at any time in office and (b) one-third of the number of directors established by the Board pursuant to Section 3.2 of these bylaws shall constitute a quorum of the Board for the transaction of business. The affirmative vote of a majority of the directors present at any meeting at which a quorum is present shall be the act of the Board, except as may be otherwise specifically provided by statute, the Certificate of Incorporation or these bylaws. If a quorum is not present at any meeting of the Board, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present.
3.9    BOARD ACTION BY CONSENT WITHOUT A MEETING.
Unless otherwise restricted by the Certificate of Incorporation or these bylaws, any action required or permitted to be taken at any meeting of the Board, or of any committee thereof, may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing or by electronic transmission. Any such consent may be documented, signed and delivered in any manner permitted by Section 116 of the DGCL. After any such action is taken, the writing or writings or electronic transmission or transmissions relating thereto shall be filed with the minutes of proceedings of the Board or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.
- 18 -


3.10    FEES AND COMPENSATION OF DIRECTORS.
Unless otherwise restricted by the Certificate of Incorporation or these bylaws, the Board shall have the authority to fix the compensation, including fees and reimbursement of expenses, of directors.
3.11    REMOVAL OF DIRECTORS.
Subject to the rights of the holders of the shares of any series of Preferred Stock, the Board or any individual director may be removed from office only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon.
ARTICLE IV - COMMITTEES
4.1    COMMITTEES OF DIRECTORS.
The Board may designate one (1) or more committees, each committee to consist of one (1) or more of the directors of the Corporation. The Board may designate one (1) or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board or in these bylaws, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require it; but no such committee shall have the power or authority to (a) approve or adopt, or recommend to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (b) adopt, amend or repeal any bylaw of the Corporation.
4.2    COMMITTEE MINUTES.
Each committee shall keep regular minutes of its meetings and report the same to the Board when required.
4.3    MEETINGS AND ACTION OF COMMITTEES.
Meetings and actions of committees shall be governed by, and held and taken in accordance with, the provisions of:
(a)    Section 3.5 of these bylaws (place of meetings and meetings by telephone);
(b)    Section 3.6 of these bylaws (regular meetings);
- 19 -


(c)    Section 3.7 of these bylaws (special meetings and notice);
(d)    Section 3.8 of these bylaws (quorum);
(e)    Section 3.9 of these bylaws (action without a meeting); and
(f)    Section 7.12 of these bylaws (waiver of notice),
with such changes in the context of those bylaws as are necessary to substitute the committee and its members for the Board and its members. However:
(i)    the time of regular meetings of committees may be determined either by resolution of the Board or by resolution of the committee;
(ii)    special meetings of committees may also be called by resolution of the Board or the chairperson of the applicable committee; and
(iii)    the Board may adopt rules for the governance of any committee to override the provisions that would otherwise apply to the committee pursuant to this Section 4.3, provided that such rules do not violate the provisions of the Certificate of Incorporation or applicable law.
ARTICLE V - OFFICERS
5.1    OFFICERS.
The officers of the Corporation shall include a president and a secretary. The Corporation may also have a chief executive officer, a chief financial officer or treasurer, one (1) or more vice presidents, one (1) or more assistant vice presidents, one (1) or more assistant treasurers, one (1) or more assistant secretaries, and any such other officers as may be appointed in accordance with the provisions of these bylaws. Any number of offices may be held by the same person. If determined by the Board, the chairperson (or any vice chairperson) of the Board may be an officer of the Corporation.
5.2    APPOINTMENT OF OFFICERS.
All officers of the Corporation whose responsibilities include participation in major policy making functions of the Corporation, including any such officers determined to be an “executive officer,” as such term is defined under Rule 3b-7 of the Exchange Act, or an “officer,” as such term is defined under Rule 16a-1(f) of the Exchange Act (the “executive officers”), shall be appointed by the Board, subject to the rights, if any, of an executive officer under any contract of employment.
5.3    SUBORDINATE OFFICERS.
All officers that are not executive officers, including vice presidents, assistant vice presidents, assistant treasurers and other officers (the “subordinate officers”), and any such
- 20 -


agents as the business of the Corporation may require, may be appointed by the Board, by the chief executive officer of the Corporation, or in the absence of a chief executive officer, by the then acting president of the Corporation, or by any other officer to whom the Board has conferred such authority. Each of such subordinate officers and agents shall hold office for such period, have such authority, and perform such duties as the Board, the chief executive officer (or the president in his or her absence) or any other officer upon whom the Board has conferred such authority may from time to time determine.
5.4    REMOVAL AND RESIGNATION OF OFFICERS.
Subject to the rights, if any, of an officer under any contract of employment, any officer may be removed, either with or without cause, by the Board or, except in the case of an executive officer or any other officer chosen by the Board, by the chief executive officer (or the president in his or her absence) or by any other officer upon whom such power of removal may be conferred by the Board.
Any officer may resign at any time by giving written notice to the Corporation. Any resignation shall take effect at the date of the receipt of that notice or at any later time specified in that notice. Unless otherwise specified in the notice of resignation, the acceptance of the resignation shall not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party.
5.5    VACANCIES IN OFFICES.
Any vacancy occurring in any office of the Corporation shall be filled by the Board, or as provided in Section 5.3 of these bylaws.
5.6    REPRESENTATION OF SHARES OF OTHER CORPORATIONS.
The chief executive officer, the president, any vice president, the treasurer, the secretary or assistant secretary of this Corporation, or any other person authorized by the Board or the chief executive officer or the president or a vice president, is authorized to vote, represent and exercise on behalf of this Corporation all rights incident to any and all securities of any other entity or entities standing in the name of this Corporation. The authority granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority.
5.7    AUTHORITY AND DUTIES OF OFFICERS.
All officers of the Corporation shall respectively have such authority and perform such duties in the management of the business of the Corporation as may be designated from time to time by the Board, the chief executive officer of the Corporation (or the president in his or her absence), or by any officer upon whom the Board has conferred such authority, and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board or the chief executive officer, as applicable.
- 21 -


ARTICLE VI - RECORDS AND REPORTS
6.1    MAINTENANCE OF RECORDS.
The Corporation shall, either at its principal executive office or at such place or places as designated by the Board, keep a record of its stockholders listing their names and addresses and the number and class of shares held by each stockholder, a copy of these bylaws as amended to date, accounting books and other records.
ARTICLE VII - GENERAL MATTERS
7.1    EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS.
The Board, except as otherwise provided in these bylaws, may authorize any officer or officers, or agent or agents, to enter into any contract or execute any instrument in the name of and on behalf of the Corporation; such authority may be general or confined to specific instances. Unless so authorized or ratified by the Board or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.
7.2    CERTIFICATED AND UNCERTIFICATED STOCK; PARTLY PAID SHARES.
The shares of the Corporation shall be represented by certificates or shall be uncertificated. The Corporation may adopt a system of issuance, recordation and transfer of its shares of stock by electronic or other means not involving the issuance of certificates, provided the use of such system by the Corporation is permitted in accordance with applicable law. Certificates for the shares of stock, if any, shall be in such form as is consistent with the Certificate of Incorporation and applicable law. Every holder of stock represented by a certificate shall be entitled to have a certificate signed by or in the name of the Corporation by any two authorized officers of the Corporation in a manner that complies with Section 158 of the DGCL (it being understood that each of the chief executive officer, the president, any vice president, the treasurer, any assistant treasurer, the secretary or any assistant secretary of the Corporation shall be an authorized person for purposes of signing certificates in the name of the Corporation representing the number of shares registered in certificate form). Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer, transfer agent or registrar at the date of issue.
The Corporation may issue the whole or any part of its shares as partly paid and subject to call for the remainder of the consideration to be paid therefor. Upon the face or back of each stock certificate issued to represent any such partly paid shares, or upon the books and records of the Corporation in the case of uncertificated partly paid shares, the total amount of the consideration to be paid therefor and the amount paid thereon shall be stated. Upon the
- 22 -


declaration of any dividend on fully paid shares, the Corporation shall declare a dividend upon partly paid shares of the same class, but only upon the basis of the percentage of the consideration actually paid thereon.
7.3    SPECIAL DESIGNATION ON CERTIFICATES.
If the Corporation is authorized to issue more than one class of stock or more than one series of any class, then the powers, the designations, the preferences and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of the certificate that the Corporation shall issue to represent such class or series of stock; provided, however, that, except as otherwise provided in Section 202 of the DGCL, in lieu of the foregoing requirements, there may be set forth on the face or back of the certificate that the Corporation shall issue to represent such class or series of stock a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, the designations, the preferences and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.
7.4    LOST CERTIFICATES.
Except as provided in this Section 7.4, no new certificates for shares shall be issued to replace a previously issued certificate unless the latter is surrendered to the Corporation and cancelled at the same time. The Corporation may issue a new certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner’s legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares.
7.5    CONSTRUCTION; DEFINITIONS.
Unless the context requires otherwise, the general provisions, rules of construction and definitions in the DGCL shall govern the construction of these bylaws. Without limiting the generality of this provision, the singular number includes the plural, the plural number includes the singular, and the term “person” includes both a corporation and a natural person.
7.6    DIVIDENDS.
The Board, subject to any restrictions contained in either (a) the DGCL or (b) the Certificate of Incorporation, may declare and pay dividends upon the shares of its capital stock. Dividends may be paid in cash, in property or in shares of the Corporation’s capital stock.
The Board may set apart out of any of the funds of the Corporation available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve. Such
- 23 -


purposes shall include but not be limited to equalizing dividends, repairing or maintaining any property of the Corporation, and meeting contingencies.
7.7    FISCAL YEAR.
The fiscal year of the Corporation shall be fixed by resolution of the Board and may be changed by the Board.
7.8    SEAL.
The Corporation may adopt a corporate seal, which shall be adopted and which may be altered by the Board. The Corporation may use the corporate seal by causing it or a facsimile thereof to be impressed or affixed or in any other manner reproduced.
7.9    TRANSFER OF STOCK.
Shares of the Corporation shall be transferable in the manner prescribed by law and in these bylaws. Shares of stock of the Corporation shall be transferred on the books of the Corporation only by the holder of record thereof or by such holder’s attorney duly authorized in writing, upon surrender to the Corporation of the certificate or certificates representing such shares endorsed by the appropriate person or persons (or by delivery of duly executed instructions with respect to uncertificated shares), with such evidence of the authenticity of such endorsement or execution, transfer, authorization and other matters as the Corporation may reasonably require, and accompanied by all necessary stock transfer stamps. No transfer of stock shall be valid as against the Corporation for any purpose until it shall have been entered in the stock records of the Corporation by an entry showing the names of the persons from and to whom it was transferred.
7.10    STOCK TRANSFER AGREEMENTS.
The Corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL.
7.11    REGISTERED STOCKHOLDERS.
The Corporation:
(a)    shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner;
(b)    shall be entitled to hold liable for calls and assessments the person registered on its books as the owner of shares; and
- 24 -


(c)    shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of another person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware.
7.12    WAIVER OF NOTICE.
Whenever notice is required to be given under any provision of the DGCL, the Certificate of Incorporation or these bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting need be specified in any written waiver of notice or any waiver by electronic transmission unless so required by the Certificate of Incorporation or these bylaws.
7.13    ELECTRONIC SIGNATURES, ETC.
Any document, including, without limitation, any consent, agreement, certificate or instrument, required by the DGCL, the Certificate of Incorporation or these Bylaws to be executed by any officer, director, stockholder, employee or agent of the Corporation may be executed using a facsimile or other form of electronic signature to the fullest extent permitted by applicable law. All other contracts, agreements, certificates or instruments to be executed on behalf of the Corporation may be executed using a facsimile or other form of electronic signature to the fullest extent permitted by applicable law.
ARTICLE VIII - NOTICE BY ELECTRONIC TRANSMISSION
8.1    NOTICE BY ELECTRONIC TRANSMISSION.
Without limiting the manner by which notice otherwise may be given effectively to stockholders pursuant to the DGCL, the Certificate of Incorporation or these bylaws, but subject to Section 232(e) of the DGCL, any notice to stockholders given by the Corporation under any provision of the DGCL, the Certificate of Incorporation or these bylaws shall be effective if given by (a) electronic mail to such person’s electronic mail address as it appears on the Corporation’s records, with a prominent legend that the communication is an important notice regarding the Corporation, or (2) any other form of electronic transmission consented to by the stockholder to whom the notice is given. Any consent provided pursuant to the foregoing clause (B) shall be revocable by the stockholder by written notice or electronic transmission to the Corporation. Any such consent shall be deemed revoked if:
(a)    the Corporation is unable to deliver by electronic transmission two (2) consecutive notices given by the Corporation in accordance with such consent; and
- 25 -


(b)    such inability becomes known to the secretary or an assistant secretary of the Corporation or to the transfer agent, or other person responsible for the giving of notice.
However, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action.
Any notice given pursuant to the preceding paragraph shall be deemed given:
(a)    if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice;
(b)    if by electronic mail, when directed to the stockholder’s electronic mail address unless the stockholder has notified the Corporation in writing or by electronic transmission of an objection to receiving notice by electronic mail or such notice is prohibited by Section 232(e) of the DGCL;
(c)    if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of (i) such posting and (ii) the giving of such separate notice; and
(d)    if by any other form of electronic transmission, when directed to the stockholder.
An affidavit of the secretary or an assistant secretary of the Corporation or of the transfer agent or other agent of the Corporation that the notice has been given by a form of electronic transmission shall, in the absence of fraud, be prima facie evidence of the facts stated therein.
8.2    DEFINITION OF ELECTRONIC TRANSMISSION.
For the purposes of these bylaws, “electronic transmission,” “electronic mail” and “electronic mail address” shall have the meaning given in Section 232 of the DGCL.
ARTICLE IX - INDEMNIFICATION
9.1    INDEMNIFICATION OF DIRECTORS AND OFFICERS.
The Corporation shall indemnify and hold harmless, to the fullest extent permitted by the DGCL as it presently exists or may hereafter be amended, any director or officer of the Corporation who was or is made or is threatened to be made a party or is otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”) by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director or officer of the Corporation or, while serving as a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or non-profit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys’ fees, judgments, fines ERISA excise taxes or penalties and amounts paid in settlement) actually and
- 26 -


reasonably incurred by such person in connection with any such Proceeding. Notwithstanding the preceding sentence, except as otherwise provided in Section 9.4 of these bylaws, the Corporation shall be required to indemnify a person in connection with a Proceeding initiated by such person only if the Proceeding was authorized in the specific case by the Board.
9.2    INDEMNIFICATION OF OTHERS.
The Corporation shall have the power to indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any employee or agent of the Corporation who was or is made or is threatened to be made a party or is otherwise involved in any Proceeding by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was an employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or non-profit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses reasonably incurred by such person in connection with any such Proceeding.
9.3    PREPAYMENT OF EXPENSES.
The Corporation shall to the fullest extent not prohibited by applicable law pay the expenses (including attorneys’ fees) incurred by any officer or director of the Corporation, and may pay the expenses incurred by any employee or agent of the Corporation, in defending any Proceeding in advance of its final disposition; provided, however, that, to the extent required by law, such payment of expenses in advance of the final disposition of the Proceeding shall be made only upon receipt of an undertaking by the person to repay all amounts advanced if it should be ultimately determined that the person is not entitled to be indemnified under this Article IX or otherwise.
9.4    DETERMINATION; CLAIM.
If a claim for indemnification (following the final disposition of such Proceeding) under this Article IX is not paid in full within sixty (60) days, or a claim for advancement of expenses under this Article IX is not paid in full within thirty (30) days, after a written claim therefor has been received by the Corporation the claimant may thereafter (but not before) file suit to recover the unpaid amount of such claim and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim to the fullest extent permitted by law. In any such action the Corporation shall have the burden of proving that the claimant was not entitled to the requested indemnification or payment of expenses under applicable law.
9.5    NON-EXCLUSIVITY OF RIGHTS.
The rights conferred on any person by this Article IX shall not be exclusive of any other rights which such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, these bylaws, agreement, vote of stockholders or disinterested directors or otherwise.
- 27 -


9.6    INSURANCE.
The Corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust enterprise or non-profit entity against any liability asserted against him or her and incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the Corporation would have the power to indemnify him or her against such liability under the provisions of the DGCL.
9.7    OTHER INDEMNIFICATION.
The Corporation’s obligation, if any, to indemnify or advance expenses to any person who was or is serving at its request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, enterprise or non-profit entity shall be reduced by any amount such person may collect as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust, enterprise or non-profit enterprise.
9.8    AMENDMENT OR REPEAL; INTERPRETATION.
The provisions of this Article IX shall constitute a contract between the Corporation, on the one hand, and, on the other hand, each individual who serves or has served as a director or officer of the Corporation (whether before or after the adoption of these bylaws), in consideration of such person’s performance of such services, and pursuant to this Article IX the Corporation intends to be legally bound to each such current or former director or officer of the Corporation. With respect to current and former directors and officers of the Corporation, the rights conferred under this Article IX are present contractual rights and such rights are fully vested, and shall be deemed to have vested fully, immediately upon adoption of theses bylaws. With respect to any directors or officers of the Corporation who commence service following adoption of these bylaws, the rights conferred under this provision shall be present contractual rights and such rights shall fully vest, and be deemed to have vested fully, immediately upon such director or officer commencing service as a director or officer of the Corporation. Any repeal or modification of the foregoing provisions of this Article IX shall not adversely affect any right or protection (i) hereunder of any person in respect of any act or omission occurring prior to the time of such repeal or modification or (ii) under any agreement providing for indemnification or advancement of expenses to an officer or director of the Corporation in effect prior to the time of such repeal or modification.
Any reference to an officer of the Corporation in this Article IX shall be deemed to refer exclusively to the president, a chief executive officer, a chief financial officer, a treasurer appointed pursuant to Article V of these bylaws, and to any vice president, assistant secretary, assistant treasurer, or other officer of the Corporation appointed by (x) the Board pursuant to Article V of these bylaws or (y) an officer to whom the Board has delegated the power to appoint officers pursuant to Article V of these bylaws, and any reference to an officer of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be deemed to refer exclusively to an officer appointed by the board of directors (or equivalent
- 28 -


governing body) of such other entity pursuant to the Certificate of Incorporation and bylaws (or equivalent organizational documents) of such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise. The fact that any person who is or was an employee of the Corporation or an employee of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise has been given or has used the title of “vice president” or any other title that could be construed to suggest or imply that such person is or may be an officer of the Corporation or of such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall not result in such person being constituted as, or being deemed to be, an officer of the Corporation or of such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise for purposes of this Article IX.
9.9    DEFINITIONS.
Terms used in this Article IX and defined in Section 145(h) and Section 145(i) of the DGCL shall have the respective meanings assigned to such terms in such Section 145(h) and Section 145(i).
ARTICLE X - AMENDMENTS
The Board is expressly empowered to adopt, amend or repeal the bylaws of the Corporation. The stockholders also shall have power to adopt, amend or repeal the bylaws of the Corporation; provided, however, that, in addition to any vote of the holders of any class or series of stock of the Corporation required by law or by the Certificate of Incorporation, such action by stockholders shall require the affirmative vote of the holders of at least two-thirds (2/3) in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon.

- 29 -


Inari Medical, Inc.
Certificate of Amendment and Restatement of Bylaws




The undersigned hereby certifies that he or she is the duly elected, qualified, and acting Secretary of Inari Medical, Inc., a Delaware corporation (the “Corporation”), and that the foregoing bylaws were approved on October 25, 2024, effective as of October 25, 2024 by the Corporation’s Board of Directors.
IN WITNESS WHEREOF, the undersigned has hereunto set his or her hand this 25th day of October 2024.

/s/ Angela Ahmad
Angela Ahmad
Secretary




 EX-10.1 3 exhibit101-employmentagree.htm EX-10.1 Document
Exhibit 10.1
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (this “Agreement”), effective as of October 1, 2024, is entered into by and between Inari Medical, Inc., a Delaware corporation (the “Company”) and Kevin Strange (the “Executive”).
WHEREAS, the Executive is currently employed as the Senior Vice President of Finance, Accounting, Strategy and Business Development of the Company and, effective October 1, 2024, will be employed as Chief Financial Officer of the Company; and
WHEREAS, the Company desires to continue the employment of the Executive, and the Company and the Executive desire to enter into an agreement embodying the terms of such employment, subject to the terms and conditions of this Agreement.
NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:
1.Employment Period. Effective as of October 1, 2024, (the “Effective Date”), the Executive’s employment hereunder shall be for a term (the “Employment Period”) commencing on the Effective Date and will continue until the fifth anniversary of the Effective Date (the “Initial Term”). The Executive’s employment hereunder will be extended for additional one year periods (a “Renewal Term”) on the last day of the Initial Term or the end of any preceding Renewal Term, respectively, unless either the Executive or the Company elects not to so extend the Employment Period by notifying the other party, in writing, of such election not less than 60 days prior to the last day of the Initial Term or Renewal Term, as applicable, or unless earlier terminated in accordance with the terms of this Agreement. Notwithstanding anything to the contrary in the foregoing, the Executive’s employment hereunder is terminable at will by the Company or by the Executive at any time (for any reason or for no reason), subject to the provisions of Section 4 hereof.

2.Terms of Employment.

(a)Position and Duties.

(i)Role and Responsibilities. During the Employment Period, the Executive shall serve as Chief Financial Officer of the Company, and shall perform such employment duties as are usual and customary for such position. The Executive shall report directly to the Chief Executive Officer of the Company (the “CEO”). At the Company’s request, the Executive shall serve the Company and/or its subsidiaries and affiliates in other capacities in addition to the foregoing, consistent with the Executive’s position hereunder. In the event that the Executive, during the Employment Period, serves in any one or more of such additional capacities, the Executive’s compensation shall not be increased beyond that specified in Section 2(b) hereof. In addition, in the event the Executive’s service in one or more of such additional capacities is terminated, the Executive’s compensation, as specified in Section 2(b) hereof, shall not be diminished or reduced in any manner as a result of such termination provided that the Executive otherwise remains employed under the terms of this Agreement.

(ii)Exclusivity. During the Employment Period, and excluding any periods of leave to which the Executive may be entitled, the Executive agrees to devote his full business time and attention to the business and affairs of the Company. Notwithstanding the foregoing, during the Employment Period, it shall not be a violation of this Agreement for the Executive to: (A) serve on the board of directors of other corporations, (B) serve on boards, committees or similar bodies of charitable or nonprofit organizations, (C) fulfill limited teaching, speaking and writing engagements, and (D) manage his personal investments, in each case, so long as such activities do not individually or in the aggregate materially interfere or conflict with the performance of the Executive’s duties and responsibilities under this Agreement; provided, that with respect to the activities in subclauses (A) and/or (B), the Executive receives prior written approval from the Board of Directors of the Company (the “Board”).

(iii)Principal Location. During the Employment Period, the Executive shall perform the services required by this Agreement at the Company’s offices located in Irvine, California (the “Principal Location”).


(b)Compensation, Benefits, Etc.

(i)Base Salary. Effective as of the Effective Date and during the Employment Period, the Executive shall receive a base salary (the “Base Salary”) of $480,000 per annum. The Base Salary shall be paid in accordance with the Company’s normal payroll practices for executive salaries generally, but no less often than monthly and shall be pro-rated for partial years of employment. The Base Salary may be increased in the discretion of the Board or a subcommittee thereof, but not reduced, and the term “Base Salary” as utilized in this Agreement shall refer to the Base Salary as so increased.

(ii)Annual Cash Bonus. For each calendar year ending during the Employment Period, the Executive shall be eligible to earn a cash performance bonus (an “Annual Bonus”) under the Company’s bonus plan or program applicable to senior executives targeted at 60% of the Executive’s Base Salary (the “Target Bonus”). The Target Bonus may be increased in the discretion of the Board or a subcommittee thereof, but not reduced, and the term “Target Bonus” as utilized in this Agreement shall refer to the Target Bonus as so increased. The actual amount of any Annual Bonus shall be determined by the Board (or a subcommittee thereof) in its discretion, based on the achievement of individual and/or Company performance goals as determined by the Board (or a subcommittee thereof). The payment of any Annual Bonus, to the extent any Annual Bonus becomes payable, will be made on the date on which annual bonuses are paid generally to the Company’s senior executives, but in no event later than March 15th of the calendar year following the calendar year in which such Annual Bonus was earned, subject to the Executive’s continued employment through the payment date.

(iii)Benefits. During the Employment Period, the Executive (and the Executive’s spouse and/or eligible dependents to the extent provided in the applicable plans and programs) shall be eligible to participate in and be covered under the health and welfare benefit plans and programs maintained by the Company for the benefit of its employees from time to time, pursuant to the terms of such plans and programs including any medical, life, hospitalization, dental, disability, accidental death and dismemberment and travel accident insurance plans and programs on the same terms and conditions as those applicable to similarly situated senior executives. In addition, during the Employment Period, the Executive shall be eligible to participate in any retirement, savings and other employee benefit plans and programs maintained from time to time by the Company for the benefit of its senior executive officers. Nothing contained in this Section 2(b)(iii) shall create or be deemed to create any obligation on the part of the Company to adopt or maintain any health, welfare, retirement or other benefit plan or program at any time or to create any limitation on the Company’s ability to modify or terminate any such plan or program.

(iv)Expenses. During the Employment Period, the Executive shall be entitled to receive prompt reimbursement for all reasonable business expenses incurred by the Executive in connection with the performance of his duties under this Agreement in accordance with the policies, practices and procedures of the Company provided to employees of the Company.

(v)Fringe Benefits. During the Employment Period, the Executive shall be eligible to receive such fringe benefits and perquisites as are provided by the Company to its employees from time to time, in accordance with the policies, practices and procedures of the Company, and shall receive such additional fringe benefits and perquisites as the Company may, in its discretion, from time-to-time provide.

(vi)Vacation. During the Employment Period, the Executive shall be entitled to paid vacation in accordance with the plans, policies, programs and practices of the Company applicable to its senior executive officers.

3.Termination of Employment.

(a)Death or Disability. The Executive’s employment shall terminate automatically upon the Executive’s death during the Employment Period. Either the Company or the Executive may terminate the Executive’s employment in the event of the Executive’s Disability during the Employment Period.



(b)Termination by the Company. The Company may terminate the Executive’s employment during the Employment Period for Cause or without Cause.

(c)Termination by the Executive. The Executive’s employment may be terminated by the Executive for any or no reason, including with Good Reason or by the Executive without Good Reason.

(d)Notice of Termination. Any termination of employment (other than due to the Executive’s death), shall be communicated by a Notice of Termination to the other parties hereto given in accordance with Section 11(b) hereof. The failure by the Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of the Executive or the Company, respectively, hereunder or preclude the Executive or the Company, respectively, from asserting such fact or circumstance in enforcing the Executive’s or the Company’s rights hereunder.

(e)Termination of Offices and Directorships; Return of Property. Upon termination of the Executive’s employment for any reason, unless otherwise specified in a written agreement between the Executive and the Company, the Executive shall be deemed to have resigned from all offices, directorships, and other employment positions if any, then held with the Company, and shall take all actions reasonably requested by the Company to effectuate the foregoing. In addition, upon the termination of the Executive’s employment for any reason, the Executive agrees to return to the Company all documents of the Company and its affiliates (and all copies thereof) and all other Company or Company affiliate property that the Executive has in his possession, custody or control. Such Company property, if applicable, includes, without limitation: (i) any materials of any kind that the Executive knows contain or embody any proprietary or confidential information of the Company or an affiliate of the Company (and all reproductions thereof), (ii) computers (including, but not limited to, laptop computers, desktop computers and similar devices) and other portable electronic devices (including, but not limited to, tablet computers), cellular phones/smartphones, credit cards, phone cards, entry cards, identification badges and keys, and (iii) any correspondence, drawings, manuals, letters, notes, notebooks, reports, programs, plans, proposals, financial documents, or any other documents concerning the customers, business plans, marketing strategies, products and/or processes of the Company or any of its affiliates and any information received from the Company or any of its affiliates regarding third parties.

4.Obligations of the Company upon Termination.

(a)Accrued Obligations. In the event that the Executive’s employment under this Agreement terminates during the Employment Period for any reason, the Company will pay or provide to the Executive: (i) any earned but unpaid Base Salary, (ii) reimbursement of any business expenses incurred by the Executive prior to the Date of Termination that are reimbursable in accordance with Section 2(b)(iv) hereof and (iii) any vested amounts due to the Executive under any plan, program or policy of the Company (together, the “Accrued Obligations”). The Accrued Obligations described in clauses (i) – (ii) of the preceding sentence shall be paid within 30 days after the Date of Termination (or such earlier date as may be required by applicable law) and the Accrued Obligations described in clause (iii) of the preceding sentence shall be paid in accordance with the terms of the governing plan or program.

(b)Qualifying Termination. Subject to Sections 4(c), 4(e) and 11(d), and the Executive’s continued compliance with the provisions of Section 7 hereof, if the Executive’s employment with the Company is terminated during the Employment Period due to a Qualifying Termination, then in addition to the Accrued Obligations:

(i)Cash Severance. The Company shall pay the Executive an amount equal to 0.75 (the “Severance Multiplier”) multiplied by the Base Salary (the “Severance”). In the event the Qualifying Termination occurs within three months prior to, on, or within 12 months following a Change in Control (a “Change in Control Qualifying Termination”), then the Severance Multiplier instead shall be 1.5 and the Severance Multiplier will be multiplied by the sum of Base Salary and Target Bonus. The Severance shall be paid in substantially equal installments in accordance with the Company’s normal payroll practices during the nine-month period, or in the case of a Change in Control Qualifying Termination, the 18-month period, following the Date of Termination, but, in each case, shall commence on the first payroll date following the effective date of the Release (as defined below),


and amounts otherwise payable prior to such first payroll date shall be paid on such date without interest thereon; provided, however that if the Date of Termination occurs on or within three months prior to or 12 months following a Change in Control that constitutes a “change in control event” for purposes of Section 409A (as defined below), (A) if the Date of Termination occurs on or within 12 months following a Change in Control, the Severance shall be paid in a single lump sum cash payment within 30 days following the Date of Termination, and (B) if the Date of Termination occurs within three months prior to a Change in Control, the remaining Severance payable as of the Change in Control shall be paid in a single lump sum cash payment within 30 days following the Change in Control.

(ii)COBRA. Subject to the Executive’s valid election to continue healthcare coverage under Section 4980B of the Code, the Company shall continue to provide, during the COBRA Period, the Executive and the Executive’s eligible dependents with coverage under its group health plans at the same levels and the same cost to the Executive as would have applied if the Executive’s employment had not been terminated based on the Executive’s elections in effect on the Date of Termination, provided, however, that (A) if any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the period of continuation coverage to be, exempt from the application of Section 409A under Treasury Regulation Section 1.409A-1(a)(5), or (B) the Company is otherwise unable to continue to cover the Executive under its group health plans without incurring penalties (including without limitation, pursuant to Section 2716 of the Public Health Service Act or the Patient Protection and Affordable Care Act), then, in either case, an amount equal to each remaining Company subsidy shall thereafter be paid to the Executive in substantially equal monthly installments over the continuation coverage period (or the remaining portion thereof). For purposes of this Agreement, “COBRA Period” shall mean the period beginning on the Date of Termination and ending on the nine-month anniversary thereof; provided, however, that in the event of a Change in Control Qualifying Termination, then the COBRA Period instead shall end on the 18-month anniversary thereof.

(iii)Pro-Rated Bonus. In addition, in the event of a Qualifying Termination, the Executive shall be paid a pro-rata Annual Bonus for the year of termination. For a Qualifying Termination that is not a Change in Control Qualifying Termination, the Annual Bonus shall be based on the degree to which the Company has attained any applicable Company-wide performance metrics for the full year, with any discretionary or personal performance goals, should they apply, treated as having been attained at target. The portion of such Annual Bonus to be received by Executive (a “Pro-Rata Annual Cash Bonus”) shall be determined by multiplying the Annual Bonus amount determined under the first sentence of this clause (iii) by a fraction whose numerator is the number of days during the calendar year of termination that he was employed with the Company and whose denominator is 365. Any Pro-Rata Annual Cash Bonus will be paid in cash when the corresponding Annual Cash Bonus would have been paid to Executive for such year absent such termination but no later than March 15 of the immediately following year. For a Change in Control Qualifying Termination, the Pro-Rata Annual Cash Bonus shall be based on the Target Bonus and paid in a single lump sum cash payment (A) if the Date of Termination occurs on or within 12 months following a Change in Control, within 30 days following the Date of Termination, and (B) if such Date of Termination occurs within three months prior to a Change in Control, within 30 days following the Change in Control.
(iv)Equity Acceleration. In addition, in the event of a Change in Control Qualifying Termination, then all outstanding Company equity awards that vest based solely on the passage of time (each, a “Time-Based Equity Award”) that are held by the Executive on the Date of Termination shall become fully vested and, to the extent applicable, exercisable immediately prior to the Date of Termination (or if such Date of Termination occurs within three months prior to a Change in Control, immediately prior to the Change in Control). In the event that a Qualifying Termination occurs within three months prior to a Change in Control, then each outstanding Time-Based Equity Award held by the Executive as of his Date of Termination shall remain outstanding until the earlier to occur of (i) the three-month anniversary of the Date of Termination and (ii) a Change in Control (but in no event beyond the outside expiration date of a Time-Based Equity Award that is a stock option), and the unvested portion of each such award shall remain eligible to vest in connection with a Change in Control that occurs during such three-month period. For the avoidance of doubt, should a Change in Control not occur during the three-month period following the Date of Termination, all unvested Time-Based Equity Awards will be forfeited. Any outstanding Company equity awards that include pre-established performance conditions (each, a “Performance-Based Equity Award”) shall be treated in accordance with the terms of their respective award agreements.



(c)Release. Notwithstanding the foregoing, it shall be a condition to the Executive’s right to receive the amounts provided for in Section 4(b) hereof that the Executive execute and deliver to the Company an effective release of claims in substantially the form attached hereto as Exhibit A (the “Release”) within 21 days (or, to the extent required by law, 45 days) following the Date of Termination and that the Executive not revoke such Release during any applicable revocation period. For the avoidance of doubt, all equity awards eligible for accelerated vesting upon a Change in Control Qualifying Termination pursuant to Section 4(b) hereof shall remain outstanding and eligible to vest following the Date of Termination and shall actually vest and become exercisable (if applicable) and non-forfeitable upon the effectiveness of the Release, or, if later, immediately prior to the Change in Control.

(d)Other Terminations. If the Executive’s employment is terminated for any reason not described in Section 4(b) hereof, the Company will pay the Executive only the Accrued Obligations.

(e)Six-Month Delay. Notwithstanding anything to the contrary in this Agreement, no compensation or benefits, including without limitation any severance payments or benefits payable under this Section 4, shall be paid to the Executive during the six-month period following the Executive’s Separation from Service if the Company determines that paying such amounts at the time or times indicated in this Agreement would be a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code. If the payment of any such amounts is delayed as a result of the previous sentence, then on the first day of the seventh month following the date of Separation from Service (or such earlier date upon which such amount can be paid under Section 409A without resulting in a prohibited distribution, including as a result of the Executive’s death), the Company shall pay the Executive a lump-sum amount equal to the cumulative amount that would have otherwise been payable to the Executive during such period.

(f)Exclusive Benefits. Except as expressly provided in this Section 4 and subject to Section 5 hereof, the Executive shall not be entitled to any additional payments or benefits upon or in connection with the Executive’s termination of employment.

5.Non-Exclusivity of Rights. Amounts which are vested benefits or which the Executive is otherwise entitled to receive under any plan, policy, practice or program of or any contract or agreement with the Company at or subsequent to the Date of Termination shall be payable in accordance with such plan, policy, practice or program or contract or agreement except as explicitly modified by this Agreement.

6.Excess Parachute Payments; Limitation on Payments.

(a)Best Pay Cap. Notwithstanding any other provision of this Agreement, in the event that any payment or benefit received or to be received by the Executive (including any payment or benefit received in connection with a termination of the Executive’s employment, whether pursuant to the terms of this Agreement or any other plan, arrangement or agreement) (all such payments and benefits, including the payments and benefits under Section 4 hereof, being hereinafter referred to as the “Total Payments”) would be subject (in whole or part), to the excise tax imposed under Section 4999 of the Code (the “Excise Tax”), then, after taking into account any reduction in the Total Payments provided by reason of Section 280G of the Code in such other plan, arrangement or agreement, the cash severance payments under this Agreement shall first be reduced, and the noncash severance payments hereunder shall thereafter be reduced, to the extent necessary so that no portion of the Total Payments is subject to the Excise Tax but only if (i) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (ii) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which the Executive would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments).

(b)Certain Exclusions. For purposes of determining whether and the extent to which the Total Payments will be subject to the Excise Tax, (i) no portion of the Total Payments the receipt or enjoyment of which the Executive shall have waived at such time and in such manner as not to constitute a “payment” within the


meaning of Section 280G(b) of the Code shall be taken into account; (ii) no portion of the Total Payments shall be taken into account which, in the written opinion of an independent, nationally recognized accounting firm (the “Independent Advisors”) selected by the Company, does not constitute a “parachute payment” within the meaning of Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, no portion of such Total Payments shall be taken into account which, in the opinion of Independent Advisors, constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the “base amount” (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation; and (iii) the value of any non-cash benefit or any deferred payment or benefit included in the Total Payments shall be determined by the Independent Advisors in accordance with the principles of Sections 280G(d)(3) and (4) of the Code.

7.Restrictive Covenants.

(a)The Executive hereby acknowledges that the Executive has previously entered into an agreement with the Company containing confidentiality, intellectual property assignment and other protective covenants (the “Confidentiality Agreement”), that the Executive remains bound by the terms and conditions of the Confidentiality Agreement, and that such agreement shall be additional to, and not in limitation of, the covenants contained in this Section 7.

(b)Notwithstanding anything in this Agreement or the Confidentiality Agreement to the contrary, nothing contained in this Agreement shall prohibit either party (or either party’s attorney(s)) from (i) filing a charge with, reporting possible violations of federal law or regulation to, participating in any investigation by, or cooperating with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority, the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the U.S. Commodity Futures Trading Commission, the U.S. Department of Justice or any other securities regulatory agency, self-regulatory authority or federal, state or local regulatory authority (collectively, “Government Agencies”), or making other disclosures that are protected under the whistleblower provisions of applicable law or regulation, (ii) communicating directly with, cooperating with, or providing information (including trade secrets) in confidence to any Government Agencies for the purpose of reporting or investigating a suspected violation of law, or from providing such information to such party’s attorney(s) or in a sealed complaint or other document filed in a lawsuit or other governmental proceeding, and/or (iii) receiving an award for information provided to any Government Agency. Pursuant to 18 USC Section 1833(b), the Executive will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made: (x) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (y) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Further, nothing in this Agreement is intended to or shall preclude either party from providing truthful testimony in response to a valid subpoena, court order, regulatory request or other judicial, administrative or legal process or otherwise as required by law. If the Executive is required to provide testimony, then unless otherwise directed or requested by a Government Agency or law enforcement, the Executive shall notify the Company as soon as reasonably practicable after receiving any such request of the anticipated testimony. Further, nothing in this Agreement prevents Executive from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that Executive has reason to believe is unlawful.

8.Representations. The Executive hereby represents and warrants to the Company that (a) the Executive is entering into this Agreement voluntarily and that the performance of the Executive’s obligations hereunder will not violate any agreement between the Executive and any other person, firm, organization or other entity, and (b) the Executive is not bound by the terms of any agreement with any previous employer or other party to refrain from competing, directly or indirectly, with the business of such previous employer or other party that would be violated by the Executive’s entering into this Agreement and/or providing services to the Company pursuant to the terms of this Agreement.

9.Successors.



(a)This Agreement is personal to the Executive and, without the prior written consent of the Company, shall not be assignable by the Executive otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Executive’s legal representatives.

(b)This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

10.Certain Definitions.

(a)“Board” means the Board of Directors of the Company.

(b)“Cause” means the occurrence of any one or more of the following events:

(i)the Executive’s willful failure to substantially perform his duties with the Company (other than any such failure resulting from the Executive’s incapacity due to physical or mental illness or any such actual or anticipated failure after his issuance of a Notice of Termination for Good Reason), including the Executive’s failure to follow any lawful directive from the CEO within the reasonable scope of the Executive’s duties and the Executive’s failure to correct the same (if capable of correction, as determined by the CEO), within 30 days after a written notice is delivered to the Executive, which demand specifically identifies the manner in which the CEO believes that the Executive has not performed his duties;

(ii)the Executive’s commission of, indictment for or entry of a plea of guilty or nolo contendere to a felony crime (excluding vehicular crimes) or a crime of moral turpitude;

(iii)the Executive’s material breach of any material obligation under any written agreement with the Company or its affiliates or under any applicable policy of the Company or its affiliates (including any code of conduct or harassment policies), and the Executive’s failure to correct the same (if capable of correction, as determined by the CEO), within 30 days after a written notice is delivered to the Executive, which demand specifically identifies the manner in which the CEO believes that the Executive has materially breached such agreement;

(iv)any act of fraud, embezzlement, theft or misappropriation from the Company or its affiliates by the Executive;

(v)the Executive’s willful misconduct or gross negligence with respect to any material aspect of the Company’s business or a material breach by the Executive of his fiduciary duty to the Company or its affiliates, which willful misconduct, gross negligence or material breach has a material and demonstrable adverse effect on the Company or its affiliates; and

(vi)the Executive’s commission of an act of material dishonesty resulting in material reputational, economic or financial injury to the Company or its affiliates.

(c) “Change in Control” has the meaning set forth in the Company’s 2020 Incentive Award Plan.

(d) “Code” means the Internal Revenue Code of 1986, as amended and the regulations thereunder.

(e)“Date of Termination” means the date on which the Executive’s employment with the Company terminates.

(f)“Disability” means that the Executive has become entitled to receive benefits under an applicable Company long-term disability plan or, if no such plan covers the Executive, as determined in the reasonable discretion of the Board.



(g)“Good Reason” means the occurrence of any one or more of the following events without the Executive’s prior written consent, unless the Company fully corrects the circumstances constituting Good Reason (provided such circumstances are capable of correction) as provided below:

(i)a material diminution in the Executive’s Base Salary or Target Bonus;

(ii)a change in the geographic location of the Principal Location by more than 35 miles from its existing location;

(iii)a material diminution in the Executive’s title, authority or duties, as contemplated by this Agreement, excluding for this purpose any isolated, insubstantial or inadvertent actions not taken in bad faith and which are remedied by the Company promptly after receipt of notice thereof given by the Executive;

(iv)the Company’s material breach of this Agreement.
Notwithstanding the foregoing, the Executive will not be deemed to have resigned for Good Reason unless (1) the Executive provides the Company with written notice setting forth in reasonable detail the facts and circumstances claimed by the Executive to constitute Good Reason within 30 days after the date of the occurrence of any event that the Executive knows or should reasonably have known to constitute Good Reason, (2) the Company fails to cure such acts or omissions within 30 days following its receipt of such notice, and (3) the effective date of the Executive’s termination for Good Reason occurs no later than 60 days after the expiration of the Company’s cure period.
(h)“Notice of Termination” means a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive’s employment under the provision so indicated and (iii) if the Date of Termination is other than the date of receipt of such notice, specifies the termination date (which date shall be not more than 30 days after the giving of such notice unless as otherwise provided upon a termination for Good Reason).

(i)“Qualifying Termination” means a termination of the Executive’s employment (i) by the Company without Cause (other than by reason of the Executive’s death or Disability), or (ii) by the Executive for Good Reason.

(j)“Section 409A” means Section 409A of the Code and Department of Treasury regulations and other interpretive guidance issued thereunder.

(k)“Separation from Service” means a “separation from service” (within the meaning of Section 409A).

11.Miscellaneous.

(a)Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California, without reference to principles of conflict of laws. The captions of this Agreement are not part of the provisions hereof and shall have no force or effect.

(b)Notices. All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows:
If to the Executive: at the Executive’s most recent address on the records of the Company.
If to the Company:
Inari Medical, Inc.


6001 Oak Canyon, Suite 100
Irvine, CA 92618
Attention: General Counsel
or to such other address as either party shall have furnished to the other in writing in accordance herewith. Notice and communications shall be effective when actually received by the addressee.
(c)Sarbanes-Oxley Act of 2002. Notwithstanding anything herein to the contrary, if the Company determines, in its good faith judgment, that any transfer or deemed transfer of funds hereunder is likely to be construed as a personal loan prohibited by Section 13(k) of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”), then such transfer or deemed transfer shall not be made to the extent necessary or appropriate so as not to violate the Exchange Act and the rules and regulations promulgated thereunder.

(d)Section 409A of the Code.

(i)To the extent applicable, this Agreement shall be interpreted in accordance with Section 409A. Notwithstanding any provision of this Agreement to the contrary, if the Company determines that any compensation or benefits payable under this Agreement may be subject to Section 409A, the Company shall work in good faith with the Executive to adopt such amendments to this Agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Company determines are necessary or appropriate to avoid the imposition of taxes under Section 409A, including without limitation, actions intended to (i) exempt the compensation and benefits payable under this Agreement from Section 409A, and/or (ii) comply with the requirements of Section 409A; provided, however, that this Section 11(d) shall not create an obligation on the part of the Company to adopt any such amendment, policy or procedure or take any such other action, nor shall the Company have any liability for failing to do so.

(ii)Any right to a series of installment payments pursuant to this Agreement is to be treated as a right to a series of separate payments. To the extent permitted under Section 409A, any separate payment or benefit under this Agreement or otherwise shall not be deemed “nonqualified deferred compensation” subject to Section 409A to the extent provided in the exceptions in Treasury Regulation Section 1.409A-1(b)(4), Section 1.409A-1(b)(9) or any other applicable exception or provision of Section 409A. Any payments subject to Section 409A that are subject to execution of a waiver and release which may be executed and/or revoked in a calendar year following the calendar year in which the payment event (such as termination of employment) occurs shall commence payment only in the calendar year in which the consideration period or, if applicable, release revocation period ends, as necessary to comply with Section 409A. All payments of nonqualified deferred compensation subject to Section 409A to be made upon a termination of employment under this Agreement may only be made upon the Executive’s Separation from Service.

(iii)To the extent that any payments or reimbursements provided to the Executive under this Agreement are deemed to constitute compensation to the Executive to which Treasury Regulation Section 1.409A-3(i)(1)(iv) would apply, such amounts shall be paid or reimbursed reasonably promptly, but not later than December 31 of the year following the year in which the expense was incurred. The amount of any such payments eligible for reimbursement in one year shall not affect the payments or expenses that are eligible for payment or reimbursement in any other taxable year, and the Executive’s right to such payments or reimbursement of any such expenses shall not be subject to liquidation or exchange for any other benefit.

(e)Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.

(f)Withholding. The Company may withhold from any amounts payable under this Agreement such federal, state, local or foreign taxes as shall be required to be withheld pursuant to any applicable law or regulation.



(g)No Waiver. The Executive’s or the Company’s failure to insist upon strict compliance with any provision of this Agreement or the failure to assert any right the Executive or the Company may have hereunder, including, without limitation, the right of the Executive to terminate employment for Good Reason pursuant to Section 3(c) hereof, shall not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement.

(h)Entire Agreement. As of the Effective Date, this Agreement (including the Confidentiality Agreement), constitutes the final, complete and exclusive agreement between the Executive and the Company with respect to the subject matter hereof and replaces and supersedes any and all other agreements, offers or promises, whether oral or written, by any member of the Company and its subsidiaries or affiliates, or representative thereof (including any employment offer letter between the Company and the Executive). Notwithstanding anything herein to the contrary, this Agreement and the obligations and commitments hereunder shall neither commence nor be of any force or effect prior to the Effective Date.

(i)Arbitration.

(i)Any controversy or dispute that establishes a legal or equitable cause of action (“Arbitration Claim”) between any two or more Persons Subject to Arbitration (as defined below), including any controversy or dispute, whether based on contract, common law, or federal, state or local statute or regulation, arising out of, or relating to the Executive’s service or the termination thereof, shall be submitted to final and binding arbitration as the sole and exclusive remedy for such controversy or dispute in accordance with the rules of JAMS pursuant to its Employment Arbitration Rules and Procedures, which are available at http://www.jamsadr.com/rules-employment-arbitration/, and the Company will provide a copy upon the Executive’s request. Notwithstanding the foregoing, this Agreement shall not require any Person Subject to Arbitration to arbitrate pursuant to this Agreement any claims: (A) under a Company benefit plan subject to the Employee Retirement Income Security Act, as amended; or (B) as to which applicable law not preempted by the Federal Arbitration Act prohibits resolution by binding arbitration. Either party may seek provisional non-monetary remedies in a court of competent jurisdiction to the extent that such remedies are not available or not available in a timely fashion through arbitration. It is the parties’ intent that issues of arbitrability of any dispute shall be decided by the arbitrator.

(ii)“Persons Subject to Arbitration” means, individually and collectively, (A) the Executive, (B) any person in privity with or claiming through, on behalf of or in the right of the Executive, (C) the Company, (D) any past, present or future affiliate, employee, officer, director or agent of the Company, and/or (E) any person or entity alleged to be acting in concert with or to be jointly liable with any of the foregoing.

(iii)The arbitration shall take place before a single neutral arbitrator at the JAMS office in Orange County, California. Such arbitrator shall be provided through JAMS by mutual agreement of the parties to the arbitration; provided that, absent such agreement, the arbitrator shall be selected in accordance with the rules of JAMS then in effect. The arbitrator shall permit reasonable discovery. The award or decision of the arbitrator shall be rendered in writing; shall be final and binding on the parties; and may be enforced by judgment or order of a court of competent jurisdiction.

(iv)In the event of arbitration relating to this Agreement, the non-prevailing party shall reimburse the prevailing party for all costs incurred by the prevailing party in connection with such arbitration (including reasonable legal fees in connection with such arbitration, including any litigation or appeal therefrom).

(v)THE EXECUTIVE AND THE COMPANY UNDERSTAND THAT BY AGREEING TO ARBITRATE ANY ARBITRATION CLAIM, THEY WILL NOT HAVE THE RIGHT TO HAVE ANY ARBITRATION CLAIM DECIDED BY A JURY OR A COURT, BUT SHALL INSTEAD HAVE ANY ARBITRATION CLAIM DECIDED THROUGH ARBITRATION.

(vi)THE EXECUTIVE AND THE COMPANY WAIVE ANY CONSTITUTIONAL OR OTHER RIGHT TO BRING CLAIMS COVERED BY THIS AGREEMENT OTHER THAN IN THEIR


INDIVIDUAL CAPACITIES. EXCEPT AS MAY BE PROHIBITED BY LAW, THIS WAIVER INCLUDES THE ABILITY TO ASSERT CLAIMS AS A PLAINTIFF OR CLASS MEMBER IN ANY PURPORTED CLASS OR REPRESENTATIVE PROCEEDING.

(vii)This Section 11(i) shall be interpreted to conform to any applicable law concerning the terms and enforcement of agreements to arbitrate service disputes. To the extent any terms or conditions of this Section 11(i) would preclude its enforcement, such terms shall be severed or interpreted in a manner to allow for the enforcement of this Section 11(i). To the extent applicable law imposes additional requirements to allow enforcement of this Section 11(i), this Agreement shall be interpreted to include such terms or conditions.

(j)Amendment; Survival. No amendment or other modification of this Agreement shall be effective unless made in writing and signed by the parties hereto. The respective rights and obligations of the parties under this Agreement shall survive the Executive’s termination of employment and the termination of this Agreement to the extent necessary for the intended preservation of such rights and obligations.

(k)Counterparts. This Agreement and any agreement referenced herein may be executed in two or more counterparts, each of which shall be deemed an original but which together shall constitute one and the same instrument.

(l)Clawback. All bonuses and equity awards granted under this Agreement, the Company’s 2020 Incentive Award Plan or any other incentive plan are subject to the terms of the Company’s Clawback Policy or similar policy, as the same may be amended from time to time, as well as any similar provisions of applicable law, any of which could in certain circumstances require repayment or forfeiture of bonuses or awards or any shares or other cash or property received with respect to the bonuses or awards (including any value received from a disposition of the shares acquired upon payment of the bonuses or equity awards).
[SIGNATURES APPEAR ON FOLLOWING PAGE]





IN WITNESS WHEREOF, the Executive has hereunto set the Executive’s hand and, pursuant to the authorization from the Board, the Company has caused these presents to be executed in its name on its behalf, all as of the day and year first above written.
 
“COMPANY”
By: /s/ Andrew Hykes
Name: Andrew Hykes
Title: Chief Executive Officer and President
“EXECUTIVE”
By: /s/ Kevin Strange
Name: Kevin Strange




EXHIBIT A
GENERAL RELEASE
1.Release. For valuable consideration, the receipt and adequacy of which are hereby acknowledged, the undersigned does hereby release and forever discharge the “Releasees” hereunder, consisting of Inari Medical, Inc., a Delaware corporation (the “Company”), and the Company’s partners, subsidiaries, associates, affiliates, successors, heirs, assigns, agents, directors, officers, employees, representatives, lawyers, insurers, and all persons acting by, through, under or in concert with them, or any of them, of and from any and all manner of action or actions, cause or causes of action, in law or in equity, suits, debts, liens, contracts, agreements, promises, liability, claims, demands, damages, losses, costs, attorneys’ fees or expenses, of any nature whatsoever, known or unknown, fixed or contingent (hereinafter called “Claims”), which the undersigned now has or may hereafter have against the Releasees, or any of them, by reason of any matter, cause, or thing whatsoever from the beginning of time to the date hereof. The Claims released herein include, without limiting the generality of the foregoing, any Claims in any way arising out of, based upon, or related to the employment or termination of employment of the undersigned by the Releasees, or any of them; any alleged breach of any express or implied contract of employment; any alleged torts or other alleged legal restrictions on Releasees’ right to terminate the employment of the undersigned; and any alleged violation of any federal, state or local statute or ordinance including, without limitation, Title VII of the Civil Rights Act of 1964, the Age Discrimination In Employment Act, the Americans With Disabilities Act.

2.Claims Not Released. Notwithstanding the foregoing, this general release (the “Release”) shall not operate to release any rights or claims of the undersigned (i) to payments or benefits under Section 4(b) of that certain Employment Agreement, effective as of October 1, 2024, between the Company and the undersigned (the “Employment Agreement”), with respect to the payments and benefits provided in exchange for this Release, (ii) to payments or benefits under any equity award agreement between the undersigned and the Company, (iii) with respect to Section 2(b)(iv) of the Employment Agreement, (iv) to accrued or vested benefits the undersigned may have, if any, as of the date hereof under any applicable plan, policy, practice, program, contract or agreement with the Company, (v) to any Claims, including claims for indemnification and/or advancement of expenses arising under any indemnification agreement between the undersigned and the Company or under the bylaws, certificate of incorporation or other similar governing document of the Company, (vi) to any Claims which cannot be waived by an employee under applicable law or (vii) with respect to the undersigned’s right to communicate directly with, cooperate with, or provide information to, any federal, state or local government regulator.

3.Unknown Claims.
THE UNDERSIGNED ACKNOWLEDGES THAT THE UNDERSIGNED HAS BEEN ADVISED BY LEGAL COUNSEL AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS:
“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”
THE UNDERSIGNED, BEING AWARE OF SAID CODE SECTION, HEREBY EXPRESSLY WAIVES ANY RIGHTS THE UNDERSIGNED MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.
4.Exceptions. Notwithstanding anything in this Release to the contrary, nothing contained in this Release shall prohibit the undersigned from (i) filing a charge with, reporting possible violations of federal law or regulation to, participating in any investigation by, or cooperating with any governmental agency or entity or making other disclosures that are protected under the whistleblower provisions of applicable law or regulation and/or (ii) communicating directly with, cooperating with, or providing information (including trade secrets) in confidence


to, any federal, state or local government regulator (including, but not limited to, the U.S. Securities and Exchange Commission, the U.S. Commodity Futures Trading Commission, or the U.S. Department of Justice) for the purpose of reporting or investigating a suspected violation of law, or from providing such information to the undersigned’s attorney or in a sealed complaint or other document filed in a lawsuit or other governmental proceeding. Pursuant to 18 USC Section 1833(b), the undersigned will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made: (x) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (y) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Further, nothing in this Agreement prevents the undersigned from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that the undersigned has reason to believe is unlawful.

5.Representations. The undersigned represents and warrants that there has been no assignment or other transfer of any interest in any Claim which the undersigned may have against Releasees, or any of them, and the undersigned agrees to indemnify and hold Releasees, and each of them, harmless from any liability, Claims, demands, damages, costs, expenses and attorneys’ fees incurred by Releasees, or any of them, as the result of any such assignment or transfer or any rights or Claims under any such assignment or transfer. It is the intention of the parties that this indemnity does not require payment as a condition precedent to recovery by the Releasees against the undersigned under this indemnity.

6.No Action. The undersigned agrees that if the undersigned hereafter commences any suit arising out of, based upon, or relating to any of the Claims released hereunder or in any manner asserts against Releasees, or any of them, any of the Claims released hereunder, then the undersigned agrees to pay to Releasees, and each of them, in addition to any other damages caused to Releasees thereby, all attorneys’ fees incurred by Releasees in defending or otherwise responding to said suit or Claim.

7.No Admission. The undersigned further understands and agrees that neither the payment of any sum of money nor the execution of this Release shall constitute or be construed as an admission of any liability whatsoever by the Releasees, or any of them, who have consistently taken the position that they have no liability whatsoever to the undersigned.

8.[OWBPA. The undersigned agrees and acknowledges that this Release constitutes a knowing and voluntary waiver and release of all Claims the undersigned has or may have against the Company and/or any of the Releasees as set forth herein, including, but not limited to, all Claims arising under the Older Worker’s Benefit Protection Act and the Age Discrimination in Employment Act. In accordance with the Older Worker’s Benefit Protection Act, the undersigned is hereby advised as follows:

(a)the undersigned has read the terms of this Release, and understands its terms and effects, including the fact that the undersigned agreed to release and forever discharge the Company and each of the Releasees, from any Claims released in this Release;

(b)the undersigned understands that, by entering into this Release, the undersigned does not waive any Claims that may arise after the date of the undersigned’s execution of this Release, including without limitation any rights or claims that the undersigned may have to secure enforcement of the terms and conditions of this Release;

(c)the undersigned has signed this Release voluntarily and knowingly in exchange for the consideration described in this Release, which the undersigned acknowledges is adequate and satisfactory to the undersigned and which the undersigned acknowledges is in addition to any other benefits to which the undersigned is otherwise entitled;

(d)the Company advises the undersigned to consult with an attorney prior to executing this Release;



(e)the undersigned has been given at least 21 days in which to review and consider this Release. To the extent that the undersigned chooses to sign this Release prior to the expiration of such period, the undersigned acknowledges that the undersigned has done so voluntarily, had sufficient time to consider the Release, to consult with counsel and that the undersigned does not desire additional time and hereby waives the remainder of the 21-day period; and

(f)the undersigned may revoke this Release within seven days from the date the undersigned signs this Release and this Release will become effective upon the expiration of that revocation period. If the undersigned revokes this Release during such seven-day period, this Release will be null and void and of no force or effect on either the Company or the undersigned and the undersigned will not be entitled to any of the payments or benefits which are expressly conditioned upon the execution and non-revocation of this Release. Any revocation must be in writing and sent to [name], via electronic mail at [email address], on or before [5:00 p.m. Pacific time] on the seventh day after this Release is executed by the undersigned.]

9.Governing Law. This Release is deemed made and entered into in the State of California, and in all respects shall be interpreted, enforced and governed under the internal laws of the State of California, to the extent not preempted by federal law.
IN WITNESS WHEREOF, the undersigned has executed this Release this ____ day of ___________, ____.
 
 
Name: Kevin Strange


 EX-31.1 4 nari-20240930xexx311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Andrew Hykes, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Inari Medical, Inc. (the "registrant");
2.Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;
3.Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and
(d)Disclosed in this Report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: October 28, 2024
By:/s/ Andrew Hykes
Andrew Hykes
Chief Executive Officer and President
(Principal Executive Officer)

 EX-31.2 5 nari-20240930xexx312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Kevin Strange, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Inari Medical, Inc. (the "registrant");
2.Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;
3.Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and
(d)Disclosed in this Report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: October 28, 2024
By:/s/ Kevin Strange
Kevin Strange
Chief Financial Officer
(Principal Financial Officer and
Principal Accounting Officer)

 EX-32.1 6 nari-20240930xexx321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Inari Medical, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: October 28, 2024
By:/s/ Andrew Hykes
Andrew Hykes
Chief Executive Officer and President
(Principal Executive Officer)
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 EX-32.2 7 nari-20240930xexx322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Inari Medical, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: October 28, 2024
By:/s/ Kevin Strange
Kevin Strange
Chief Financial Officer
(Principal Financial Officer and
Principal Accounting Officer)
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 EX-101.SCH 8 nari-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 9952156 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Business Combination link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Cash Equivalents and Investments link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Inventories, net link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Concentrations link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Related Party link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Credit Facility link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Equity Incentive Plans link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Retirement Plan link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Business Combination (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Cash Equivalents and Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Inventories, net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Credit Facility (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Equity Incentive Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash Flow, Supplemental Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Business Combination - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Business Combination - Schedule of Total Purchase Price Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Business Combination - Schedule of Fair Values of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Business Combination - Schedule of Fair Value Assigned to the Intangible Asset Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Business Combination - Schedule of Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value of the Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Cash Equivalents and Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Inventories, net (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Property and Equipment, net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Goodwill and Intangible Assets - Schedule of Carrying Amounts of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Goodwill and Intangible Assets - Schedule of Identifiable Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Annual Amortization of the Intangible Asset (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Disclosure (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Commitments and Contingencies - Schedule of Total Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating Leases Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating Leases Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Related Party (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Credit Facility - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Credit Facility - Schedule of Costs Incurred Directly Related to Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Equity Incentive Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Equity Incentive Plans - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Equity Incentive Plans - Schedule of RSU and PSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Equity Incentive Plans - Schedule of Estimated Fair Value of Option Grant and ESPP on Date of Grant (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Equity Incentive Plans - Schedule of Total Compensation Cost for All Share-Based Payment Arrangements Recognized (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Retirement Plan (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Net Income (Loss) Per Share - Schedule of Computation of Net Loss (Income) per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Net Income (Loss) Per Share - Schedule of Outstanding Potentially Dilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 nari-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 nari-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 nari-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Federal Funds Rate Fed Funds Effective Rate Overnight Index Swap Rate [Member] Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Adjustments to reconcile net (loss) income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement Statistical Measurement [Domain] Related Party Related Party Transactions Disclosure [Text Block] Unrealized Loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Schedule of Total Lease Cost Lease, Cost [Table Text Block] 401 (k) Plan Defined Contribution Plan, Tax Status [Extensible Enumeration] Assets in progress Asset under Construction [Member] Cover [Abstract] Cover [Abstract] Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Future Minimum Lease Payments Under Operating Leases Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Percentage of voting interests acquired Business Acquisition, Percentage of Voting Interests Acquired Trading Symbol Trading Symbol Lease not yet commenced, term of contract (in years) Lessee, Finance Lease, Lease Not yet Commenced, Term of Contract All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Components of Net (Loss) Income per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes (in shares) Equity Awards, Shares Issued Net of Shares for Tax Withholdings Equity Awards, Shares Issued Net of Shares for Tax Withholdings Award vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Cash paid for income taxes Income Taxes Paid, Net Allowance for credit losses Accounts Receivable, Allowance for Credit Loss, Current Working capital adjustment Working capital adjustment Goodwill, Measurement Period Adjustment Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Short-Term Investments Short-Term Investments [Member] Accounts receivable Increase (Decrease) in Accounts Receivable Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Fair Value Measurements Fair Value Disclosures [Text Block] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount 2020 Employee Share Purchase Plan Two Thousand Twenty Employee Stock Purchase Plan [Member] Two thousand twenty employee stock purchase plan. 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Schedule of RSU Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Common stock, outstanding (in shares) Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Outstanding Operating lease cost Operating Lease, Cost Number of shares available for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Operating lease liabilities, noncurrent portion Lease liabilities - noncurrent portion Operating Lease, Liability, Noncurrent Loss on disposal of fixed assets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Minimum employee service period (in months) Deferred Compensation Arrangement with Individual, Requisite Service Period Plan Name Plan Name [Domain] United States UNITED STATES Entity Tax Identification Number Entity Tax Identification Number Gross Carrying Amount Finite-Lived Intangible Assets, Gross Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Schedule of Costs Incurred Directly Related to Debt Schedule of Long-Term Debt Instruments [Table Text Block] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Amortization of premium and discount on marketable securities Investment Income, Net, Amortization of Discount and Premium Money market mutual funds Money Market Funds [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Numerator: Earnings Per Share Reconciliation [Abstract] U.S. treasury securities US Treasury Securities [Member] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Plan Name Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Lease, liability to be paid Finance Lease, Liability, to be Paid Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Total included in short-term investments Short-term investments in debt securities Debt Securities, Available-for-Sale Net loss Business Acquisition, Pro Forma Net Income (Loss) Measurement Frequency Measurement Frequency [Axis] Reimbursement Milestones Reimbursement Milestones [Member] Reimbursement Milestones Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Vesting, Option [Domain] Vesting, Option [Domain] Vesting, Option [Domain] Management Estimates Use of Estimates, Policy [Policy Text Block] Impairment of capitalized software development costs Capitalized Computer Software, Impairments Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Balance at beginning of period Balance at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Additional paid in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical Geographical [Axis] Tabular List, Table Tabular List [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Contingent consideration, liability, current Business Combination, Contingent Consideration, Liability, Current Lessee Lease Description [Line Items] Lessee, Lease, Description [Line Items] Shares issued under Employee Stock Purchase Plan (in shares) Shares issued under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Total potentially dilutive common stock equivalents excluded from calculation due to anti-dilutive effect (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Deposits and other assets Deposits And Other Assets Noncurrent Deposits and other assets noncurrent. Share Based Compensation Award Tranche One Share-Based Payment Arrangement, Tranche One [Member] Cash Equivalents and Investments Cash, Cash Equivalents, and Short-Term Investments [Text Block] 2011 Equity Incentive Plan Two Thousand And Eleven Equity Incentive Plan [Member] 2011 equity incentive plan. Credit Facility Credit Facility [Domain] Cash, cash equivalents and restricted cash beginning of period Cash, cash equivalents and restricted cash end of period Total cash, cash equivalents and restricted cash as shown in the statement of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Corporate debt securities and commercial paper Corporate debt securities and commercial paper Corporate Debt Securities And Commercial Paper [Member] Corporate debt securities and commercial paper. Nonvested award, cost not yet recognized, amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current assets Assets, Current [Abstract] Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Payment of taxes related to vested equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Inventories, net Inventory Disclosure [Text Block] LimFlow LimFlow [Member] LimFlow Vesting, Option One Vesting, Option One [Member] Vesting, Option One Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service Product and Service [Domain] Employee Stock Option Stock options Share-Based Payment Arrangement, Option [Member] Short-term lease cost Short-Term Lease, Cost Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Goodwill [Roll Forward] Goodwill [Roll Forward] Depreciation expense Depreciation Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Term loan variable interest rate (as percent) Debt Instrument, Basis Spread on Variable Rate Award Type Award Type [Axis] Foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Number of Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Work-in-process Inventory, Work in Process, Net of Reserves Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Payroll-related accruals, accrued expenses and other liabilities Increase Decrease In Payroll Related Accruals Accrued Expenses And Other Liabilities Increase (decrease) in payroll related accruals accrued expenses and other liabilities. Total liabilities Liabilities Net Revenue Net Revenue [Member] Net Revenue Weighted Average Exercise Price, Vested and exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Cash Equivalents and Investments Debt Securities, Available-for-Sale [Table Text Block] Research and development Research and Development Expense Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Useful life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Revolving Line of Credit Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date Thereafter Finite-Lived Intangible Asset, Expected Amortization, After Year Four Finite-Lived Intangible Asset, Expected Amortization, After Year Four Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Percentage of fronting fee on stated amount of each letter of credit outstanding Percentage Of Fronting Fee On Stated Amount Of Each Letter Of Credit Outstanding Percentage of fronting fee on stated amount of each letter of credit outstanding. Goodwill and Intangible Assets Disclosure [Abstract] Percentage of fee on average daily stated amount of outstanding letter of credit Percentage Of Fee On Average Daily Stated Amount Of Outstanding Letter Of Credit Percentage of fee on average daily stated amount of outstanding letter of credit. Operating lease liabilities, current portion Less: lease liabilities - current portion Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, issued (in shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Computer hardware Computer Equipment [Member] Lease prepayments for lessor's owned leasehold improvements Lease Prepayments For Lessor's Owned Leasehold Improvements Lease prepayments for lessor's owned leasehold improvements Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Patent Infringement Lawsuit Against Imperative Care and Truvic Patent Infringement Lawsuit Against Imperative Care and Truvic [Member] Patent Infringement Lawsuit Against Imperative Care and Truvic Total property and equipment, gross Property, Plant and Equipment, Gross Options exercised for common stock (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development Research and Development Expense [Member] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Common stock, authorized (in shares) Common Stock, Shares Authorized Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted (in shares) Weighted average number of common shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Unrealized gain (loss) on available-for-sale debt securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Remainder of 2024 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total stockholders' equity Balance at beginning of period Balance at end of period Equity, Attributable to Parent Schedule of Cash Flow, Supplemental Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Related Party Related Party [Member] Option to extend, operating lease, term (in years) Lessee, Operating Lease, Renewal Term Litigation Case [Axis] Litigation Case [Axis] Balance Sheet Location Statement of Financial Position Location, Balance [Axis] Interest expense Interest Expense, Nonoperating Schedule of Carrying Amounts of Goodwill Schedule of Goodwill [Table Text Block] Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Letters of credit outstanding amount Letters of Credit Outstanding, Amount Schedule of Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Selling, general and administrative Selling, General and Administrative Expense Matching contribution expense recognized Defined Contribution Plan, Cost Total other comprehensive income (loss) Other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Fair Value, Recurring Fair Value, Recurring [Member] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Cost of goods sold Cost of Sales [Member] Antidilutive Securities Excluded From Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Acquisition-related expenses Business Combination, Acquisition Related Costs All Executive Categories All Executive Categories [Member] Common stock equivalents from outstanding equity grants (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Employer matching contribution, percent of match Defined Contribution Plan, Employer Matching Contribution, Percent of Match Balance Sheet Location Statement of Financial Position Location, Balance [Domain] Unrealized Gain (Loss) on Investments AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Restricted cash Restricted Cash, Current Document Type Document Type Participating employee eligible compensation Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Schedule of Investment Income Reported Amounts by Category [Table] Investment Income [Table] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Purchases of marketable securities Payments to Acquire Marketable Securities Vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Contingent consideration, liability, noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Amortized Cost Basis Debt Securities, Available-for-Sale, Amortized Cost Schedule of Estimated Future Annual Amortization of the Intangible Asset Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Risk free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Maximum Maximum [Member] Amortization of intangible asset Amortization of Intangible Assets Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Intangible Assets, Net Finite-Lived Intangible Assets, Net Furniture and fixtures Furniture and Fixtures [Member] Antidilutive Securities Antidilutive Securities [Axis] International Non-US [Member] Accounts payable Accounts Payable, Current Bank of America Credit Facility Bank Of America Credit Facility [Member] Bank of America credit facility. Accounting Policies [Abstract] Accounting Policies [Abstract] Leasehold improvements Leasehold Improvements [Member] Schedule of Estimated Fair Value of Option Grant and ESPP Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Business Combination Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Development expenses incurred Related Party Transaction, Amounts of Transaction Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total lease costs Lease, Cost Statistical Measurement Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Award cliff vesting period (in years) Share-Based Compensation Arrangement By Share-Based Payment Award, Award Cliff Vesting Period Share-Based Compensation Arrangement By Share-Based Payment Award, Award Cliff Vesting Period (Loss) income before income taxes (Loss) income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Vesting Vesting [Axis] Award Type Award Type [Domain] Fair value of previously held investment Fair value of previously held investment Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Name Outstanding Recovery, Individual Name Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Variable lease cost Variable Lease, Cost Schedule of Outstanding Potentially Dilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Total net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Non-PEO NEO Non-PEO NEO [Member] Additional Paid In Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Capitalized software, amortization Capitalized Computer Software, Amortization BSBY Bloomberg Short Term Bank Yield Index (BSBY) [Member] Bloomberg Short Term Bank Yield Index (BSBY) Emerging Therapies Emerging Therapies [Member] Emerging Therapies Retirement Plan Retirement Benefits [Text Block] Concentrations Concentration Risk Disclosure [Text Block] Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Unbilled receivables Unbilled Receivables, Current Recently Issued Not Yet Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Diluted (in dollars per share) Earnings Per Share, Diluted Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Amortization of right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Schedule of PSU Activity Schedule of Nonvested Performance-Based Units Activity [Table Text Block] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Cliff vesting, percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Payout percentage Share Based Compensation Arrangement By Share Based Payment Award, Payout Percentage Share Based Compensation Arrangement By Share Based Payment Award, Payout Percentage Retirement Benefits [Abstract] Retirement Benefits [Abstract] Preferred stock, issued (in shares) Preferred Stock, Shares Issued Schedule of Financial Assets and Liabilities Measured at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Other comprehensive income (loss) Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract] Amended Credit Agreement Amended Credit Agreement [Member] Credit agreement. Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Basis spread on variable rate, floor (as percent) Debt Instrument, Basis Spread On Variable Rate, Floor Debt Instrument, Basis Spread On Variable Rate, Floor Total fair value of RSUs vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Net (loss) income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Maximum participating employee annual contributions Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount Share-Based Payment Arrangement, Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Provision for income taxes Income Tax Expense (Benefit) Short-term investments in debt securities Debt Securities, Available-for-Sale, Current Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Nonvested award, cost not yet recognized, period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Operating expenses Operating Expense [Member] Revenue Revenue from Contract with Customer, Excluding Assessed Tax Total other income Nonoperating Income (Expense) Provision for income taxes as a percentage of (loss) income before income taxes Effective Income Tax Rate Reconciliation, Percent Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities (Loss) income from operations Operating Income (Loss) Variable Rate Variable Rate [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Total liabilities and stockholders' equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Payroll-related accruals Employee-related Liabilities, Current Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Individual limit on employer match Defined Contribution Plan, Employer Matching Contribution Per Employee, Amount Defined Contribution Plan, Employer Matching Contribution Per Employee, Amount Interest income Investment Income, Interest Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Manufacturing equipment Manufacturing Facility [Member] Lease liabilities arising from obtaining new right-of-use assets Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Cancelled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Restricted cash Restricted Cash Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Inventories, net Total inventories, net Inventory, Net U.S. government agencies US Government Agencies Debt Securities [Member] Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Thereafter Lessee, Operating Lease, Liability, To Be Paid, After Year Four Lessee operating lease liability payments thereafter. Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Operating expenses Operating Expenses [Abstract] Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments Financial Instruments [Domain] Vesting Vesting [Domain] Total purchase price Business Combination, Consideration Transferred Balance at beginning of period (in dollars per share) Balance at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Number of Awards, Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Capitalized software, Accumulated Amortization Capitalized Computer Software, Accumulated Amortization Related Party Transactions [Abstract] Related Party Transactions [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Balance at beginning of period (in dollars per share) Balance at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Balance at beginning of period (in shares) Balance at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Allowance for credit losses, net Accounts Receivable, Credit Loss Expense (Reversal) Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Revenue Business Acquisition, Pro Forma Revenue Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Exercise Price Award Exercise Price Net Income (Loss) Per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Shares issued under Employee Stock Purchase Plan Stock Issued During Period, Value, Employee Stock Purchase Plan Options exercised for common stock Stock Issued During Period, Value, Stock Options Exercised Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Stockholders' equity Equity, Attributable to Parent [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Debt instrument, term (in years) Debt Instrument, Term 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Working capital adjustment related to acquisition Working Capital Adjustment, Acquisitions Working Capital Adjustment, Acquisitions PEO PEO [Member] Variable Rate Variable Rate [Axis] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other expense Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible assets Intangible Assets, Net (Excluding Goodwill) Gain contingency, patents allegedly infringed upon, number Gain Contingency, Patents Allegedly Infringed upon, Number Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Unrealized Gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Capitalized software development costs Payments to Develop Software Unused line fee at annual rate (as percent) Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Share-Based Payment Arrangement, Tranche Three Share-Based Payment Arrangement, Tranche Three [Member] Lender Name Lender Name [Axis] Other income (expense) Other Nonoperating Income (Expense) [Abstract] Financial Assets Assets, Fair Value Disclosure [Abstract] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Shares of common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Related Party Related and Nonrelated Parties [Domain] Total included in cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Deferred tax liability Deferred Income Tax Liabilities, Net Risk free interest rate - maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Changes in: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Percentage of purchase price on fair market value of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Intangible asset Fair value Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Income Statement Location Statement of Income Location, Balance [Axis] Weighted Average Exercise Price, Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Principal amount outstanding Line of Credit Facility, Maximum Amount Outstanding During Period Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Changes in the Estimated Fair Value Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Capitalized software, Gross Carrying Amount Capitalized Computer Software, Gross Line of Credit Line of Credit [Member] Entity Emerging Growth Company Entity Emerging Growth Company Total financial liabilities Liabilities, Fair Value Disclosure Entity Central Index Key Entity Central Index Key Schedule of Inventories, Net Schedule of Inventory, Current [Table Text Block] Lessee Lease Description [Table] Lessee, Lease, Description [Table] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract] Share based compensation arrangement by share based payment award options intrinsic value. Expected volatility - minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Stockholders' Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument Financial Instrument [Axis] Reconciliation of cash, cash equivalents and restricted cash: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] VTE Venous Thromboembolism ("VTE") [Member] Venous Thromboembolism ("VTE") Change in estimated fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Share-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Change in fair value of contingent consideration Change in fair value of contingent consideration liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Line of credit facility, accordion feature, higher borrowing capacity option Line Of Credit Facility, Accordion Feature, Higher Borrowing Capacity Option, Increase Limit Line Of Credit Facility, Accordion Feature, Higher Borrowing Capacity Option, Increase Limit Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Held-to-Maturity Securities Title Trading Arrangement, Individual Title Cash pledged under credit agreement Cash Pledged Under Credit Agreement Cash pledged under credit agreement. Statement [Table] Statement [Table] Measurement Frequency Measurement Frequency [Domain] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] City Area Code City Area Code Current liabilities Liabilities, Current [Abstract] Number of letter of credit Debt Instrument, Number Of Letters Of Credit Number of letter of credit. Fair value of contingent consideration Contingent consideration Fair value of contingent consideration Business Combination, Contingent Consideration, Liability Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Noncash investing and financing: Noncash Investing and Financing Items [Abstract] Number of Awards, Vested and exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Prepaid expenses, deposits and other assets Increase (Decrease) In Prepaid Expenses Deposits And Other Assets Increase (decrease) in prepaid expenses, deposits and other assets Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] Weighted-average fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity securities without readily determinable fair value, amount Equity Securities without Readily Determinable Fair Value, Amount Accumulated amortization Accumulated Amortization, Debt Issuance Costs Income Taxes Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Net (loss) income per share Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Accumulated deficit Retained Earnings (Accumulated Deficit) Related Party Transaction [Line Items] Related Party Transaction [Line Items] Inventories Increase (Decrease) in Inventories 2020 Incentive Award Plan Two Thousand Twenty Incentive Award Plan [Member] Two thousand twenty incentive award plan. Schedule of Investment Income Reported Amounts by Category [Line Items] Net Investment Income [Line Items] Deferred financing costs Debt Issuance Costs, Gross Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes Equity Awards, Value, Shares Issued Net of Tax Withholdings Equity Awards, Value, Shares Issued Net of Tax Withholdings Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Total lease liabilities Operating Lease, Liability Debt instrument, fee amount Debt Instrument, Fee Amount Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Performance Stock Units Performance Shares [Member] Credit Facility Credit Facility [Axis] Amendment Flag Amendment Flag Vesting, Option [Axis] Vesting, Option [Axis] Vesting, Option Employee Stock Purchase Plan Employee Stock Purchase Plan [Member] Employee stock purchase plan. Entity Registrant Name Entity Registrant Name Cash Payments to Acquire Businesses, Gross Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation, Depletion and Amortization Gross profit Gross Profit Net (loss) income per share: Earnings Per Share, Basic And Diluted, EPS [Abstract] Earnings Per Share, Basic And Diluted, EPS Fair Value as of Grant Date Award Grant Date Fair Value Unamortized deferred financing costs Debt Issuance Costs, Net Level 2 Fair Value, Inputs, Level 2 [Member] Credit Facility Debt Disclosure [Text Block] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Unvested RSUs and PSUs Unvested Restricted Stock Units and Performance Stock Units [Member] Unvested Restricted Stock Units. Geographical Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Annual increase in number of shares available for issuance percentage Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Developed technology Developed technology Technology-Based Intangible Assets [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Total Compensation Cost for All Share-Based Payment Arrangements Recognized Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Share-Based Payment Arrangement, Tranche Four Share-Based Payment Arrangement, Tranche Four [Member] Share-Based Payment Arrangement, Tranche Four Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Common stock, $0.001 par value, 300,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 58,435,576 and 57,762,414 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Severance and integration related costs Business Combination, Integration Related Costs Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Vesting, Option Two Vesting, Option Two [Member] Vesting, Option Two Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Intrinsic Value, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Equity Investments Equity Securities without Readily Determinable Fair Value [Policy Text Block] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued Equity awards Share-Based Payment Arrangement [Member] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Cash and Cash Equivalents Cash and Cash Equivalents [Domain] ESPP Employee Stock [Member] Basic (in dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Proceeds from issuance of common stock under employee stock purchase plan Proceeds from Stock Plans Cash paid for amounts included in the measurement of operating lease liabilities Operating Lease, Payments Cash and Cash Equivalents Cash and Cash Equivalents [Member] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Term of award (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Acquiring equity interest percentage Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Percentage of annual increase in shares reserved for issuance on capital stock outstanding at year end Percentage Of Annual Increase In Shares Reserved For Issuance On Capital Stock Outstanding At Year End Percentage of annual increase in shares reserved for issuance on capital stock outstanding at year end. Weighted average common shares used to compute net (loss) income per share Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Total assets Assets 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Cost of goods sold Cost of Goods and Services Sold Maximum contingent consideration Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Schedule of Acquired Finite-Lived Intangible Assets by Major Class Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other long-term liability Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 9) Commitments and Contingencies Risk free interest rate- minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Termination Date Trading Arrangement Termination Date Expected volatility - maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Equity Incentive Plans Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Schedule of Fair Values of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Debt Instrument Debt Instrument [Axis] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Compensation cost Total share-based compensation expense Share-Based Payment Arrangement, Expense Net (loss) income Net (loss) income Net Income (Loss) Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Other current and noncurrent liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current And Noncurrent Liabilities, Other Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current And Noncurrent Liabilities, Other Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Gain recognized, amount Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Identifiable Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Line of credit facility, amount available to borrow Line of Credit Facility, Current Borrowing Capacity Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Weighted Average Remaining Contractual Life (in years) Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Life [Abstract] Share based compensation arrangement by share based payment award options weighted average remaining contractual life. Cash and Cash Equivalents Cash and Cash Equivalents [Axis] Financial Liability Liabilities, Fair Value Disclosure [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Debt Instrument, Name Debt Instrument, Name [Domain] Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Total financial assets Assets, Fair Value Disclosure Name Forgone Recovery, Individual Name Intrinsic Value, Vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Remainder of 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Weighted average remaining term (in years) Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Finished goods Inventory, Finished Goods, Net of Reserves Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Base Rate Base Rate [Member] Impairment loss on strategic investment Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount Total lease payments Lessee, Operating Lease, Liability, to be Paid Balance at beginning of period (in shares) Balance at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Line of Credit Facility, Lender Line of Credit Facility, Lender [Domain] Insider Trading Arrangements [Line Items] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Schedule of Total Purchase Price Consideration Schedule of Business Acquisitions, by Acquisition [Table Text Block] Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Purchases of other investments Payments to Acquire Other Investments Litigation Case [Domain] Litigation Case [Domain] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Amortization of deferred financing costs Amortization of Debt Issuance Costs Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Other current and noncurrent assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current And Noncurrent Assets, Other Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current And Noncurrent Assets, Other Related Party Related and Nonrelated Parties [Axis] Basic (in shares) Weighted average number of common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Capitalized software, Net Capitalized computer software, net Capitalized Computer Software, Net Restricted Stock Units Restricted Stock Units (RSUs) [Member] Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Range of outcomes on contingent consideration arrangements Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities Accrued expenses and other current liabilities. Name Awards Close in Time to MNPI Disclosures, Individual Name Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Schedule of Provision for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Entity Filer Category Entity Filer Category Income Statement Location Statement of Income Location, Balance [Domain] Letter of Credit Subline Facility Letter of Credit [Member] Company Selected Measure Name Company Selected Measure Name Qualified Plan [Member] EX-101.PRE 12 nari-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 nari-20240930_g1.jpg begin 644 nari-20240930_g1.jpg M_]C_X 02D9)1@ ! 0$ E@"6 #_X1%T17AI9@ 34T *@ @ "@$ , M !!+ $! , ! ; $" , # (D@$& , ! ( $2 M , ! $ $5 , ! , $Q ( D (F $R ( 4 ( MO(=I 0 ! (T.H< < @, A@ 0 9&5S8P M 2D!\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$" M>@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0, PL#%@,A RT#. -# T\#6@-F M W(#?@.* Y8#H@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$ MC 2:!*@$M@3$!-,$X03P!/X%#044%]@8&!A8&)P8W!D@&609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\' M80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0 M"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+ M"PLB"SD+40MI"X +F NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF M#4 -6@UT#8X-J0W##=X-^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/ ME@^S#\\/[! )$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F M$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5 M$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@; M&$ 891B*&*\8U1CZ&2 911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,; MBANR&]H< APJ'%(<>QRC',P<]1T>'4<=:AZ4'KX>Z1\3 M'SX?:1^4'[\?ZB 5($$@;""8(,0@\"$<(4@A=2&A(B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDK MG2O1+ 4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<-] M1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^), M*DQR3+I- DU*39--W$XE3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\ M4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9 M:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7&EYL7KU?#U]A7[-@!6!7 M8*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-G MZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X M;]%P*W"&<.!Q.G&5&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E M@$> J($*@6N!S8(P@I*"](-7@[J$'82 A..%1X6KA@Z&I+CDTV3MI0@E(J4])5?EAMJ(FHI:C!J-VH^:D5J3' MI3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H_R#W(O,DZR;G*.,JWRS;+MLPUS+7--&UP;65T82!X;6QN&UL;G,Z&UP M.D-R96%T;W)4;V]L/CQX;7 Z0W)E871E1&%T93XR,#$S+3$P+3$P5#$R.C U M.C,W/"]X;7 Z0W)E871E1&%T93X\+W)D9CI$97-C'!A M8VME="!E;F0])W7J# MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3 MU-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! 0$! 0 M $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" Q$$!2$Q M!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V M-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F* MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G: MXN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ HHHH **** M "BBB@ IK,J*SNRHB+N9F.U5 ZDGT%?E7_P4F_X*[_LQ?\$VO#:67CF]F^)/ MQTUW3C>^"?@'X,U"%?%6HHP80WNL7)#II5@S_*+F='DD^;R+>X,<@3\+/%7@ M+]OG_@H5\/+W]J'_ (*S?M4K_P $T_\ @GE+LU#2_@'X5U%O 7BCQ[8R8EMK M6ZLYBUQ,]TD;/#_:XO;J:2,-:Z3ⅅ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htm IDEA: XBRL DOCUMENT v3.24.3
Cover - shares
 9 Months Ended
Sep. 30, 2024
Oct. 24, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Entity File Number 001-39293  
Entity Registrant Name Inari Medical, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 45-2902923  
Entity Address, Address Line One 6001 Oak Canyon  
Entity Address, Address Line Two Suite 100  
Entity Address, City or Town Irvine  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92618  
City Area Code 877  
Local Phone Number 923-4747  
Title of 12(b) Security Common stock, $0.001 par value per share  
Trading Symbol NARI  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   58,544,158
Entity Central Index Key 0001531048  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 41,141,000 $ 38,597,000
Restricted cash 67,000 611,000
Short-term investments in debt securities 70,397,000 76,855,000
Accounts receivable, net 84,403,000 70,119,000
Inventories, net 55,210,000 42,900,000
Prepaid expenses and other current assets 12,168,000 6,481,000
Total current assets 263,386,000 235,563,000
Property and equipment, net 24,098,000 20,929,000
Operating lease right-of-use assets 48,301,000 48,407,000
Goodwill 213,345,000 214,335,000
Intangible assets 143,808,000 150,884,000
Deposits and other assets 4,301,000 4,117,000
Total assets 697,239,000 674,235,000
Current liabilities    
Accounts payable 15,523,000 10,577,000
Payroll-related accruals 54,797,000 48,706,000
Accrued expenses and other current liabilities 76,881,000 15,364,000
Operating lease liabilities, current portion 1,579,000 1,692,000
Total current liabilities 148,780,000 76,339,000
Operating lease liabilities, noncurrent portion 31,145,000 30,355,000
Deferred tax liability 36,748,000 36,231,000
Other long-term liability 45,805,000 66,400,000
Total liabilities 262,478,000 209,325,000
Commitments and contingencies (Note 9)
Stockholders' equity    
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2024 and December 31, 2023 0 0
Common stock, $0.001 par value, 300,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 58,435,576 and 57,762,414 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 58,000 58,000
Additional paid in capital 543,961,000 504,453,000
Accumulated other comprehensive income 13,145,000 8,885,000
Accumulated deficit (122,403,000) (48,486,000)
Total stockholders' equity 434,761,000 464,910,000
Total liabilities and stockholders' equity $ 697,239,000 $ 674,235,000
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, authorized (in shares) 10,000,000 10,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, authorized (in shares) 300,000,000 300,000,000
Common stock, issued (in shares) 58,435,576 57,762,414
Common stock, outstanding (in shares) 58,435,576 57,762,414
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Revenue $ 153,390,000 $ 126,366,000 $ 442,404,000 $ 361,538,000
Cost of goods sold 19,846,000 14,477,000 58,732,000 42,062,000
Gross profit 133,544,000 111,889,000 383,672,000 319,476,000
Operating expenses        
Research and development 29,431,000 21,492,000 81,216,000 64,641,000
Selling, general and administrative 108,271,000 85,603,000 325,479,000 256,889,000
Change in fair value of contingent consideration 6,578,000 0 18,609,000 0
Amortization of intangible asset 2,504,000 0 7,414,000 0
Acquisition-related expenses 328,000 2,681,000 4,143,000 2,681,000
Total operating expenses 147,112,000 109,776,000 436,861,000 324,211,000
(Loss) income from operations (13,568,000) 2,113,000 (53,189,000) (4,735,000)
Other income (expense)        
Interest income 1,104,000 4,202,000 3,371,000 12,899,000
Interest expense (78,000) (43,000) (233,000) (127,000)
Other expense (130,000) (682,000) (130,000) (617,000)
Total other income 896,000 3,477,000 3,008,000 12,155,000
(Loss) income before income taxes (12,672,000) 5,590,000 (50,181,000) 7,420,000
Provision for income taxes 5,695,000 2,428,000 23,736,000 4,391,000
Net (loss) income (18,367,000) 3,162,000 (73,917,000) 3,029,000
Other comprehensive income (loss)        
Foreign currency translation adjustments 13,918,000 (68,000) 4,200,000 (138,000)
Unrealized gain (loss) on available-for-sale debt securities 64,000 91,000 60,000 (1,869,000)
Total other comprehensive income (loss) 13,982,000 23,000 4,260,000 (2,007,000)
Comprehensive income (loss) $ (4,385,000) $ 3,185,000 $ (69,657,000) $ 1,022,000
Net (loss) income per share        
Basic (in dollars per share) $ (0.31) $ 0.06 $ (1.27) $ 0.05
Diluted (in dollars per share) $ (0.31) $ 0.05 $ (1.27) $ 0.05
Weighted average common shares used to compute net (loss) income per share        
Basic (in shares) 58,366,364 57,384,884 58,149,296 56,478,317
Diluted (in shares) 58,366,364 58,588,452 58,149,296 58,495,921
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2022   54,021,656      
Balance at beginning of period at Dec. 31, 2022 $ 417,002 $ 54 $ 462,949 $ 849 $ (46,850)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Options exercised for common stock (in shares)   209,966      
Options exercised for common stock 226   226    
Shares issued under Employee Stock Purchase Plan (in shares)   86,051      
Shares issued under Employee Stock Purchase Plan 4,172   4,172    
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes (in shares)   2,766,043      
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes (1,929) $ 3 (1,932)    
Share-based compensation expense 10,339   10,339    
Other comprehensive income (loss) (856)     (856)  
Net (loss) income (2,218)       (2,218)
Balance at end of period (in shares) at Mar. 31, 2023   57,083,716      
Balance at end of period at Mar. 31, 2023 426,736 $ 57 475,754 (7) (49,068)
Balance at beginning of period (in shares) at Dec. 31, 2022   54,021,656      
Balance at beginning of period at Dec. 31, 2022 417,002 $ 54 462,949 849 (46,850)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Other comprehensive income (loss) (2,007)        
Net (loss) income 3,029        
Balance at end of period (in shares) at Sep. 30, 2023   57,506,462      
Balance at end of period at Sep. 30, 2023 452,142 $ 58 497,063 (1,158) (43,821)
Balance at beginning of period (in shares) at Mar. 31, 2023   57,083,716      
Balance at beginning of period at Mar. 31, 2023 426,736 $ 57 475,754 (7) (49,068)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Options exercised for common stock (in shares)   81,712      
Options exercised for common stock 214   214    
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes (in shares)   101,027      
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes (2,569)   (2,569)    
Share-based compensation expense 10,353   10,353    
Other comprehensive income (loss) (1,174)     (1,174)  
Net (loss) income 2,085       2,085
Balance at end of period (in shares) at Jun. 30, 2023   57,266,455      
Balance at end of period at Jun. 30, 2023 435,645 $ 57 483,752 (1,181) (46,983)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Options exercised for common stock (in shares)   43,547      
Options exercised for common stock 107   107    
Shares issued under Employee Stock Purchase Plan (in shares)   118,494      
Shares issued under Employee Stock Purchase Plan 5,749 $ 1 5,748    
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes (in shares)   77,966      
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes (2,388)   (2,388)    
Share-based compensation expense 9,844   9,844    
Other comprehensive income (loss) 23     23  
Net (loss) income 3,162       3,162
Balance at end of period (in shares) at Sep. 30, 2023   57,506,462      
Balance at end of period at Sep. 30, 2023 $ 452,142 $ 58 497,063 (1,158) (43,821)
Balance at beginning of period (in shares) at Dec. 31, 2023 57,762,414 57,762,414      
Balance at beginning of period at Dec. 31, 2023 $ 464,910 $ 58 504,453 8,885 (48,486)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Options exercised for common stock (in shares)   81,952      
Options exercised for common stock 145   145    
Shares issued under Employee Stock Purchase Plan (in shares)   82,816      
Shares issued under Employee Stock Purchase Plan 3,983   3,983    
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes (in shares)   73,963      
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes (3,113)   (3,113)    
Share-based compensation expense 12,870   12,870    
Other comprehensive income (loss) (7,363)     (7,363)  
Net (loss) income (24,202)       (24,202)
Balance at end of period (in shares) at Mar. 31, 2024   58,001,145      
Balance at end of period at Mar. 31, 2024 $ 447,230 $ 58 518,338 1,522 (72,688)
Balance at beginning of period (in shares) at Dec. 31, 2023 57,762,414 57,762,414      
Balance at beginning of period at Dec. 31, 2023 $ 464,910 $ 58 504,453 8,885 (48,486)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Other comprehensive income (loss) 4,260        
Net (loss) income $ (73,917)        
Balance at end of period (in shares) at Sep. 30, 2024 58,435,576 58,435,576      
Balance at end of period at Sep. 30, 2024 $ 434,761 $ 58 543,961 13,145 (122,403)
Balance at beginning of period (in shares) at Mar. 31, 2024   58,001,145      
Balance at beginning of period at Mar. 31, 2024 447,230 $ 58 518,338 1,522 (72,688)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Options exercised for common stock (in shares)   47,750      
Options exercised for common stock 98   98    
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes (in shares)   117,414      
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes (2,851)   (2,851)    
Share-based compensation expense 13,039   13,039    
Other comprehensive income (loss) (2,359)     (2,359)  
Net (loss) income (31,348)       (31,348)
Balance at end of period (in shares) at Jun. 30, 2024   58,166,309      
Balance at end of period at Jun. 30, 2024 423,809 $ 58 528,624 (837) (104,036)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Options exercised for common stock (in shares)   41,104      
Options exercised for common stock 117   117    
Shares issued under Employee Stock Purchase Plan (in shares)   133,430      
Shares issued under Employee Stock Purchase Plan 5,281   5,281    
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes (in shares)   94,733      
Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes (3,012)   (3,012)    
Share-based compensation expense 12,951   12,951    
Other comprehensive income (loss) 13,982     13,982  
Net (loss) income $ (18,367)       (18,367)
Balance at end of period (in shares) at Sep. 30, 2024 58,435,576 58,435,576      
Balance at end of period at Sep. 30, 2024 $ 434,761 $ 58 $ 543,961 $ 13,145 $ (122,403)
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities    
Net (loss) income $ (73,917,000) $ 3,029,000
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Depreciation and amortization 11,879,000 4,186,000
Amortization of deferred financing costs 65,000 30,000
Amortization of right-of-use assets 2,858,000 3,099,000
Share-based compensation expense 38,860,000 30,536,000
Impairment loss on strategic investment 0 565,000
Allowance for credit losses, net 622,000 526,000
Loss on disposal of fixed assets 436,000 26,000
Impairment of capitalized software development costs 3,789,000 0
Amortization of premium and discount on marketable securities (1,707,000) (11,407,000)
Change in fair value of contingent consideration liability 18,609,000 0
Changes in:    
Accounts receivable (15,107,000) (11,566,000)
Inventories (12,378,000) (7,797,000)
Prepaid expenses, deposits and other assets (3,278,000) 4,294,000
Accounts payable 4,927,000 2,436,000
Payroll-related accruals, accrued expenses and other liabilities 28,356,000 7,218,000
Operating lease liabilities (1,797,000) (1,031,000)
Lease prepayments for lessor's owned leasehold improvements (280,000) (458,000)
Net cash provided by operating activities 1,937,000 23,686,000
Cash flows from investing activities    
Purchases of property and equipment (7,899,000) (3,801,000)
Purchases of marketable securities (91,085,000) (394,496,000)
Maturities of marketable securities 96,708,000 400,560,000
Purchases of other investments 0 (565,000)
Working capital adjustment related to acquisition 3,722,000 0
Capitalized software development costs (2,298,000) 0
Net cash (used in) provided by investing activities (852,000) 1,698,000
Cash flows from financing activities    
Proceeds from issuance of common stock under employee stock purchase plan 9,264,000 9,920,000
Proceeds from exercise of stock options 360,000 547,000
Payment of taxes related to vested equity awards (8,976,000) (6,886,000)
Net cash provided by financing activities 648,000 3,581,000
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash 267,000 (5,000)
Net increase in cash, cash equivalents and restricted cash 2,000,000 28,960,000
Cash, cash equivalents and restricted cash beginning of period 39,208,000 60,222,000
Cash, cash equivalents and restricted cash end of period $ 41,208,000 $ 89,182,000
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.24.3
Organization
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization ORGANIZATION
Description of Business
Inari Medical, Inc. (the “Company”) was incorporated in Delaware in July 2011 and is headquartered in Irvine, California. The Company purpose builds and markets a variety of medical products, including minimally invasive, novel, catheter-based mechanical thrombectomy systems for the unique characteristics of specific disease states.
On November 15, 2023, the Company acquired LimFlow S.A. (“LimFlow”), a medical device company focused on limb salvage for patients with chronic limb-threatening ischemia (“CLTI”). LimFlow focuses on transforming the treatment of CLTI, an advanced stage of peripheral artery disease that is associated with increased mortality, risk of amputation and impaired quality of life.
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and include the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to prior period financial statements to conform to classifications used in the current period.
The interim condensed consolidated balance sheet as of September 30, 2024 and the condensed consolidated statements of operations and comprehensive income (loss), stockholders’ equity, and cash flows for the three and nine months ended September 30, 2024 and 2023 are unaudited. The consolidated balance sheet as of December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed consolidated financial position as of September 30, 2024 and its consolidated results of operations and cash flows for the three and nine months ended September 30, 2024 and 2023. The financial data and the other financial information disclosed in the notes to the condensed consolidated financial statements related to the three and nine months ended September 30, 2024 and 2023 are also unaudited. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. These interim condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
Management Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements may include, but are not limited to, contingent consideration liability, collectability of receivables, recoverability of long-lived assets, valuation of inventory, operating lease right-of-use (“ROU”) assets and liabilities, other investments, fair value of stock options, recoverability of net deferred tax assets and related valuation allowance, and certain accruals. Estimates are based on historical experience and on various assumptions that the Company believes are reasonable under current circumstances. Actual results could differ materially from those estimates. Management periodically evaluates such estimates and assumptions, and they are adjusted prospectively based upon such periodic evaluation.
Revenue Recognition
The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company sells its products primarily to hospitals in the United States through its direct sales force and also sells its products directly and through distributors in select international markets. The Company recognizes revenue for arrangements where the Company has satisfied its performance obligation of shipping or delivering the product. For sales where the Company’s sales representatives hand-deliver products directly to the hospitals, control of the products transfers to the customers upon such hand-delivery. For sales where products are shipped, control of the products transfers either upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. Revenue from product sales is comprised of product revenue, net of product returns, discounts, administrative fees and sales rebates. The Company has elected to account for shipping and handling activities that occur after the customer has obtained control as a fulfillment activity, and not a separate performance obligation.
Performance Obligation—The Company has revenue arrangements that consist of a single performance obligation, the shipping or delivery of the Company’s products. The satisfaction of this performance obligation occurs with the transfer of control of the Company’s product to its customers, either upon shipment or delivery of the product.
Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of revenue recognized is based on the transaction price, which represents the invoiced amount, net of discounts, administrative fees and sales rebates, where applicable. The Company provides a standard 30-day unconditional right of return period. The Company establishes estimated provisions for returns at the time of sale based on historical experience. Historically, the actual product returns have been insignificant to the Company’s condensed consolidated financial statements.
As of September 30, 2024 and December 31, 2023, the Company recorded $1.2 million of unbilled receivables, and $1.9 million and $1.3 million, respectively, of allowance for credit losses, which are included in accounts receivable, net, in the accompanying condensed consolidated balance sheets.
The Company disaggregates revenue between Venous Thromboembolism (“VTE”) and Emerging Therapies. VTE comprises revenue from the sale of the Company’s solutions addressing deep vein thrombosis and pulmonary embolism. Emerging Therapies comprises revenue from the sale of the Company’s solutions addressing chronic venous disease, CLTI, acute limb ischemia and dialysis access management. Revenue from VTE and Emerging Therapies is as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
VTE
$145,346 $121,460 $420,213 $349,604 
Emerging Therapies
8,044 4,906 22,191 11,934 
Total revenue
$153,390 $126,366 $442,404 $361,538 
Revenue from the Company's products by geographic area, based on the location where title transfers, is as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
United States$141,854$119,825$411,321$345,473
International11,5366,54131,08316,065
Total revenue
$153,390 $126,366$442,404$361,538
The Company offers payment terms to its customers of less than three months and these terms do not include a significant financing component. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.
The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to cost of goods sold.
Costs associated with product sales include commissions which are recorded in selling, general and administrative (“SG&A”) expenses. The Company applies the practical expedient and recognizes commissions as an expense when incurred because the amortization period is less than one year.
Equity Investments
The Company has strategic investments in certain privately held companies, with no readily determinable fair value. The Company elected the measurement alternative under which it measures these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments. The Company will monitor the information that becomes available from time to time and adjust the carrying values of these investments if there are identified events or changes in circumstances that have a significant adverse effect on the fair values or if there are observable changes in fair value. Impairment loss, which is generally the difference between the carrying value and the fair value of the investment, is recorded in other income (expense) in the consolidated statements of operations and comprehensive income (loss). As of September 30, 2024 and December 31, 2023, the Company’s equity investments were $1.5 million and were included in deposits and other assets on the condensed consolidated balance sheets. Additionally, during the three and nine months ended September 30, 2023, the Company recorded an impairment loss of $0.6 million in other income (expense) within the condensed consolidated statements of operations and comprehensive income (loss). There was no impairment recorded during the three and nine months ended September 30, 2024.
Significant Accounting Policies
As of September 30, 2024, there were no changes to the Company’s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
Recently Issued Not Yet Adopted Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting, Topic 280, which requires enhanced disclosures primarily around segment expenses for all public entities, including public entities with a single reportable segment. On an annual and interim basis, entities are required to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of the new standard and does not expect there to be a material impact on its consolidated financial statements and related disclosures upon adoption.
In December 2023, FASB issued ASU 2023-09, Income Tax, Topic 740, which requires public companies to disclose specific categories in the rate reconciliation, disaggregate information related to income taxes paid, income or loss from operations before income tax expense or benefit, and income tax expense or benefit from operations. The ASU is effective for annual fiscal years beginning after December 15, 2024, with early adoption permitted. Amendments are applicable on a prospective basis with retrospective application permitted. The Company is currently evaluating the impact of the new standard on its consolidated financial statements and related disclosures.
Supplemental Cash Flow Information
Supplemental cash flow information includes the following (in thousands):
Nine Months Ended September 30,
20242023
Supplemental disclosures of cash flow information:
Cash paid for income taxes$7,371 $3,562 
Cash paid for interest$168 $98 
Noncash investing and financing:
Lease liabilities arising from obtaining new right-of-use assets$2,447 $1,030 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
$41,141 $89,182 
Restricted cash
67 — 
Total cash, cash equivalents and restricted cash as shown in the statement of cash flows
$41,208 $89,182 
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.24.3
Business Combination
 9 Months Ended
Sep. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Business Combination BUSINESS COMBINATION
Acquisition of LimFlow S.A.
On November 15, 2023, the Company completed its acquisition of LimFlow, a medical device company focused on limb salvage for patients with CLTI. As a result of the acquisition, LimFlow’s stockholders received as consideration (i) cash, and (ii) contingent consideration related to certain commercial and reimbursement milestones. The results of operations of LimFlow have been included in the condensed consolidated financial statements from the date of the acquisition.
During the nine months ended September 30, 2024, the Company recorded an adjustment related to the finalization of the working capital, which reduced the consideration transferred and the acquisition date fair value of goodwill by $3.7 million.
Purchase Price
The total purchase price as of the date of the acquisition consisted of the following (in thousands):
As of November 15, 2023
Cash$238,279 
Fair value of contingent consideration65,931 
Fair value of previously held investment10,235 
Total purchase price$314,445 
Contingent Consideration
The LimFlow stockholders can achieve up to $165.0 million of additional contingent consideration if certain commercial and reimbursement milestones are achieved, as outlined under the Contingent Payments section of the share purchase agreement with LimFlow. Such payments include (i) up to $140.0 million based on net revenue generated from the sale of the LimFlow System for the years 2024 through 2026 and (ii) up to $25.0 million based on the achievement of certain reimbursement milestones related to the LimFlow System.
The acquisition-date fair value of the contingent consideration was measured using a Monte Carlo simulation which represents Level 3 measurements because they are supported by little or no market activity and reflect the Company’s assumptions in measuring fair value. Estimates and assumptions used in the fair value assessment included forecasted revenues for LimFlow, revenue risk premium, revenue volatility, operational leverage ratio, counterparty credit spread, and weighted average cost of capital. The Company has determined that the range of the potential payments on such contingencies is $65.9 million to $165.0 million. The fair value of the contingent consideration was $65.9 million as of the acquisition date. See Note 4. Fair Value Measurements for additional information.
Previously Held Investment
Prior to the acquisition, the Company held an investment in LimFlow, which represented approximately 3.7% of LimFlow's outstanding equity, and was recorded at cost minus impairment. Authoritative guidance on accounting for business combinations requires that an acquirer remeasure its previously held equity investment in the acquiree at its acquisition-date fair value and recognize the resulting gain or loss in earnings. In connection with acquiring the remaining 96.3% equity interest of LimFlow, the Company remeasured its previously held equity investment to its fair value, as of the date of acquisition, based on the fair value of total consideration transferred. Estimates and assumptions used in the remeasurement represent a Level 3 measurement because they are supported by little or no market activity and reflect the Company’s assumptions in measuring the fair value. As a result of the remeasurement, the Company valued its previously held equity investment in LimFlow at $10.2 million and recognized a gain of $3.5 million, included in other income (expense) in the consolidated statements of operations and comprehensive income (loss) during the year ended December 31, 2023.
Transaction Costs
The transaction costs associated with the acquisition of LimFlow consisted primarily of legal and financial advisory fees of approximately $8.7 million in addition to $1.7 million of severance and integration related costs, which were expensed as incurred as SG&A expense during the year ended December 31, 2023.
Net Assets Acquired and Liabilities Assumed
The purchase price allocation for the LimFlow acquisition was finalized as of September 30, 2024, and there were no measurement period adjustments recorded. The final allocation of fair value of assets acquired and liabilities assumed were (in thousands):
As of November 15, 2023
Cash and cash equivalents$1,582 
Accounts receivable919 
Inventories2,635 
Property and equipment266 
Goodwill204,078 
Intangible asset146,000 
Other current and noncurrent assets2,155 
Accounts payable(2,509)
Deferred tax liability(36,500)
Other current and noncurrent liabilities(4,181)
Total net assets acquired$314,445 
The fair value assigned to the intangible asset acquired was as follows (in thousands, except for estimated useful life which is in years):
Fair value
Useful life
Developed technology$146,000 15 years
The fair value assigned to identifiable intangible asset, the developed technology, acquired as part of the LimFlow acquisition, was estimated using the multi-period excess earnings method. Under this method, an intangible asset’s fair value is equal to the present value of future economic benefits to be derived from ownership of the asset. The estimated fair value was developed by discounting future net cash flows to their present value at market-based rates of return. Such assumptions included forecasted revenues, cost of sales and operating expenses, technology obsolescence, and weighted average cost of capital. The useful life of the developed technology for amortization purposes was determined by considering the period of expected cash flows used to measure the fair values of the intangible asset adjusted as appropriate for entity-specific factors including competitive, economic and other factors that may limit the useful life. The developed technology asset will be amortized on a straight-line basis over its estimated useful life.
Unaudited Pro Forma Financial Information
The following unaudited pro forma financial information summarizes the combined results of operations of the Company and LimFlow as if the companies had been combined as of the beginning of fiscal year 2023 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
20232023
Revenue$126,757 $362,848 
Net loss
$(6,245)$(28,452)
The unaudited pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved had the acquisition been completed at the beginning of the fiscal year ended December 31, 2023. In addition, the unaudited pro forma financial information is not a projection of future results of operations of the combined company nor does it reflect the expected realization of any synergies or cost savings associated with the acquisition. The unaudited pro forma financial information includes adjustments to reflect the elimination of intercompany transactions, incremental amortization of the identifiable intangible asset and elimination of the remeasurement the Company’s previously held investment in LimFlow.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements FAIR VALUE MEASUREMENTS
Investments in debt securities have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. As of September 30, 2024, all of the Company's investments in debt securities had maturities of less than 12 months and were classified as short-term investments on the condensed consolidated balance sheets.
The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024
Level 1Level 2Level 3Aggregate Fair Value
Financial Assets
Cash and cash equivalents:
Money market mutual funds$7,288 $— $— $7,288 
Total included in cash and cash equivalents7,288 — — 7,288 
Investments:
U.S. treasury securities
70,397 — — 70,397 
Total included in short-term investments70,397 — — 70,397 
Total financial assets
$77,685 $— $— $77,685 
Financial Liability
Contingent consideration$— $— $84,540 $84,540 
Total financial liabilities$— $— $84,540 $84,540 
December 31, 2023
Level 1Level 2Level 3Aggregate Fair Value
Financial Assets
Cash and cash equivalents:
Money market mutual funds$2,753 $— $— $2,753 
Total included in cash and cash equivalents2,753 — — 2,753 
Investments:
U.S. treasury securities
41,685 — — 41,685 
U.S. government agencies
— 26,238 — 26,238 
Corporate debt securities and commercial paper— 8,932 — 8,932 
Total included in short-term investments41,685 35,170 — 76,855 
Total financial assets
$44,438 $35,170 $— $79,608 
Financial Liability
Contingent consideration$— $— $65,931 $65,931 
Total financial liabilities$— $— $65,931 $65,931 
There were no transfers between Levels 1, 2 or 3 for the periods presented.
Contingent payments are related to the acquisition of LimFlow and consist of commercial and reimbursement milestones, which were valued using a Monte Carlo simulation and probability weighted discounted cash flow analysis, respectively, and represent Level 3 measurements because they are based upon significant unobservable inputs such as forecasted revenues of LimFlow, revenue risk premium, revenue volatility, operational leverage ratio, credit risk, weighted average cost of capital, and probability assumptions in achieving certain milestones.
The following table summarizes the changes in the estimated fair value of the Company’s contingent consideration liabilities (in thousands):
Contingent Consideration Fair Value
Balance as of December 31, 2023
$65,931 
Change in estimated fair value
18,609 
Balance as of September 30, 2024
$84,540 
The fair value of the contingent consideration was $84.5 million as of September 30, 2024, of which $39.2 million was recorded within accrued expenses and other current liabilities and $45.3 million was recorded within other long-term liabilities, and $65.9 million as of December 31, 2023, which was recorded within other long-term liabilities. The change in estimated fair value of contingent consideration was recorded in operating expenses within the condensed consolidated statements of operations and comprehensive income (loss).
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.24.3
Cash Equivalents and Investments
 9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Cash Equivalents and Investments CASH EQUIVALENTS AND INVESTMENTS
The following is a summary of the Company’s cash equivalents and investments in debt securities as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024
Amortized Cost BasisUnrealized GainUnrealized LossFair Value
Financial Assets
Cash and cash equivalents:
Money market mutual funds$7,288 $— $— $7,288 
Total included in cash and cash equivalents7,288 — — 7,288 
Investments:
U.S. treasury securities
70,346 51 — 70,397 
Total included in short-term investments70,346 51 — 70,397 
Total financial assets
$77,634 $51 $— $77,685 
December 31, 2023
Amortized Cost BasisUnrealized GainUnrealized LossFair Value
Financial Assets
Cash and cash equivalents:
Money market mutual funds$2,753 $— $— $2,753 
Total included in cash and cash equivalents2,753 — — 2,753 
Investments:
U.S. treasury securities
41,672 13 — 41,685 
U.S. government agencies
26,248 — (10)26,238 
Corporate debt securities and commercial paper8,935 — (3)8,932 
Total included in short-term investments76,855 13 (13)76,855 
Total financial assets
$79,608 $13 $(13)$79,608 
The Company regularly reviews any changes to the rating of its debt securities and reasonably monitors the surrounding economic conditions to assess the risk of expected credit losses. As of September 30, 2024, the risk of expected credit losses was not significant.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.24.3
Inventories, net
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Inventories, net INVENTORIES, NET
Inventories, net of reserves, consist of the following (in thousands):
September 30,
2024		December 31,
2023
Raw materials$21,983 $14,310 
Work-in-process6,179 5,330 
Finished goods27,048 23,260 
Total inventories, net
$55,210 $42,900 
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.24.3
Property and Equipment, net
 9 Months Ended
Sep. 30, 2024
Property, Plant and Equipment [Abstract]  
Property and Equipment, net PROPERTY AND EQUIPMENT, NET
Property and equipment consist of the following (in thousands):
September 30,
2024		December 31,
2023
Manufacturing equipment$18,527 $16,653 
Computer hardware6,671 5,641 
Assets in progress5,902 3,135 
Furniture and fixtures4,584 4,491 
Leasehold improvements4,531 4,682 
Total property and equipment, gross40,215 34,602 
Accumulated depreciation(16,117)(13,673)
Total property and equipment, net$24,098 $20,929 
Depreciation expense of $1.1 million was included in operating expenses and $0.3 million was included in cost of goods sold for the three months ended September 30, 2024 and 2023, respectively. Depreciation expense of $3.4 million was included in operating expenses for the nine months ended September 30, 2024 and 2023, and $1.0 million and $0.8 million was included in cost of goods sold for the nine months ended September 30, 2024 and 2023, respectively.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.24.3
Goodwill and Intangible Assets
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets GOODWILL AND INTANGIBLE ASSETS
Goodwill
The changes in carrying amount of goodwill for the nine months ended September 30, 2024 were as follows (in thousands):
Balance as of December 31, 2023
$214,335 
Working capital adjustment
(3,722)
Foreign currency translation adjustments2,732 
Balance as of September 30, 2024
$213,345 
The working capital adjustment relates to the acquisition of LimFlow. See Note 3. Business Combination for additional information.
Intangible Assets
The intangible assets consist of the following (in thousands):
September 30, 2024
Gross Carrying AmountAccumulated AmortizationIntangible Assets, Net
Developed technology
$152,716 $(8,908)$143,808 
Total intangible assets, net
$152,716 $(8,908)$143,808 
December 31, 2023
Gross Carrying AmountAccumulated AmortizationIntangible Assets, Net
Developed technology
$150,649 $(1,256)$149,393 
Capitalized software(a)
1,491 — 1,491 
Total intangible assets, net
$152,140 $(1,256)$150,884 
_____________
(a) The useful life of the capitalized software was not determined as of December 31, 2023 as the asset was not put into service. No amortization expense has been recorded related to the capitalized software during the three and nine months ended September 30, 2023.
The gross carrying amount and the accumulated amortization of the developed technology asset is subject to foreign currency translation effects. During the three and nine months ended September 30, 2024, $2.5 million and $7.4 million, respectively, of amortization expense was recorded in operating expenses within the condensed consolidated statements of operations and comprehensive income (loss) related to the developed technology asset. There were no intangible assets and no amortization recorded for the three and nine months ended September 30, 2023.
During the three months ended September 30, 2024, the Company recorded a non-cash impairment of $3.8 million related to previously capitalized software development costs that reduced the carrying value of such asset to zero. The impairment charge was recorded in research and development expenses within the condensed consolidated statements of operations and comprehensive income (loss).
The estimated future annual amortization of the intangible assets in service is as follows (in thousands):
Year ending December 31:Amount
Remainder of 2024$2,545 
202510,181 
202610,181 
202710,181 
202810,181 
Thereafter100,539 
Total$143,808 
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies COMMITMENTS AND CONTINGENCIES
Operating Leases
The Company has operating leases for facilities and certain equipment. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. Lease expense for operating leases is recognized on a straight-line basis over the lease term. For lease agreements, other than long-term real estate leases, the Company combines lease and non-lease components. The variable lease payments primarily relate to common area maintenance, property taxes, and insurance. The operating leases for facilities expire at various dates through July 2041 and some contain renewal options, the longest of which is for five years. The ROU asset and lease liability includes renewal options if the Company is reasonably certain to exercise such renewal options.
The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest rate the Company would incur to borrow on a collateralized basis, considering factors such as length of lease term.
The following table presents the weighted average remaining lease term and discount rate:
September 30,
20242023
Weighted average remaining term (in years)
16.118.2
Weighted average discount rate6.1 %6.1 %
Cash paid for amounts included in the measurement of operating leases were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Cash paid for amounts included in the measurement of operating lease liabilities$1,048 $866 $2,877 $2,564 
Total lease costs are as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Operating lease cost$1,385 $1,137 $3,929 $3,456 
Short-term lease cost48 22 141 85 
Variable lease cost184 402 746 809 
Total lease costs$1,617 $1,561 $4,816 $4,350 
Future minimum lease payments under operating leases liabilities as of September 30, 2024 are as follows (in thousands):
Year ending December 31:
Amount
Remainder of 2024$858 
20253,373 
20263,512 
20273,594 
20283,396 
Thereafter35,771 
Total lease payments50,504 
Less imputed interest(17,780)
Total lease liabilities32,724 
Less: lease liabilities - current portion(1,579)
Lease liabilities - noncurrent portion$31,145 
The Company signed a ten-year lease in Costa Rica for its second manufacturing facility in October 2023, with total undiscounted contractual payments of the lease of approximately $7.2 million, which is expected to commence in the fourth quarter of 2024.
Indemnification
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not been subject to any claims or required to defend any action related to its indemnification obligations.
The Company’s amended and restated certificate of incorporation contains provisions limiting the liability of directors, and its amended and restated bylaws provide that the Company will indemnify each of its directors to the fullest extent permitted under Delaware law. The Company’s amended and restated certificate of incorporation and amended and restated bylaws also provide its board of directors with discretion to indemnify its officers and employees when determined appropriate by the board. In addition, the Company has entered and expects to continue to enter into agreements to indemnify its directors and executive officers.
Legal Proceedings
From time to time, the Company is involved in various claims and proceedings arising in the ordinary course of its business. Management does not believe that any existing claims and proceedings, including potential losses relating to such contingencies, will have a material adverse effect on its consolidated financial position, results of operations or cash flows.
Civil Investigative Demand
As previously disclosed, in December 2023, the Company received a civil investigative demand (“CID”) from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act (the “Investigation”). The CID requests information and documents primarily relating to meals and consulting service payments provided to health care professionals. The Company is cooperating with the Investigation. The Company is unable to express a view at this time regarding the likely duration, or ultimate outcome, of the Investigation or estimate the possibility of, or amount or range of, any possible financial impact. Depending on the outcome of the Investigation, there may be a material impact on the Company’s business, results of operations, or financial condition.
Patent and Trade Secret Litigation
As previously disclosed, on May 22, 2024, the Company filed a patent infringement lawsuit against Imperative Care, Inc. (“Imperative Care”) and Truvic Medical, Inc. (“Truvic”) in the United States District Court for the Northern District of California, alleging that Imperative Care's Symphony Thrombectomy System infringes eight patents related to mechanical thrombectomy devices used for treating pulmonary emboli and deep vein thrombosis. On July 9, 2024, the Company filed an amended complaint to allege infringement of an additional, ninth patent, and to drop Truvic as a named defendant because Imperative Care confirmed that Truvic has been merged into Imperative Care. In the complaint, the Company seeks injunctive relief and damages for the alleged infringement. On July 24, 2024, the Company filed a motion for a preliminary injunction seeking to enjoin Imperative Care's sale or use, among other activities, of the Symphony Thrombectomy System outside of clinical trials. The court has indicated that it is likely to hear the preliminary injunction motion in December 2024. It has not otherwise set a case schedule.
On September 11, 2024, the Company filed a lawsuit against Inquis Medical, Inc. (“Inquis”) in the United States District Court for the District of Delaware. The Company’s complaint alleges that Inquis misappropriated the Company’s trade secrets in relation to Inquis’ engagement of the services of an Inari employee, and that Inquis’ Aventus Thrombectomy System and Aventus Clot Management System infringe four Inari patents related to mechanical thrombectomy devices used for treating pulmonary emboli and deep vein thrombosis. Inquis’ response to the Company’s complaint is due November 4, 2024. The court has not otherwise set a case schedule.
Securities Class Action
As previously disclosed, on May 13, 2024, purported stockholder Michiana Area Electrical Workers’ Pension Fund filed a verified class action complaint on behalf of itself and similarly situated Inari stockholders in the United States District Court for the Southern District of New York, captioned Michiana Area Elec. Workers’ Pension Fund v. Inari Medical, Inc., No. 1:24-cv-03686-JHR (the “MAEW Action”). On June 18, 2024, purported stockholder Paul Hartmann filed a verified class action complaint on behalf of himself and similarly situated Inari stockholders in the United States District Court for the Southern District of New York, captioned Hartmann v. Inari Medical, Inc., No. 1:24-cv-04662-JHR (the “Hartmann Action” and together with the MAEW Action, the “Related Actions”). Each of the Related Actions alleges the Company and certain of its officer and directors violated Sections 10(b) and 20(a) of the Securities Exchange Act by making false or misleading statements regarding the Company’s revenue and expenses.
As previously disclosed, on July 12, 2024, a group of pension funds consisting of Oklahoma Law Enforcement Retirement Systems, Local 353, I.B.E.W. Pension Fund, and City of Pontiac Reestablished General Employees’ Retirement System, Mr. Hartmann, and purported stockholder Arvin Nazerzadeh-Yazdi, each filed motions seeking to consolidate the Related Actions, be appointed lead plaintiff, and have their counsel appointed lead counsel. The matter is at a preliminary stage and the Company is not able to quantify the extent of any potential liability.
The Company believes that these complaints are without merit and intends to defend against them vigorously.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Concentrations
 9 Months Ended
Sep. 30, 2024
Risks and Uncertainties [Abstract]  
Concentrations CONCENTRATIONS
The Company’s revenue is derived primarily from the sale of catheter-based therapeutic devices in the United States. For the three and nine months ended September 30, 2024 and 2023, there were no customers which accounted for more than 10% of the Company’s revenue. As of September 30, 2024 and December 31, 2023, there were no customers that accounted for more than 10% of the Company’s accounts receivable.
No vendor accounted for more than 10% of the Company’s purchases for the three and nine months ended September 30, 2024 and 2023. There were no vendors that accounted for more than 10% of the Company’s accounts payable as of September 30, 2024 and December 31, 2023.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.24.3
Related Party
 9 Months Ended
Sep. 30, 2024
Related Party Transactions [Abstract]  
Related Party RELATED PARTY
The Company utilizes MRI The Hoffman Group (“MRI”), a recruiting services company owned by the brother of the former Chief Executive Officer and President and current member of the board of directors of the Company. The Company paid for recruiting services provided by MRI amounting to nil and $67,000 for the three months ended September 30, 2024 and 2023, respectively, and $31,000 and $147,000 for the nine months ended September 30, 2024 and 2023, respectively, which was recorded in SG&A expenses within the condensed consolidated statements of operations and comprehensive income (loss). As of September 30, 2024 and December 31, 2023, there was no balance payable to MRI.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.24.3
Credit Facility
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Credit Facility CREDIT FACILITY
Bank of America Credit Facility
On December 16, 2022, the Company amended its senior secured revolving credit facility with Bank of America (the “Previously Amended Credit Agreement”) under which the Company may borrow loans up to a maximum principal amount of $40.0 million and increase the optional accordion to $120.0 million.
Advances under the Previously Amended Credit Agreement will bear interest at a base rate per annum (“the Base Rate”) plus an applicable margin (the “Margin”). The Base Rate equals the greater of (i) the Prime Rate, (ii) the Federal funds rate plus 0.50%, or (iii) the Bloomberg Short-Term Bank Yield Index (“the BSBY”) rate based upon an interest period of one month plus 1.00%, in any case has a floor of 0%. The Margin ranges, depending on average daily availability, from 0.50% to 1.00% in the case of Prime Rate and the Federal funds rate loans, and 1.50% to 2.00% in the case of BSBY Rate loans. As a condition to entering into the Previously Amended Credit Agreement, the Company was obligated to pay a nonrefundable fee of $10,000. The Company is also required to pay an unused line fee at an annual rate of 0.25% per annum of the average daily unused portion of the aggregate revolving credit commitments under the Previously Amended Credit Agreement.
The Previously Amended Credit Agreement also includes a Letter of Credit subline facility (the “LC Facility”) of up to $5.0 million. In February 2023, the Company amended the LC Facility to increase the limit to up to $10.0 million. The Company is required to pay the following fees under the LC Facility: (a) a fee equal to the applicable margin in effect for BSBY loans (currently 2.25%) times the average daily stated amount of outstanding letters of credit; and (b) a fronting fee equal to 0.125% per annum on the stated amount of each letter of credit outstanding.
On November 1, 2023, the Company further amended its credit facility (the “Amended Credit Agreement”) to, among other things, increase the amount available for borrowing up to a maximum principal amount of $75.0 million. Additionally, advances under the Amended Credit Agreement will bear interest at the Base Rate or the BSBY rate, plus the Margin. The Margin ranges from 0.60% to 1.10% in the case of the Base Rate loans and 1.60% to 2.10% in the case of the BSBY rate loans depending on average daily availability, in each case with a floor of 0%. As a condition of entering into the Amended Credit Agreement, the Company was obligated to pay a nonrefundable fee of $88,000. Lastly, the Company amended the LC Facility to increase the limit up to $18.8 million. This amendment was accounted for as a debt modification in accordance ASC 470, Debt.
The Amended Credit Agreement contains certain customary covenants subject to certain exceptions, including, among others, the following: a fixed charge coverage ratio covenant, and limitations of indebtedness, liens, investments, asset sales, mergers, consolidations, liquidations, dispositions, restricted payments, transactions with affiliates and prepayments of certain debt. The Amended Credit Agreement also contains certain events of default subject to certain customary grace periods, including, among others, payment defaults, breaches of any representation, warranty or covenants, judgment defaults, cross defaults to certain other contracts, bankruptcy and insolvency defaults, material judgment defaults and a change of control default.
As of September 30, 2024, the amount available to borrow under the Amended Credit Agreement is approximately $67.9 million, and the Company had four letters of credit in the aggregated amount of $2.4 million outstanding under the LC Facility. The aggregate stated amount outstanding of the letter of credits reduces the total borrowing base available under the Amended Credit Agreement and is subject to certain fees.
As of September 30, 2024, there was no principal amount outstanding, and no cash was pledged under the Amended Credit Agreement, and the Company was in compliance with its covenant requirements. Obligations under the Amended Credit Agreement are secured by substantially all of the Company’s assets, excluding intellectual property. The Amended Credit Agreement matures on December 16, 2027.
Deferred Financing Costs
Costs incurred directly related to debt are presented in other assets and are being amortized over the five-year life of the Credit Agreement on the straight-line basis. The unamortized deferred financings costs as of September 30, 2024 and December 31, 2023 are as follows (in thousands):
September 30, 2024December 31, 2023
Deferred financing costs
$729 $1,454 
Accumulated amortization
(447)(382)
Unamortized deferred financing costs
$282 $1,072 
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Stockholders' Equity STOCKHOLDERS’ EQUITY
Accumulated Other Comprehensive Income (Loss)
The following is a summary of the changes in accumulated balances of other comprehensive income (loss) for the nine months ended September 30, 2024 and 2023 (in thousands):
Unrealized Gain (Loss) on InvestmentsForeign Currency Translation
Accumulated Other Comprehensive Income (Loss)
Balance, December 31, 2023$(9)$8,894 $8,885 
Other comprehensive loss
(4)(7,359)(7,363)
Balance, March 31, 2024
(13)1,535 1,522 
Other comprehensive loss
— (2,359)(2,359)
Balance, June 30, 2024
(13)(824)(837)
Other comprehensive income64 13,918 13,982 
Balance, September 30, 2024
$51 $13,094 $13,145 
Unrealized Gain (Loss) on InvestmentsForeign Currency Translation
Accumulated Other Comprehensive Income (Loss)
Balance, December 31, 2022$1,820 $(971)$849 
Other comprehensive loss
(865)9 (856)
Balance, March 31, 2023
955 (962)(7)
Other comprehensive loss
(1,095)(79)(1,174)
Balance, June 30, 2023
(140)(1,041)(1,181)
Other comprehensive income (loss)91 (68)23 
Balance, September 30, 2023
$(49)$(1,109)$(1,158)
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.24.3
Equity Incentive Plans
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Equity Incentive Plans EQUITY INCENTIVE PLANS
In 2011, the Company adopted the 2011 Equity Incentive Plan (the “2011 Plan”) to permit the grant of share-based awards, such as stock grants and incentives and non-qualified stock options to employees and directors. The Board has the authority to determine to whom awards will be granted, the number of shares, the term and the exercise price.
In March 2020, the Company adopted the 2020 Incentive Award Plan (the “2020 Plan”), which became effective in connection with the Company’s initial public offering in May 2020. As a result, the Company may not grant any additional awards under the 2011 Plan. The 2011 Plan will continue to govern outstanding equity awards granted thereunder. In addition, the number of shares of common stock reserved for issuance under the 2020 Plan will automatically increase on the first day of January for a period of up to ten years, commencing on January 1, 2021, in an amount equal to 3% of the total number of shares of the Company’s capital stock outstanding on the last day of the preceding year, or a lesser number of shares determined by the Company’s board of directors. As of September 30, 2024, there were 7,183,239 shares available for issuance under the 2020 Plan, including 1,732,872 additional shares reserved effective January 1, 2024.
2011 Equity Incentive Plan
Stock Options
A summary of stock option activity under the 2011 Plan for the nine months ended September 30, 2024 is as follows (intrinsic values in thousands):
Number of
Options
Weighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (in years)		Intrinsic
Value
Outstanding, December 31, 2023937,696$2.24 5.2$58,778 
Exercised(170,540)2.02 $8,211 
Cancelled(29)9.05 
Outstanding, September 30, 2024767,1272.28 4.5$29,884 
Vested and exercisable at September 30, 2024767,1272.28 4.5$29,884 
Vested and expected to vest at September 30, 2024767,127$2.28 4.5$29,884 
The aggregate intrinsic values of options outstanding, vested and exercisable, and vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair market value of the Company’s common stock.
2020 Incentive Award Plan
Restricted Stock Units
Restricted stock units (“RSUs”) are share awards that entitle the holder to receive freely tradable shares of the Company’s common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest over a four-year period with straight-line vesting and a 25% one-year cliff or over a three-year period in equal amounts on a quarterly basis, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of the Company’s common stock on the grant date.
RSU activity under the 2020 Plan is set forth below:
Number of
Awards 		Weighted
Average
Fair Value
Outstanding, December 31, 20231,307,998$67.91 
Granted1,006,24446.95 
Vested(456,160)67.69 
Cancelled(104,090)61.87 
Outstanding, September 30, 20241,753,992$56.30 
The total fair value of RSUs vested under the 2020 Plan was $7.7 million and $6.9 million for the three months ended September 30, 2024 and 2023, respectively, and $23.9 million and $21.0 million for the nine months ended September 30, 2024 and 2023, respectively.
Performance Stock Units
During the nine months ended September 30, 2024, the Company granted performance stock units (“PSUs”) to certain employees that are eligible to vest three years from the award date, based on achieving certain revenue based performance targets. The number of shares that may be earned can range from 0% to 200% of the target amount. The fair value of PSUs is determined by the closing stock price of the Company’s common stock on the awards’ grant date. The share-based compensation expense associated with PSUs is recognized on a straight-line basis based on the estimated number of awards that are expected to vest. At each reporting period, the Company monitors the probability of achieving the performance targets and adjusts the share-based compensation expense associated with PSUs accordingly.
PSU activity under the 2020 Plan is set forth below:
Number of
Awards		Weighted
Average
Fair Value
Outstanding, December 31, 2023— $— 
Granted90,48855.48 
Outstanding, September 30, 202490,488$55.48 
Stock Options
The Company grants non-qualified stock options to certain employees with vesting over a four-year period on a quarterly basis. The fair value of the stock options was calculated using the Black-Scholes option pricing model. The fair value for options granted was calculated using the following weighted average assumptions:
Nine Months Ended September 30,
20242023
Expected term (in years)4.54.6
Expected volatility
48.7% to 48.9%
50.4%
Dividend yield0.0%0.0%
Risk free interest rate
4.2% to 4.3%
4.1%
Weighted-average fair value of options granted$24.89 per share$25.98 per share
A summary of stock option activities under the 2020 Plan for the nine months ended September 30, 2024 is as follows (intrinsic values in thousands):
Number of
Options
Weighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (in years)		Intrinsic
Value
Outstanding, December 31, 2023166,203 $56.00 6.1$1,483 
Granted210,18854.83 
Exercised(270)56.00 $— 
Cancelled(7,157)56.00 
Outstanding, September 30, 2024368,96455.33 5.9$— 
Vested and exercisable at September 30, 202486,548 55.65 5.6$— 
Vested and expected to vest at September 30, 2024343,736$55.35 5.9$— 
Employee Stock Purchase Plan
In May 2020, the Company adopted the 2020 Employee Stock Purchase Plan (“ESPP”), which became effective on the date the ESPP was adopted by the Company’s board of directors. Each offering to the employees to purchase stock under the ESPP will begin on each August 1 and February 1 and will end on the following January 31 and July 31, respectively. The first offering period began on August 1, 2020. On each purchase date, which falls on the last date of each offering period, ESPP participants will purchase shares of common stock at a price per share equal to 85% of the lesser of (1) the fair market value per share of the common stock on the offering date or (2) the fair market value of the common stock on the purchase date. The occurrence and duration of offering periods under the ESPP are subject to the determinations of the Compensation Committee, in its sole discretion. The number of shares available for issuance under the ESPP increases automatically on January 1 of each calendar year of the Company beginning in 2021 and ending in 2030, in an amount equal to the lesser of (i) 1% of the aggregate number of outstanding shares of the Company’s common stock on the final day of the immediately preceding calendar year and (ii) such smaller number of shares determined by the Company’s board of directors.
The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model with the following assumptions:
Nine Months Ended September 30,
20242023
Expected term (in years)0.50.5
Expected volatility
57.0% - 60.8%
42.1% - 49.9%
Dividend yield0.0%0.0%
Risk free interest rate
5.1% - 5.2%
4.8% - 5.5%
As of September 30, 2024, a total of (i) 639,355 shares of common stock, including 133,430 shares purchased in July 2024 and 82,816 shares purchased in January 2024, have been purchased under the ESPP, and (ii) 2,465,007 shares of common stock are reserved under the ESPP for future purchases, including 577,624 additional shares, which were automatically added to the reserve on January 1, 2024 pursuant to the terms of the ESPP.
Share-based Compensation Expense
Total compensation cost for all share-based payment arrangements recognized, including $1.2 million and $0.7 million for the three months ended September 30, 2024 and 2023, respectively, and $3.5 million and $2.9 million for the nine months ended September 30, 2024 and 2023, respectively, of share-based compensation expense related to the ESPP, was as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Cost of goods sold$537 $393 $1,570 $1,232 
Research and development1,779 1,587 5,347 4,981 
Selling, general and administrative10,635 7,864 31,943 24,323 
Total share-based compensation expense
$12,951 $9,844 $38,860 $30,536 
Total compensation costs as of September 30, 2024 related to all non-vested awards to be recognized in future periods was $87.4 million and is expected to be recognized over the remaining weighted average period of 2.6 years.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.24.3
Income Taxes
 9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
Income Taxes INCOME TAXES
The following table reflects the Company’s provision for income taxes for the periods indicated (in thousands, except for percentages):
Three Months Ended September 30, Nine Months Ended September 30,
2024202320242023
(Loss) income before income taxes
$(12,672)$5,590$(50,181)$7,420
Provision for income taxes5,6952,42823,7364,391
Net (loss) income
$(18,367)$3,162$(73,917)$3,029
Provision for income taxes as a percentage of (loss) income before income taxes
(44.9%)43.4%(47.3%)59.2 %
The effective tax rate for all periods is driven by pre-tax income/(loss), business credits, equity compensation, state taxes, and the change in valuation allowance. The Company's income tax provision for interim reporting periods historically has been calculated by applying an estimate of the annual effective income tax rate for the full year to “ordinary” income (loss) for the interim reporting period. In addition, the tax effects of certain significant or unusual items are recognized discretely in the quarter in which they occur. For the nine months ended September 30, 2024 and September 30, 2023, the Company calculated the income tax provision using this methodology.
Beginning in 2024, many countries are implementing some or all of the Organization for Economic Co-operation and Development’s Base Erosion and Profit Shifting Two-Pillar in response to tax challenges arising from the digitalization of the global economy. While we continue to evaluate those countries’ implementations, we do not expect those implementations to have a material impact on our consolidated financial statements in 2024.
Valuation Allowance
ASC 740, Income Taxes requires that the tax benefit of net operating losses, or (“NOLs”), temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not”. Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryback or carryforward periods. As of December 31, 2023, the Company was in a net deferred tax liability position due to the LimFlow acquisition. However, a valuation allowance was maintained against certain deferred tax assets. As of September 30, 2024, the Company believes that the net deferred tax assets are currently not considered more likely than not to be realized and, accordingly, maintains a valuation allowance against certain deferred tax assets. The Company will continue to assess its position on the realizability of its deferred tax assets, until such time as sufficient positive evidence may become available to allow the Company to reach a conclusion that a significant portion of the valuation allowance will no longer be needed. Given the Company’s current earnings and anticipated future earnings, the Company believes that there is a reasonable possibility that sufficient positive evidence may become available in the near term to allow the Company to reach a conclusion that a significant portion of the valuation allowance is no longer needed. Any release of the valuation allowance will result in a material benefit recognized in the quarter of release.
Uncertain Tax Positions
The Company has recorded uncertain tax positions related to its federal and California research and development credit carryforwards. No interest or penalties have been recorded related to the uncertain tax positions due to credit carryforwards that are available to offset the uncertain tax positions. It is not expected that there will be a significant change in the uncertain tax position in the next 12 months. The Company is subject to U.S. federal and state income tax as well as to income tax in various foreign jurisdictions. In the normal course of business, the Company is subject to examination by tax authorities. As of the date of the financial statements, there are no income tax examinations in progress. The statute of limitations for tax years ended after December 31, 2020, December 31, 2019, and December 31, 2020 are open for federal, state, and foreign tax purposes, respectively.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Retirement Plan
 9 Months Ended
Sep. 30, 2024
Retirement Benefits [Abstract]  
Retirement Plan RETIREMENT PLAN
In December 2017, the Company adopted the Inari Medical, Inc. 401(k) Plan which allows eligible employees after one month of service to contribute pre-tax and Roth contributions to the plan, as allowed by law. The plan assets are held by Vanguard and the plan administrator is Ascensus Trust Company. Beginning in January 2021, the Company contributed a $1.00 match for every $1.00 contributed by a participating employee up to the greater of $3,000 or 4% of eligible compensation under the plan, with such Company's contributions becoming fully vested immediately. On January 1, 2024, the plan was amended to provide that the Company contributes a $1.00 match for every $1.00 contributed by a participating employee for up to 5% of eligible compensation. The plan also includes a limit of $15,000 per individual of employer match, with such Company’s contributions becoming fully vested immediately. Matching contribution expense was $3.1 million and $2.0 million for the three months ended September 30, 2024 and 2023, respectively, and $10.6 million and $6.9 million for the nine months ended September 30, 2024 and 2023, respectively.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.24.3
Net Income (Loss) Per Share
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Net Income (Loss) Per Share NET INCOME (LOSS) PER SHARE
Basic net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net income (loss) per share is computed using the treasury stock method by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net income (loss) per share calculation, shares from common stock options and equity awards are potentially dilutive securities. For the periods the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.
The components of net (loss) income per share are as follows (in thousands, except share and per share amounts):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Numerator:
Net (loss) income$(18,367)$3,162 $(73,917)$3,029 
Denominator:
Weighted average number of common shares outstanding - basic58,366,36457,384,88458,149,29656,478,317
Common stock equivalents from outstanding equity grants
—1,102,642—1,173,190
Common stock equivalents from unvested RSUs and PSUs—94,531—832,873
Common stock equivalents from ESPP—6,395—11,541
Weighted average number of common shares outstanding - diluted58,366,36458,588,45258,149,29658,495,921
Net (loss) income per share:
Basic$(0.31)$0.06 $(1.27)$0.05 
Diluted$(0.31)$0.05 $(1.27)$0.05 
The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Stock options
1,136,091171,5261,136,0911,290,179
Equity awards
1,844,480555,4681,844,4801,332,500
Total potentially dilutive common stock equivalents excluded from calculation due to anti-dilutive effect
2,980,571726,9942,980,5712,622,679
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure                
Net Income (Loss) $ (18,367) $ (31,348) $ (24,202) $ 3,162 $ 2,085 $ (2,218) $ (73,917) $ 3,029
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and include the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to prior period financial statements to conform to classifications used in the current period.
The interim condensed consolidated balance sheet as of September 30, 2024 and the condensed consolidated statements of operations and comprehensive income (loss), stockholders’ equity, and cash flows for the three and nine months ended September 30, 2024 and 2023 are unaudited. The consolidated balance sheet as of December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed consolidated financial position as of September 30, 2024 and its consolidated results of operations and cash flows for the three and nine months ended September 30, 2024 and 2023. The financial data and the other financial information disclosed in the notes to the condensed consolidated financial statements related to the three and nine months ended September 30, 2024 and 2023 are also unaudited. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. These interim condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
Management Estimates
Management Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements may include, but are not limited to, contingent consideration liability, collectability of receivables, recoverability of long-lived assets, valuation of inventory, operating lease right-of-use (“ROU”) assets and liabilities, other investments, fair value of stock options, recoverability of net deferred tax assets and related valuation allowance, and certain accruals. Estimates are based on historical experience and on various assumptions that the Company believes are reasonable under current circumstances. Actual results could differ materially from those estimates. Management periodically evaluates such estimates and assumptions, and they are adjusted prospectively based upon such periodic evaluation.
Revenue Recognition
Revenue Recognition
The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company sells its products primarily to hospitals in the United States through its direct sales force and also sells its products directly and through distributors in select international markets. The Company recognizes revenue for arrangements where the Company has satisfied its performance obligation of shipping or delivering the product. For sales where the Company’s sales representatives hand-deliver products directly to the hospitals, control of the products transfers to the customers upon such hand-delivery. For sales where products are shipped, control of the products transfers either upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. Revenue from product sales is comprised of product revenue, net of product returns, discounts, administrative fees and sales rebates. The Company has elected to account for shipping and handling activities that occur after the customer has obtained control as a fulfillment activity, and not a separate performance obligation.
Performance Obligation—The Company has revenue arrangements that consist of a single performance obligation, the shipping or delivery of the Company’s products. The satisfaction of this performance obligation occurs with the transfer of control of the Company’s product to its customers, either upon shipment or delivery of the product.
Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of revenue recognized is based on the transaction price, which represents the invoiced amount, net of discounts, administrative fees and sales rebates, where applicable. The Company provides a standard 30-day unconditional right of return period. The Company establishes estimated provisions for returns at the time of sale based on historical experience. Historically, the actual product returns have been insignificant to the Company’s condensed consolidated financial statements.
As of September 30, 2024 and December 31, 2023, the Company recorded $1.2 million of unbilled receivables, and $1.9 million and $1.3 million, respectively, of allowance for credit losses, which are included in accounts receivable, net, in the accompanying condensed consolidated balance sheets.
The Company disaggregates revenue between Venous Thromboembolism (“VTE”) and Emerging Therapies. VTE comprises revenue from the sale of the Company’s solutions addressing deep vein thrombosis and pulmonary embolism. Emerging Therapies comprises revenue from the sale of the Company’s solutions addressing chronic venous disease, CLTI, acute limb ischemia and dialysis access management. Revenue from VTE and Emerging Therapies is as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
VTE
$145,346 $121,460 $420,213 $349,604 
Emerging Therapies
8,044 4,906 22,191 11,934 
Total revenue
$153,390 $126,366 $442,404 $361,538 
Revenue from the Company's products by geographic area, based on the location where title transfers, is as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
United States$141,854$119,825$411,321$345,473
International11,5366,54131,08316,065
Total revenue
$153,390 $126,366$442,404$361,538
The Company offers payment terms to its customers of less than three months and these terms do not include a significant financing component. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.
The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to cost of goods sold.
Costs associated with product sales include commissions which are recorded in selling, general and administrative (“SG&A”) expenses. The Company applies the practical expedient and recognizes commissions as an expense when incurred because the amortization period is less than one year.
Equity Investments
Equity Investments
The Company has strategic investments in certain privately held companies, with no readily determinable fair value. The Company elected the measurement alternative under which it measures these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments. The Company will monitor the information that becomes available from time to time and adjust the carrying values of these investments if there are identified events or changes in circumstances that have a significant adverse effect on the fair values or if there are observable changes in fair value. Impairment loss, which is generally the difference between the carrying value and the fair value of the investment, is recorded in other income (expense) in the consolidated statements of operations and comprehensive income (loss).
Recently Issued Not Yet Adopted Accounting Pronouncements
Recently Issued Not Yet Adopted Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting, Topic 280, which requires enhanced disclosures primarily around segment expenses for all public entities, including public entities with a single reportable segment. On an annual and interim basis, entities are required to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of the new standard and does not expect there to be a material impact on its consolidated financial statements and related disclosures upon adoption.
In December 2023, FASB issued ASU 2023-09, Income Tax, Topic 740, which requires public companies to disclose specific categories in the rate reconciliation, disaggregate information related to income taxes paid, income or loss from operations before income tax expense or benefit, and income tax expense or benefit from operations. The ASU is effective for annual fiscal years beginning after December 15, 2024, with early adoption permitted. Amendments are applicable on a prospective basis with retrospective application permitted. The Company is currently evaluating the impact of the new standard on its consolidated financial statements and related disclosures.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Schedule of Disaggregation of Revenue Revenue from VTE and Emerging Therapies is as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
VTE
$145,346 $121,460 $420,213 $349,604 
Emerging Therapies
8,044 4,906 22,191 11,934 
Total revenue
$153,390 $126,366 $442,404 $361,538 
Revenue from the Company's products by geographic area, based on the location where title transfers, is as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
United States$141,854$119,825$411,321$345,473
International11,5366,54131,08316,065
Total revenue
$153,390 $126,366$442,404$361,538
Schedule of Cash Flow, Supplemental Disclosures
Supplemental cash flow information includes the following (in thousands):
Nine Months Ended September 30,
20242023
Supplemental disclosures of cash flow information:
Cash paid for income taxes$7,371 $3,562 
Cash paid for interest$168 $98 
Noncash investing and financing:
Lease liabilities arising from obtaining new right-of-use assets$2,447 $1,030 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
$41,141 $89,182 
Restricted cash
67 — 
Total cash, cash equivalents and restricted cash as shown in the statement of cash flows
$41,208 $89,182 
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.24.3
Business Combination (Tables)
 9 Months Ended
Sep. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Schedule of Total Purchase Price Consideration
The total purchase price as of the date of the acquisition consisted of the following (in thousands):
As of November 15, 2023
Cash$238,279 
Fair value of contingent consideration65,931 
Fair value of previously held investment10,235 
Total purchase price$314,445 
Schedule of Fair Values of Assets Acquired and Liabilities Assumed The final allocation of fair value of assets acquired and liabilities assumed were (in thousands):
As of November 15, 2023
Cash and cash equivalents$1,582 
Accounts receivable919 
Inventories2,635 
Property and equipment266 
Goodwill204,078 
Intangible asset146,000 
Other current and noncurrent assets2,155 
Accounts payable(2,509)
Deferred tax liability(36,500)
Other current and noncurrent liabilities(4,181)
Total net assets acquired$314,445 
Schedule of Acquired Finite-Lived Intangible Assets by Major Class
The fair value assigned to the intangible asset acquired was as follows (in thousands, except for estimated useful life which is in years):
Fair value
Useful life
Developed technology$146,000 15 years
Schedule of Pro Forma Information
The following unaudited pro forma financial information summarizes the combined results of operations of the Company and LimFlow as if the companies had been combined as of the beginning of fiscal year 2023 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
20232023
Revenue$126,757 $362,848 
Net loss
$(6,245)$(28,452)
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets and Liabilities Measured at Fair Value
The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024
Level 1Level 2Level 3Aggregate Fair Value
Financial Assets
Cash and cash equivalents:
Money market mutual funds$7,288 $— $— $7,288 
Total included in cash and cash equivalents7,288 — — 7,288 
Investments:
U.S. treasury securities
70,397 — — 70,397 
Total included in short-term investments70,397 — — 70,397 
Total financial assets
$77,685 $— $— $77,685 
Financial Liability
Contingent consideration$— $— $84,540 $84,540 
Total financial liabilities$— $— $84,540 $84,540 
December 31, 2023
Level 1Level 2Level 3Aggregate Fair Value
Financial Assets
Cash and cash equivalents:
Money market mutual funds$2,753 $— $— $2,753 
Total included in cash and cash equivalents2,753 — — 2,753 
Investments:
U.S. treasury securities
41,685 — — 41,685 
U.S. government agencies
— 26,238 — 26,238 
Corporate debt securities and commercial paper— 8,932 — 8,932 
Total included in short-term investments41,685 35,170 — 76,855 
Total financial assets
$44,438 $35,170 $— $79,608 
Financial Liability
Contingent consideration$— $— $65,931 $65,931 
Total financial liabilities$— $— $65,931 $65,931 
Schedule of Changes in the Estimated Fair Value
The following table summarizes the changes in the estimated fair value of the Company’s contingent consideration liabilities (in thousands):
Contingent Consideration Fair Value
Balance as of December 31, 2023
$65,931 
Change in estimated fair value
18,609 
Balance as of September 30, 2024
$84,540 
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.24.3
Cash Equivalents and Investments (Tables)
 9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Schedule of Cash Equivalents and Investments
The following is a summary of the Company’s cash equivalents and investments in debt securities as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024
Amortized Cost BasisUnrealized GainUnrealized LossFair Value
Financial Assets
Cash and cash equivalents:
Money market mutual funds$7,288 $— $— $7,288 
Total included in cash and cash equivalents7,288 — — 7,288 
Investments:
U.S. treasury securities
70,346 51 — 70,397 
Total included in short-term investments70,346 51 — 70,397 
Total financial assets
$77,634 $51 $— $77,685 
December 31, 2023
Amortized Cost BasisUnrealized GainUnrealized LossFair Value
Financial Assets
Cash and cash equivalents:
Money market mutual funds$2,753 $— $— $2,753 
Total included in cash and cash equivalents2,753 — — 2,753 
Investments:
U.S. treasury securities
41,672 13 — 41,685 
U.S. government agencies
26,248 — (10)26,238 
Corporate debt securities and commercial paper8,935 — (3)8,932 
Total included in short-term investments76,855 13 (13)76,855 
Total financial assets
$79,608 $13 $(13)$79,608 
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.24.3
Inventories, net (Tables)
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventories, Net
Inventories, net of reserves, consist of the following (in thousands):
September 30,
2024		December 31,
2023
Raw materials$21,983 $14,310 
Work-in-process6,179 5,330 
Finished goods27,048 23,260 
Total inventories, net
$55,210 $42,900 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.24.3
Property and Equipment, net (Tables)
 9 Months Ended
Sep. 30, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment, Net
Property and equipment consist of the following (in thousands):
September 30,
2024		December 31,
2023
Manufacturing equipment$18,527 $16,653 
Computer hardware6,671 5,641 
Assets in progress5,902 3,135 
Furniture and fixtures4,584 4,491 
Leasehold improvements4,531 4,682 
Total property and equipment, gross40,215 34,602 
Accumulated depreciation(16,117)(13,673)
Total property and equipment, net$24,098 $20,929 
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.24.3
Goodwill and Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Carrying Amounts of Goodwill
The changes in carrying amount of goodwill for the nine months ended September 30, 2024 were as follows (in thousands):
Balance as of December 31, 2023
$214,335 
Working capital adjustment
(3,722)
Foreign currency translation adjustments2,732 
Balance as of September 30, 2024
$213,345 
Schedule of Identifiable Intangible Assets
The intangible assets consist of the following (in thousands):
September 30, 2024
Gross Carrying AmountAccumulated AmortizationIntangible Assets, Net
Developed technology
$152,716 $(8,908)$143,808 
Total intangible assets, net
$152,716 $(8,908)$143,808 
December 31, 2023
Gross Carrying AmountAccumulated AmortizationIntangible Assets, Net
Developed technology
$150,649 $(1,256)$149,393 
Capitalized software(a)
1,491 — 1,491 
Total intangible assets, net
$152,140 $(1,256)$150,884 
_____________
(a) The useful life of the capitalized software was not determined as of December 31, 2023 as the asset was not put into service. No amortization expense has been recorded related to the capitalized software during the three and nine months ended September 30, 2023.
Schedule of Estimated Future Annual Amortization of the Intangible Asset
The estimated future annual amortization of the intangible assets in service is as follows (in thousands):
Year ending December 31:Amount
Remainder of 2024$2,545 
202510,181 
202610,181 
202710,181 
202810,181 
Thereafter100,539 
Total$143,808 
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies (Tables)
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Total Lease Cost
The following table presents the weighted average remaining lease term and discount rate:
September 30,
20242023
Weighted average remaining term (in years)
16.118.2
Weighted average discount rate6.1 %6.1 %
Cash paid for amounts included in the measurement of operating leases were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Cash paid for amounts included in the measurement of operating lease liabilities$1,048 $866 $2,877 $2,564 
Total lease costs are as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Operating lease cost$1,385 $1,137 $3,929 $3,456 
Short-term lease cost48 22 141 85 
Variable lease cost184 402 746 809 
Total lease costs$1,617 $1,561 $4,816 $4,350 
Schedule of Future Minimum Lease Payments Under Operating Leases Liabilities
Future minimum lease payments under operating leases liabilities as of September 30, 2024 are as follows (in thousands):
Year ending December 31:
Amount
Remainder of 2024$858 
20253,373 
20263,512 
20273,594 
20283,396 
Thereafter35,771 
Total lease payments50,504 
Less imputed interest(17,780)
Total lease liabilities32,724 
Less: lease liabilities - current portion(1,579)
Lease liabilities - noncurrent portion$31,145 
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.24.3
Credit Facility (Tables)
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Schedule of Costs Incurred Directly Related to Debt The unamortized deferred financings costs as of September 30, 2024 and December 31, 2023 are as follows (in thousands):
September 30, 2024December 31, 2023
Deferred financing costs
$729 $1,454 
Accumulated amortization
(447)(382)
Unamortized deferred financing costs
$282 $1,072 
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
The following is a summary of the changes in accumulated balances of other comprehensive income (loss) for the nine months ended September 30, 2024 and 2023 (in thousands):
Unrealized Gain (Loss) on InvestmentsForeign Currency Translation
Accumulated Other Comprehensive Income (Loss)
Balance, December 31, 2023$(9)$8,894 $8,885 
Other comprehensive loss
(4)(7,359)(7,363)
Balance, March 31, 2024
(13)1,535 1,522 
Other comprehensive loss
— (2,359)(2,359)
Balance, June 30, 2024
(13)(824)(837)
Other comprehensive income64 13,918 13,982 
Balance, September 30, 2024
$51 $13,094 $13,145 
Unrealized Gain (Loss) on InvestmentsForeign Currency Translation
Accumulated Other Comprehensive Income (Loss)
Balance, December 31, 2022$1,820 $(971)$849 
Other comprehensive loss
(865)9 (856)
Balance, March 31, 2023
955 (962)(7)
Other comprehensive loss
(1,095)(79)(1,174)
Balance, June 30, 2023
(140)(1,041)(1,181)
Other comprehensive income (loss)91 (68)23 
Balance, September 30, 2023
$(49)$(1,109)$(1,158)
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.24.3
Equity Incentive Plans (Tables)
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
A summary of stock option activity under the 2011 Plan for the nine months ended September 30, 2024 is as follows (intrinsic values in thousands):
Number of
Options
Weighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (in years)		Intrinsic
Value
Outstanding, December 31, 2023937,696$2.24 5.2$58,778 
Exercised(170,540)2.02 $8,211 
Cancelled(29)9.05 
Outstanding, September 30, 2024767,1272.28 4.5$29,884 
Vested and exercisable at September 30, 2024767,1272.28 4.5$29,884 
Vested and expected to vest at September 30, 2024767,127$2.28 4.5$29,884 
A summary of stock option activities under the 2020 Plan for the nine months ended September 30, 2024 is as follows (intrinsic values in thousands):
Number of
Options
Weighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (in years)		Intrinsic
Value
Outstanding, December 31, 2023166,203 $56.00 6.1$1,483 
Granted210,18854.83 
Exercised(270)56.00 $— 
Cancelled(7,157)56.00 
Outstanding, September 30, 2024368,96455.33 5.9$— 
Vested and exercisable at September 30, 202486,548 55.65 5.6$— 
Vested and expected to vest at September 30, 2024343,736$55.35 5.9$— 
Schedule of RSU Activity
RSU activity under the 2020 Plan is set forth below:
Number of
Awards 		Weighted
Average
Fair Value
Outstanding, December 31, 20231,307,998$67.91 
Granted1,006,24446.95 
Vested(456,160)67.69 
Cancelled(104,090)61.87 
Outstanding, September 30, 20241,753,992$56.30 
Schedule of PSU Activity
PSU activity under the 2020 Plan is set forth below:
Number of
Awards		Weighted
Average
Fair Value
Outstanding, December 31, 2023— $— 
Granted90,48855.48 
Outstanding, September 30, 202490,488$55.48 
Schedule of Estimated Fair Value of Option Grant and ESPP The fair value for options granted was calculated using the following weighted average assumptions:
Nine Months Ended September 30,
20242023
Expected term (in years)4.54.6
Expected volatility
48.7% to 48.9%
50.4%
Dividend yield0.0%0.0%
Risk free interest rate
4.2% to 4.3%
4.1%
Weighted-average fair value of options granted$24.89 per share$25.98 per share
The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model with the following assumptions:
Nine Months Ended September 30,
20242023
Expected term (in years)0.50.5
Expected volatility
57.0% - 60.8%
42.1% - 49.9%
Dividend yield0.0%0.0%
Risk free interest rate
5.1% - 5.2%
4.8% - 5.5%
Schedule of Total Compensation Cost for All Share-Based Payment Arrangements Recognized
Total compensation cost for all share-based payment arrangements recognized, including $1.2 million and $0.7 million for the three months ended September 30, 2024 and 2023, respectively, and $3.5 million and $2.9 million for the nine months ended September 30, 2024 and 2023, respectively, of share-based compensation expense related to the ESPP, was as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Cost of goods sold$537 $393 $1,570 $1,232 
Research and development1,779 1,587 5,347 4,981 
Selling, general and administrative10,635 7,864 31,943 24,323 
Total share-based compensation expense
$12,951 $9,844 $38,860 $30,536 
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.24.3
Income Taxes (Tables)
 9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
Schedule of Provision for Income Taxes
The following table reflects the Company’s provision for income taxes for the periods indicated (in thousands, except for percentages):
Three Months Ended September 30, Nine Months Ended September 30,
2024202320242023
(Loss) income before income taxes
$(12,672)$5,590$(50,181)$7,420
Provision for income taxes5,6952,42823,7364,391
Net (loss) income
$(18,367)$3,162$(73,917)$3,029
Provision for income taxes as a percentage of (loss) income before income taxes
(44.9%)43.4%(47.3%)59.2 %
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.24.3
Net Income (Loss) Per Share (Tables)
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Schedule of Components of Net (Loss) Income per Share
The components of net (loss) income per share are as follows (in thousands, except share and per share amounts):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Numerator:
Net (loss) income$(18,367)$3,162 $(73,917)$3,029 
Denominator:
Weighted average number of common shares outstanding - basic58,366,36457,384,88458,149,29656,478,317
Common stock equivalents from outstanding equity grants
—1,102,642—1,173,190
Common stock equivalents from unvested RSUs and PSUs—94,531—832,873
Common stock equivalents from ESPP—6,395—11,541
Weighted average number of common shares outstanding - diluted58,366,36458,588,45258,149,29658,495,921
Net (loss) income per share:
Basic$(0.31)$0.06 $(1.27)$0.05 
Diluted$(0.31)$0.05 $(1.27)$0.05 
Schedule of Outstanding Potentially Dilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share
The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Stock options
1,136,091171,5261,136,0911,290,179
Equity awards
1,844,480555,4681,844,4801,332,500
Total potentially dilutive common stock equivalents excluded from calculation due to anti-dilutive effect
2,980,571726,9942,980,5712,622,679
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Accounting Policies [Abstract]          
Unbilled receivables $ 1,200,000   $ 1,200,000   $ 1,200,000
Allowance for credit losses 1,900,000   1,900,000   1,300,000
Equity securities without readily determinable fair value, amount 1,500,000   1,500,000   $ 1,500,000
Impairment loss on strategic investment $ 0 $ 600,000 $ 0 $ 565,000  
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Revenue $ 153,390 $ 126,366 $ 442,404 $ 361,538
United States        
Disaggregation of Revenue [Line Items]        
Revenue 141,854 119,825 411,321 345,473
International        
Disaggregation of Revenue [Line Items]        
Revenue 11,536 6,541 31,083 16,065
VTE        
Disaggregation of Revenue [Line Items]        
Revenue 145,346 121,460 420,213 349,604
Emerging Therapies        
Disaggregation of Revenue [Line Items]        
Revenue $ 8,044 $ 4,906 $ 22,191 $ 11,934
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies - Schedule of Cash Flow, Supplemental Disclosures (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Supplemental disclosures of cash flow information:        
Cash paid for income taxes $ 7,371 $ 3,562    
Cash paid for interest 168 98    
Noncash investing and financing:        
Lease liabilities arising from obtaining new right-of-use assets 2,447 1,030    
Reconciliation of cash, cash equivalents and restricted cash:        
Cash and cash equivalents 41,141 89,182 $ 38,597  
Restricted cash 67 0    
Total cash, cash equivalents and restricted cash as shown in the statement of cash flows $ 41,208 $ 89,182 $ 39,208 $ 60,222
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.24.3
Business Combination - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Nov. 15, 2023
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Nov. 14, 2023
Business Acquisition [Line Items]              
Working capital adjustment       $ 3,722      
Acquisition-related expenses   $ 328 $ 2,681 4,143 $ 2,681    
LimFlow              
Business Acquisition [Line Items]              
Working capital adjustment       $ 3,700      
Maximum contingent consideration $ 165,000            
Range of outcomes on contingent consideration arrangements $ 65,900            
Acquiring equity interest percentage             3.70%
Percentage of voting interests acquired 96.30%            
Fair value of previously held investment $ 10,235         $ 10,200  
Gain recognized, amount           3,500  
Acquisition-related expenses           8,700  
Severance and integration related costs           $ 1,700  
LimFlow | Net Revenue              
Business Acquisition [Line Items]              
Maximum contingent consideration 140,000            
LimFlow | Reimbursement Milestones              
Business Acquisition [Line Items]              
Maximum contingent consideration $ 25,000            
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.24.3
Business Combination - Schedule of Total Purchase Price Consideration (Details) - USD ($)
$ in Thousands
 12 Months Ended
Nov. 15, 2023
Dec. 31, 2023
Sep. 30, 2024
Business Acquisition [Line Items]      
Fair value of contingent consideration     $ 84,500
LimFlow      
Business Acquisition [Line Items]      
Cash $ 238,279    
Fair value of contingent consideration 65,931    
Fair value of previously held investment 10,235 $ 10,200  
Total purchase price $ 314,445    
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.24.3
Business Combination - Schedule of Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Nov. 15, 2023
Business Acquisition [Line Items]      
Goodwill $ 213,345 $ 214,335  
LimFlow      
Business Acquisition [Line Items]      
Cash and cash equivalents     $ 1,582
Accounts receivable     919
Inventories     2,635
Property and equipment     266
Goodwill     204,078
Other current and noncurrent assets     2,155
Accounts payable     (2,509)
Deferred tax liability     (36,500)
Other current and noncurrent liabilities     (4,181)
Total net assets acquired     314,445
LimFlow | Developed technology      
Business Acquisition [Line Items]      
Intangible asset     $ 146,000
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.24.3
Business Combination - Schedule of Fair Value Assigned to the Intangible Asset Acquired (Details) - LimFlow - Developed technology
$ in Thousands
Nov. 15, 2023
USD ($)
Business Acquisition [Line Items]  
Fair value $ 146,000
Useful life 15 years
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.24.3
Business Combination - Schedule of Pro Forma Information (Details) - LimFlow - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2023
Business Acquisition [Line Items]    
Revenue $ 126,757 $ 362,848
Net loss $ (6,245) $ (28,452)
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Financial Assets    
Total included in short-term investments $ 77,685 $ 79,608
Financial Liability    
Contingent consideration 84,500  
Fair Value, Recurring    
Financial Assets    
Total included in cash and cash equivalents 7,288 2,753
Total included in short-term investments 70,397 76,855
Total financial assets 77,685 79,608
Financial Liability    
Contingent consideration 84,540 65,931
Total financial liabilities 84,540 65,931
Fair Value, Recurring | U.S. treasury securities    
Financial Assets    
Total included in short-term investments 70,397 41,685
Fair Value, Recurring | U.S. government agencies    
Financial Assets    
Total included in short-term investments   26,238
Fair Value, Recurring | Corporate debt securities and commercial paper    
Financial Assets    
Total included in short-term investments   8,932
Level 1 | Fair Value, Recurring    
Financial Assets    
Total included in cash and cash equivalents 7,288 2,753
Total included in short-term investments 70,397 41,685
Total financial assets 77,685 44,438
Financial Liability    
Contingent consideration 0 0
Total financial liabilities 0 0
Level 1 | Fair Value, Recurring | U.S. treasury securities    
Financial Assets    
Total included in short-term investments 70,397 41,685
Level 1 | Fair Value, Recurring | U.S. government agencies    
Financial Assets    
Total included in short-term investments   0
Level 1 | Fair Value, Recurring | Corporate debt securities and commercial paper    
Financial Assets    
Total included in short-term investments   0
Level 2 | Fair Value, Recurring    
Financial Assets    
Total included in cash and cash equivalents 0 0
Total included in short-term investments 0 35,170
Total financial assets 0 35,170
Financial Liability    
Contingent consideration 0 0
Total financial liabilities 0 0
Level 2 | Fair Value, Recurring | U.S. treasury securities    
Financial Assets    
Total included in short-term investments 0 0
Level 2 | Fair Value, Recurring | U.S. government agencies    
Financial Assets    
Total included in short-term investments   26,238
Level 2 | Fair Value, Recurring | Corporate debt securities and commercial paper    
Financial Assets    
Total included in short-term investments   8,932
Level 3 | Fair Value, Recurring    
Financial Assets    
Total included in cash and cash equivalents 0 0
Total included in short-term investments 0 0
Total financial assets 0 0
Financial Liability    
Contingent consideration 84,540 65,931
Total financial liabilities 84,540 65,931
Level 3 | Fair Value, Recurring | U.S. treasury securities    
Financial Assets    
Total included in short-term investments 0 0
Level 3 | Fair Value, Recurring | U.S. government agencies    
Financial Assets    
Total included in short-term investments   0
Level 3 | Fair Value, Recurring | Corporate debt securities and commercial paper    
Financial Assets    
Total included in short-term investments   0
Money market mutual funds | Fair Value, Recurring    
Financial Assets    
Total included in cash and cash equivalents 7,288 2,753
Money market mutual funds | Level 1 | Fair Value, Recurring    
Financial Assets    
Total included in cash and cash equivalents 7,288 2,753
Money market mutual funds | Level 2 | Fair Value, Recurring    
Financial Assets    
Total included in cash and cash equivalents 0 0
Money market mutual funds | Level 3 | Fair Value, Recurring    
Financial Assets    
Total included in cash and cash equivalents $ 0 $ 0
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements - Schedule of Estimated Fair Value of the Contingent Consideration Liabilities (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Beginning balance $ 65,931
Change in estimated fair value 18,609
Ending balance $ 84,540
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements - Narrative (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Fair Value Disclosures [Abstract]    
Fair value of contingent consideration $ 84.5  
Contingent consideration, liability, current 39.2  
Contingent consideration, liability, noncurrent $ 45.3 $ 65.9
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.24.3
Cash Equivalents and Investments (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Schedule of Investment Income Reported Amounts by Category [Line Items]    
Amortized Cost Basis $ 77,634 $ 79,608
Unrealized Gain 51 13
Unrealized Loss 0 (13)
Short-term investments in debt securities 77,685 79,608
Cash and Cash Equivalents    
Schedule of Investment Income Reported Amounts by Category [Line Items]    
Amortized Cost Basis 7,288 2,753
Unrealized Gain 0 0
Unrealized Loss 0 0
Short-term investments in debt securities 7,288 2,753
Cash and Cash Equivalents | Money market mutual funds    
Schedule of Investment Income Reported Amounts by Category [Line Items]    
Amortized Cost Basis 7,288 2,753
Unrealized Gain 0 0
Unrealized Loss 0 0
Short-term investments in debt securities 7,288 2,753
Short-Term Investments    
Schedule of Investment Income Reported Amounts by Category [Line Items]    
Amortized Cost Basis 70,346 76,855
Unrealized Gain 51 13
Unrealized Loss 0 (13)
Short-term investments in debt securities 70,397 76,855
Short-Term Investments | U.S. treasury securities    
Schedule of Investment Income Reported Amounts by Category [Line Items]    
Amortized Cost Basis 70,346 41,672
Unrealized Gain 51 13
Unrealized Loss 0 0
Short-term investments in debt securities $ 70,397 41,685
Short-Term Investments | U.S. government agencies    
Schedule of Investment Income Reported Amounts by Category [Line Items]    
Amortized Cost Basis   26,248
Unrealized Gain   0
Unrealized Loss   (10)
Short-term investments in debt securities   26,238
Short-Term Investments | Corporate debt securities and commercial paper    
Schedule of Investment Income Reported Amounts by Category [Line Items]    
Amortized Cost Basis   8,935
Unrealized Gain   0
Unrealized Loss   (3)
Short-term investments in debt securities   $ 8,932
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.24.3
Inventories, net (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 21,983 $ 14,310
Work-in-process 6,179 5,330
Finished goods 27,048 23,260
Total inventories, net $ 55,210 $ 42,900
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.24.3
Property and Equipment, net - Schedule of Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Property Plant And Equipment [Line Items]    
Total property and equipment, gross $ 40,215 $ 34,602
Accumulated depreciation (16,117) (13,673)
Total property and equipment, net 24,098 20,929
Manufacturing equipment    
Property Plant And Equipment [Line Items]    
Total property and equipment, gross 18,527 16,653
Computer hardware    
Property Plant And Equipment [Line Items]    
Total property and equipment, gross 6,671 5,641
Assets in progress    
Property Plant And Equipment [Line Items]    
Total property and equipment, gross 5,902 3,135
Furniture and fixtures    
Property Plant And Equipment [Line Items]    
Total property and equipment, gross 4,584 4,491
Leasehold improvements    
Property Plant And Equipment [Line Items]    
Total property and equipment, gross $ 4,531 $ 4,682
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.24.3
Property and Equipment, net - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating expenses        
Property Plant And Equipment [Line Items]        
Depreciation expense $ 1,100 $ 1,100 $ 3,400 $ 3,400
Cost of goods sold        
Property Plant And Equipment [Line Items]        
Depreciation expense $ 300 $ 300 $ 1,000 $ 800
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.24.3
Goodwill and Intangible Assets - Schedule of Carrying Amounts of Goodwill (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
USD ($)
Goodwill [Roll Forward]  
Goodwill, beginning balance $ 214,335
Working capital adjustment (3,722)
Foreign currency translation adjustments 2,732
Goodwill, ending balance $ 213,345
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.24.3
Goodwill and Intangible Assets - Schedule of Identifiable Intangible Assets (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]        
Gross Carrying Amount     $ 152,716,000 $ 152,140,000
Accumulated Amortization     (8,908,000) (1,256,000)
Intangible Assets, Net     143,808,000 150,884,000
Capitalized software, Gross Carrying Amount       1,491,000
Capitalized software, Accumulated Amortization       0
Capitalized software, Net     0 1,491,000
Capitalized software, amortization $ 0 $ 0    
Developed technology        
Finite-Lived Intangible Assets [Line Items]        
Gross Carrying Amount     152,716,000 150,649,000
Accumulated Amortization     (8,908,000) (1,256,000)
Intangible Assets, Net     $ 143,808,000 $ 149,393,000
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.24.3
Goodwill and Intangible Assets - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]          
Amortization of intangible asset $ 2,504,000 $ 0 $ 7,414,000 $ 0  
Intangible assets 143,808,000 $ 0 143,808,000 0 $ 150,884,000
Impairment of capitalized software development costs 3,800,000   3,789,000 $ 0  
Capitalized computer software, net $ 0   $ 0   $ 1,491,000
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.24.3
Goodwill and Intangible Assets - Schedule of Estimated Future Annual Amortization of the Intangible Asset (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Intangible Assets, Net $ 143,808 $ 150,884
Developed technology    
Finite-Lived Intangible Assets [Line Items]    
Remainder of 2024 2,545  
2025 10,181  
2026 10,181  
2027 10,181  
2028 10,181  
Thereafter 100,539  
Intangible Assets, Net $ 143,808 $ 149,393
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies - Narrative (Details)
$ in Millions
Jul. 09, 2024
patent
May 22, 2024
patent
Sep. 30, 2024
Oct. 31, 2023
USD ($)
Lessee Lease Description [Line Items]        
Lease not yet commenced, term of contract (in years)       10 years
Lease, liability to be paid | $       $ 7.2
Patent Infringement Lawsuit Against Imperative Care and Truvic        
Lessee Lease Description [Line Items]        
Gain contingency, patents allegedly infringed upon, number | patent 1 8    
Maximum        
Lessee Lease Description [Line Items]        
Option to extend, operating lease, term (in years)     5 years  
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies - Schedule of Operating Lease Disclosure (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]        
Weighted average remaining term (in years) 16 years 1 month 6 days 18 years 2 months 12 days 16 years 1 month 6 days 18 years 2 months 12 days
Weighted average discount rate 6.10% 6.10% 6.10% 6.10%
Cash paid for amounts included in the measurement of operating lease liabilities $ 1,048 $ 866 $ 2,877 $ 2,564
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies - Schedule of Total Lease Cost (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]        
Operating lease cost $ 1,385 $ 1,137 $ 3,929 $ 3,456
Short-term lease cost 48 22 141 85
Variable lease cost 184 402 746 809
Total lease costs $ 1,617 $ 1,561 $ 4,816 $ 4,350
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating Leases Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]    
Remainder of 2024 $ 858  
2025 3,373  
2026 3,512  
2027 3,594  
2028 3,396  
Thereafter 35,771  
Total lease payments 50,504  
Less imputed interest (17,780)  
Total lease liabilities 32,724  
Less: lease liabilities - current portion (1,579) $ (1,692)
Lease liabilities - noncurrent portion $ 31,145 $ 30,355
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.24.3
Related Party (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Related Party Transaction [Line Items]          
Development expenses incurred $ 0 $ 67,000 $ 31,000 $ 147,000  
Accounts payable 15,523,000   15,523,000   $ 10,577,000
Related Party          
Related Party Transaction [Line Items]          
Accounts payable $ 0   $ 0   $ 0
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.24.3
Credit Facility - Narrative (Details) - Amended Credit Agreement - Bank of America Credit Facility - Line of Credit
 9 Months Ended 12 Months Ended
Nov. 01, 2023
USD ($)
Dec. 16, 2022
USD ($)
Sep. 30, 2024
USD ($)
letterOfCredit
Dec. 31, 2023
Feb. 28, 2023
USD ($)
Revolving Line of Credit          
Debt Instrument [Line Items]          
Line of credit facility, maximum borrowing capacity $ 75,000,000 $ 40,000,000.0      
Line of credit facility, accordion feature, higher borrowing capacity option   120,000,000      
Debt instrument, fee amount $ 88,000 $ 10,000      
Unused line fee at annual rate (as percent)   0.25%      
Line of credit facility, amount available to borrow     $ 67,900,000    
Principal amount outstanding     0    
Cash pledged under credit agreement     $ 0    
Debt instrument, term (in years)     5 years 5 years  
Revolving Line of Credit | Federal Funds Rate          
Debt Instrument [Line Items]          
Term loan variable interest rate (as percent)   0.50%      
Revolving Line of Credit | Federal Funds Rate | Minimum          
Debt Instrument [Line Items]          
Term loan variable interest rate (as percent)   0.50%      
Revolving Line of Credit | Federal Funds Rate | Maximum          
Debt Instrument [Line Items]          
Term loan variable interest rate (as percent)   1.00%      
Revolving Line of Credit | BSBY          
Debt Instrument [Line Items]          
Term loan variable interest rate (as percent)   1.00%      
Basis spread on variable rate, floor (as percent) 0.00% 0.00%      
Revolving Line of Credit | BSBY | Minimum          
Debt Instrument [Line Items]          
Term loan variable interest rate (as percent) 1.60% 1.50%      
Revolving Line of Credit | BSBY | Maximum          
Debt Instrument [Line Items]          
Term loan variable interest rate (as percent) 2.10% 2.00%      
Revolving Line of Credit | Base Rate | Minimum          
Debt Instrument [Line Items]          
Term loan variable interest rate (as percent) 0.60%        
Revolving Line of Credit | Base Rate | Maximum          
Debt Instrument [Line Items]          
Term loan variable interest rate (as percent) 1.10%        
Letter of Credit Subline Facility          
Debt Instrument [Line Items]          
Line of credit facility, maximum borrowing capacity $ 18,800,000 $ 5,000,000.0     $ 10,000,000
Percentage of fee on average daily stated amount of outstanding letter of credit     2.25%    
Percentage of fronting fee on stated amount of each letter of credit outstanding     0.125%    
Number of letter of credit | letterOfCredit     4    
Letters of credit outstanding amount     $ 2,400,000    
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.24.3
Credit Facility - Schedule of Costs Incurred Directly Related to Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Debt Disclosure [Abstract]    
Deferred financing costs $ 729 $ 1,454
Accumulated amortization (447) (382)
Unamortized deferred financing costs $ 282 $ 1,072
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Balance at beginning of period $ 423,809 $ 447,230 $ 464,910 $ 435,645 $ 426,736 $ 417,002 $ 464,910 $ 417,002
Other comprehensive income (loss) 13,982 (2,359) (7,363) 23 (1,174) (856) 4,260 (2,007)
Balance at end of period 434,761 423,809 447,230 452,142 435,645 426,736 434,761 452,142
Accumulated Other Comprehensive Income (Loss)                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Balance at beginning of period (837) 1,522 8,885 (1,181) (7) 849 8,885 849
Other comprehensive income (loss) 13,982 (2,359) (7,363) 23 (1,174) (856)    
Balance at end of period 13,145 (837) 1,522 (1,158) (1,181) (7) 13,145 (1,158)
Unrealized Gain (Loss) on Investments                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Balance at beginning of period (13) (13) (9) (140) 955 1,820 (9) 1,820
Other comprehensive income (loss) 64 0 (4) 91 (1,095) (865)    
Balance at end of period 51 (13) (13) (49) (140) 955 51 (49)
Foreign Currency Translation                
AOCI Attributable to Parent, Net of Tax [Roll Forward]                
Balance at beginning of period (824) 1,535 8,894 (1,041) (962) (971) 8,894 (971)
Other comprehensive income (loss) 13,918 (2,359) (7,359) (68) (79) 9    
Balance at end of period $ 13,094 $ (824) $ 1,535 $ (1,109) $ (1,041) $ (962) $ 13,094 $ (1,109)
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.24.3
Equity Incentive Plans - Narrative (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 53 Months Ended
Jan. 01, 2021
Jul. 31, 2024
Jan. 31, 2024
May 31, 2020
Mar. 31, 2020
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Jan. 01, 2024
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Shares of common stock reserved for future issuance (in shares)                         577,624
Shares issued under employee stock purchase plan (in shares)   133,430 82,816                    
Compensation cost           $ 12,951   $ 9,844   $ 38,860 $ 30,536    
Nonvested award, cost not yet recognized, amount           $ 87,400       $ 87,400   $ 87,400  
Nonvested award, cost not yet recognized, period                   2 years 7 months 6 days      
Common Stock                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Shares issued under employee stock purchase plan (in shares)           133,430 82,816 118,494 86,051        
Restricted Stock Units | Vesting, Option Two                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Award vesting period (in years)                   3 years      
Employee Stock Option                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Award vesting period (in years)                   4 years      
Employee Stock Purchase Plan                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Compensation cost           $ 1,200   $ 700   $ 3,500 2,900    
2020 Incentive Award Plan                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Percentage of annual increase in shares reserved for issuance on capital stock outstanding at year end         3.00%                
Number of shares available for issuance (in shares)           7,183,239       7,183,239   7,183,239  
Shares of common stock reserved for future issuance (in shares)                         1,732,872
2020 Incentive Award Plan | Restricted Stock Units                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Award vesting period (in years)                   4 years      
Award cliff vesting period (in years)                   1 year      
Total fair value of RSUs vested           $ 7,700   $ 6,900   $ 23,900 $ 21,000    
2020 Incentive Award Plan | Restricted Stock Units | Vesting, Option One | Share Based Compensation Award Tranche One                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Cliff vesting, percentage                   25.00%      
2020 Incentive Award Plan | Restricted Stock Units | Vesting, Option One | Share-Based Payment Arrangement, Tranche Two                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Cliff vesting, percentage                   25.00%      
2020 Incentive Award Plan | Restricted Stock Units | Vesting, Option One | Share-Based Payment Arrangement, Tranche Three                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Cliff vesting, percentage                   25.00%      
2020 Incentive Award Plan | Restricted Stock Units | Vesting, Option One | Share-Based Payment Arrangement, Tranche Four                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Cliff vesting, percentage                   25.00%      
2020 Incentive Award Plan | Performance Stock Units                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Award vesting period (in years)                   3 years      
2020 Employee Share Purchase Plan                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Shares of common stock reserved for future issuance (in shares)           2,465,007       2,465,007   2,465,007  
Percentage of purchase price on fair market value of common stock       85.00%                  
Annual increase in number of shares available for issuance percentage 1.00%                        
2020 Employee Share Purchase Plan | Common Stock                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Shares issued under employee stock purchase plan (in shares)                       639,355  
Maximum | 2020 Incentive Award Plan                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Term of award (in years)         10 years                
Maximum | 2020 Incentive Award Plan | Performance Stock Units                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Payout percentage           200.00%       200.00%   200.00%  
Minimum | 2020 Incentive Award Plan | Performance Stock Units                          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                          
Payout percentage           0.00%       0.00%   0.00%  
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.24.3
Equity Incentive Plans - Schedule of Stock Option Activity (Details)
$ / shares in Units, $ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2024
USD ($)
$ / shares
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
2011 Equity Incentive Plan    
Number of Options    
Balance at beginning of period (in shares) | shares 937,696  
Exercised (in shares) | shares (170,540)  
Cancelled (in shares) | shares (29)  
Balance at end of period (in shares) | shares 767,127 937,696
Number of Awards, Vested and exercisable (in shares) | shares 767,127  
Number of Awards, Vested and expected to vest (in shares) | shares 767,127  
Weighted Average Exercise Price    
Balance at beginning of period (in dollars per share) | $ / shares $ 2.24  
Exercised (in dollars per share) | $ / shares 2.02  
Cancelled (in dollars per share) | $ / shares 9.05  
Balance at end of period (in dollars per share) | $ / shares 2.28 $ 2.24
Weighted Average Exercise Price, Vested and exercisable (in dollars per share) | $ / shares 2.28  
Weighted Average Exercise Price, Vested and expected to vest (in dollars per share) | $ / shares $ 2.28  
Weighted Average Remaining Contractual Life (in years)    
Outstanding 4 years 6 months 5 years 2 months 12 days
Vested and exercisable 4 years 6 months  
Vested and expected to vest 4 years 6 months  
Intrinsic Value    
Balance at beginning of period | $ $ 58,778  
Exercised | $ 8,211  
Balance at end of period | $ 29,884 $ 58,778
Intrinsic Value, Vested and exercisable | $ 29,884  
Intrinsic Value, Vested and expected to vest | $ $ 29,884  
2020 Incentive Award Plan    
Number of Options    
Balance at beginning of period (in shares) | shares 166,203  
Granted (in shares) | shares 210,188  
Exercised (in shares) | shares (270)  
Cancelled (in shares) | shares (7,157)  
Balance at end of period (in shares) | shares 368,964 166,203
Number of Awards, Vested and exercisable (in shares) | shares 86,548  
Number of Awards, Vested and expected to vest (in shares) | shares 343,736  
Weighted Average Exercise Price    
Balance at beginning of period (in dollars per share) | $ / shares $ 56.00  
Granted (in dollars per share) | $ / shares 54.83  
Exercised (in dollars per share) | $ / shares 56.00  
Cancelled (in dollars per share) | $ / shares 56.00  
Balance at end of period (in dollars per share) | $ / shares 55.33 $ 56.00
Weighted Average Exercise Price, Vested and exercisable (in dollars per share) | $ / shares 55.65  
Weighted Average Exercise Price, Vested and expected to vest (in dollars per share) | $ / shares $ 55.35  
Weighted Average Remaining Contractual Life (in years)    
Outstanding 5 years 10 months 24 days 6 years 1 month 6 days
Vested and exercisable 5 years 7 months 6 days  
Vested and expected to vest 5 years 10 months 24 days  
Intrinsic Value    
Balance at beginning of period | $ $ 1,483  
Exercised | $ 0  
Balance at end of period | $ 0 $ 1,483
Intrinsic Value, Vested and exercisable | $ 0  
Intrinsic Value, Vested and expected to vest | $ $ 0  
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.24.3
Equity Incentive Plans - Schedule of RSU and PSU Activity (Details) - 2020 Incentive Award Plan
 9 Months Ended
Sep. 30, 2024
$ / shares
shares
Restricted Stock Units  
Number of Awards  
Balance at beginning of period (in shares) | shares 1,307,998
Granted (in shares) | shares 1,006,244
Vested (in shares) | shares (456,160)
Cancelled (in shares) | shares (104,090)
Balance at end of period (in shares) | shares 1,753,992
Weighted Average Fair Value  
Balance at beginning of period (in dollars per share) | $ / shares $ 67.91
Granted (in dollars per share) | $ / shares 46.95
Vested (in dollars per share) | $ / shares 67.69
Cancelled (in dollars per share) | $ / shares 61.87
Balance at end of period (in dollars per share) | $ / shares $ 56.30
Performance Stock Units  
Number of Awards  
Balance at beginning of period (in shares) | shares 0
Granted (in shares) | shares 90,488
Balance at end of period (in shares) | shares 90,488
Weighted Average Fair Value  
Balance at beginning of period (in dollars per share) | $ / shares $ 0
Granted (in dollars per share) | $ / shares 55.48
Balance at end of period (in dollars per share) | $ / shares $ 55.48
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.24.3
Equity Incentive Plans - Schedule of Estimated Fair Value of Option Grant and ESPP on Date of Grant (Details) - $ / shares
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
2020 Incentive Award Plan | Stock options    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Expected term (in years) 4 years 6 months 4 years 7 months 6 days
Expected volatility - minimum 48.70%  
Expected volatility - maximum 48.90%  
Expected volatility   50.40%
Dividend yield 0.00% 0.00%
Risk free interest rate- minimum 4.20%  
Risk free interest rate - maximum 4.30%  
Risk free interest rate   4.10%
Weighted-average fair value of options granted (in dollars per share) $ 24.89 $ 25.98
2020 Employee Share Purchase Plan    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Expected term (in years) 6 months 6 months
Expected volatility - minimum 57.00% 42.10%
Expected volatility - maximum 60.80% 49.90%
Dividend yield 0.00% 0.00%
Risk free interest rate- minimum 5.10% 4.80%
Risk free interest rate - maximum 5.20% 5.50%
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.24.3
Equity Incentive Plans - Schedule of Total Compensation Cost for All Share-Based Payment Arrangements Recognized (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share-based compensation expense $ 12,951 $ 9,844 $ 38,860 $ 30,536
Cost of goods sold        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share-based compensation expense 537 393 1,570 1,232
Research and development        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share-based compensation expense 1,779 1,587 5,347 4,981
Selling, general and administrative        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total share-based compensation expense $ 10,635 $ 7,864 $ 31,943 $ 24,323
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.24.3
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Tax Disclosure [Abstract]                
(Loss) income before income taxes $ (12,672)     $ 5,590     $ (50,181) $ 7,420
Provision for income taxes 5,695     2,428     23,736 4,391
Net (loss) income $ (18,367) $ (31,348) $ (24,202) $ 3,162 $ 2,085 $ (2,218) $ (73,917) $ 3,029
Provision for income taxes as a percentage of (loss) income before income taxes (44.90%)     43.40%     (47.30%) 59.20%
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.24.3
Retirement Plan (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Jan. 01, 2024
Jan. 31, 2021
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Retirement Benefits [Abstract]            
401 (k) Plan         Qualified Plan [Member]  
Minimum employee service period (in months)         1 month  
Employer matching contribution, percent of match 100.00% 100.00%        
Maximum participating employee annual contributions   $ 3,000        
Participating employee eligible compensation 5.00% 4.00%        
Individual limit on employer match         $ 15,000  
Matching contribution expense recognized     $ 3,100,000 $ 2,000,000.0 $ 10,600,000 $ 6,900,000
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.24.3
Net Income (Loss) Per Share - Schedule of Computation of Net Loss (Income) per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Numerator:                
Net (loss) income $ (18,367) $ (31,348) $ (24,202) $ 3,162 $ 2,085 $ (2,218) $ (73,917) $ 3,029
Denominator:                
Weighted average number of common shares outstanding - basic (in shares) 58,366,364     57,384,884     58,149,296 56,478,317
Weighted average number of common shares outstanding - diluted (in shares) 58,366,364     58,588,452     58,149,296 58,495,921
Net (loss) income per share:                
Basic (in dollars per share) $ (0.31)     $ 0.06     $ (1.27) $ 0.05
Diluted (in dollars per share) $ (0.31)     $ 0.05     $ (1.27) $ 0.05
Stock options                
Denominator:                
Common stock equivalents from outstanding equity grants (in shares) 0     1,102,642     0 1,173,190
Unvested RSUs and PSUs                
Denominator:                
Common stock equivalents from outstanding equity grants (in shares) 0     94,531     0 832,873
ESPP                
Denominator:                
Common stock equivalents from outstanding equity grants (in shares) 0     6,395     0 11,541
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.24.3
Net Income (Loss) Per Share - Schedule of Outstanding Potentially Dilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Antidilutive Securities Excluded From Computation of Earnings Per Share [Line Items]        
Total potentially dilutive common stock equivalents excluded from calculation due to anti-dilutive effect (in shares) 2,980,571 726,994 2,980,571 2,622,679
Stock options        
Antidilutive Securities Excluded From Computation of Earnings Per Share [Line Items]        
Total potentially dilutive common stock equivalents excluded from calculation due to anti-dilutive effect (in shares) 1,136,091 171,526 1,136,091 1,290,179
Equity awards        
Antidilutive Securities Excluded From Computation of Earnings Per Share [Line Items]        
Total potentially dilutive common stock equivalents excluded from calculation due to anti-dilutive effect (in shares) 1,844,480 555,468 1,844,480 1,332,500
EXCEL 90 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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end XML 91 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 92 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 94 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 287 343 1 false 63 0 false 6 false false R1.htm 0000001 - Document - Cover Sheet http://inarimedical.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - Condensed Consolidated Balance Sheets Sheet http://inarimedical.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://inarimedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) Sheet http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) Statements 4 false false R5.htm 9952154 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 9952155 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 9952156 - Disclosure - Organization Sheet http://inarimedical.com/role/Organization Organization Notes 7 false false R8.htm 9952157 - Disclosure - Summary of Significant Accounting Policies Sheet http://inarimedical.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 9952158 - Disclosure - Business Combination Sheet http://inarimedical.com/role/BusinessCombination Business Combination Notes 9 false false R10.htm 9952159 - Disclosure - Fair Value Measurements Sheet http://inarimedical.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 9952160 - Disclosure - Cash Equivalents and Investments Sheet http://inarimedical.com/role/CashEquivalentsandInvestments Cash Equivalents and Investments Notes 11 false false R12.htm 9952161 - Disclosure - Inventories, net Sheet http://inarimedical.com/role/Inventoriesnet Inventories, net Notes 12 false false R13.htm 9952162 - Disclosure - Property and Equipment, net Sheet http://inarimedical.com/role/PropertyandEquipmentnet Property and Equipment, net Notes 13 false false R14.htm 9952163 - Disclosure - Goodwill and Intangible Assets Sheet http://inarimedical.com/role/GoodwillandIntangibleAssets Goodwill and Intangible Assets Notes 14 false false R15.htm 9952164 - Disclosure - Commitments and Contingencies Sheet http://inarimedical.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 15 false false R16.htm 9952165 - Disclosure - Concentrations Sheet http://inarimedical.com/role/Concentrations Concentrations Notes 16 false false R17.htm 9952166 - Disclosure - Related Party Sheet http://inarimedical.com/role/RelatedParty Related Party Notes 17 false false R18.htm 9952167 - Disclosure - Credit Facility Sheet http://inarimedical.com/role/CreditFacility Credit Facility Notes 18 false false R19.htm 9952168 - Disclosure - Stockholders' Equity Sheet http://inarimedical.com/role/StockholdersEquity Stockholders' Equity Notes 19 false false R20.htm 9952169 - Disclosure - Equity Incentive Plans Sheet http://inarimedical.com/role/EquityIncentivePlans Equity Incentive Plans Notes 20 false false R21.htm 9952170 - Disclosure - Income Taxes Sheet http://inarimedical.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 9952171 - Disclosure - Retirement Plan Sheet http://inarimedical.com/role/RetirementPlan Retirement Plan Notes 22 false false R23.htm 9952172 - Disclosure - Net Income (Loss) Per Share Sheet http://inarimedical.com/role/NetIncomeLossPerShare Net Income (Loss) Per Share Notes 23 false false R24.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 24 false false R25.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 25 false false R26.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://inarimedical.com/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://inarimedical.com/role/SummaryofSignificantAccountingPolicies 27 false false R28.htm 9954473 - Disclosure - Business Combination (Tables) Sheet http://inarimedical.com/role/BusinessCombinationTables Business Combination (Tables) Tables http://inarimedical.com/role/BusinessCombination 28 false false R29.htm 9954474 - Disclosure - Fair Value Measurements (Tables) Sheet http://inarimedical.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://inarimedical.com/role/FairValueMeasurements 29 false false R30.htm 9954475 - Disclosure - Cash Equivalents and Investments (Tables) Sheet http://inarimedical.com/role/CashEquivalentsandInvestmentsTables Cash Equivalents and Investments (Tables) Tables http://inarimedical.com/role/CashEquivalentsandInvestments 30 false false R31.htm 9954476 - Disclosure - Inventories, net (Tables) Sheet http://inarimedical.com/role/InventoriesnetTables Inventories, net (Tables) Tables http://inarimedical.com/role/Inventoriesnet 31 false false R32.htm 9954477 - Disclosure - Property and Equipment, net (Tables) Sheet http://inarimedical.com/role/PropertyandEquipmentnetTables Property and Equipment, net (Tables) Tables http://inarimedical.com/role/PropertyandEquipmentnet 32 false false R33.htm 9954478 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://inarimedical.com/role/GoodwillandIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://inarimedical.com/role/GoodwillandIntangibleAssets 33 false false R34.htm 9954479 - Disclosure - Commitments and Contingencies (Tables) Sheet http://inarimedical.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://inarimedical.com/role/CommitmentsandContingencies 34 false false R35.htm 9954480 - Disclosure - Credit Facility (Tables) Sheet http://inarimedical.com/role/CreditFacilityTables Credit Facility (Tables) Tables http://inarimedical.com/role/CreditFacility 35 false false R36.htm 9954481 - Disclosure - Stockholders' Equity (Tables) Sheet http://inarimedical.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://inarimedical.com/role/StockholdersEquity 36 false false R37.htm 9954482 - Disclosure - Equity Incentive Plans (Tables) Sheet http://inarimedical.com/role/EquityIncentivePlansTables Equity Incentive Plans (Tables) Tables http://inarimedical.com/role/EquityIncentivePlans 37 false false R38.htm 9954483 - Disclosure - Income Taxes (Tables) Sheet http://inarimedical.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://inarimedical.com/role/IncomeTaxes 38 false false R39.htm 9954484 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://inarimedical.com/role/NetIncomeLossPerShareTables Net Income (Loss) Per Share (Tables) Tables http://inarimedical.com/role/NetIncomeLossPerShare 39 false false R40.htm 9954485 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 40 false false R41.htm 9954486 - Disclosure - Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue (Details) Sheet http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofDisaggregationofRevenueDetails Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue (Details) Details 41 false false R42.htm 9954487 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash Flow, Supplemental Disclosures (Details) Sheet http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashFlowSupplementalDisclosuresDetails Summary of Significant Accounting Policies - Schedule of Cash Flow, Supplemental Disclosures (Details) Details 42 false false R43.htm 9954488 - Disclosure - Business Combination - Narrative (Details) Sheet http://inarimedical.com/role/BusinessCombinationNarrativeDetails Business Combination - Narrative (Details) Details 43 false false R44.htm 9954489 - Disclosure - Business Combination - Schedule of Total Purchase Price Consideration (Details) Sheet http://inarimedical.com/role/BusinessCombinationScheduleofTotalPurchasePriceConsiderationDetails Business Combination - Schedule of Total Purchase Price Consideration (Details) Details 44 false false R45.htm 9954490 - Disclosure - Business Combination - Schedule of Fair Values of Assets Acquired and Liabilities Assumed (Details) Sheet http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails Business Combination - Schedule of Fair Values of Assets Acquired and Liabilities Assumed (Details) Details 45 false false R46.htm 9954491 - Disclosure - Business Combination - Schedule of Fair Value Assigned to the Intangible Asset Acquired (Details) Sheet http://inarimedical.com/role/BusinessCombinationScheduleofFairValueAssignedtotheIntangibleAssetAcquiredDetails Business Combination - Schedule of Fair Value Assigned to the Intangible Asset Acquired (Details) Details 46 false false R47.htm 9954492 - Disclosure - Business Combination - Schedule of Pro Forma Information (Details) Sheet http://inarimedical.com/role/BusinessCombinationScheduleofProFormaInformationDetails Business Combination - Schedule of Pro Forma Information (Details) Details 47 false false R48.htm 9954493 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) Sheet http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) Details 48 false false R49.htm 9954494 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value of the Contingent Consideration Liabilities (Details) Sheet http://inarimedical.com/role/FairValueMeasurementsScheduleofEstimatedFairValueoftheContingentConsiderationLiabilitiesDetails Fair Value Measurements - Schedule of Estimated Fair Value of the Contingent Consideration Liabilities (Details) Details 49 false false R50.htm 9954495 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://inarimedical.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 50 false false R51.htm 9954496 - Disclosure - Cash Equivalents and Investments (Details) Sheet http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails Cash Equivalents and Investments (Details) Details http://inarimedical.com/role/CashEquivalentsandInvestmentsTables 51 false false R52.htm 9954497 - Disclosure - Inventories, net (Details) Sheet http://inarimedical.com/role/InventoriesnetDetails Inventories, net (Details) Details http://inarimedical.com/role/InventoriesnetTables 52 false false R53.htm 9954498 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, Net (Details) Sheet http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails Property and Equipment, net - Schedule of Property and Equipment, Net (Details) Details 53 false false R54.htm 9954499 - Disclosure - Property and Equipment, net - Narrative (Details) Sheet http://inarimedical.com/role/PropertyandEquipmentnetNarrativeDetails Property and Equipment, net - Narrative (Details) Details 54 false false R55.htm 9954500 - Disclosure - Goodwill and Intangible Assets - Schedule of Carrying Amounts of Goodwill (Details) Sheet http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountsofGoodwillDetails Goodwill and Intangible Assets - Schedule of Carrying Amounts of Goodwill (Details) Details 55 false false R56.htm 9954501 - Disclosure - Goodwill and Intangible Assets - Schedule of Identifiable Intangible Assets (Details) Sheet http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails Goodwill and Intangible Assets - Schedule of Identifiable Intangible Assets (Details) Details 56 false false R57.htm 9954502 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) Sheet http://inarimedical.com/role/GoodwillandIntangibleAssetsNarrativeDetails Goodwill and Intangible Assets - Narrative (Details) Details 57 false false R58.htm 9954503 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Annual Amortization of the Intangible Asset (Details) Sheet http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails Goodwill and Intangible Assets - Schedule of Estimated Future Annual Amortization of the Intangible Asset (Details) Details 58 false false R59.htm 9954504 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://inarimedical.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 59 false false R60.htm 9954505 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Disclosure (Details) Sheet http://inarimedical.com/role/CommitmentsandContingenciesScheduleofOperatingLeaseDisclosureDetails Commitments and Contingencies - Schedule of Operating Lease Disclosure (Details) Details 60 false false R61.htm 9954506 - Disclosure - Commitments and Contingencies - Schedule of Total Lease Cost (Details) Sheet http://inarimedical.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails Commitments and Contingencies - Schedule of Total Lease Cost (Details) Details 61 false false R62.htm 9954507 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating Leases Liabilities (Details) Sheet http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating Leases Liabilities (Details) Details 62 false false R63.htm 9954508 - Disclosure - Related Party (Details) Sheet http://inarimedical.com/role/RelatedPartyDetails Related Party (Details) Details http://inarimedical.com/role/RelatedParty 63 false false R64.htm 9954509 - Disclosure - Credit Facility - Narrative (Details) Sheet http://inarimedical.com/role/CreditFacilityNarrativeDetails Credit Facility - Narrative (Details) Details 64 false false R65.htm 9954510 - Disclosure - Credit Facility - Schedule of Costs Incurred Directly Related to Debt (Details) Sheet http://inarimedical.com/role/CreditFacilityScheduleofCostsIncurredDirectlyRelatedtoDebtDetails Credit Facility - Schedule of Costs Incurred Directly Related to Debt (Details) Details 65 false false R66.htm 9954511 - Disclosure - Stockholders' Equity (Details) Sheet http://inarimedical.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://inarimedical.com/role/StockholdersEquityTables 66 false false R67.htm 9954512 - Disclosure - Equity Incentive Plans - Narrative (Details) Sheet http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails Equity Incentive Plans - Narrative (Details) Details 67 false false R68.htm 9954513 - Disclosure - Equity Incentive Plans - Schedule of Stock Option Activity (Details) Sheet http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails Equity Incentive Plans - Schedule of Stock Option Activity (Details) Details 68 false false R69.htm 9954514 - Disclosure - Equity Incentive Plans - Schedule of RSU and PSU Activity (Details) Sheet http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails Equity Incentive Plans - Schedule of RSU and PSU Activity (Details) Details 69 false false R70.htm 9954515 - Disclosure - Equity Incentive Plans - Schedule of Estimated Fair Value of Option Grant and ESPP on Date of Grant (Details) Sheet http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails Equity Incentive Plans - Schedule of Estimated Fair Value of Option Grant and ESPP on Date of Grant (Details) Details 70 false false R71.htm 9954516 - Disclosure - Equity Incentive Plans - Schedule of Total Compensation Cost for All Share-Based Payment Arrangements Recognized (Details) Sheet http://inarimedical.com/role/EquityIncentivePlansScheduleofTotalCompensationCostforAllShareBasedPaymentArrangementsRecognizedDetails Equity Incentive Plans - Schedule of Total Compensation Cost for All Share-Based Payment Arrangements Recognized (Details) Details 71 false false R72.htm 9954517 - Disclosure - Income Taxes (Details) Sheet http://inarimedical.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://inarimedical.com/role/IncomeTaxesTables 72 false false R73.htm 9954518 - Disclosure - Retirement Plan (Details) Sheet http://inarimedical.com/role/RetirementPlanDetails Retirement Plan (Details) Details http://inarimedical.com/role/RetirementPlan 73 false false R74.htm 9954519 - Disclosure - Net Income (Loss) Per Share - Schedule of Computation of Net Loss (Income) per Share (Details) Sheet http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails Net Income (Loss) Per Share - Schedule of Computation of Net Loss (Income) per Share (Details) Details http://inarimedical.com/role/NetIncomeLossPerShareTables 74 false false R75.htm 9954520 - Disclosure - Net Income (Loss) Per Share - Schedule of Outstanding Potentially Dilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) Sheet http://inarimedical.com/role/NetIncomeLossPerShareScheduleofOutstandingPotentiallyDilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails Net Income (Loss) Per Share - Schedule of Outstanding Potentially Dilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) Details http://inarimedical.com/role/NetIncomeLossPerShareTables 75 false false All Reports Book All Reports nari-20240930.htm nari-20240930.xsd nari-20240930_cal.xml nari-20240930_def.xml nari-20240930_lab.xml nari-20240930_pre.xml nari-20240930_g1.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 97 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nari-20240930.htm": { "nsprefix": "nari", "nsuri": "http://inarimedical.com/20240930", "dts": { "inline": { "local": [ "nari-20240930.htm" ] }, "schema": { "local": [ "nari-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "nari-20240930_cal.xml" ] }, "definitionLink": { "local": [ "nari-20240930_def.xml" ] }, "labelLink": { "local": [ "nari-20240930_lab.xml" ] }, "presentationLink": { "local": [ "nari-20240930_pre.xml" ] } }, "keyStandard": 320, "keyCustom": 23, "axisStandard": 25, "axisCustom": 1, "memberStandard": 43, "memberCustom": 18, "hidden": { "total": 7, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 2 }, "contextCount": 287, "entityCount": 1, "segmentCount": 63, "elementCount": 639, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 972, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://inarimedical.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets", "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCashCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R3": { "role": "http://inarimedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R5": { "role": "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "longName": "9952154 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-40", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-45", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R6": { "role": "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://inarimedical.com/role/Organization", "longName": "9952156 - Disclosure - Organization", "shortName": "Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://inarimedical.com/role/SummaryofSignificantAccountingPolicies", "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://inarimedical.com/role/BusinessCombination", "longName": "9952158 - Disclosure - Business Combination", "shortName": "Business Combination", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://inarimedical.com/role/FairValueMeasurements", "longName": "9952159 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://inarimedical.com/role/CashEquivalentsandInvestments", "longName": "9952160 - Disclosure - Cash Equivalents and Investments", "shortName": "Cash Equivalents and Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://inarimedical.com/role/Inventoriesnet", "longName": "9952161 - Disclosure - Inventories, net", "shortName": "Inventories, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://inarimedical.com/role/PropertyandEquipmentnet", "longName": "9952162 - Disclosure - Property and Equipment, net", "shortName": "Property and Equipment, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://inarimedical.com/role/GoodwillandIntangibleAssets", "longName": "9952163 - Disclosure - Goodwill and Intangible Assets", "shortName": "Goodwill and Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://inarimedical.com/role/CommitmentsandContingencies", "longName": "9952164 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://inarimedical.com/role/Concentrations", "longName": "9952165 - Disclosure - Concentrations", "shortName": "Concentrations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://inarimedical.com/role/RelatedParty", "longName": "9952166 - Disclosure - Related Party", "shortName": "Related Party", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://inarimedical.com/role/CreditFacility", "longName": "9952167 - Disclosure - Credit Facility", "shortName": "Credit Facility", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://inarimedical.com/role/StockholdersEquity", "longName": "9952168 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://inarimedical.com/role/EquityIncentivePlans", "longName": "9952169 - Disclosure - Equity Incentive Plans", "shortName": "Equity Incentive Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://inarimedical.com/role/IncomeTaxes", "longName": "9952170 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://inarimedical.com/role/RetirementPlan", "longName": "9952171 - Disclosure - Retirement Plan", "shortName": "Retirement Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://inarimedical.com/role/NetIncomeLossPerShare", "longName": "9952172 - Disclosure - Net Income (Loss) Per Share", "shortName": "Net Income (Loss) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://inarimedical.com/role/BusinessCombinationTables", "longName": "9954473 - Disclosure - Business Combination (Tables)", "shortName": "Business Combination (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://inarimedical.com/role/FairValueMeasurementsTables", "longName": "9954474 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://inarimedical.com/role/CashEquivalentsandInvestmentsTables", "longName": "9954475 - Disclosure - Cash Equivalents and Investments (Tables)", "shortName": "Cash Equivalents and Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://inarimedical.com/role/InventoriesnetTables", "longName": "9954476 - Disclosure - Inventories, net (Tables)", "shortName": "Inventories, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://inarimedical.com/role/PropertyandEquipmentnetTables", "longName": "9954477 - Disclosure - Property and Equipment, net (Tables)", "shortName": "Property and Equipment, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://inarimedical.com/role/GoodwillandIntangibleAssetsTables", "longName": "9954478 - Disclosure - Goodwill and Intangible Assets (Tables)", "shortName": "Goodwill and Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://inarimedical.com/role/CommitmentsandContingenciesTables", "longName": "9954479 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://inarimedical.com/role/CreditFacilityTables", "longName": "9954480 - Disclosure - Credit Facility (Tables)", "shortName": "Credit Facility (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://inarimedical.com/role/StockholdersEquityTables", "longName": "9954481 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://inarimedical.com/role/EquityIncentivePlansTables", "longName": "9954482 - Disclosure - Equity Incentive Plans (Tables)", "shortName": "Equity Incentive Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://inarimedical.com/role/IncomeTaxesTables", "longName": "9954483 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://inarimedical.com/role/NetIncomeLossPerShareTables", "longName": "9954484 - Disclosure - Net Income (Loss) Per Share (Tables)", "shortName": "Net Income (Loss) Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954485 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:UnbilledReceivablesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "us-gaap:UnbilledReceivablesCurrent", "span", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:UnbilledReceivablesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R41": { "role": "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofDisaggregationofRevenueDetails", "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-82", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R42": { "role": "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashFlowSupplementalDisclosuresDetails", "longName": "9954487 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash Flow, Supplemental Disclosures (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Cash Flow, Supplemental Disclosures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxesPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxesPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://inarimedical.com/role/BusinessCombinationNarrativeDetails", "longName": "9954488 - Disclosure - Business Combination - Narrative (Details)", "shortName": "Business Combination - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-90", "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R44": { "role": "http://inarimedical.com/role/BusinessCombinationScheduleofTotalPurchasePriceConsiderationDetails", "longName": "9954489 - Disclosure - Business Combination - Schedule of Total Purchase Price Consideration (Details)", "shortName": "Business Combination - Schedule of Total Purchase Price Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-91", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R45": { "role": "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "longName": "9954490 - Disclosure - Business Combination - Schedule of Fair Values of Assets Acquired and Liabilities Assumed (Details)", "shortName": "Business Combination - Schedule of Fair Values of Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-92", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R46": { "role": "http://inarimedical.com/role/BusinessCombinationScheduleofFairValueAssignedtotheIntangibleAssetAcquiredDetails", "longName": "9954491 - Disclosure - Business Combination - Schedule of Fair Value Assigned to the Intangible Asset Acquired (Details)", "shortName": "Business Combination - Schedule of Fair Value Assigned to the Intangible Asset Acquired (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-97", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-98", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R47": { "role": "http://inarimedical.com/role/BusinessCombinationScheduleofProFormaInformationDetails", "longName": "9954492 - Disclosure - Business Combination - Schedule of Pro Forma Information (Details)", "shortName": "Business Combination - Schedule of Pro Forma Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-99", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-99", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "longName": "9954493 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details)", "shortName": "Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-108", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R49": { "role": "http://inarimedical.com/role/FairValueMeasurementsScheduleofEstimatedFairValueoftheContingentConsiderationLiabilitiesDetails", "longName": "9954494 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value of the Contingent Consideration Liabilities (Details)", "shortName": "Fair Value Measurements - Schedule of Estimated Fair Value of the Contingent Consideration Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://inarimedical.com/role/FairValueMeasurementsNarrativeDetails", "longName": "9954495 - Disclosure - Fair Value Measurements - Narrative (Details)", "shortName": "Fair Value Measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R51": { "role": "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails", "longName": "9954496 - Disclosure - Cash Equivalents and Investments (Details)", "shortName": "Cash Equivalents and Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R52": { "role": "http://inarimedical.com/role/InventoriesnetDetails", "longName": "9954497 - Disclosure - Inventories, net (Details)", "shortName": "Inventories, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R53": { "role": "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails", "longName": "9954498 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment, Net (Details)", "shortName": "Property and Equipment, net - Schedule of Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R54": { "role": "http://inarimedical.com/role/PropertyandEquipmentnetNarrativeDetails", "longName": "9954499 - Disclosure - Property and Equipment, net - Narrative (Details)", "shortName": "Property and Equipment, net - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-153", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-153", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R55": { "role": "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountsofGoodwillDetails", "longName": "9954500 - Disclosure - Goodwill and Intangible Assets - Schedule of Carrying Amounts of Goodwill (Details)", "shortName": "Goodwill and Intangible Assets - Schedule of Carrying Amounts of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R56": { "role": "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails", "longName": "9954501 - Disclosure - Goodwill and Intangible Assets - Schedule of Identifiable Intangible Assets (Details)", "shortName": "Goodwill and Intangible Assets - Schedule of Identifiable Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R57": { "role": "http://inarimedical.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "longName": "9954502 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)", "shortName": "Goodwill and Intangible Assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:CapitalizedComputerSoftwareImpairments1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R58": { "role": "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails", "longName": "9954503 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Annual Amortization of the Intangible Asset (Details)", "shortName": "Goodwill and Intangible Assets - Schedule of Estimated Future Annual Amortization of the Intangible Asset (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-161", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R59": { "role": "http://inarimedical.com/role/CommitmentsandContingenciesNarrativeDetails", "longName": "9954504 - Disclosure - Commitments and Contingencies - Narrative (Details)", "shortName": "Commitments and Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-164", "name": "us-gaap:LesseeFinanceLeaseLeaseNotYetCommencedTermOfContract1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-164", "name": "us-gaap:LesseeFinanceLeaseLeaseNotYetCommencedTermOfContract1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofOperatingLeaseDisclosureDetails", "longName": "9954505 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Disclosure (Details)", "shortName": "Commitments and Contingencies - Schedule of Operating Lease Disclosure (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R61": { "role": "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails", "longName": "9954506 - Disclosure - Commitments and Contingencies - Schedule of Total Lease Cost (Details)", "shortName": "Commitments and Contingencies - Schedule of Total Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails", "longName": "9954507 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating Leases Liabilities (Details)", "shortName": "Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating Leases Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R63": { "role": "http://inarimedical.com/role/RelatedPartyDetails", "longName": "9954508 - Disclosure - Related Party (Details)", "shortName": "Related Party (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R64": { "role": "http://inarimedical.com/role/CreditFacilityNarrativeDetails", "longName": "9954509 - Disclosure - Credit Facility - Narrative (Details)", "shortName": "Credit Facility - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-180", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-180", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R65": { "role": "http://inarimedical.com/role/CreditFacilityScheduleofCostsIncurredDirectlyRelatedtoDebtDetails", "longName": "9954510 - Disclosure - Credit Facility - Schedule of Costs Incurred Directly Related to Debt (Details)", "shortName": "Credit Facility - Schedule of Costs Incurred Directly Related to Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DeferredFinanceCostsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DeferredFinanceCostsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R66": { "role": "http://inarimedical.com/role/StockholdersEquityDetails", "longName": "9954511 - Disclosure - Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-31", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-201", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R67": { "role": "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "longName": "9954512 - Disclosure - Equity Incentive Plans - Narrative (Details)", "shortName": "Equity Incentive Plans - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-257", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-257", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R68": { "role": "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails", "longName": "9954513 - Disclosure - Equity Incentive Plans - Schedule of Stock Option Activity (Details)", "shortName": "Equity Incentive Plans - Schedule of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-223", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-225", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R69": { "role": "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails", "longName": "9954514 - Disclosure - Equity Incentive Plans - Schedule of RSU and PSU Activity (Details)", "shortName": "Equity Incentive Plans - Schedule of RSU and PSU Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-233", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-233", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R70": { "role": "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails", "longName": "9954515 - Disclosure - Equity Incentive Plans - Schedule of Estimated Fair Value of Option Grant and ESPP on Date of Grant (Details)", "shortName": "Equity Incentive Plans - Schedule of Estimated Fair Value of Option Grant and ESPP on Date of Grant (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-244", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-244", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R71": { "role": "http://inarimedical.com/role/EquityIncentivePlansScheduleofTotalCompensationCostforAllShareBasedPaymentArrangementsRecognizedDetails", "longName": "9954516 - Disclosure - Equity Incentive Plans - Schedule of Total Compensation Cost for All Share-Based Payment Arrangements Recognized (Details)", "shortName": "Equity Incentive Plans - Schedule of Total Compensation Cost for All Share-Based Payment Arrangements Recognized (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-155", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R72": { "role": "http://inarimedical.com/role/IncomeTaxesDetails", "longName": "9954517 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R73": { "role": "http://inarimedical.com/role/RetirementPlanDetails", "longName": "9954518 - Disclosure - Retirement Plan (Details)", "shortName": "Retirement Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } }, "R74": { "role": "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails", "longName": "9954519 - Disclosure - Net Income (Loss) Per Share - Schedule of Computation of Net Loss (Income) per Share (Details)", "shortName": "Net Income (Loss) Per Share - Schedule of Computation of Net Loss (Income) per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-272", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "unique": true } }, "R75": { "role": "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofOutstandingPotentiallyDilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails", "longName": "9954520 - Disclosure - Net Income (Loss) Per Share - Schedule of Outstanding Potentially Dilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)", "shortName": "Net Income (Loss) Per Share - Schedule of Outstanding Potentially Dilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nari-20240930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://inarimedical.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets", "http://inarimedical.com/role/RelatedPartyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r61", "r819" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r966" ] }, "nari_AccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "AccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Expenses And Other Current Liabilities", "documentation": "Accrued expenses and other current liabilities." } } }, "auth_ref": [] }, "us-gaap_AccumulatedAmortizationDeferredFinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedAmortizationDeferredFinanceCosts", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CreditFacilityScheduleofCostsIncurredDirectlyRelatedtoDebtDetails": { "parentTag": "us-gaap_DeferredFinanceCostsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CreditFacilityScheduleofCostsIncurredDirectlyRelatedtoDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated amortization", "label": "Accumulated Amortization, Debt Issuance Costs", "documentation": "Amount of accumulated amortization of debt issuance costs." } } }, "auth_ref": [ "r1071", "r1073" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r36", "r149", "r630" ] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": [ "http://inarimedical.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gain (Loss) on Investments", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r157", "r158", "r159", "r161", "r168", "r169", "r944" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://inarimedical.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r167", "r168", "r514", "r515", "r516", "r517", "r518", "r519" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r22", "r23", "r83", "r153", "r626", "r656", "r657" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://inarimedical.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r167", "r168", "r514", "r515", "r516", "r517", "r518", "r519" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://inarimedical.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "verboseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r12", "r23", "r481", "r484", "r538", "r652", "r653", "r944", "r945", "r946", "r955", "r956", "r957", "r958" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://inarimedical.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r5", "r12", "r23", "r81", "r82", "r168", "r169", "r515", "r516", "r517", "r518", "r519", "r944" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofFairValueAssignedtotheIntangibleAssetAcquiredDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r293", "r762" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r882" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r73" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r668", "r955", "r956", "r957", "r958", "r1058", "r1124" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r895" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r895" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r895" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r895" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r44", "r45", "r402" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net (loss) income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r928" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r854", "r864", "r874", "r906" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r857", "r867", "r877", "r909" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r929" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r895" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r902" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r858", "r868", "r878", "r902", "r910", "r914", "r922" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r920" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofTotalCompensationCostforAllShareBasedPaymentArrangementsRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation cost", "verboseLabel": "Total share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r432", "r437" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit losses", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r154", "r236", "r274" ] }, "nari_AmendedCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "AmendedCreditAgreementMember", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amended Credit Agreement", "label": "Amended Credit Agreement [Member]", "documentation": "Credit agreement." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred financing costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r94", "r350", "r950", "r1072" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://inarimedical.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible asset", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r290", "r297", "r781" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofOutstandingPotentiallyDilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total potentially dilutive common stock equivalents excluded from calculation due to anti-dilutive effect (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r215" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails", "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofOutstandingPotentiallyDilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r30" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails", "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofOutstandingPotentiallyDilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded From Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails", "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofOutstandingPotentiallyDilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r30" ] }, "us-gaap_AssetUnderConstructionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetUnderConstructionMember", "presentation": [ "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets in progress", "label": "Asset under Construction [Member]", "documentation": "Asset in process of being built." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r122", "r132", "r152", "r184", "r219", "r221", "r229", "r230", "r271", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r474", "r478", "r512", "r620", "r695", "r776", "r777", "r819", "r845", "r1024", "r1025", "r1079" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r145", "r156", "r184", "r271", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r474", "r478", "r512", "r819", "r1024", "r1025", "r1079" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r492", "r493", "r806" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Assets", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gain", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r242" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized Loss", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r243" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost Basis", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r239", "r281", "r619" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 }, "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails", "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total included in short-term investments", "terseLabel": "Short-term investments in debt securities", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r240", "r281", "r492", "r614", "r806", "r810", "r968", "r1062", "r1063", "r1064" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments in debt securities", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r237", "r281" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r917" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r918" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r913" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r913" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r913" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r913" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r913" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r913" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r916" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r915" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r914" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r914" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r309", "r1092", "r1093" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r55", "r56", "r309", "r1092", "r1093" ] }, "nari_BankOfAmericaCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "BankOfAmericaCreditFacilityMember", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bank of America Credit Facility", "label": "Bank Of America Credit Facility [Member]", "documentation": "Bank of America credit facility." } } }, "auth_ref": [] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "nari_BloombergShortTermBankYieldIndexBSBYMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "BloombergShortTermBankYieldIndexBSBYMember", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSBY", "label": "Bloomberg Short Term Bank Yield Index (BSBY) [Member]", "documentation": "Bloomberg Short Term Bank Yield Index (BSBY)" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofFairValueAssignedtotheIntangibleAssetAcquiredDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofProFormaInformationDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofTotalPurchasePriceConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r466", "r798", "r799" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofFairValueAssignedtotheIntangibleAssetAcquiredDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofProFormaInformationDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofTotalPurchasePriceConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r47", "r50", "r291", "r292", "r293", "r294", "r295", "r466", "r798", "r799" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofFairValueAssignedtotheIntangibleAssetAcquiredDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofProFormaInformationDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofTotalPurchasePriceConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r466" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of voting interests acquired", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r48" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://inarimedical.com/role/BusinessCombinationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Pro Forma Information", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r932", "r933" ] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r464", "r465" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r464", "r465" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails", "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition-related expenses", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r46" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofTotalPurchasePriceConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total purchase price", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r11" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 }, "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows", "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in fair value of contingent consideration", "terseLabel": "Change in fair value of contingent consideration liability", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r470", "r949" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": [ "r54" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range of outcomes on contingent consideration arrangements", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": [ "r54" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://inarimedical.com/role/FairValueMeasurementsNarrativeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofTotalPurchasePriceConsiderationDetails", "http://inarimedical.com/role/FairValueMeasurementsNarrativeDetails", "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of contingent consideration", "verboseLabel": "Contingent consideration", "totalLabel": "Fair value of contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r53", "r119", "r469", "r494", "r495", "r496" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://inarimedical.com/role/FairValueMeasurementsNarrativeDetails": { "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, liability, current", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r53", "r119" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://inarimedical.com/role/FairValueMeasurementsNarrativeDetails": { "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, liability, noncurrent", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r53", "r119" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://inarimedical.com/role/BusinessCombination" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r117", "r467" ] }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationIntegrationRelatedCosts", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Severance and integration related costs", "label": "Business Combination, Integration Related Costs", "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r52" ] }, "nari_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAndNoncurrentAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAndNoncurrentAssetsOther", "crdr": "debit", "calculation": { "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current and noncurrent assets", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current And Noncurrent Assets, Other", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current And Noncurrent Assets, Other" } } }, "auth_ref": [] }, "nari_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAndNoncurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAndNoncurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other current and noncurrent liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current And Noncurrent Liabilities, Other", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current And Noncurrent Liabilities, Other" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r52" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts payable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r52" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred tax liability", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r52" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofFairValueAssignedtotheIntangibleAssetAcquiredDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset", "verboseLabel": "Fair value", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r51", "r52" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r51", "r52" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r51", "r52" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total net assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r52" ] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofTotalPurchasePriceConsiderationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of previously held investment", "terseLabel": "Fair value of previously held investment", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages." } } }, "auth_ref": [ "r16" ] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquiring equity interest percentage", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain recognized, amount", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain", "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination." } } }, "auth_ref": [ "r49" ] }, "us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedComputerSoftwareAccumulatedAmortization", "crdr": "credit", "calculation": { "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails": { "parentTag": "us-gaap_CapitalizedComputerSoftwareNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capitalized software, Accumulated Amortization", "label": "Capitalized Computer Software, Accumulated Amortization", "documentation": "For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs." } } }, "auth_ref": [ "r296", "r762" ] }, "us-gaap_CapitalizedComputerSoftwareAmortization1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedComputerSoftwareAmortization1", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized software, amortization", "label": "Capitalized Computer Software, Amortization", "documentation": "Amount of expense for amortization of capitalized computer software costs." } } }, "auth_ref": [ "r760", "r762" ] }, "us-gaap_CapitalizedComputerSoftwareGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedComputerSoftwareGross", "crdr": "debit", "calculation": { "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails": { "parentTag": "us-gaap_CapitalizedComputerSoftwareNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized software, Gross Carrying Amount", "label": "Capitalized Computer Software, Gross", "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software." } } }, "auth_ref": [ "r296", "r762" ] }, "us-gaap_CapitalizedComputerSoftwareImpairments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedComputerSoftwareImpairments1", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows", "http://inarimedical.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of capitalized software development costs", "label": "Capitalized Computer Software, Impairments", "documentation": "Amount of impairment loss from capitalized computer software costs." } } }, "auth_ref": [ "r761", "r762" ] }, "us-gaap_CapitalizedComputerSoftwareNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedComputerSoftwareNet", "crdr": "debit", "calculation": { "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Capitalized software, Net", "terseLabel": "Capitalized computer software, net", "label": "Capitalized Computer Software, Net", "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date." } } }, "auth_ref": [ "r759" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashFlowSupplementalDisclosuresDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets", "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashFlowSupplementalDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r27", "r147", "r767" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r147" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total included in cash and cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1060", "r1061" ] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock", "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestments" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents and Investments", "label": "Cash, Cash Equivalents, and Short-Term Investments [Text Block]", "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities." } } }, "auth_ref": [ "r967" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashFlowSupplementalDisclosuresDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows", "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashFlowSupplementalDisclosuresDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash end of period", "totalLabel": "Total cash, cash equivalents and restricted cash as shown in the statement of cash flows", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r27", "r98", "r180" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashFlowSupplementalDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r98" ] }, "nari_CashPledgedUnderCreditAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "CashPledgedUnderCreditAgreement", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash pledged under credit agreement", "label": "Cash Pledged Under Credit Agreement", "documentation": "Cash pledged under credit agreement." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r893" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r890" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r888" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r894" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r894" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 9)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r69", "r125", "r623", "r682" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r107", "r311", "r312", "r747", "r1013", "r1018" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares of common stock reserved for future issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r72" ] }, "nari_CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAnnualIncreasePercentOfAggregateSharesOutstanding", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual increase in number of shares available for issuance percentage", "label": "Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding", "documentation": "Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r835", "r836", "r837", "r839", "r840", "r841", "r842", "r955", "r956", "r958", "r1058", "r1123", "r1124" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r72" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r72", "r683" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r72" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, outstanding (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r13", "r72", "r683", "r701", "r1124", "r1125" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value, 300,000,000 shares authorized as of September\u00a030, 2024 and December\u00a031, 2023; 58,435,576 and 57,762,414 shares issued and outstanding as of September\u00a030, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r72", "r625", "r819" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r899" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r898" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r900" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r897" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r24", "r164", "r166", "r170", "r615", "r637", "r638" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": [ "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer hardware", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": [ "http://inarimedical.com/role/Concentrations" ], "lang": { "en-us": { "role": { "terseLabel": "Concentrations", "label": "Concentration Risk Disclosure [Text Block]", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": [ "r102" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "nari_CorporateDebtSecuritiesAndCommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "CorporateDebtSecuritiesAndCommercialPaperMember", "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails", "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Corporate debt securities and commercial paper", "terseLabel": "Corporate debt securities and commercial paper", "label": "Corporate Debt Securities And Commercial Paper [Member]", "documentation": "Corporate debt securities and commercial paper." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r86", "r87", "r579" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofTotalCompensationCostforAllShareBasedPaymentArrangementsRecognizedDetails", "http://inarimedical.com/role/PropertyandEquipmentnetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r318", "r1022" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r318", "r1022", "r1023" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://inarimedical.com/role/CreditFacility" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r108", "r182", "r304", "r305", "r306", "r307", "r308", "r317", "r318", "r328", "r334", "r335", "r336", "r337", "r338", "r339", "r344", "r351", "r352", "r354", "r520" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r20", "r63", "r64", "r123", "r124", "r188", "r329", "r330", "r331", "r332", "r333", "r335", "r340", "r341", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r350", "r782", "r783", "r784", "r785", "r786", "r817", "r952", "r1014", "r1015", "r1016", "r1071", "r1073" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan variable interest rate (as percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "nari_DebtInstrumentBasisSpreadOnVariableRateFloor": { "xbrltype": "percentItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "DebtInstrumentBasisSpreadOnVariableRateFloor", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate, floor (as percent)", "label": "Debt Instrument, Basis Spread On Variable Rate, Floor", "documentation": "Debt Instrument, Basis Spread On Variable Rate, Floor" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, fee amount", "label": "Debt Instrument, Fee Amount", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": [ "r66" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r188", "r329", "r330", "r331", "r332", "r333", "r335", "r340", "r341", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r350", "r353", "r782", "r783", "r784", "r785", "r786", "r817", "r952", "r1071", "r1073" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r20", "r188", "r329", "r330", "r331", "r332", "r333", "r335", "r340", "r341", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r350", "r782", "r783", "r784", "r785", "r786", "r817", "r952", "r1014", "r1015", "r1016", "r1071", "r1073" ] }, "nari_DebtInstrumentNumberOfLettersOfCredit": { "xbrltype": "integerItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "DebtInstrumentNumberOfLettersOfCredit", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of letter of credit", "label": "Debt Instrument, Number Of Letters Of Credit", "documentation": "Number of letter of credit." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r20", "r38", "r39", "r59", "r110", "r111", "r188", "r329", "r330", "r331", "r332", "r333", "r335", "r340", "r341", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r350", "r353", "r782", "r783", "r784", "r785", "r786", "r817", "r952", "r1071", "r1073" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, term (in years)", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Equivalents and Investments", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981" ] }, "us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1", "presentation": [ "http://inarimedical.com/role/RetirementPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum employee service period (in months)", "label": "Deferred Compensation Arrangement with Individual, Requisite Service Period", "documentation": "Minimum period the individual is required to perform services to be fully vested under the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r40", "r42" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CreditFacilityScheduleofCostsIncurredDirectlyRelatedtoDebtDetails": { "parentTag": "us-gaap_DeferredFinanceCostsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CreditFacilityScheduleofCostsIncurredDirectlyRelatedtoDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred financing costs", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1071", "r1073" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CreditFacilityScheduleofCostsIncurredDirectlyRelatedtoDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/CreditFacilityScheduleofCostsIncurredDirectlyRelatedtoDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Unamortized deferred financing costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1027", "r1070", "r1071", "r1073" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r441", "r442", "r621" ] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/RetirementPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Matching contribution expense recognized", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r398" ] }, "nari_DefinedContributionPlanEmployerMatchingContributionPerEmployeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "DefinedContributionPlanEmployerMatchingContributionPerEmployeeAmount", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/RetirementPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Individual limit on employer match", "label": "Defined Contribution Plan, Employer Matching Contribution Per Employee, Amount", "documentation": "Defined Contribution Plan, Employer Matching Contribution Per Employee, Amount" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://inarimedical.com/role/RetirementPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer matching contribution, percent of match", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/RetirementPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum participating employee annual contributions", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount", "documentation": "Maximum amount the employee may contribute to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "presentation": [ "http://inarimedical.com/role/RetirementPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Participating employee eligible compensation", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanTaxStatusExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanTaxStatusExtensibleList", "presentation": [ "http://inarimedical.com/role/RetirementPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "401 (k) Plan", "label": "Defined Contribution Plan, Tax Status [Extensible Enumeration]", "documentation": "Indicates tax status of defined contribution plan designed to provide retirement benefits." } } }, "auth_ref": [] }, "nari_DepositsAndOtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "DepositsAndOtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits and other assets", "label": "Deposits And Other Assets Noncurrent", "documentation": "Deposits and other assets noncurrent." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/PropertyandEquipmentnetNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r9", "r35" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r9", "r219", "r226", "r230", "r776", "r777" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r379", "r788", "r789", "r790", "r791", "r792", "r793", "r794" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r379", "r788", "r789", "r790", "r791", "r792", "r793", "r794" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1028" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlans" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Incentive Plans", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r400", "r405", "r433", "r434", "r436", "r801" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r849" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r881" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r892" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income per share", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r171", "r194", "r195", "r196", "r197", "r198", "r199", "r204", "r206", "r212", "r213", "r214", "r218", "r462", "r472", "r489", "r490", "r616", "r639", "r773" ] }, "nari_EarningsPerShareBasicAndDilutedEPSAbstract": { "xbrltype": "stringItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "EarningsPerShareBasicAndDilutedEPSAbstract", "presentation": [ "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income per share:", "label": "Earnings Per Share, Basic And Diluted, EPS [Abstract]", "documentation": "Earnings Per Share, Basic And Diluted, EPS" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r171", "r194", "r195", "r196", "r197", "r198", "r199", "r206", "r212", "r213", "r214", "r218", "r462", "r472", "r489", "r490", "r616", "r639", "r773" ] }, "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareReconciliationAbstract", "presentation": [ "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://inarimedical.com/role/NetIncomeLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss) Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r203", "r215", "r216", "r217" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r513" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://inarimedical.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes as a percentage of (loss) income before income taxes", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r444", "r803" ] }, "nari_EmergingTherapiesMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "EmergingTherapiesMember", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Emerging Therapies", "label": "Emerging Therapies [Member]", "documentation": "Emerging Therapies" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Payroll-related accruals", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r64" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofTotalCompensationCostforAllShareBasedPaymentArrangementsRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonvested award, cost not yet recognized, amount", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r435" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonvested award, cost not yet recognized, period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r435" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [ "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ESPP", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails", "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails", "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofOutstandingPotentiallyDilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee Stock Option", "terseLabel": "Stock options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "nari_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "EmployeeStockPurchasePlanMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Purchase Plan", "label": "Employee Stock Purchase Plan [Member]", "documentation": "Employee stock purchase plan." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r847" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r847" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r847" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r931" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r847" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r847" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r847" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r847" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r886" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r927" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r927" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r927" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "nari_EquityAwardsSharesIssuedNetOfSharesForTaxWithholdings": { "xbrltype": "sharesItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "EquityAwardsSharesIssuedNetOfSharesForTaxWithholdings", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes (in shares)", "label": "Equity Awards, Shares Issued Net of Shares for Tax Withholdings", "documentation": "Equity Awards, Shares Issued Net of Shares for Tax Withholdings" } } }, "auth_ref": [] }, "nari_EquityAwardsValueSharesIssuedNetOfTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "EquityAwardsValueSharesIssuedNetOfTaxWithholdings", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon vesting of equity awards, net of shares withheld for taxes", "label": "Equity Awards, Value, Shares Issued Net of Tax Withholdings", "documentation": "Equity Awards, Value, Shares Issued Net of Tax Withholdings" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "http://inarimedical.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r13", "r143", "r167", "r168", "r169", "r189", "r190", "r191", "r193", "r198", "r200", "r202", "r220", "r272", "r273", "r302", "r369", "r452", "r453", "r459", "r460", "r461", "r463", "r471", "r472", "r480", "r481", "r482", "r483", "r484", "r485", "r488", "r514", "r515", "r516", "r517", "r518", "r519", "r521", "r522", "r538", "r635", "r652", "r653", "r654", "r668", "r725" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities without readily determinable fair value, amount", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r268" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows", "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss on strategic investment", "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount", "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r269" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Investments", "label": "Equity Securities without Readily Determinable Fair Value [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change." } } }, "auth_ref": [ "r270" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r896" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r854", "r864", "r874", "r906" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r851", "r861", "r871", "r903" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r902" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r492", "r493", "r504", "r806" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r492", "r493", "r504", "r806" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r342", "r383", "r384", "r385", "r386", "r387", "r388", "r491", "r493", "r494", "r495", "r496", "r503", "r504", "r506", "r550", "r551", "r552", "r783", "r784", "r795", "r796", "r797", "r806", "r810" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r492", "r493", "r494", "r496", "r806", "r1063", "r1066" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://inarimedical.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r499", "r501", "r502", "r503", "r506", "r507", "r508", "r509", "r510", "r612", "r806", "r811" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r342", "r383", "r388", "r493", "r504", "r550", "r795", "r796", "r797", "r806" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r342", "r383", "r388", "r493", "r494", "r504", "r551", "r783", "r784", "r795", "r796", "r797", "r806" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r342", "r383", "r384", "r385", "r386", "r387", "r388", "r493", "r494", "r495", "r496", "r504", "r552", "r783", "r784", "r795", "r796", "r797", "r806", "r810" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofEstimatedFairValueoftheContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in the Estimated Fair Value", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r497", "r500", "r505" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r492", "r493", "r494", "r496", "r806", "r1063", "r1066" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofEstimatedFairValueoftheContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in estimated fair value", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r498", "r505" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofEstimatedFairValueoftheContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r497", "r505" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r342", "r383", "r384", "r385", "r386", "r387", "r388", "r491", "r493", "r494", "r495", "r496", "r503", "r504", "r506", "r550", "r551", "r552", "r783", "r784", "r795", "r796", "r797", "r806", "r810" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r806", "r1060", "r1061", "r1062", "r1063", "r1064", "r1066" ] }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalFundsEffectiveSwapRateMember", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal Funds Rate", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg." } } }, "auth_ref": [ "r1057" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, liability to be paid", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r535" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails", "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r275", "r276", "r278", "r279", "r280", "r282", "r283", "r284", "r353", "r367", "r486", "r511", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r636", "r779", "r806", "r808", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r820", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r981", "r982", "r983", "r984", "r1059", "r1062", "r1063", "r1064", "r1065", "r1066" ] }, "nari_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "calculation": { "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r151", "r286", "r296", "r781" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r298", "r762", "r781" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [ "r1130" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r298", "r762", "r781" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r298", "r762", "r781" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r298", "r762", "r781" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofFairValueAssignedtotheIntangibleAssetAcquiredDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails", "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r289", "r291", "r292", "r293", "r295", "r296", "r299", "r300", "r580", "r581", "r762" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r286", "r296", "r581", "r781" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails", "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r289", "r296", "r299", "r300", "r301", "r580", "r762", "r781" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofFairValueAssignedtotheIntangibleAssetAcquiredDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails", "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r289", "r291", "r292", "r293", "r295", "r296", "r299", "r300", "r762" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails", "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible Assets, Net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r580", "r1006" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r858", "r868", "r878", "r910" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r858", "r868", "r878", "r910" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r858", "r868", "r878", "r910" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r858", "r868", "r878", "r910" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r858", "r868", "r878", "r910" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r891" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain contingency, patents allegedly infringed upon, number", "label": "Gain Contingency, Patents Allegedly Infringed upon, Number", "documentation": "Number of entity's patents that another entity has allegedly infringed." } } }, "auth_ref": [ "r1021" ] }, "us-gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal of fixed assets", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": [ "r950", "r1011", "r1012" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets", "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountsofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Goodwill, beginning balance", "periodEndLabel": "Goodwill, ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r150", "r287", "r613", "r777", "r780", "r807", "r819", "r988", "r995" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r986", "r998" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountsofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r288" ] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails", "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountsofGoodwillDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Working capital adjustment", "terseLabel": "Working capital adjustment", "label": "Goodwill, Measurement Period Adjustment", "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r0", "r994" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofCarryingAmountsofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r84", "r88", "r131", "r184", "r271", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r512", "r775", "r776", "r961", "r962", "r963", "r964", "r965", "r1024" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://inarimedical.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income before income taxes", "terseLabel": "(Loss) income before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r85", "r127", "r131", "r617", "r632", "r775", "r776", "r961", "r962", "r963", "r964", "r965" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofTotalCompensationCostforAllShareBasedPaymentArrangementsRecognizedDetails", "http://inarimedical.com/role/PropertyandEquipmentnetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r303", "r309", "r310", "r498", "r500", "r505", "r649", "r651", "r710", "r762", "r809", "r1094" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofTotalCompensationCostforAllShareBasedPaymentArrangementsRecognizedDetails", "http://inarimedical.com/role/PropertyandEquipmentnetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r309", "r310", "r498", "r500", "r505", "r649", "r651", "r710", "r762", "r809", "r1094" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://inarimedical.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r185", "r440", "r444", "r445", "r446", "r447", "r448", "r449", "r454", "r456", "r457", "r458", "r663", "r803" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://inarimedical.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r133", "r141", "r201", "r202", "r219", "r227", "r230", "r443", "r444", "r455", "r640", "r803" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashFlowSupplementalDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r28", "r179", "r450", "r451" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r934", "r949" ] }, "nari_IncreaseDecreaseInPayrollRelatedAccrualsAccruedExpensesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "IncreaseDecreaseInPayrollRelatedAccrualsAccruedExpensesAndOtherLiabilities", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Payroll-related accruals, accrued expenses and other liabilities", "label": "Increase Decrease In Payroll Related Accruals Accrued Expenses And Other Liabilities", "documentation": "Increase (decrease) in payroll related accruals accrued expenses and other liabilities." } } }, "auth_ref": [] }, "nari_IncreaseDecreaseInPrepaidExpensesDepositsAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "IncreaseDecreaseInPrepaidExpensesDepositsAndOtherAssets", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses, deposits and other assets", "label": "Increase (Decrease) In Prepaid Expenses Deposits And Other Assets", "documentation": "Increase (decrease) in prepaid expenses, deposits and other assets" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock equivalents from outstanding equity grants (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r207", "r208", "r209", "r214", "r404" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r858", "r868", "r878", "r902", "r910", "r914", "r922" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r920" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r850", "r926" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r850", "r926" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r850", "r926" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets", "http://inarimedical.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r289", "r1006", "r1008" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r225", "r948" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashFlowSupplementalDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r174", "r177", "r178" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://inarimedical.com/role/Inventoriesnet" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r285" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://inarimedical.com/role/InventoriesnetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/InventoriesnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r104", "r769" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 }, "http://inarimedical.com/role/InventoriesnetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets", "http://inarimedical.com/role/InventoriesnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "totalLabel": "Total inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r155", "r768", "r819" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://inarimedical.com/role/InventoriesnetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/InventoriesnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r104", "r771" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://inarimedical.com/role/InventoriesnetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/InventoriesnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r104", "r770" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r219", "r224", "r230", "r776", "r947" ] }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization of premium and discount on marketable securities", "label": "Investment Income, Net, Amortization of Discount and Premium", "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities." } } }, "auth_ref": [ "r94" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease costs", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r527", "r818" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Lease Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1076" ] }, "nari_LeasePrepaymentsForLessorsOwnedLeaseholdImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "LeasePrepaymentsForLessorsOwnedLeaseholdImprovements", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Lease prepayments for lessor's owned leasehold improvements", "label": "Lease Prepayments For Lessor's Owned Leasehold Improvements", "documentation": "Lease prepayments for lessor's owned leasehold improvements" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r106", "r536" ] }, "us-gaap_LesseeFinanceLeaseLeaseNotYetCommencedTermOfContract1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeaseLeaseNotYetCommencedTermOfContract1", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease not yet commenced, term of contract (in years)", "label": "Lessee, Finance Lease, Lease Not yet Commenced, Term of Contract", "documentation": "Term of lessee's finance lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1075" ] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Lease Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r526", "r537" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Lease Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r526", "r537" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Payments Under Operating Leases Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1077" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r535" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r535" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r535" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r535" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r535" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1077" ] }, "nari_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "documentation": "Lessee operating lease liability payments thereafter." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r535" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option to extend, operating lease, term (in years)", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1074" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit Subline Facility", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit outstanding amount", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r20", "r63", "r64", "r65", "r67", "r68", "r69", "r70", "r184", "r271", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r475", "r478", "r479", "r512", "r681", "r774", "r845", "r1024", "r1079", "r1080" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r77", "r126", "r628", "r819", "r953", "r985", "r1067" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders' Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r65", "r146", "r184", "r271", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r475", "r478", "r479", "r512", "r819", "r1024", "r1079", "r1080" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r493", "r1060" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Liability", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "nari_LimFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "LimFlowMember", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofFairValueAssignedtotheIntangibleAssetAcquiredDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofProFormaInformationDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofTotalPurchasePriceConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LimFlow", "label": "LimFlow [Member]", "documentation": "LimFlow" } } }, "auth_ref": [] }, "nari_LineOfCreditFacilityAccordionFeatureHigherBorrowingCapacityOptionIncreaseLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "LineOfCreditFacilityAccordionFeatureHigherBorrowingCapacityOptionIncreaseLimit", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, accordion feature, higher borrowing capacity option", "label": "Line Of Credit Facility, Accordion Feature, Higher Borrowing Capacity Option, Increase Limit", "documentation": "Line Of Credit Facility, Accordion Feature, Higher Borrowing Capacity Option, Increase Limit" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lender Name", "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r62", "r66", "r952", "r1022", "r1023" ] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, amount available to borrow", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r62", "r66" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Lender", "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r62", "r66", "r952", "r1022" ] }, "us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal amount outstanding", "label": "Line of Credit Facility, Maximum Amount Outstanding During Period", "documentation": "Maximum amount borrowed under the credit facility at any time during the period." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r62", "r66" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unused line fee at annual rate (as percent)", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r20", "r1014", "r1015", "r1016" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r20", "r37", "r1014", "r1015", "r1016" ] }, "us-gaap_ManufacturingFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ManufacturingFacilityMember", "presentation": [ "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing equipment", "label": "Manufacturing Facility [Member]", "documentation": "Structure used in the manufacturing of goods." } } }, "auth_ref": [ "r106" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesNarrativeDetails", "http://inarimedical.com/role/CreditFacilityNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r313", "r314", "r315", "r316", "r399", "r438", "r496", "r578", "r648", "r650", "r658", "r673", "r674", "r733", "r735", "r737", "r738", "r740", "r757", "r758", "r778", "r787", "r800", "r810", "r811", "r815", "r816", "r830", "r1026", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r894" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r894" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r313", "r314", "r315", "r316", "r399", "r438", "r496", "r578", "r648", "r650", "r658", "r673", "r674", "r733", "r735", "r737", "r738", "r740", "r757", "r758", "r778", "r787", "r800", "r810", "r811", "r815", "r830", "r1026", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r913" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails", "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market mutual funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1029" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r921" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r895" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r176" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r176" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r98", "r99", "r100" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://inarimedical.com/role/IncomeTaxesDetails", "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income", "verboseLabel": "Net (loss) income", "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r89", "r100", "r128", "r144", "r162", "r165", "r169", "r184", "r192", "r194", "r195", "r196", "r197", "r198", "r201", "r202", "r211", "r271", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r462", "r472", "r490", "r512", "r634", "r703", "r723", "r724", "r843", "r1024" ] }, "nari_NetRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "NetRevenueMember", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Revenue", "label": "Net Revenue [Member]", "documentation": "Net Revenue" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Not Yet Adopted Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r894" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r858", "r868", "r878", "r902", "r910" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r885" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r884" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r902" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r921" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r921" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1126", "r1127", "r1128", "r1129" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashFlowSupplementalDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash investing and financing:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r93" ] }, "us-gaap_OperatingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenseMember", "presentation": [ "http://inarimedical.com/role/PropertyandEquipmentnetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expense [Member]", "documentation": "Primary financial statement caption encompassing expenses associated with normal operations." } } }, "auth_ref": [ "r18" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r131", "r775", "r961", "r962", "r963", "r964", "r965" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r528", "r818" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r524" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails", "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, current portion", "negatedLabel": "Less: lease liabilities - current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r524" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderOperatingLeasesLiabilitiesDetails", "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, noncurrent portion", "verboseLabel": "Lease liabilities - noncurrent portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r524" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofOperatingLeaseDisclosureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r525", "r531" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r523" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r950" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofOperatingLeaseDisclosureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r534", "r818" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofOperatingLeaseDisclosureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining term (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r533", "r818" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://inarimedical.com/role/Organization" ], "lang": { "en-us": { "role": { "terseLabel": "Organization", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r60", "r120", "r659", "r660" ] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on available-for-sale debt securities", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r157", "r158", "r160", "r635" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5", "r635" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://inarimedical.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss)", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r7", "r12", "r121", "r163", "r166", "r198" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liability", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r68" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r95" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r894" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r856", "r866", "r876", "r908" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r859", "r869", "r879", "r911" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r859", "r869", "r879", "r911" ] }, "nari_PatentInfringementLawsuitAgainstImperativeCareAndTruvicMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "PatentInfringementLawsuitAgainstImperativeCareAndTruvicMember", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patent Infringement Lawsuit Against Imperative Care and Truvic", "label": "Patent Infringement Lawsuit Against Imperative Care and Truvic [Member]", "documentation": "Patent Infringement Lawsuit Against Imperative Care and Truvic" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r883" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of taxes related to vested equity awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r173" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofTotalPurchasePriceConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r26", "r468" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r969" ] }, "us-gaap_PaymentsToAcquireOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherInvestments", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of other investments", "label": "Payments to Acquire Other Investments", "documentation": "Amount of cash outflow to acquire investments classified as other." } } }, "auth_ref": [ "r96" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r97" ] }, "us-gaap_PaymentsToDevelopSoftware": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToDevelopSoftware", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capitalized software development costs", "label": "Payments to Develop Software", "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization." } } }, "auth_ref": [ "r97" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r893" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r893" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://inarimedical.com/role/RetirementPlan" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r380", "r381", "r382", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r797" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r885" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r902" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r895" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r884" ] }, "nari_PercentageOfAnnualIncreaseInSharesReservedForIssuanceOnCapitalStockOutstandingAtYearEnd": { "xbrltype": "percentItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "PercentageOfAnnualIncreaseInSharesReservedForIssuanceOnCapitalStockOutstandingAtYearEnd", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of annual increase in shares reserved for issuance on capital stock outstanding at year end", "label": "Percentage Of Annual Increase In Shares Reserved For Issuance On Capital Stock Outstanding At Year End", "documentation": "Percentage of annual increase in shares reserved for issuance on capital stock outstanding at year end." } } }, "auth_ref": [] }, "nari_PercentageOfFeeOnAverageDailyStatedAmountOfOutstandingLetterOfCredit": { "xbrltype": "percentItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "PercentageOfFeeOnAverageDailyStatedAmountOfOutstandingLetterOfCredit", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of fee on average daily stated amount of outstanding letter of credit", "label": "Percentage Of Fee On Average Daily Stated Amount Of Outstanding Letter Of Credit", "documentation": "Percentage of fee on average daily stated amount of outstanding letter of credit." } } }, "auth_ref": [] }, "nari_PercentageOfFrontingFeeOnStatedAmountOfEachLetterOfCreditOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "PercentageOfFrontingFeeOnStatedAmountOfEachLetterOfCreditOutstanding", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of fronting fee on stated amount of each letter of credit outstanding", "label": "Percentage Of Fronting Fee On Stated Amount Of Each Letter Of Credit Outstanding", "documentation": "Percentage of fronting fee on stated amount of each letter of credit outstanding." } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Stock Units", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r886" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r930" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r885" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r71", "r356" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r71", "r683" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r71", "r356" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r71", "r683", "r701", "r1124", "r1125" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September\u00a030, 2024 and December\u00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r71", "r624", "r819" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r943" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of marketable securities", "label": "Proceeds from Maturities, Prepayments and Calls of Held-to-Maturity Securities", "documentation": "The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity." } } }, "auth_ref": [ "r25", "r969" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r6", "r17" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r6" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r231", "r579", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r764", "r788", "r829", "r830", "r831", "r833", "r834", "r1019", "r1020", "r1028", "r1091", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r231", "r579", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r764", "r788", "r829", "r830", "r831", "r833", "r834", "r1019", "r1020", "r1028", "r1091", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r144", "r162", "r165", "r175", "r184", "r192", "r198", "r201", "r202", "r271", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r462", "r472", "r473", "r476", "r477", "r490", "r512", "r617", "r633", "r667", "r703", "r723", "r724", "r804", "r805", "r844", "r946", "r1024" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r10", "r536" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://inarimedical.com/role/PropertyandEquipmentnet" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r105", "r136", "r139", "r140" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r106", "r148", "r631" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://inarimedical.com/role/PropertyandEquipmentnetNarrativeDetails", "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property Plant And Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r536" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets", "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r10", "r536", "r618", "r631", "r819" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://inarimedical.com/role/PropertyandEquipmentnetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r106", "r536" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit losses, net", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r172", "r277" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r883" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r883" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesNarrativeDetails", "http://inarimedical.com/role/CreditFacilityNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r313", "r314", "r315", "r316", "r381", "r399", "r428", "r429", "r430", "r438", "r496", "r553", "r562", "r578", "r648", "r650", "r658", "r673", "r674", "r733", "r735", "r737", "r738", "r740", "r757", "r758", "r778", "r787", "r800", "r810", "r811", "r815", "r816", "r830", "r837", "r1017", "r1026", "r1063", "r1082", "r1083", "r1084", "r1085", "r1086" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesNarrativeDetails", "http://inarimedical.com/role/CreditFacilityNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r313", "r314", "r315", "r316", "r381", "r399", "r428", "r429", "r430", "r438", "r496", "r553", "r562", "r578", "r648", "r650", "r658", "r673", "r674", "r733", "r735", "r737", "r738", "r740", "r757", "r758", "r778", "r787", "r800", "r810", "r811", "r815", "r816", "r830", "r837", "r1017", "r1026", "r1063", "r1082", "r1083", "r1084", "r1085", "r1086" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r851", "r861", "r871", "r903" ] }, "nari_ReimbursementMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "ReimbursementMilestonesMember", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reimbursement Milestones", "label": "Reimbursement Milestones [Member]", "documentation": "Reimbursement Milestones" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://inarimedical.com/role/RelatedPartyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r235", "r390", "r542", "r543", "r622", "r629", "r676", "r677", "r678", "r679", "r680", "r700", "r702", "r732" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://inarimedical.com/role/RelatedPartyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r186", "r187", "r542", "r543", "r544", "r545", "r622", "r629", "r676", "r677", "r678", "r679", "r680", "r700", "r702", "r732" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/RelatedPartyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development expenses incurred", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r58", "r542" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://inarimedical.com/role/RelatedPartyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r235", "r706", "r707", "r710" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://inarimedical.com/role/RelatedPartyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r235", "r390", "r542", "r543", "r622", "r629", "r676", "r677", "r678", "r679", "r680", "r700", "r702", "r732", "r1078" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://inarimedical.com/role/RelatedParty" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r539", "r540", "r541", "r543", "r546", "r664", "r665", "r666", "r708", "r709", "r710", "r729", "r731" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r439", "r762", "r776", "r1087" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofTotalCompensationCostforAllShareBasedPaymentArrangementsRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r852", "r862", "r872", "r904" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r853", "r863", "r873", "r905" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r860", "r870", "r880", "r912" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashFlowSupplementalDisclosuresDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashFlowSupplementalDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r942", "r951", "r1088", "r1090" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r147" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r942", "r951" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r74", "r112", "r627", "r655", "r657", "r662", "r684", "r819" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r143", "r189", "r190", "r191", "r193", "r198", "r200", "r202", "r272", "r273", "r302", "r452", "r453", "r459", "r460", "r461", "r463", "r471", "r472", "r480", "r482", "r483", "r485", "r488", "r521", "r522", "r652", "r654", "r668", "r1124" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r129", "r130", "r219", "r222", "r223", "r228", "r230", "r231", "r232", "r234", "r378", "r379", "r579" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r142", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r763" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Line of Credit", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashFlowSupplementalDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities arising from obtaining new right-of-use assets", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r532", "r818" ] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Risks and Uncertainties [Abstract]", "label": "Risks and Uncertainties [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r921" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r921" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://inarimedical.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r23", "r1068", "r1069" ] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "presentation": [ "http://inarimedical.com/role/BusinessCombinationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": [ "r1000", "r1004" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://inarimedical.com/role/NetIncomeLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Outstanding Potentially Dilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://inarimedical.com/role/BusinessCombinationNarrativeDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofFairValueAssignedtotheIntangibleAssetAcquiredDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofProFormaInformationDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofTotalPurchasePriceConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r47", "r50", "r466" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [ "http://inarimedical.com/role/BusinessCombinationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Purchase Price Consideration", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": [ "r47", "r50" ] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://inarimedical.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Provision for Income Taxes", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r1056" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://inarimedical.com/role/CreditFacilityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Costs Incurred Directly Related to Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r20", "r38", "r39", "r59", "r110", "r111", "r783", "r785", "r954", "r1071" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://inarimedical.com/role/NetIncomeLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Net (Loss) Income per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r959" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": [ "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofOutstandingPotentiallyDilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]", "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": [ "r29", "r31", "r206", "r210", "r212" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofTotalCompensationCostforAllShareBasedPaymentArrangementsRecognizedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Compensation Cost for All Share-Based Payment Arrangements Recognized", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://inarimedical.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1060", "r1061" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails", "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r289", "r296", "r299", "r300", "r301", "r580", "r762", "r781" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Identifiable Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r781", "r1005" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Amounts of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r780", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://inarimedical.com/role/InventoriesnetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories, Net", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r21", "r78", "r79", "r80" ] }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems", "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investment Income Reported Amounts by Category [Line Items]", "label": "Net Investment Income [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r636" ] }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investment Income Reported Amounts by Category [Table]", "label": "Investment Income [Table]", "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments." } } }, "auth_ref": [ "r91", "r92", "r94", "r636" ] }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of PSU Activity", "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units." } } }, "auth_ref": [ "r114" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of RSU Activity", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r114" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://inarimedical.com/role/PropertyandEquipmentnetNarrativeDetails", "http://inarimedical.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10", "r536" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://inarimedical.com/role/BusinessCombinationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Values of Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r118" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://inarimedical.com/role/RelatedPartyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r57", "r58", "r706", "r707", "r710" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r401", "r403", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r14", "r15", "r113" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Fair Value of Option Grant and ESPP", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r116" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://inarimedical.com/role/GoodwillandIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Future Annual Amortization of the Intangible Asset", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r781", "r1007" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r846" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r848" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r232", "r233", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r670", "r671", "r672", "r734", "r736", "r739", "r741", "r746", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r765", "r789", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r832", "r837", "r1028", "r1091", "r1095", "r1096", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r90" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofTotalCompensationCostforAllShareBasedPaymentArrangementsRecognizedDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "nari_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award cliff vesting period (in years)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Cliff Vesting Period", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Cliff Vesting Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r801" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cancelled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r422" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cancelled (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r422" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r420" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r420" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r417", "r418" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Awards", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period (in dollars per share)", "periodEndLabel": "Balance at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r417", "r418" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r421" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value of RSUs vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r424" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r421" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r429" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r428" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility - maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility - minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r430" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate - maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate- minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r401", "r403", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares available for issuance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Awards, Vested and exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r411" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Vested and exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r411" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r424" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cancelled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r415" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average fair value of options granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r423" ] }, "nari_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic Value", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]", "documentation": "Share based compensation arrangement by share based payment award options intrinsic value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period (in shares)", "periodEndLabel": "Balance at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r409", "r410" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period (in dollars per share)", "periodEndLabel": "Balance at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r409", "r410" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic Value, Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r426" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Awards, Vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r425" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r425" ] }, "nari_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life (in years)", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Life [Abstract]", "documentation": "Share based compensation arrangement by share based payment award options weighted average remaining contractual life." } } }, "auth_ref": [] }, "nari_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage": { "xbrltype": "percentItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payout percentage", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Payout Percentage", "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Payout Percentage" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r414" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cancelled (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r415" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Award Tranche One", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Three", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Two", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "nari_ShareBasedPaymentArrangementTrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "ShareBasedPaymentArrangementTrancheFourMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Four", "label": "Share-Based Payment Arrangement, Tranche Four [Member]", "documentation": "Share-Based Payment Arrangement, Tranche Four" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cliff vesting, percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r1030" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of award (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r802" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r427" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic Value, Vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r41" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r41" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r115" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r425" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of purchase price on fair market value of common stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsMember", "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-Term Investments", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": [ "r742", "r743", "r744", "r766" ] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r529", "r818" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r101", "r181" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "http://inarimedical.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r13", "r72", "r75", "r76", "r143", "r167", "r168", "r169", "r189", "r190", "r191", "r193", "r198", "r200", "r202", "r220", "r272", "r273", "r302", "r369", "r452", "r453", "r459", "r460", "r461", "r463", "r471", "r472", "r480", "r481", "r482", "r483", "r484", "r485", "r488", "r514", "r515", "r516", "r517", "r518", "r519", "r521", "r522", "r538", "r635", "r652", "r653", "r654", "r668", "r725" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r232", "r233", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r670", "r671", "r672", "r734", "r736", "r739", "r741", "r746", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r765", "r789", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r832", "r837", "r1028", "r1091", "r1095", "r1096", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r189", "r190", "r191", "r220", "r522", "r579", "r661", "r669", "r675", "r676", "r677", "r678", "r679", "r680", "r683", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r696", "r697", "r698", "r699", "r700", "r702", "r704", "r705", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r725", "r838" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r189", "r190", "r191", "r220", "r235", "r522", "r579", "r661", "r669", "r675", "r676", "r677", "r678", "r679", "r680", "r683", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r696", "r697", "r698", "r699", "r700", "r702", "r704", "r705", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r725", "r838" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r855", "r865", "r875", "r907" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockCompensationPlanMember", "presentation": [ "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofOutstandingPotentiallyDilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity awards", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": [ "r960" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued under Employee Stock Purchase Plan (in shares)", "verboseLabel": "Shares issued under employee stock purchase plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r13", "r71", "r72", "r112" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercised for common stock (in shares)", "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r13", "r71", "r72", "r112", "r414" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued under Employee Stock Purchase Plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r13", "r71", "r72", "r112" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercised for common stock", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r13", "r72", "r75", "r76", "r112" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets", "http://inarimedical.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://inarimedical.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r72", "r75", "r76", "r103", "r685", "r701", "r726", "r727", "r819", "r845", "r953", "r985", "r1067", "r1124" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://inarimedical.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r109", "r183", "r355", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r368", "r369", "r487", "r728", "r730", "r745" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashFlowSupplementalDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosures of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r901" ] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://inarimedical.com/role/BusinessCombinationScheduleofFairValueAssignedtotheIntangibleAssetAcquiredDetails", "http://inarimedical.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails", "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofEstimatedFutureAnnualAmortizationoftheIntangibleAssetDetails", "http://inarimedical.com/role/GoodwillandIntangibleAssetsScheduleofIdentifiableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed technology", "verboseLabel": "Developed technology", "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r19", "r999", "r1001", "r1002", "r1003", "r1004", "r1006", "r1009", "r1010" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r893" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r900" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r920" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r922" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://inarimedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails", "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r353", "r367", "r486", "r511", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r636", "r806", "r808", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r820", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r981", "r982", "r983", "r984", "r1059", "r1062", "r1063", "r1064", "r1065", "r1066" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r923" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r924" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r924" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r922" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r922" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r925" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r923" ] }, "nari_TwoThousandAndElevenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "TwoThousandAndElevenEquityIncentivePlanMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2011 Equity Incentive Plan", "label": "Two Thousand And Eleven Equity Incentive Plan [Member]", "documentation": "2011 equity incentive plan." } } }, "auth_ref": [] }, "nari_TwoThousandTwentyEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Employee Share Purchase Plan", "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]", "documentation": "Two thousand twenty employee stock purchase plan." } } }, "auth_ref": [] }, "nari_TwoThousandTwentyIncentiveAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "TwoThousandTwentyIncentiveAwardPlanMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofEstimatedFairValueofOptionGrantandESPPonDateofGrantDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofRSUandPSUActivityDetails", "http://inarimedical.com/role/EquityIncentivePlansScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Incentive Award Plan", "label": "Two Thousand Twenty Incentive Award Plan [Member]", "documentation": "Two thousand twenty incentive award plan." } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails", "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. government agencies", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r772", "r795", "r1089" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://inarimedical.com/role/CashEquivalentsandInvestmentsDetails", "http://inarimedical.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. treasury securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r772", "r795", "r797", "r806", "r1089" ] }, "us-gaap_UnbilledReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnbilledReceivablesCurrent", "crdr": "debit", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unbilled receivables", "label": "Unbilled Receivables, Current", "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r919" ] }, "nari_UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember", "presentation": [ "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested RSUs and PSUs", "label": "Unvested Restricted Stock Units and Performance Stock Units [Member]", "documentation": "Unvested Restricted Stock Units." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Management Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r32", "r33", "r34", "r134", "r135", "r137", "r138" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/CommitmentsandContingenciesScheduleofTotalLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r530", "r818" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://inarimedical.com/role/CreditFacilityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "nari_VenousThromboembolismVTEMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "VenousThromboembolismVTEMember", "presentation": [ "http://inarimedical.com/role/SummaryofSignificantAccountingPoliciesScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VTE", "label": "Venous Thromboembolism (\"VTE\") [Member]", "documentation": "Venous Thromboembolism (\"VTE\")" } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055" ] }, "nari_VestingOptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "VestingOptionAxis", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting, Option [Axis]", "label": "Vesting, Option [Axis]", "documentation": "Vesting, Option" } } }, "auth_ref": [] }, "nari_VestingOptionDomain": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "VestingOptionDomain", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting, Option [Domain]", "label": "Vesting, Option [Domain]", "documentation": "Vesting, Option [Domain]" } } }, "auth_ref": [] }, "nari_VestingOptionOneMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "VestingOptionOneMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting, Option One", "label": "Vesting, Option One [Member]", "documentation": "Vesting, Option One" } } }, "auth_ref": [] }, "nari_VestingOptionTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "VestingOptionTwoMember", "presentation": [ "http://inarimedical.com/role/EquityIncentivePlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting, Option Two", "label": "Vesting, Option Two [Member]", "documentation": "Vesting, Option Two" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r889" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average number of common shares outstanding - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r205", "r214" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares used to compute net (loss) income per share", "verboseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://inarimedical.com/role/NetIncomeLossPerShareScheduleofComputationofNetLossIncomeperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average number of common shares outstanding - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r204", "r214" ] }, "nari_WorkingCapitalAdjustmentAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://inarimedical.com/20240930", "localname": "WorkingCapitalAdjustmentAcquisitions", "crdr": "debit", "calculation": { "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inarimedical.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Working capital adjustment related to acquisition", "label": "Working Capital Adjustment, Acquisitions", "documentation": "Working Capital Adjustment, Acquisitions" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r887" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-13" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482943/710-10-55-7" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 98 0001531048-24-000060-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001531048-24-000060-xbrl.zip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end XML 99 nari-20240930_htm.xml IDEA: XBRL DOCUMENT 0001531048 2024-01-01 2024-09-30 0001531048 2024-10-24 0001531048 2024-09-30 0001531048 2023-12-31 0001531048 2024-07-01 2024-09-30 0001531048 2023-07-01 2023-09-30 0001531048 2023-01-01 2023-09-30 0001531048 us-gaap:CommonStockMember 2023-12-31 0001531048 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001531048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001531048 us-gaap:RetainedEarningsMember 2023-12-31 0001531048 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001531048 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001531048 2024-01-01 2024-03-31 0001531048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001531048 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001531048 us-gaap:CommonStockMember 2024-03-31 0001531048 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001531048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001531048 us-gaap:RetainedEarningsMember 2024-03-31 0001531048 2024-03-31 0001531048 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001531048 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001531048 2024-04-01 2024-06-30 0001531048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001531048 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001531048 us-gaap:CommonStockMember 2024-06-30 0001531048 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001531048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001531048 us-gaap:RetainedEarningsMember 2024-06-30 0001531048 2024-06-30 0001531048 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001531048 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001531048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001531048 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001531048 us-gaap:CommonStockMember 2024-09-30 0001531048 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001531048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001531048 us-gaap:RetainedEarningsMember 2024-09-30 0001531048 us-gaap:CommonStockMember 2022-12-31 0001531048 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001531048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001531048 us-gaap:RetainedEarningsMember 2022-12-31 0001531048 2022-12-31 0001531048 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001531048 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001531048 2023-01-01 2023-03-31 0001531048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001531048 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001531048 us-gaap:CommonStockMember 2023-03-31 0001531048 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001531048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001531048 us-gaap:RetainedEarningsMember 2023-03-31 0001531048 2023-03-31 0001531048 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001531048 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001531048 2023-04-01 2023-06-30 0001531048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001531048 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001531048 us-gaap:CommonStockMember 2023-06-30 0001531048 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001531048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001531048 us-gaap:RetainedEarningsMember 2023-06-30 0001531048 2023-06-30 0001531048 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001531048 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001531048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001531048 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001531048 us-gaap:CommonStockMember 2023-09-30 0001531048 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001531048 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001531048 us-gaap:RetainedEarningsMember 2023-09-30 0001531048 2023-09-30 0001531048 nari:VenousThromboembolismVTEMember 2024-07-01 2024-09-30 0001531048 nari:VenousThromboembolismVTEMember 2023-07-01 2023-09-30 0001531048 nari:VenousThromboembolismVTEMember 2024-01-01 2024-09-30 0001531048 nari:VenousThromboembolismVTEMember 2023-01-01 2023-09-30 0001531048 nari:EmergingTherapiesMember 2024-07-01 2024-09-30 0001531048 nari:EmergingTherapiesMember 2023-07-01 2023-09-30 0001531048 nari:EmergingTherapiesMember 2024-01-01 2024-09-30 0001531048 nari:EmergingTherapiesMember 2023-01-01 2023-09-30 0001531048 country:US 2024-07-01 2024-09-30 0001531048 country:US 2023-07-01 2023-09-30 0001531048 country:US 2024-01-01 2024-09-30 0001531048 country:US 2023-01-01 2023-09-30 0001531048 us-gaap:NonUsMember 2024-07-01 2024-09-30 0001531048 us-gaap:NonUsMember 2023-07-01 2023-09-30 0001531048 us-gaap:NonUsMember 2024-01-01 2024-09-30 0001531048 us-gaap:NonUsMember 2023-01-01 2023-09-30 0001531048 nari:LimFlowMember 2024-01-01 2024-09-30 0001531048 nari:LimFlowMember 2023-11-15 2023-11-15 0001531048 nari:LimFlowMember 2023-11-15 0001531048 nari:LimFlowMember nari:NetRevenueMember 2023-11-15 0001531048 nari:LimFlowMember nari:ReimbursementMilestonesMember 2023-11-15 0001531048 nari:LimFlowMember 2023-11-14 0001531048 nari:LimFlowMember 2023-01-01 2023-12-31 0001531048 nari:LimFlowMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-11-15 0001531048 nari:LimFlowMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-11-15 2023-11-15 0001531048 nari:LimFlowMember 2023-07-01 2023-09-30 0001531048 nari:LimFlowMember 2023-01-01 2023-09-30 0001531048 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001531048 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001531048 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001531048 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001531048 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001531048 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001531048 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001531048 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001531048 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001531048 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001531048 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001531048 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001531048 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001531048 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001531048 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001531048 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001531048 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001531048 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001531048 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001531048 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001531048 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001531048 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001531048 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001531048 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001531048 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001531048 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001531048 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001531048 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001531048 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember nari:CorporateDebtSecuritiesAndCommercialPaperMember 2023-12-31 0001531048 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember nari:CorporateDebtSecuritiesAndCommercialPaperMember 2023-12-31 0001531048 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember nari:CorporateDebtSecuritiesAndCommercialPaperMember 2023-12-31 0001531048 us-gaap:FairValueMeasurementsRecurringMember nari:CorporateDebtSecuritiesAndCommercialPaperMember 2023-12-31 0001531048 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001531048 us-gaap:CashAndCashEquivalentsMember 2024-09-30 0001531048 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001531048 us-gaap:ShortTermInvestmentsMember 2024-09-30 0001531048 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001531048 us-gaap:CashAndCashEquivalentsMember 2023-12-31 0001531048 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001531048 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001531048 us-gaap:ShortTermInvestmentsMember nari:CorporateDebtSecuritiesAndCommercialPaperMember 2023-12-31 0001531048 us-gaap:ShortTermInvestmentsMember 2023-12-31 0001531048 us-gaap:ManufacturingFacilityMember 2024-09-30 0001531048 us-gaap:ManufacturingFacilityMember 2023-12-31 0001531048 us-gaap:ComputerEquipmentMember 2024-09-30 0001531048 us-gaap:ComputerEquipmentMember 2023-12-31 0001531048 us-gaap:AssetUnderConstructionMember 2024-09-30 0001531048 us-gaap:AssetUnderConstructionMember 2023-12-31 0001531048 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001531048 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001531048 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001531048 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001531048 us-gaap:OperatingExpenseMember 2024-07-01 2024-09-30 0001531048 us-gaap:OperatingExpenseMember 2023-07-01 2023-09-30 0001531048 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0001531048 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001531048 us-gaap:OperatingExpenseMember 2023-01-01 2023-09-30 0001531048 us-gaap:OperatingExpenseMember 2024-01-01 2024-09-30 0001531048 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001531048 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001531048 us-gaap:TechnologyBasedIntangibleAssetsMember 2024-09-30 0001531048 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0001531048 srt:MaximumMember 2024-09-30 0001531048 2023-10-31 0001531048 nari:PatentInfringementLawsuitAgainstImperativeCareAndTruvicMember 2024-05-22 2024-05-22 0001531048 nari:PatentInfringementLawsuitAgainstImperativeCareAndTruvicMember 2024-07-09 2024-07-09 0001531048 us-gaap:RelatedPartyMember 2024-09-30 0001531048 us-gaap:RelatedPartyMember 2023-12-31 0001531048 us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2022-12-16 0001531048 us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:FederalFundsEffectiveSwapRateMember 2022-12-16 2022-12-16 0001531048 us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember nari:BloombergShortTermBankYieldIndexBSBYMember 2022-12-16 2022-12-16 0001531048 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:FederalFundsEffectiveSwapRateMember 2022-12-16 2022-12-16 0001531048 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:FederalFundsEffectiveSwapRateMember 2022-12-16 2022-12-16 0001531048 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember nari:BloombergShortTermBankYieldIndexBSBYMember 2022-12-16 2022-12-16 0001531048 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember nari:BloombergShortTermBankYieldIndexBSBYMember 2022-12-16 2022-12-16 0001531048 us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2022-12-16 2022-12-16 0001531048 us-gaap:LetterOfCreditMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2022-12-16 0001531048 us-gaap:LetterOfCreditMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2023-02-28 0001531048 us-gaap:LetterOfCreditMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2024-01-01 2024-09-30 0001531048 us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2023-11-01 0001531048 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2023-11-01 2023-11-01 0001531048 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2023-11-01 2023-11-01 0001531048 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember nari:BloombergShortTermBankYieldIndexBSBYMember 2023-11-01 2023-11-01 0001531048 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember nari:BloombergShortTermBankYieldIndexBSBYMember 2023-11-01 2023-11-01 0001531048 us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember nari:BloombergShortTermBankYieldIndexBSBYMember 2023-11-01 2023-11-01 0001531048 us-gaap:LetterOfCreditMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2023-11-01 0001531048 us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2024-09-30 0001531048 us-gaap:LetterOfCreditMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2024-09-30 0001531048 us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2024-01-01 2024-09-30 0001531048 us-gaap:RevolvingCreditFacilityMember nari:AmendedCreditAgreementMember nari:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2023-01-01 2023-12-31 0001531048 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0001531048 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0001531048 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-01 2024-03-31 0001531048 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-03-31 0001531048 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-03-31 0001531048 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 0001531048 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-04-01 2024-06-30 0001531048 us-gaap:AccumulatedTranslationAdjustmentMember 2024-04-01 2024-06-30 0001531048 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-06-30 0001531048 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-30 0001531048 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-07-01 2024-09-30 0001531048 us-gaap:AccumulatedTranslationAdjustmentMember 2024-07-01 2024-09-30 0001531048 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-09-30 0001531048 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0001531048 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0001531048 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001531048 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-03-31 0001531048 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0001531048 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-03-31 0001531048 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0001531048 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-04-01 2023-06-30 0001531048 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-01 2023-06-30 0001531048 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-06-30 0001531048 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0001531048 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-07-01 2023-09-30 0001531048 us-gaap:AccumulatedTranslationAdjustmentMember 2023-07-01 2023-09-30 0001531048 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-09-30 0001531048 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0001531048 srt:MaximumMember nari:TwoThousandTwentyIncentiveAwardPlanMember 2020-03-01 2020-03-31 0001531048 nari:TwoThousandTwentyIncentiveAwardPlanMember 2020-03-01 2020-03-31 0001531048 nari:TwoThousandTwentyIncentiveAwardPlanMember 2024-09-30 0001531048 nari:TwoThousandTwentyIncentiveAwardPlanMember 2024-01-01 0001531048 nari:TwoThousandAndElevenEquityIncentivePlanMember 2023-12-31 0001531048 nari:TwoThousandAndElevenEquityIncentivePlanMember 2023-01-01 2023-12-31 0001531048 nari:TwoThousandAndElevenEquityIncentivePlanMember 2024-01-01 2024-09-30 0001531048 nari:TwoThousandAndElevenEquityIncentivePlanMember 2024-09-30 0001531048 us-gaap:RestrictedStockUnitsRSUMember nari:TwoThousandTwentyIncentiveAwardPlanMember 2024-01-01 2024-09-30 0001531048 us-gaap:RestrictedStockUnitsRSUMember nari:TwoThousandTwentyIncentiveAwardPlanMember nari:ShareBasedPaymentArrangementTrancheFourMember nari:VestingOptionOneMember 2024-01-01 2024-09-30 0001531048 us-gaap:RestrictedStockUnitsRSUMember nari:TwoThousandTwentyIncentiveAwardPlanMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember nari:VestingOptionOneMember 2024-01-01 2024-09-30 0001531048 us-gaap:RestrictedStockUnitsRSUMember nari:TwoThousandTwentyIncentiveAwardPlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember nari:VestingOptionOneMember 2024-01-01 2024-09-30 0001531048 us-gaap:RestrictedStockUnitsRSUMember nari:TwoThousandTwentyIncentiveAwardPlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember nari:VestingOptionOneMember 2024-01-01 2024-09-30 0001531048 us-gaap:RestrictedStockUnitsRSUMember nari:VestingOptionTwoMember 2024-01-01 2024-09-30 0001531048 us-gaap:RestrictedStockUnitsRSUMember nari:TwoThousandTwentyIncentiveAwardPlanMember 2023-12-31 0001531048 us-gaap:RestrictedStockUnitsRSUMember nari:TwoThousandTwentyIncentiveAwardPlanMember 2024-09-30 0001531048 us-gaap:RestrictedStockUnitsRSUMember nari:TwoThousandTwentyIncentiveAwardPlanMember 2024-07-01 2024-09-30 0001531048 us-gaap:RestrictedStockUnitsRSUMember nari:TwoThousandTwentyIncentiveAwardPlanMember 2023-07-01 2023-09-30 0001531048 us-gaap:RestrictedStockUnitsRSUMember nari:TwoThousandTwentyIncentiveAwardPlanMember 2023-01-01 2023-09-30 0001531048 us-gaap:PerformanceSharesMember nari:TwoThousandTwentyIncentiveAwardPlanMember 2024-01-01 2024-09-30 0001531048 srt:MinimumMember us-gaap:PerformanceSharesMember nari:TwoThousandTwentyIncentiveAwardPlanMember 2024-09-30 0001531048 srt:MaximumMember us-gaap:PerformanceSharesMember nari:TwoThousandTwentyIncentiveAwardPlanMember 2024-09-30 0001531048 us-gaap:PerformanceSharesMember nari:TwoThousandTwentyIncentiveAwardPlanMember 2023-12-31 0001531048 us-gaap:PerformanceSharesMember nari:TwoThousandTwentyIncentiveAwardPlanMember 2024-09-30 0001531048 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001531048 us-gaap:EmployeeStockOptionMember nari:TwoThousandTwentyIncentiveAwardPlanMember 2024-01-01 2024-09-30 0001531048 us-gaap:EmployeeStockOptionMember nari:TwoThousandTwentyIncentiveAwardPlanMember 2023-01-01 2023-09-30 0001531048 nari:TwoThousandTwentyIncentiveAwardPlanMember 2023-12-31 0001531048 nari:TwoThousandTwentyIncentiveAwardPlanMember 2023-01-01 2023-12-31 0001531048 nari:TwoThousandTwentyIncentiveAwardPlanMember 2024-01-01 2024-09-30 0001531048 nari:TwoThousandTwentyEmployeeStockPurchasePlanMember 2020-05-01 2020-05-31 0001531048 nari:TwoThousandTwentyEmployeeStockPurchasePlanMember 2021-01-01 2021-01-01 0001531048 nari:TwoThousandTwentyEmployeeStockPurchasePlanMember 2024-01-01 2024-09-30 0001531048 nari:TwoThousandTwentyEmployeeStockPurchasePlanMember 2023-01-01 2023-09-30 0001531048 nari:TwoThousandTwentyEmployeeStockPurchasePlanMember us-gaap:CommonStockMember 2020-05-01 2024-09-30 0001531048 2024-07-01 2024-07-31 0001531048 2024-01-01 2024-01-31 0001531048 nari:TwoThousandTwentyEmployeeStockPurchasePlanMember 2024-09-30 0001531048 2024-01-01 0001531048 nari:EmployeeStockPurchasePlanMember 2024-07-01 2024-09-30 0001531048 nari:EmployeeStockPurchasePlanMember 2023-07-01 2023-09-30 0001531048 nari:EmployeeStockPurchasePlanMember 2024-01-01 2024-09-30 0001531048 nari:EmployeeStockPurchasePlanMember 2023-01-01 2023-09-30 0001531048 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001531048 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001531048 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001531048 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001531048 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0001531048 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001531048 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0001531048 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001531048 2021-01-01 2021-01-31 0001531048 2024-01-01 2024-01-01 0001531048 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001531048 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001531048 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001531048 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001531048 nari:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember 2024-07-01 2024-09-30 0001531048 nari:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember 2023-07-01 2023-09-30 0001531048 nari:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember 2024-01-01 2024-09-30 0001531048 nari:UnvestedRestrictedStockUnitsAndPerformanceStockUnitsMember 2023-01-01 2023-09-30 0001531048 us-gaap:EmployeeStockMember 2024-07-01 2024-09-30 0001531048 us-gaap:EmployeeStockMember 2023-07-01 2023-09-30 0001531048 us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001531048 us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0001531048 us-gaap:StockCompensationPlanMember 2024-07-01 2024-09-30 0001531048 us-gaap:StockCompensationPlanMember 2023-07-01 2023-09-30 0001531048 us-gaap:StockCompensationPlanMember 2024-01-01 2024-09-30 0001531048 us-gaap:StockCompensationPlanMember 2023-01-01 2023-09-30 shares iso4217:USD iso4217:USD shares pure nari:patent nari:letterOfCredit 0001531048 --12-31 2024 Q3 false 1 http://fasb.org/us-gaap/2024#QualifiedPlanMember 10-Q true 2024-09-30 false 001-39293 Inari Medical, Inc. DE 45-2902923 6001 Oak Canyon Suite 100 Irvine CA 92618 877 923-4747 Common stock, $0.001 par value per share NARI NASDAQ Yes Yes Large Accelerated Filer false false false 58544158 41141000 38597000 67000 611000 70397000 76855000 84403000 70119000 55210000 42900000 12168000 6481000 263386000 235563000 24098000 20929000 48301000 48407000 213345000 214335000 143808000 150884000 4301000 4117000 697239000 674235000 15523000 10577000 54797000 48706000 76881000 15364000 1579000 1692000 148780000 76339000 31145000 30355000 36748000 36231000 45805000 66400000 262478000 209325000 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 300000000 300000000 58435576 58435576 57762414 57762414 58000 58000 543961000 504453000 13145000 8885000 -122403000 -48486000 434761000 464910000 697239000 674235000 153390000 126366000 442404000 361538000 19846000 14477000 58732000 42062000 133544000 111889000 383672000 319476000 29431000 21492000 81216000 64641000 108271000 85603000 325479000 256889000 6578000 0 18609000 0 2504000 0 7414000 0 328000 2681000 4143000 2681000 147112000 109776000 436861000 324211000 -13568000 2113000 -53189000 -4735000 1104000 4202000 3371000 12899000 78000 43000 233000 127000 -130000 -682000 -130000 -617000 896000 3477000 3008000 12155000 -12672000 5590000 -50181000 7420000 5695000 2428000 23736000 4391000 -18367000 3162000 -73917000 3029000 13918000 -68000 4200000 -138000 64000 91000 60000 -1869000 13982000 23000 4260000 -2007000 -4385000 3185000 -69657000 1022000 -0.31 0.06 -1.27 0.05 -0.31 0.05 -1.27 0.05 58366364 57384884 58149296 56478317 58366364 58588452 58149296 58495921 57762414 58000 504453000 8885000 -48486000 464910000 81952 145000 145000 82816 3983000 3983000 73963 -3113000 -3113000 12870000 12870000 -7363000 -7363000 -24202000 -24202000 58001145 58000 518338000 1522000 -72688000 447230000 47750 98000 98000 117414 -2851000 -2851000 13039000 13039000 -2359000 -2359000 -31348000 -31348000 58166309 58000 528624000 -837000 -104036000 423809000 41104 117000 117000 133430 5281000 5281000 94733 -3012000 -3012000 12951000 12951000 13982000 13982000 -18367000 -18367000 58435576 58000 543961000 13145000 -122403000 434761000 54021656 54000 462949000 849000 -46850000 417002000 209966 226000 226000 86051 4172000 4172000 2766043 3000 -1932000 -1929000 10339000 10339000 -856000 -856000 -2218000 -2218000 57083716 57000 475754000 -7000 -49068000 426736000 81712 214000 214000 101027 -2569000 -2569000 10353000 10353000 -1174000 -1174000 2085000 2085000 57266455 57000 483752000 -1181000 -46983000 435645000 43547 107000 107000 118494 1000 5748000 5749000 77966 -2388000 -2388000 9844000 9844000 23000 23000 3162000 3162000 57506462 58000 497063000 -1158000 -43821000 452142000 -73917000 3029000 11879000 4186000 65000 30000 2858000 3099000 38860000 30536000 0 565000 622000 526000 -436000 -26000 3789000 0 1707000 11407000 18609000 0 15107000 11566000 12378000 7797000 3278000 -4294000 4927000 2436000 28356000 7218000 -1797000 -1031000 -280000 -458000 1937000 23686000 7899000 3801000 91085000 394496000 96708000 400560000 0 565000 3722000 0 2298000 0 -852000 1698000 9264000 9920000 360000 547000 8976000 6886000 648000 3581000 267000 -5000 2000000 28960000 39208000 60222000 41208000 89182000 ORGANIZATION<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inari Medical, Inc. (the “Company”) was incorporated in Delaware in July 2011 and is headquartered in Irvine, California. The Company purpose builds and markets a variety of medical products, including minimally invasive, novel, catheter-based mechanical thrombectomy systems for the unique characteristics of specific disease states.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2023, the Company acquired LimFlow S.A. (“LimFlow”), a medical device company focused on limb salvage for patients with chronic limb-threatening ischemia (“CLTI”). LimFlow focuses on transforming the treatment of CLTI, an advanced stage of peripheral artery disease that is associated with increased mortality, risk of amputation and impaired quality of life.</span></div> SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and include the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to prior period financial statements to conform to classifications used in the current period.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed consolidated balance sheet as of September 30, 2024 and the condensed consolidated statements of operations and comprehensive income (loss), stockholders’ equity, and cash flows for the three and nine months ended September 30, 2024 and 2023 are unaudited. The consolidated balance sheet as of December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed consolidated financial position as of September 30, 2024 and its consolidated results of operations and cash flows for the three and nine months ended September 30, 2024 and 2023. The financial data and the other financial information disclosed in the notes to the condensed consolidated financial statements related to the three and nine months ended September 30, 2024 and 2023 are also unaudited. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. These interim condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management Estimates</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements may include, but are not limited to, contingent consideration liability, collectability of receivables, recoverability of long-lived assets, valuation of inventory, operating lease right-of-use (“ROU”) assets and liabilities, other investments, fair value of stock options, recoverability of net deferred tax assets and related valuation allowance, and certain accruals. Estimates are based on historical experience and on various assumptions that the Company believes are reasonable under current circumstances. Actual results could differ materially from those estimates. Management periodically evaluates such estimates and assumptions, and they are adjusted prospectively based upon such periodic evaluation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its products primarily to hospitals in the United States through its direct sales force and also sells its products directly and through distributors in select international markets. The Company recognizes revenue for arrangements where the Company has satisfied its performance obligation of shipping or delivering the product. For sales where the Company’s sales representatives hand-deliver products directly to the hospitals, control of the products transfers to the customers upon such hand-delivery. For sales where products are shipped, control of the products transfers either upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. Revenue from product sales is comprised of product revenue, net of product returns, discounts, administrative fees and sales rebates. The Company has elected to account for shipping and handling activities that occur after the customer has obtained control as a fulfillment activity, and not a separate performance obligation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company has revenue arrangements that consist of a single performance obligation, the shipping or delivery of the Company’s products. The satisfaction of this performance obligation occurs with the transfer of control of the Company’s product to its customers, either upon shipment or delivery of the product.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of revenue recognized is based on the transaction price, which represents the invoiced amount, net of discounts, administrative fees and sales rebates, where applicable. The Company provides a standard 30-day unconditional right of return period. The Company establishes estimated provisions for returns at the time of sale based on historical experience. Historically, the actual product returns have been insignificant to the Company’s condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024 and December 31, 2023, the Company recorded $1.2 million of unbilled receivables, and $1.9 million and $1.3 million, respectively, of allowance for credit losses, which are included in accounts receivable, net, in the accompanying condensed consolidated balance sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue between Venous Thromboembolism (“VTE”) and Emerging Therapies. VTE comprises revenue from the sale of the Company’s solutions addressing deep vein thrombosis and pulmonary embolism. Emerging Therapies comprises revenue from the sale of the Company’s solutions addressing chronic venous disease, CLTI, acute limb ischemia and dialysis access management. Revenue from VTE and Emerging Therapies is as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VTE</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145,346 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121,460 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">420,213 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">349,604 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging Therapies</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,934 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153,390 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,366 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">442,404 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">361,538 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the Company's products by geographic area, based on the location where title transfers, is as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141,854</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,825</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">411,321</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">345,473</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,536</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,541</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,083</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,065</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153,390 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,366</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">442,404</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">361,538</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers payment terms to its customers of less than three months and these terms do not include a significant financing component. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to cost of goods sold.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with product sales include commissions which are recorded in selling, general and administrative (“SG&amp;A”) expenses. The Company applies the practical expedient and recognizes commissions as an expense when incurred because the amortization period is less than one year.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Investments</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has strategic investments in certain privately held companies, with no readily determinable fair value. The Company elected the measurement alternative under which it measures these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments. The Company will monitor the information that becomes available from time to time and adjust the carrying values of these investments if there are identified events or changes in circumstances that have a significant adverse effect on the fair values or if there are observable changes in fair value. Impairment loss, which is generally the difference between the carrying value and the fair value of the investment, is recorded in other income (expense) in the consolidated statements of operations and comprehensive income (loss). As of September 30, 2024 and December 31, 2023, the Company’s equity investments were $1.5 million and were included in deposits and other assets on the condensed consolidated balance sheets. Additionally, during the three and nine months ended September 30, 2023, the Company recorded an impairment loss of $0.6 million in other income (expense) within the condensed consolidated statements of operations and comprehensive income (loss). There was no impairment recorded during the three and nine months ended September 30, 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, there were no changes to the Company’s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Not Yet Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting, Topic 280, which requires enhanced disclosures primarily around segment expenses for all public entities, including public entities with a single reportable segment. On an annual and interim basis, entities are required to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of the new standard and does not expect there to be a material impact on its consolidated financial statements and related disclosures upon adoption.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, FASB issued ASU 2023-09, Income Tax, Topic 740, which requires public companies to disclose specific categories in the rate reconciliation, disaggregate information related to income taxes paid, income or loss from operations before income tax expense or benefit, and income tax expense or benefit from operations. The ASU is effective for annual fiscal years beginning after December 15, 2024, with early adoption permitted. Amendments are applicable on a prospective basis with retrospective application permitted. The Company is currently evaluating the impact of the new standard on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Cash Flow Information</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information includes the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:105%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:105%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">7,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Cash paid for interest</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">168 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">98 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Noncash investing and financing:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Lease liabilities arising from obtaining new right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2,447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of cash, cash equivalents and restricted cash:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,141 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89,182 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash as shown in the statement of cash flows</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,208 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89,182 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and include the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Certain reclassifications have been made to prior period financial statements to conform to classifications used in the current period.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed consolidated balance sheet as of September 30, 2024 and the condensed consolidated statements of operations and comprehensive income (loss), stockholders’ equity, and cash flows for the three and nine months ended September 30, 2024 and 2023 are unaudited. The consolidated balance sheet as of December 31, 2023 included herein was derived from the audited consolidated financial statements as of that date. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed consolidated financial position as of September 30, 2024 and its consolidated results of operations and cash flows for the three and nine months ended September 30, 2024 and 2023. The financial data and the other financial information disclosed in the notes to the condensed consolidated financial statements related to the three and nine months ended September 30, 2024 and 2023 are also unaudited. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. These interim condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023.</span></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management Estimates</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements may include, but are not limited to, contingent consideration liability, collectability of receivables, recoverability of long-lived assets, valuation of inventory, operating lease right-of-use (“ROU”) assets and liabilities, other investments, fair value of stock options, recoverability of net deferred tax assets and related valuation allowance, and certain accruals. Estimates are based on historical experience and on various assumptions that the Company believes are reasonable under current circumstances. Actual results could differ materially from those estimates. Management periodically evaluates such estimates and assumptions, and they are adjusted prospectively based upon such periodic evaluation.</span></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its products primarily to hospitals in the United States through its direct sales force and also sells its products directly and through distributors in select international markets. The Company recognizes revenue for arrangements where the Company has satisfied its performance obligation of shipping or delivering the product. For sales where the Company’s sales representatives hand-deliver products directly to the hospitals, control of the products transfers to the customers upon such hand-delivery. For sales where products are shipped, control of the products transfers either upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. Revenue from product sales is comprised of product revenue, net of product returns, discounts, administrative fees and sales rebates. The Company has elected to account for shipping and handling activities that occur after the customer has obtained control as a fulfillment activity, and not a separate performance obligation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company has revenue arrangements that consist of a single performance obligation, the shipping or delivery of the Company’s products. The satisfaction of this performance obligation occurs with the transfer of control of the Company’s product to its customers, either upon shipment or delivery of the product.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of revenue recognized is based on the transaction price, which represents the invoiced amount, net of discounts, administrative fees and sales rebates, where applicable. The Company provides a standard 30-day unconditional right of return period. The Company establishes estimated provisions for returns at the time of sale based on historical experience. Historically, the actual product returns have been insignificant to the Company’s condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024 and December 31, 2023, the Company recorded $1.2 million of unbilled receivables, and $1.9 million and $1.3 million, respectively, of allowance for credit losses, which are included in accounts receivable, net, in the accompanying condensed consolidated balance sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue between Venous Thromboembolism (“VTE”) and Emerging Therapies. VTE comprises revenue from the sale of the Company’s solutions addressing deep vein thrombosis and pulmonary embolism. Emerging Therapies comprises revenue from the sale of the Company’s solutions addressing chronic venous disease, CLTI, acute limb ischemia and dialysis access management. Revenue from VTE and Emerging Therapies is as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VTE</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145,346 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121,460 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">420,213 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">349,604 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging Therapies</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,934 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153,390 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,366 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">442,404 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">361,538 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the Company's products by geographic area, based on the location where title transfers, is as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141,854</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,825</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">411,321</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">345,473</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,536</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,541</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,083</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,065</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153,390 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,366</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">442,404</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">361,538</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers payment terms to its customers of less than three months and these terms do not include a significant financing component. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to cost of goods sold.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with product sales include commissions which are recorded in selling, general and administrative (“SG&amp;A”) expenses. The Company applies the practical expedient and recognizes commissions as an expense when incurred because the amortization period is less than one year.</span></div> 1200000 1200000 1900000 1300000 Revenue from VTE and Emerging Therapies is as follows (in thousands):<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VTE</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145,346 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121,460 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">420,213 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">349,604 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging Therapies</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,934 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153,390 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,366 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">442,404 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">361,538 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the Company's products by geographic area, based on the location where title transfers, is as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141,854</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119,825</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">411,321</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">345,473</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,536</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,541</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,083</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,065</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153,390 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,366</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">442,404</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">361,538</span></td></tr></table></div> 145346000 121460000 420213000 349604000 8044000 4906000 22191000 11934000 153390000 126366000 442404000 361538000 141854000 119825000 411321000 345473000 11536000 6541000 31083000 16065000 153390000 126366000 442404000 361538000 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Investments</span></div>The Company has strategic investments in certain privately held companies, with no readily determinable fair value. The Company elected the measurement alternative under which it measures these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments. The Company will monitor the information that becomes available from time to time and adjust the carrying values of these investments if there are identified events or changes in circumstances that have a significant adverse effect on the fair values or if there are observable changes in fair value. Impairment loss, which is generally the difference between the carrying value and the fair value of the investment, is recorded in other income (expense) in the consolidated statements of operations and comprehensive income (loss). 1500000 1500000 600000 600000 0 0 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Not Yet Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting, Topic 280, which requires enhanced disclosures primarily around segment expenses for all public entities, including public entities with a single reportable segment. On an annual and interim basis, entities are required to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of the new standard and does not expect there to be a material impact on its consolidated financial statements and related disclosures upon adoption.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, FASB issued ASU 2023-09, Income Tax, Topic 740, which requires public companies to disclose specific categories in the rate reconciliation, disaggregate information related to income taxes paid, income or loss from operations before income tax expense or benefit, and income tax expense or benefit from operations. The ASU is effective for annual fiscal years beginning after December 15, 2024, with early adoption permitted. Amendments are applicable on a prospective basis with retrospective application permitted. The Company is currently evaluating the impact of the new standard on its consolidated financial statements and related disclosures.</span></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information includes the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:105%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:105%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">7,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Cash paid for interest</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">168 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">98 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Noncash investing and financing:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Lease liabilities arising from obtaining new right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2,447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of cash, cash equivalents and restricted cash:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,141 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89,182 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash as shown in the statement of cash flows</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,208 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89,182 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7371000 3562000 168000 98000 2447000 1030000 41141000 89182000 67000 0 41208000 89182000 BUSINESS COMBINATION<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of LimFlow S.A.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2023, the Company completed its acquisition of LimFlow, a medical device company focused on limb salvage for patients with CLTI. As a result of the acquisition, LimFlow’s stockholders received as consideration (i) cash, and (ii) contingent consideration related to certain commercial and reimbursement milestones. The results of operations of LimFlow have been included in the condensed consolidated financial statements from the date of the acquisition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2024, the Company recorded an adjustment related to the finalization of the working capital, which reduced the consideration transferred and the acquisition date fair value of goodwill by $3.7 million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Price</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price as of the date of the acquisition consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of November 15, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">238,279 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of previously held investment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,235 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total purchase price</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">314,445 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LimFlow stockholders can achieve up to $165.0 million of additional contingent consideration if certain commercial and reimbursement milestones are achieved, as outlined under the Contingent Payments section of the share purchase agreement with LimFlow. Such payments include (i) up to $140.0 million based on net revenue generated from the sale of the LimFlow System for the years 2024 through 2026 and (ii) up to $25.0 million based on the achievement of certain reimbursement milestones related to the LimFlow System.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition-date fair value of the contingent consideration was measured using a Monte Carlo simulation which represents Level 3 measurements because they are supported by little or no market activity and reflect the Company’s assumptions in measuring fair value. Estimates and assumptions used in the fair value assessment included forecasted revenues for LimFlow, revenue risk premium, revenue volatility, operational leverage ratio, counterparty credit spread, and weighted average cost of capital. The Company has determined that the range of the potential payments on such contingencies is $65.9 million to $165.0 million. The fair value of the contingent consideration was $65.9 million as of the acquisition date. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i440c9ae1a86443cb891026d9174f9d63_46" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4. Fair Value Measurements</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Previously Held Investment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the acquisition, the Company held an investment in LimFlow, which represented approximately 3.7% of LimFlow's outstanding equity, and was recorded at cost minus impairment. Authoritative guidance on accounting for business combinations requires that an acquirer remeasure its previously held equity investment in the acquiree at its acquisition-date fair value and recognize the resulting gain or loss in earnings. In connection with acquiring the remaining 96.3% equity interest of LimFlow, the Company remeasured its previously held equity investment to its fair value, as of the date of acquisition, based on the fair value of total consideration transferred. Estimates and assumptions used in the remeasurement represent a Level 3 measurement because they are supported by little or no market activity and reflect the Company’s assumptions in measuring the fair value. As a result of the remeasurement, the Company valued its previously held equity investment in LimFlow at $10.2 million and recognized a gain of $3.5 million, included in other income (expense) in the consolidated statements of operations and comprehensive income (loss) during the year ended December 31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction costs associated with the acquisition of LimFlow consisted primarily of legal and financial advisory fees of approximately $8.7 million in addition to $1.7 million of severance and integration related costs, which were expensed as incurred as SG&amp;A expense during the year ended December 31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price allocation for the LimFlow acquisition was finalized as of September 30, 2024, and there were no measurement period adjustments recorded. The final allocation of fair value of assets acquired and liabilities assumed were (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of November 15, 2023 </span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,582 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,635 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">204,078 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current and noncurrent assets</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,155 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liability</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(36,500)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current and noncurrent liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets acquired</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">314,445 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value assigned to the intangible asset acquired was as follows (in thousands, except for estimated useful life which is in years):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful life</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,000 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 years</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value assigned to identifiable intangible asset, the developed technology, acquired as part of the LimFlow acquisition, was estimated using the multi-period excess earnings method. Under this method, an intangible asset’s fair value is equal to the present value of future economic benefits to be derived from ownership of the asset. The estimated fair value was developed by discounting future net cash flows to their present value at market-based rates of return. Such assumptions included forecasted revenues, cost of sales and operating expenses, technology obsolescence, and weighted average cost of capital. The useful life of the developed technology for amortization purposes was determined by considering the period of expected cash flows used to measure the fair values of the intangible asset adjusted as appropriate for entity-specific factors including competitive, economic and other factors that may limit the useful life. The developed technology asset will be amortized on a straight-line basis over its estimated useful life.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Pro Forma Financial Information</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information summarizes the combined results of operations of the Company and LimFlow as if the companies had been combined as of the beginning of fiscal year 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,757 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">362,848 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,452)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved had the acquisition been completed at the beginning of the fiscal year ended December 31, 2023. In addition, the unaudited pro forma financial information is not a projection of future results of operations of the combined company nor does it reflect the expected realization of any synergies or cost savings associated with the acquisition. The unaudited pro forma financial information includes adjustments to reflect the elimination of intercompany transactions, incremental amortization of the identifiable intangible asset and elimination of the remeasurement the Company’s previously held investment in LimFlow.</span></div> -3700000 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price as of the date of the acquisition consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of November 15, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">238,279 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of previously held investment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,235 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total purchase price</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">314,445 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 238279000 65931000 10235000 314445000 165000000 140000000 25000000 65900000 165000000 65900000 0.037 0.963 10200000 3500000 8700000 1700000 The final allocation of fair value of assets acquired and liabilities assumed were (in thousands):<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of November 15, 2023 </span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,582 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,635 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">204,078 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current and noncurrent assets</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,155 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liability</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(36,500)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current and noncurrent liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets acquired</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">314,445 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1582000 919000 2635000 266000 204078000 146000000 2155000 2509000 36500000 4181000 314445000 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value assigned to the intangible asset acquired was as follows (in thousands, except for estimated useful life which is in years):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful life</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,000 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 years</span></td></tr></table></div> 146000000 P15Y <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information summarizes the combined results of operations of the Company and LimFlow as if the companies had been combined as of the beginning of fiscal year 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,757 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">362,848 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,452)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 126757000 362848000 -6245000 -28452000 FAIR VALUE MEASUREMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. As of September 30, 2024, all of the Company's investments in debt securities had maturities of less than 12 months and were classified as short-term investments on the condensed consolidated balance sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of September 30, 2024 and December 31, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market mutual funds</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in short-term investments</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,397 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,397 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,685 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,685 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Liability</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial liabilities</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,540 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,540 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market mutual funds</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,238 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,238 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities and commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,932 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,932 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in short-term investments</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,685 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,170 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,855 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,438 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,170 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,608 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Liability</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial liabilities</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,931 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,931 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Levels 1, 2 or 3 for the periods presented.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent payments are related to the acquisition of LimFlow and consist of commercial and reimbursement milestones, which were valued using a Monte Carlo simulation and probability weighted discounted cash flow analysis, respectively, and represent Level 3 measurements because they are based upon significant unobservable inputs such as forecasted revenues of LimFlow, revenue risk premium, revenue volatility, operational leverage ratio, credit risk, weighted average cost of capital, and probability assumptions in achieving certain milestones. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the estimated fair value of the Company’s contingent consideration liabilities (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contingent Consideration Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2023</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,931 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in estimated fair value</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of September 30, 2024</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,540 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration was $84.5 million as of September 30, 2024, of which $39.2 million was recorded within accrued expenses and other current liabilities and $45.3 million was recorded within other long-term liabilities, and $65.9 million as of December 31, 2023, which was recorded within other long-term liabilities. The change in estimated fair value of contingent consideration was recorded in operating expenses within the condensed consolidated statements of operations and comprehensive income (loss).</span></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of September 30, 2024 and December 31, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market mutual funds</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in short-term investments</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,397 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,397 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,685 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,685 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Liability</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial liabilities</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,540 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,540 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market mutual funds</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,238 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,238 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities and commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,932 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,932 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in short-term investments</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,685 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,170 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,855 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,438 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,170 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,608 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Liability</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial liabilities</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,931 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,931 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7288000 0 0 7288000 7288000 0 0 7288000 70397000 0 0 70397000 70397000 0 0 70397000 77685000 0 0 77685000 0 0 84540000 84540000 0 0 84540000 84540000 2753000 0 0 2753000 2753000 0 0 2753000 41685000 0 0 41685000 0 26238000 0 26238000 0 8932000 0 8932000 41685000 35170000 0 76855000 44438000 35170000 0 79608000 0 0 65931000 65931000 0 0 65931000 65931000 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the estimated fair value of the Company’s contingent consideration liabilities (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contingent Consideration Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2023</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,931 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in estimated fair value</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of September 30, 2024</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,540 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 65931000 18609000 84540000 84500000 39200000 45300000 65900000 CASH EQUIVALENTS AND INVESTMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company’s cash equivalents and investments in debt securities as of September 30, 2024 and December 31, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market mutual funds</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in short-term investments</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,346 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,397 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,634 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,685 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market mutual funds</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,248 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,238 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities and commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,932 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in short-term investments</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,855 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,855 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,608 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,608 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly reviews any changes to the rating of its debt securities and reasonably monitors the surrounding economic conditions to assess the risk of expected credit losses. As of September 30, 2024, the risk of expected credit losses was not significant.</span></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company’s cash equivalents and investments in debt securities as of September 30, 2024 and December 31, 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market mutual funds</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in short-term investments</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,346 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,397 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,634 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,685 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market mutual funds</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,753 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,248 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,238 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities and commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,932 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total included in short-term investments</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,855 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,855 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,608 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,608 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7288000 0 0 7288000 7288000 0 0 7288000 70346000 51000 0 70397000 70346000 51000 0 70397000 77634000 51000 0 77685000 2753000 0 0 2753000 2753000 0 0 2753000 41672000 13000 0 41685000 26248000 0 10000 26238000 8935000 0 3000 8932000 76855000 13000 13000 76855000 79608000 13000 13000 79608000 INVENTORIES, NET<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net of reserves, consist of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,983 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,310 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,048 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,260 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,210 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,900 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net of reserves, consist of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,983 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,310 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,048 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,260 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,210 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,900 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 21983000 14310000 6179000 5330000 27048000 23260000 55210000 42900000 PROPERTY AND EQUIPMENT, NET<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing equipment</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,527 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,653 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,641 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets in progress</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,902 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,135 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,531 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,682 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,215 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,602 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,117)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,673)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,098 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,929 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense of $1.1 million was included in operating expenses and $0.3 million was included in cost of goods sold for the three months ended September 30, 2024 and 2023, respectively. Depreciation expense of $3.4 million was included in operating expenses for the nine months ended September 30, 2024 and 2023, and $1.0 million and $0.8 million was included in cost of goods sold for the nine months ended September 30, 2024 and 2023, respectively.</span></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing equipment</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,527 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,653 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,641 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets in progress</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,902 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,135 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,531 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,682 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,215 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,602 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,117)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,673)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,098 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,929 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 18527000 16653000 6671000 5641000 5902000 3135000 4584000 4491000 4531000 4682000 40215000 34602000 16117000 13673000 24098000 20929000 1100000 1100000 300000 300000 3400000 3400000 1000000.0 800000 GOODWILL AND INTANGIBLE ASSETS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in carrying amount of goodwill for the nine months ended September 30, 2024 were as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2023</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214,335 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital adjustment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,722)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,732 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of September 30, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213,345 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The working capital adjustment relates to the acquisition of LimFlow. See </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i440c9ae1a86443cb891026d9174f9d63_43" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3. Business Combination</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets consist of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intangible Assets, Net</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152,716 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,908)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143,808 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152,716 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,908)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intangible Assets, Net</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,649 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,256)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149,393 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized software</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets, net</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152,140 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,256)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,884 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">_____________</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) The useful life of the capitalized software was not determined as of December 31, 2023 as the asset was not put into service. No amortization expense has been recorded related to the capitalized software during the three and nine months ended September 30, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount and the accumulated amortization of the developed technology asset is subject to foreign currency translation effects. During the three and nine months ended September 30, 2024, $2.5 million and $7.4 million, respectively, of amortization expense was recorded in operating expenses within the condensed consolidated statements of operations and comprehensive income (loss) related to the developed technology asset. There were no intangible assets and no amortization recorded for the three and nine months ended September 30, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2024, the Company recorded a non-cash impairment of $3.8 million related to previously capitalized software development costs that reduced the carrying value of such asset to zero. The impairment charge was recorded in research and development expenses within the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future annual amortization of the intangible assets in service is as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2024</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,545 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,181 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,181 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143,808 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in carrying amount of goodwill for the nine months ended September 30, 2024 were as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2023</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214,335 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital adjustment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,722)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,732 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of September 30, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213,345 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 214335000 -3722000 2732000 213345000 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets consist of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intangible Assets, Net</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152,716 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,908)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143,808 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152,716 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,908)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intangible Assets, Net</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,649 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,256)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149,393 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized software</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets, net</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152,140 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,256)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,884 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">_____________</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) The useful life of the capitalized software was not determined as of December 31, 2023 as the asset was not put into service. No amortization expense has been recorded related to the capitalized software during the three and nine months ended September 30, 2023.</span></div> 152716000 8908000 143808000 152716000 8908000 143808000 150649000 1256000 149393000 1491000 0 1491000 152140000 1256000 150884000 0 0 2500000 7400000 0 0 0 3800000 0 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future annual amortization of the intangible assets in service is as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2024</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,545 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,181 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,181 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143,808 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2545000 10181000 10181000 10181000 10181000 100539000 143808000 COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for facilities and certain equipment. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. Lease expense for operating leases is recognized on a straight-line basis over the lease term. For lease agreements, other than long-term real estate leases, the Company combines lease and non-lease components. The variable lease payments primarily relate to common area maintenance, property taxes, and insurance. The operating leases for facilities expire at various dates through July 2041 and some contain renewal options, the longest of which is for five years. The ROU asset and lease liability includes renewal options if the Company is reasonably certain to exercise such renewal options.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest rate the Company would incur to borrow on a collateralized basis, considering factors such as length of lease term.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the weighted average remaining lease term and discount rate:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining term (in years)</span></div></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.1</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating leases were as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.005%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,048 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">866 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,877 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,564 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.005%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,385 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,137 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,929 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,456 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">746 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">809 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,617 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,561 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,816 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,350 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under operating leases liabilities as of September 30, 2024 are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ending December 31:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2024</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">858 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,512 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,396 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,504 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,724 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: lease liabilities - current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities - noncurrent portion</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,145 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed a ten-year lease in Costa Rica for its second manufacturing facility in October 2023, with total undiscounted contractual payments of the lease of approximately $7.2 million, which is expected to commence in the fourth quarter of 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not been subject to any claims or required to defend any action related to its indemnification obligations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s amended and restated certificate of incorporation contains provisions limiting the liability of directors, and its amended and restated bylaws provide that the Company will indemnify each of its directors to the fullest extent permitted under Delaware law. The Company’s amended and restated certificate of incorporation and amended and restated bylaws also provide its board of directors with discretion to indemnify its officers and employees when determined appropriate by the board. In addition, the Company has entered and expects to continue to enter into agreements to indemnify its directors and executive officers.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various claims and proceedings arising in the ordinary course of its business. Management does not believe that any existing claims and proceedings, including potential losses relating to such contingencies, will have a material adverse effect on its consolidated financial position, results of operations or cash flows.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Civil Investigative Demand</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in December 2023, the Company received a civil investigative demand (“CID”) from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act (the “Investigation”). The CID requests information and documents primarily relating to meals and consulting service payments provided to health care professionals. The Company is cooperating with the Investigation. The Company is unable to express a view at this time regarding the likely duration, or ultimate outcome, of the Investigation or estimate the possibility of, or amount or range of, any possible financial impact. Depending on the outcome of the Investigation, there may be a material impact on the Company’s business, results of operations, or financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent and Trade Secret Litigation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on May 22, 2024, the Company filed a patent infringement lawsuit against Imperative Care, Inc. (“Imperative Care”) and Truvic Medical, Inc. (“Truvic”) in the United States District Court for the Northern District of California, alleging that Imperative Care's Symphony Thrombectomy System infringes eight patents related to mechanical thrombectomy devices used for treating pulmonary emboli and deep vein thrombosis. On July 9, 2024, the Company filed an amended complaint to allege infringement of an additional, ninth patent, and to drop Truvic as a named defendant because Imperative Care confirmed that Truvic has been merged into Imperative Care. In the complaint, the Company seeks injunctive relief and damages for the alleged infringement. On July 24, 2024, the Company filed a motion for a preliminary injunction seeking to enjoin Imperative Care's sale or use, among other activities, of the Symphony Thrombectomy System outside of clinical trials. The court has indicated that it is likely to hear the preliminary injunction motion in December 2024. It has not otherwise set a case schedule.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2024, the Company filed a lawsuit against Inquis Medical, Inc. (“Inquis”) in the United States District Court for the District of Delaware. The Company’s complaint alleges that Inquis misappropriated the Company’s trade secrets in relation to Inquis’ engagement of the services of an Inari employee, and that Inquis’ Aventus Thrombectomy System and Aventus Clot Management System infringe four Inari patents related to mechanical thrombectomy devices used for treating pulmonary emboli and deep vein thrombosis. Inquis’ response to the Company’s complaint is due November 4, 2024. The court has not otherwise set a case schedule.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Class Action</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on May 13, 2024, purported stockholder Michiana Area Electrical Workers’ Pension Fund filed a verified class action complaint on behalf of itself and similarly situated Inari stockholders in the United States District Court for the Southern District of New York, captioned Michiana Area Elec. Workers’ Pension Fund v. Inari Medical, Inc., No. 1:24-cv-03686-JHR (the “MAEW Action”). On June 18, 2024, purported stockholder Paul Hartmann filed a verified class action complaint on behalf of himself and similarly situated Inari stockholders in the United States District Court for the Southern District of New York, captioned Hartmann v. Inari Medical, Inc., No. 1:24-cv-04662-JHR (the “Hartmann Action” and together with the MAEW Action, the “Related Actions”). Each of the Related Actions alleges the Company and certain of its officer and directors violated Sections 10(b) and 20(a) of the Securities Exchange Act by making false or misleading statements regarding the Company’s revenue and expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on July 12, 2024, a group of pension funds consisting of Oklahoma Law Enforcement Retirement Systems, Local 353, I.B.E.W. Pension Fund, and City of Pontiac Reestablished General Employees’ Retirement System, Mr. Hartmann, and purported stockholder Arvin Nazerzadeh-Yazdi, each filed motions seeking to consolidate the Related Actions, be appointed lead plaintiff, and have their counsel appointed lead counsel. The matter is at a preliminary stage and the Company is not able to quantify the extent of any potential liability.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that these complaints are without merit and intends to defend against them vigorously.</span></div> P5Y <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the weighted average remaining lease term and discount rate:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining term (in years)</span></div></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.1</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating leases were as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.005%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,048 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">866 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,877 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,564 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.005%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,385 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,137 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,929 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,456 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">746 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">809 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,617 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,561 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,816 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,350 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> P16Y1M6D P18Y2M12D 0.061 0.061 1048000 866000 2877000 2564000 1385000 1137000 3929000 3456000 48000 22000 141000 85000 184000 402000 746000 809000 1617000 1561000 4816000 4350000 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under operating leases liabilities as of September 30, 2024 are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ending December 31:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2024</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">858 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,512 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,396 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,771 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,504 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,724 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: lease liabilities - current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities - noncurrent portion</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,145 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 858000 3373000 3512000 3594000 3396000 35771000 50504000 17780000 32724000 1579000 31145000 P10Y 7200000 8 CONCENTRATIONS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenue is derived primarily from the sale of catheter-based therapeutic devices in the United States. For the three and nine months ended September 30, 2024 and 2023, there were no customers which accounted for more than 10% of the Company’s revenue. As of September 30, 2024 and December 31, 2023, there were no customers that accounted for more than 10% of the Company’s accounts receivable.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No vendor accounted for more than 10% of the Company’s purchases for the three and nine months ended September 30, 2024 and 2023. There were no vendors that accounted for more than 10% of the Company’s accounts payable as of September 30, 2024 and December 31, 2023.</span></div> RELATED PARTY<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes MRI The Hoffman Group (“MRI”), a recruiting services company owned by the brother of the former Chief Executive Officer and President and current member of the board of directors of the Company. The Company paid for recruiting services provided by MRI amounting to nil and $67,000 for the three months ended September 30, 2024 and 2023, respectively, and $31,000 and $147,000 for the nine months ended September 30, 2024 and 2023, respectively, which was recorded in SG&amp;A expenses within the condensed consolidated statements of operations and comprehensive income (loss). As of September 30, 2024 and December 31, 2023, there was no balance payable to MRI.</span></div> 0 67000 31000 147000 0 0 CREDIT FACILITY<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bank of America Credit Facility</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2022, the Company amended its senior secured revolving credit facility with Bank of America (the “Previously Amended Credit Agreement”) under which the Company may borrow loans up to a maximum principal amount of $40.0 million and increase the optional accordion to $120.0 million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advances under the Previously Amended Credit Agreement will bear interest at a base rate per annum (“the Base Rate”) plus an applicable margin (the “Margin”). The Base Rate equals the greater of (i) the Prime Rate, (ii) the Federal funds rate plus 0.50%, or (iii) the Bloomberg Short-Term Bank Yield Index (“the BSBY”) rate based upon an interest period of one month plus 1.00%, in any case has a floor of 0%. The Margin ranges, depending on average daily availability, from 0.50% to 1.00% in the case of Prime Rate and the Federal funds rate loans, and 1.50% to 2.00% in the case of BSBY Rate loans.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition to entering into the Previously Amended Credit Agreement, the Company was obligated to pay a nonrefundable fee of $10,000. The Company is also required to pay an unused line fee at an annual rate of 0.25% per annum of the average daily unused portion of the aggregate revolving credit commitments under the Previously Amended Credit Agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Previously Amended Credit Agreement also includes a Letter of Credit subline facility (the “LC Facility”) of up to $5.0 million. In February 2023, the Company amended the LC Facility to increase the limit to up to $10.0 million. The Company is required to pay the following fees under the LC Facility: (a) a fee equal to the applicable margin in effect for BSBY loans (currently 2.25%) times the average daily stated amount of outstanding letters of credit; and (b) a fronting fee equal to 0.125% per annum on the stated amount of each letter of credit outstanding.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2023, the Company further amended its credit facility (the “Amended Credit Agreement”) to, among other things, increase the amount available for borrowing up to a maximum principal amount of $75.0 million. Additionally, advances under the Amended Credit Agreement will bear interest at the Base Rate or the BSBY rate, plus the Margin. The Margin ranges from 0.60% to 1.10% in the case of the Base Rate loans and 1.60% to 2.10% in the case of the BSBY rate loans depending on average daily availability, in each case with a floor of 0%. As a condition of entering into the Amended Credit Agreement, the Company was obligated to pay a nonrefundable fee of $88,000. Lastly, the Company amended the LC Facility to increase the limit up to $18.8 million. This amendment was accounted for as a debt modification in accordance ASC 470, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement contains certain customary covenants subject to certain exceptions, including, among others, the following: a fixed charge coverage ratio covenant, and limitations of indebtedness, liens, investments, asset sales, mergers, consolidations, liquidations, dispositions, restricted payments, transactions with affiliates and prepayments of certain debt. The Amended Credit Agreement also contains certain events of default subject to certain customary grace periods, including, among others, payment defaults, breaches of any representation, warranty or covenants, judgment defaults, cross defaults to certain other contracts, bankruptcy and insolvency defaults, material judgment defaults and a change of control default.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, the amount available to borrow under the Amended Credit Agreement is approximately $67.9 million, and the Company had four letters of credit in the aggregated amount of $2.4 million outstanding under the LC Facility. The aggregate stated amount outstanding of the letter of credits reduces the total borrowing base available under the Amended Credit Agreement and is subject to certain fees.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, there was no principal amount outstanding, and no cash was pledged under the Amended Credit Agreement, and the Company was in compliance with its covenant requirements. Obligations under the Amended Credit Agreement are secured by substantially all of the Company’s assets, excluding intellectual property. The Amended Credit Agreement matures on December 16, 2027.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Financing Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred directly related to debt are presented in other assets and are being amortized over the five-year life of the Credit Agreement on the straight-line basis. The unamortized deferred financings costs as of September 30, 2024 and December 31, 2023 are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">729 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,454 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized deferred financing costs</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">282 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,072 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 40000000.0 120000000 0.0050 0.0100 0 0.0050 0.0100 0.0150 0.0200 10000 0.0025 5000000.0 10000000 0.0225 0.00125 75000000 0.0060 0.0110 0.0160 0.0210 0 88000 18800000 67900000 4 2400000 0 0 P5Y P5Y The unamortized deferred financings costs as of September 30, 2024 and December 31, 2023 are as follows (in thousands):<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">729 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,454 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized deferred financing costs</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">282 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,072 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 729000 1454000 447000 382000 282000 1072000 STOCKHOLDERS’ EQUITY<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in accumulated balances of other comprehensive income (loss) for the nine months ended September 30, 2024 and 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain (Loss) on Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss) </span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, December 31, 2023</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,894 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,885 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,363)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, March 31, 2024</span></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,535 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,522 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, June 30, 2024</span></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(824)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(837)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, September 30, 2024</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,094 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,145 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain (Loss) on Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss) </span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, December 31, 2022</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,820 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(971)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">849 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, March 31, 2023</span></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">955 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(962)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,095)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, June 30, 2023</span></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(140)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,041)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,181)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, September 30, 2023</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,109)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,158)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in accumulated balances of other comprehensive income (loss) for the nine months ended September 30, 2024 and 2023 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain (Loss) on Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss) </span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, December 31, 2023</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,894 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,885 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,363)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, March 31, 2024</span></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,535 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,522 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, June 30, 2024</span></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(824)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(837)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, September 30, 2024</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,094 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,145 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized Gain (Loss) on Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss) </span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, December 31, 2022</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,820 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(971)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">849 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, March 31, 2023</span></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">955 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(962)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,095)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, June 30, 2023</span></div></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(140)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,041)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,181)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance, September 30, 2023</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,109)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,158)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -9000 8894000 8885000 -4000 -7359000 -7363000 -13000 1535000 1522000 0 -2359000 -2359000 -13000 -824000 -837000 64000 13918000 13982000 51000 13094000 13145000 1820000 -971000 849000 -865000 9000 -856000 955000 -962000 -7000 -1095000 -79000 -1174000 -140000 -1041000 -1181000 91000 -68000 23000 -49000 -1109000 -1158000 EQUITY INCENTIVE PLANS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2011, the Company adopted the 2011 Equity Incentive Plan (the “2011 Plan”) to permit the grant of share-based awards, such as stock grants and incentives and non-qualified stock options to employees and directors. The Board has the authority to determine to whom awards will be granted, the number of shares, the term and the exercise price.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company adopted the 2020 Incentive Award Plan (the “2020 Plan”), which became effective in connection with the Company’s initial public offering in May 2020. As a result, the Company may not grant any additional awards under the 2011 Plan. The 2011 Plan will continue to govern outstanding equity awards granted thereunder. In addition, the number of shares of common stock reserved for issuance under the 2020 Plan will automatically increase on the first day of January for a period of up to ten years, commencing on January 1, 2021, in an amount equal to 3% of the total number of shares of the Company’s capital stock outstanding on the last day of the preceding year, or a lesser number of shares determined by the Company’s board of directors. As of September 30, 2024, there were 7,183,239 shares available for issuance under the 2020 Plan, including 1,732,872 additional shares reserved effective January 1, 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2011 Equity Incentive Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the 2011 Plan for the nine months ended September 30, 2024 is as follows (intrinsic values in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, December 31, 2023</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">937,696</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.24 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,778 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(170,540)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.05 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">767,127</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,884 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and exercisable at September 30, 2024</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">767,127</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.28 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,884 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest at September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">767,127</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,884 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values of options outstanding, vested and exercisable, and vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair market value of the Company’s common stock.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Incentive Award Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (“RSUs”) are share awards that entitle the holder to receive freely tradable shares of the Company’s common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest over a four-year period with straight-line vesting and a 25% one-year cliff or over a three-year period in equal amounts on a quarterly basis, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of the Company’s common stock on the grant date.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU activity under the 2020 Plan is set forth below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Awards </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, December 31, 2023</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,307,998</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67.91 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,006,244</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(456,160)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67.69 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(104,090)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, September 30, 2024</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,753,992</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56.30 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs vested under the 2020 Plan was $7.7 million and $6.9 million for the three months ended September 30, 2024 and 2023, respectively, and $23.9 million and $21.0 million for the nine months ended September 30, 2024 and 2023, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Stock Units</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2024, the Company granted performance stock units (“PSUs”) to certain employees that are eligible to vest three years from the award date, based on achieving certain revenue based performance targets. The number of shares that may be earned can range from 0% to 200% of the target amount. The fair value of PSUs is determined by the closing stock price of the Company’s common stock on the awards’ grant date. The share-based compensation expense associated with PSUs is recognized on a straight-line basis based on the estimated number of awards that are expected to vest. At each reporting period, the Company monitors the probability of achieving the performance targets and adjusts the share-based compensation expense associated with PSUs accordingly.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSU activity under the 2020 Plan is set forth below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, December 31, 2023</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,488</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, September 30, 2024</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,488</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.48 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants non-qualified stock options to certain employees with vesting over a four-year period on a quarterly basis. The fair value of the stock options was calculated using the Black-Scholes option pricing model. The fair value for options granted was calculated using the following weighted average assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.040%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.7% to 48.9%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.4%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2% to 4.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average fair value of options granted</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$24.89 per share</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$25.98 per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activities under the 2020 Plan for the nine months ended September 30, 2024 is as follows (intrinsic values in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, December 31, 2023</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">166,203 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56.00 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,483 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">210,188</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(270)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56.00 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,157)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, September 30, 2024</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">368,964</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.33 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and exercisable at September 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86,548 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest at September 30, 2024</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">343,736</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.35 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company adopted the 2020 Employee Stock Purchase Plan (“ESPP”), which became effective on the date the ESPP was adopted by the Company’s board of directors. Each offering to the employees to purchase stock under the ESPP will begin on each August 1 and February 1 and will end on the following January 31 and July 31, respectively. The first offering period began on August 1, 2020. On each purchase date, which falls on the last date of each offering period, ESPP participants will purchase shares of common stock at a price per share equal to 85% of the lesser of (1) the fair market value per share of the common stock on the offering date or (2) the fair market value of the common stock on the purchase date. The occurrence and duration of offering periods under the ESPP are subject to the determinations of the Compensation Committee, in its sole discretion. The number of shares available for issuance under the ESPP increases automatically on January 1 of each calendar year of the Company beginning in 2021 and ending in 2030, in an amount equal to the lesser of (i) 1% of the aggregate number of outstanding shares of the Company’s common stock on the final day of the immediately preceding calendar year and (ii) such smaller number of shares determined by the Company’s board of directors.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:61.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57.0% - 60.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.1% - 49.9%</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1% - 5.2%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8% - 5.5%</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, a total of (i) 639,355 shares of common stock, including 133,430 shares purchased in July 2024 and 82,816 shares purchased in January 2024, have been purchased under the ESPP, and (ii) 2,465,007 shares of common stock are reserved under the ESPP for future purchases, including 577,624 additional shares, which were automatically added to the reserve on January 1, 2024 pursuant to the terms of the ESPP.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost for all share-based payment arrangements recognized, including $1.2 million and $0.7 million for the three months ended September 30, 2024 and 2023, respectively, and $3.5 million and $2.9 million for the nine months ended September 30, 2024 and 2023, respectively, of share-based compensation expense related to the ESPP, was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">537 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">393 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,570 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,232 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,635 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,864 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,943 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,323 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,951 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,844 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,860 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,536 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation costs as of September 30, 2024 related to all non-vested awards to be recognized in future periods was $87.4 million and is expected to be recognized over the remaining weighted average period of 2.6 years.</span></div> P10Y 0.03 7183239 1732872 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the 2011 Plan for the nine months ended September 30, 2024 is as follows (intrinsic values in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, December 31, 2023</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">937,696</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.24 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,778 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(170,540)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.05 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">767,127</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,884 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and exercisable at September 30, 2024</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">767,127</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.28 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,884 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest at September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">767,127</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,884 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activities under the 2020 Plan for the nine months ended September 30, 2024 is as follows (intrinsic values in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, December 31, 2023</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">166,203 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56.00 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,483 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">210,188</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(270)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56.00 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,157)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, September 30, 2024</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">368,964</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.33 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and exercisable at September 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86,548 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest at September 30, 2024</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">343,736</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.35 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 937696 2.24 P5Y2M12D 58778000 170540 2.02 8211000 29 9.05 767127 2.28 P4Y6M 29884000 767127 2.28 P4Y6M 29884000 767127 2.28 P4Y6M 29884000 P4Y 0.25 0.25 0.25 0.25 P1Y P3Y <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU activity under the 2020 Plan is set forth below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Awards </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, December 31, 2023</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,307,998</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67.91 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,006,244</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(456,160)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67.69 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(104,090)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, September 30, 2024</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,753,992</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56.30 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1307998 67.91 1006244 46.95 456160 67.69 104090 61.87 1753992 56.30 7700000 6900000 23900000 21000000 P3Y 0 2 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSU activity under the 2020 Plan is set forth below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, December 31, 2023</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,488</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding, September 30, 2024</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,488</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.48 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 90488 55.48 90488 55.48 P4Y The fair value for options granted was calculated using the following weighted average assumptions:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.040%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.7% to 48.9%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.4%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2% to 4.3%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average fair value of options granted</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$24.89 per share</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$25.98 per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:61.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57.0% - 60.8%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.1% - 49.9%</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1% - 5.2%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8% - 5.5%</span></div></td></tr></table></div> P4Y6M P4Y7M6D 0.487 0.489 0.504 0.000 0.000 0.042 0.043 0.041 24.89 25.98 166203 56.00 P6Y1M6D 1483000 210188 54.83 270 56.00 0 7157 56.00 368964 55.33 P5Y10M24D 0 86548 55.65 P5Y7M6D 0 343736 55.35 P5Y10M24D 0 0.85 0.01 P0Y6M P0Y6M 0.570 0.608 0.421 0.499 0.000 0.000 0.051 0.052 0.048 0.055 639355 133430 82816 2465007 577624 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost for all share-based payment arrangements recognized, including $1.2 million and $0.7 million for the three months ended September 30, 2024 and 2023, respectively, and $3.5 million and $2.9 million for the nine months ended September 30, 2024 and 2023, respectively, of share-based compensation expense related to the ESPP, was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">537 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">393 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,570 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,232 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,587 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,635 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,864 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,943 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,323 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,951 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,844 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,860 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,536 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1200000 700000 3500000 2900000 537000 393000 1570000 1232000 1779000 1587000 5347000 4981000 10635000 7864000 31943000 24323000 12951000 9844000 38860000 30536000 87400000 P2Y7M6D INCOME TAXES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the Company’s provision for income taxes for the periods indicated (in thousands, except for percentages):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(Loss) income before income taxes</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,672)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,590</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(50,181)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,420</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Provision for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,695</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,428</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,736</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,391</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Net (loss) income</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,367)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,162</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(73,917)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes as a percentage of (loss) income before income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44.9%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47.3%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate for all periods is driven by pre-tax income/(loss), business credits, equity compensation, state taxes, and the change in valuation allowance. The Company's income tax provision for interim reporting periods historically has been calculated by applying an estimate of the annual effective income tax rate for the full year to “ordinary” income (loss) for the interim reporting period. In addition, the tax effects of certain significant or unusual items are recognized discretely in the quarter in which they occur. For the nine months ended September 30, 2024 and September 30, 2023, the Company calculated the income tax provision using this methodology.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2024, many countries are implementing some or all of the Organization for Economic Co-operation and Development’s Base Erosion and Profit Shifting Two-Pillar in response to tax challenges arising from the digitalization of the global economy. While we continue to evaluate those countries’ implementations, we do not expect those implementations to have a material impact on our consolidated financial statements in 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation Allowance</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> requires that the tax benefit of net operating losses, or (“NOLs”), temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not”. Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryback or carryforward periods. As of December 31, 2023, the Company was in a net deferred tax liability position due to the LimFlow acquisition. However, a valuation allowance was maintained against certain deferred tax assets. As of September 30, 2024, the Company believes that the net deferred tax assets are currently not considered more likely than not to be realized and, accordingly, maintains a valuation allowance against certain deferred tax assets. The Company will continue to assess its position on the realizability of its deferred tax assets, until such time as sufficient positive evidence may become available to allow the Company to reach a conclusion that a significant portion of the valuation allowance will no longer be needed. Given the Company’s current earnings and anticipated future earnings, the Company believes that there is a reasonable possibility that sufficient positive evidence may become available in the near term to allow the Company to reach a conclusion that a significant portion of the valuation allowance is no longer needed. Any release of the valuation allowance will result in a material benefit recognized in the quarter of release.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Uncertain Tax Positions</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded uncertain tax positions related to its federal and California research and development credit carryforwards. No interest or penalties have been recorded related to the uncertain tax positions due to credit carryforwards that are available to offset the uncertain tax positions. It is not expected that there will be a significant change in the uncertain tax position in the next 12 months. The Company is subject to U.S. federal and state income tax as well as to income tax in various foreign jurisdictions. In the normal course of business, the Company is subject to examination by tax authorities. As of the date of the financial statements, there are no income tax examinations in progress. The statute of limitations for tax years ended after December 31, 2020, December 31, 2019, and December 31, 2020 are open for federal, state, and foreign tax purposes, respectively.</span></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the Company’s provision for income taxes for the periods indicated (in thousands, except for percentages):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(Loss) income before income taxes</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,672)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,590</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(50,181)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,420</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Provision for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,695</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,428</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,736</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,391</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Net (loss) income</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,367)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,162</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(73,917)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes as a percentage of (loss) income before income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44.9%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47.3%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> -12672000 5590000 -50181000 7420000 5695000 2428000 23736000 4391000 -18367000 3162000 -73917000 3029000 -0.449 0.434 -0.473 0.592 RETIREMENT PLAN<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company adopted the Inari Medical, Inc. 401(k) Plan which allows <span style="-sec-ix-hidden:f-992">eligible</span> employees after one month of service to contribute pre-tax and Roth contributions to the plan, as allowed by law. The plan assets are held by Vanguard and the plan administrator is Ascensus Trust Company. Beginning in January 2021, the Company contributed a $1.00 match for every $1.00 contributed by a participating employee up to the greater of $3,000 or 4% of eligible compensation under the plan, with such Company's contributions becoming fully vested immediately. On January 1, 2024, the plan was amended to provide that the Company contributes a $1.00 match for every $1.00 contributed by a participating employee for up to 5% of eligible compensation. The plan also includes a limit of $15,000 per individual of employer match, with such Company’s contributions becoming fully vested immediately. Matching contribution expense was $3.1 million and $2.0 million for the three months ended September 30, 2024 and 2023, respectively, and $10.6 million and $6.9 million for the nine months ended September 30, 2024 and 2023, respectively.</span></div> P1M 1.00 3000 0.04 1.00 0.05 15000 3100000 2000000.0 10600000 6900000 NET INCOME (LOSS) PER SHARE<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net income (loss) per share is computed using the treasury stock method by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net income (loss) per share calculation, shares from common stock options and equity awards are potentially dilutive securities. For the periods the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net (loss) income per share are as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(18,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(73,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-6pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of common shares outstanding - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,366,364</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,384,884</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,149,296</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,478,317</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents from outstanding equity grants</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,102,642</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,173,190</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-6pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents from unvested RSUs and PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,531</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">832,873</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-6pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents from ESPP</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,395</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,541</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-6pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of common shares outstanding - diluted</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,366,364</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,588,452</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,149,296</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,495,921</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net (loss) income per share:</span></div></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(0.31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(1.27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(0.31)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.05 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(1.27)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.05 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,136,091</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171,526</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,136,091</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,290,179</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity awards</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,844,480</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">555,468</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,844,480</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,332,500</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total potentially dilutive common stock equivalents excluded from calculation due to anti-dilutive effect</span></div></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,980,571</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">726,994</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,980,571</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,622,679</span></td></tr></table></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net (loss) income per share are as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(18,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(73,917)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-6pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of common shares outstanding - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,366,364</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,384,884</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,149,296</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,478,317</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents from outstanding equity grants</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,102,642</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,173,190</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-6pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents from unvested RSUs and PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,531</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">832,873</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-6pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents from ESPP</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,395</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,541</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-6pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of common shares outstanding - diluted</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,366,364</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,588,452</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,149,296</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,495,921</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net (loss) income per share:</span></div></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(0.31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(1.27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(0.31)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.05 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(1.27)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.05 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -18367000 3162000 -73917000 3029000 58366364 57384884 58149296 56478317 0 1102642 0 1173190 0 94531 0 832873 0 6395 0 11541 58366364 58588452 58149296 58495921 -0.31 0.06 -1.27 0.05 -0.31 0.05 -1.27 0.05 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,136,091</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171,526</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,136,091</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,290,179</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity awards</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,844,480</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">555,468</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,844,480</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,332,500</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total potentially dilutive common stock equivalents excluded from calculation due to anti-dilutive effect</span></div></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,980,571</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">726,994</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,980,571</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,622,679</span></td></tr></table></div> 1136091 171526 1136091 1290179 1844480 555468 1844480 1332500 2980571 726994 2980571 2622679 false false false false

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